Novel carboxamide derivative compound and pharmaceutical composition comprising same

Abstract

The present invention relates to: a carboxamide derivative compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; a composition comprising same; a method for preventing or treating IRAK-4 or IRAK-1 related diseases by using same; and uses thereof.

Description

[0001]

Description of the Invention

[0002]

Title of Invention

[0003] Novel carboxamide derivative compounds and pharmaceutical compositions containing the same

[0004]

Technology Field

[0005] The present invention relates to novel carboxamide derivative compounds, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof, and pharmaceutical compositions containing the same.

[0006] This research was conducted with funding from the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare, and with support from the National New Drug Development Project of the National New Drug Development Center (Project Registration No.: RS-2023-00284094).

[0007]

Background Techniques

[0008] Protein kinases are a large, multigene family of over 500 proteins that play a vital role in the development and treatment of numerous human diseases in oncology, neurology, and immunology. They catalyze the phosphorylation of proteins, lipids, sugars, nucleosides, and other cellular metabolites, playing a critical role in all aspects of eukaryotic cell physiology. In particular, protein kinases and lipid kinases are involved in signaling events that regulate cell activation, growth, differentiation, and survival in response to stimuli such as extracellular mediators, growth factors, cytokines, or chemokines. Generally, protein kinases are classified into two groups: those that preferentially phosphorylate tyrosine residues and those that preferentially phosphorylate serine / threonine residues.

[0009] Kinases are important therapeutic targets for the development of anti-inflammatory drugs (Cohen, 2009. Current Opinion in Cel 1 Biology 21, 1-8), and many diseases are associated with abnormal cellular responses triggered by kinase-mediated events. Kinase targets of particular interest are members of the IRAK family.

[0010] Members of the Interleukin-1 Receptor-Associated Kinase (IRAK) family, which are included in serine / threonine kinases, are recruited to the receptor through interactions with MyD88. The family consists of four members (IRAK-1, IRAK-2, IRAK-M, and IRAK-4), and some evidence indicates that IRAK-4 plays a critical and non-redundant role in initiating signal transduction through MyD88-dependent TLRs and IL-1R family members. Structural data confirmed that IRAK4 directly interacts with MyD88 and subsequently recruits IRAKI or IRAK2 to the receptor complex, thereby facilitating downstream signal transduction (Lin, S. et al., Nature, 465:885-890 (2010)). IRAK-4 directly phosphorylates IRAK-1 to facilitate downstream signaling to the E3 ubiquitin ligase TRAF6, which induces the activation of the serine / threonine kinase TAK1 and subsequent activation of the NF-KB pathway and the MAPK cascade (Flannery, S. et al., Biochem. Pharmacol., 80: 1981–1991(2010)).

[0011] In kinase pathways, the IL-1R / TLR (IL-1 receptor / Toll-like receptor) signaling pathway plays an important role in immune and inflammatory responses and has been reported to be involved in the development of various inflammatory and autoimmune diseases, such as sepsis, asthma, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, atopy, hidradenitis suppurativa, psoriasis, ulcerative colitis, and lupus (Journal of Investigative Dermatology. 2019; 139(1): 146-156 / Annals of the New York Academy of Sciences. 2008; 1143: 21— 34 / Journal of Immunology research. 2019; 1824624 / International Immunopharmaco. 2007; 7(10): 1271-1285). In particular, it has recently been reported that blocking the IL-1R / TLR signaling pathway through IRAK-4 inhibition is effective for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis (Science Translational Medicine. 2023: 15: eabj3289).

[0012] It has been reported that IL-1R / TLR expression is involved in the proliferation of various cancer cells (Oncogene. 2008; 27(2): 218-224). In particular, IL-1R / TLR signaling caused by MyD88 mutations has been reported to be overactivated in ABC DLBCL, a type of diffuse large B-cell lymphoma (DLBCL), and Waldenstrom macroglobulinemia (WM), a lymphocytic malignancy (Nature. 2011; 470(7332): 115-119 / New England journal of medicine. 2012; 367(9): 826-833), and recently, IRAK-4 and IRAK-1 have also been reported to be involved in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (Current Opinion in Hematology. 2022; 29(1): 8-19).

[0013] When pathogen-associated molecular patterns (PAMPs), which are commonly expressed in various pathogens, and damage-associated molecular patterns (DAMPs), which are released from stressed or dying cells, bind to IL-1R / TLRs, downstream signaling mechanisms are activated, leading to an inflammatory response. If this inflammatory response persists, it develops into cancer (Nature Immunology. 2011 Jul 19; 12(8): 715-723).

[0014] Based on the aforementioned reports, research is actively underway to develop substances that block TLRs themselves, which play a crucial role in the IL-1R / TLR signaling pathway, or inhibit IRAKs responsible for TLR downstream signaling; in particular, studies targeting IRAK-4 and IRAK-1, which possess kinase functions, are predominant. Although no drugs targeting IRAK-4 or IRAK-1 have yet been released, numerous Phase 1 and Phase 2 clinical trials are underway for various diseases (autoimmune diseases, inflammatory diseases, and hematological cancers). As the number of patients affected by kinase enzyme-mediated diseases increases, there appears to be an unmet demand for new agents capable of treating these diseases more efficiently.

[0015] Prior art literature

[0016] Non-patent literature

[0017] (Non-patent literature 1) Cohen, 2009. Current Opinion in Cel 1 Biology 21, 1-8 (Non-patent literature 2) Lin, S. et al., Nature, 465:885-890 (2010)

[0018] (Non-patent literature 3) Flannery, S. et al., Biochem. Pharmacol., 80: 1981-1991(2010)

[0019] (Non-patent literature 4) Journal of Investigative Dermatology. 2019; 139(1): 146-156

[0020] (Non-patent literature 5) Anna 1 s of the New York Academy of Sciences. 2008; 1143: 21-34

[0021] (Non-patent literature 6) International Immunopharmaco 1 ogy . 2007; 7(10) : 1271-1285

[0022] (Non-patent literature 7) International Immunopharmaco 1 ogy . 2007; 7(10) : 1271-1285

[0023] (Non-patent literature 8) Science Translational Medicine. 2023 : 15: eabj3289 (Non-patent literature 9) Oncogene. 2008; 27(2): 218-224

[0024] (Non-patent literature 10) Nature. 2011; 470(7332) : 115-119 (Non-patent literature 11) New England journal of medicine. 2012; 367(9) : 826-833

[0025] (Non-patent literature 12) Current Opinion in Hematology. 2022; 29(1): 8-19 (Non-patent literature 13) Nature Immunology. 2011 Jul 19; 12(8): 715-723

Description of the Invention

[0026]

Technical Challenges

[0027] The present invention provides a novel carboxamide derivative compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

[0028] The present invention provides a pharmaceutical composition comprising a novel carboxamide derivative compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

[0029] The present invention provides a pharmaceutical composition for the prevention or treatment of IRAK-4 or IRAK-1 related diseases comprising a novel carboxamide derivative compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

[0030] The present invention provides a method for preventing or treating IRAK-4 or IRAK-1 related diseases, comprising the step of administering to an individual a novel carboxamide derivative compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

[0031] The present invention provides a use of a novel carboxamide derivative compound, its stereoisomer, its pharmaceutically acceptable salt, or its hydrate or solvate for the prevention or treatment of IRAK-4 or IRAK-1 related diseases.

[0032] The present invention provides the use of novel carboxamide derivative compounds, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof in the manufacture of pharmaceuticals for the prevention or treatment of IRAK-4 or IRAK-1 related diseases.

[0033]

Technical Solution

[0034] Accordingly, the applicant developed a compound of a novel structure that potently inhibits IRAK-4 or IRAK-1. The applicant evaluated the activity against IRAK-4 and IRAK-1 enzymes, the changes in secretion of inflammatory cytokines, the activity in an animal model of systemic inflammation induced by LPS (1 ipopolysaccharide), and the in vivo pharmacokinetics of PK, and through this, confirmed that the compound is a substance with excellent activity.

[0035] The present invention relates to compounds useful for the prevention or treatment of autoimmune diseases, inflammatory diseases, or tumors associated with IRAK (Interleukin-1 Receptor-Associated Kinase), and specifically to compounds that inhibit the function of IRAK-4 or IRAK-1, and pharmaceutical compositions and health functional food compositions containing the same.

[0036] The present invention will be described in more detail below. All combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the scope of the present invention should not be considered limited by the following detailed description.

[0037] Compound represented by chemical formula I

[0038]

[0039] The present invention provides a compound represented by Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

[0040] <Chemical Formula 1>

[0041]

[0042]

[0043] And, Xi and X2 are each independently C or Si, and Yi is C, N, O, or S (where, if Yi is O or S, X2 is ), and the complements of Ai are unsubstituted or one or more complements may each independently be substituted with a straight-chain or branched-chain -Cl- C6 alkyl or halogen (-F, -Cl, -Br, or -1);

[0044] R is a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of -Cl-C6 alkyl, -CF3, -NO2, -S(=O)2-NRaRb, -S(=O)2CF3, -S(=O)2F, -ORc, N and O in a straight-chain or branched-chain form in the ring, a 6- to 10-membered aryl, -C(=O)NRdRe, -C(=O)OH, -C(=O)OCH3 or -CN, wherein Ra, Rb, Rc, Rd and Re are each independently -H, a straight-chain or branched-chain -Cl-C6 alkyl, -CF3, -CH2C(CH3)2OH, or -NH2, and in this case, the H of R is unsubstituted or substituted with one or more substituents each independently being a straight-chain or branched-chain -Cl-C6 alkyl, a straight-chain or branched-chain -Cl-C6 alkoxy, OH, or a halogen (-F, -Cl, -Br, or -I);

[0045] Qi and Q2 are each independently -N- or -N(Li-R2)-, and one of Qi and Q2 is -new- and the other is -new(1丄1—1?2)-;

[0046] Li is a single bond or C1-C8 alkylene, and when Li is C1-C8 alkylene, the H of Li is unsubstituted or substituted with one or more substituents each independently being a straight-chain or branched-chain -Cl-C6 alkyl, a halogen (-F, -Cl, -Br or -I) or -OH;

[0047] It should be noted that there seem to be some unclear or incorrect expressions in the original text, such as "-새-" and "-새(1丄1—1?2)-", which may need further clarification for a more accurate translation.R2 is a 4- to 6-membered heterocycloalkyl containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of -H, straight-chain or branched-chain -Cl-C8alkyl, straight-chain or branched-chain -Cl-C6alkyl, OH, straight-chain or branched-chain -Cl-C6alkoxy, N and O, -CN, -0CH2C(=0)NRfRg, -S(=0)2Rh, -CH2CH2P(=0)(0CH2CH3)2, -CD3, -CH2CH2P(=0)(0CH20C(=0)C(CH3)3)2, a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of N, O and S, a C3 to C6 cycloalkyl, or a 6-membered It is a 10-membered aryl, wherein Rf, Rg, and Rh are each independently H or a straight-chain or branched -C1-C6 alkyl, where the complement of R2 is unsubstituted or one or more complements may each independently be substituted with a straight-chain or branched -C1-C6 alkyl or a halogen (-F, -Cl, -Br, or -I); and R3 is -H, a straight-chain or branched -Cl-C6 alkyl or a halogen (-F, -Cl, -Br, or -I), where the complement of R3 is unsubstituted or one or more complements may each independently be substituted with a straight-chain or branched -Cl-C6 alkyl or a halogen (-F, -Cl, -Br, or -I);

[0048] A2 is a pentocycloalkylene containing 1 to 4 N atoms in the ring and is a hexavalent heterocycloalkylene;

[0049] L2 is a homogeneous, C1-C6 alkylene, -C(=0)-NRai-, -C(=0)0-, -C(=0)-, -NRa2C(=0)0-, -NRa3C(=0)-, -NRa4-, or -C(=0)-NRa5-CH2-, where Rai, Ra2, Ra3, Ra4, or Ra5 are each independently -H, straight-chain or branched-chain -C1-C6 alkyl, and the complement of L2 is unsubstituted or one or more complements may each independently be substituted with straight-chain or branched-chain -Cl-C6 alkyl or a halogen (-F, -Cl, -Br, or -1);

[0050] R4 is a 3- to 8-membered heterocycloal kyle containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of -H, straight-chain or branched -Cl-C6alkyl, N, and O, C3-C8 cycloal kyle, -(CH2)mC(=0)NRbiRb2(m is an integer from 1 to 6), -(CH2)pC(=0)0Rb3(p is an integer from 1 to 6), a 5- to 6-membered heterocycloal kyle containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of N, O, and S, -NRb4Rb5, -N(CH=CH2)2, -(CH2)qNRb6C(=0)0H(q is an integer from 0 to 6), -(CH2)rOH(r is (integer from 1 to 6), - (CH2)sNH2(s is an integer from 1 to 6), - (CH2)tCN(t is an integer from 1 to 6), straight-chain or branched-chain -C1-C6 alkoxy, -C(CH3)20H, -CH2CF3, -(CH2)2CF3, -CF 3 I — NH2 , phenyl , -C(CH3)2Br , —OH , -CH2C(CH3)20H , -S(=0)2CH3,

[0051]

[0052] 0 or0 and, where Rbi, Rb2, Rb3, Rb4, Rb5, and Rb6 are each independently H, straight-chain or branched-chain -Cl-C6alkyl, saturates

[0053]

[0054] -CH2C(CH3)20H, -CH2CH2C(CH3)20H, -C(CH3)20H, -CH2CH2OH, -OH, C3-C8 cycloal kill, -CH2CF3, -(CH2)2CF3 or -CF3, and

[0055] The R4 complement is unsubstituted or one or more complements each independently contain 1 to 4 heterocyclic alkyls in the ring independently selected from the group consisting of straight-chain or branched -Cl-C6alkyl, halogen (-F, -Cl, -Br, or -I), -C(=0)NH2, -S(=0)2NH2, -OH, -NH2, -CH(CH3)0H, -CH2OH, -C(=0)0C(CH3)3, straight-chain or branched -Cl-C6 alkoxy, -CN, -OH, N, and 0, 3 to 8 heterocyclic alkyls, -S(=0)2CH3,

[0056] -C(CH3)2OH,

[0057]

[0058] - CF3, or - S (which can be substituted with 0hCF3);

[0059] R5 is a -H or straight-chain or branched-chain -Cl- C6 alkyl.

[0060] The compound represented by Formula I according to the present invention, its stereoisomer, its pharmaceutically acceptable salt, or its hydrate or solvate can exhibit excellent activity by strongly inhibiting IRAK-4 or IRAK-1, have few or no side effects, exhibit safe and excellent pharmacokinetic properties (excellent absorption rate, bioavailability), be appropriately distributed to each tissue upon administration to exhibit desired pharmacological effects in each tissue, and be effectively metabolized in the body.

[0061] In one embodiment of the present invention, Qi and Q2 in the compound represented by the chemical formula I may be different from each other, and one of Qi and Q2 may be N and the other may be N-LI-R2, and specifically, when Q2 is N, the

[0062]

[0063]

[0064] And, when Q1 is N, the above

[0065] It could be.

[0066]

[0067] The dotted circles shown in the structure of the present invention are intended to indicate the delocalization of electrons within the ring and include all possible bonding arrangements by resonance.

[0068] In the present invention, the description of atoms that can be located at each of Xi, X2 and Yi (e.g., C, N, O, or S) is indicated by omitting bondable hydrogen, and the atoms that can be located at each of X1, X2 and Y1 mean that an appropriate number of hydrogens are bonded to satisfy the octet rule, even if hydrogen is not separately indicated.

[0069] In the present invention, the term "Cm-Cn" (where m and n are each independently an integer of 1 or more) means the number of carbon atoms. For example, 'C1-C6 alkyl' means an alkyl having 1 to 6 carbon atoms.

[0070] In the present invention, "substituted", "substitutable", or "substituted with" depends on the allowable valency of the atoms and substituents being substituted, and is defined to include the implicit condition that the substituted compound, for example, a compound not naturally deformed by rearrangement, ring formation, elimination, etc.

[0071] In the present invention, "single bond" may mean a case where adjacent atoms or atomic groups are directly bonded. In the chemical structure represented by X-Y-Z, when it is a single bond between X and Z, it means the chemical structure of x-Z.

[0072] In the present invention, deuterium is one of the isotopes of hydrogen, an element having a deuteron composed of 1 proton and 1 neutron as its atomic nucleus, and can be represented by 日.

[0073] In the present invention, "alkyl" may mean a linear (or straight-chain, linear) saturated hydrocarbon group or a branched-chain (or side-chain, branched) saturated hydrocarbon group unless otherwise specified.

[0074] Examples of alkyl include, but are not limited to, one or more selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and n-heptyl.

[0075] In the present invention, "alkylene" may mean a divalent functional group derived from an alkyl group defined as above, unless otherwise noted, and may be referred to as -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, etc., methylene, ethylene, propylene, butylene, etc.

[0076] In the present invention, "alkoxy" means an alkyl (-0-alkyl) bonded with oxygen. For example, it may be methoxy, ethoxy, propoxy, isopropoxy, butoxy, etc.

[0077] In the present invention, "cycloalkyll" may mean a monocyclic or polycyclic saturated hydrocarbon ring unless otherwise noted. Examples of cycloalkyll include, but are not limited to, one or more selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclopentyl, bicyclohexyl, bicycloheptyl, bicyclooctyl, spiropentyl, spirohexyl, spiroheptyl, spirooctyl, etc.

[0078] In the present invention, "cycloalkylene" means a divalent functional group derived from a cycloalkyle defined as above, unless otherwise noted.

[0079] In the present invention, "cycloalkenyl" means a monocyclic or polycyclic unsaturated hydrocarbon ring comprising one or more double bonds unless otherwise noted. Examples of cycloalkenyls include one or more selected from cycloprophenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, etc., but are not limited thereto.

[0080] In the present invention, "cycloalkenylene" means a divalent functional group derived from cycloalkenylene as defined above, unless otherwise noted.

[0081] In the present invention, "heterocyclic kill" may, unless otherwise noted, mean a monocyclic or polycyclic ring in which at least one carbon atom forming the cyclocyclic kill ring defined as above is substituted with a heteroatom selected from the group consisting of N, O, and S. Examples of heterocyclic kills include oxyranyl, dioxolanyl, dioxanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, morpholinyl, piperazineyl, thiomorpholinyl, and te

[0082] Trahydrothiophenyl, Tetrahydrothiopyraneyl,

[0083]

[0084]

[0085] One or more types selected from the above may be cited, but are not limited thereto.

[0086] In the present invention, "heterocycloalkylene" means a divalent functional group derived from a heterocycloalkyl as defined above, unless otherwise noted.

[0087] In the present invention, "heterocycloalkenyl" means, unless otherwise noted, a monocyclic or polycyclic ring in which at least one carbon atom forming the cycloalkenyl ring defined as above is substituted with a heteroatom selected from the group consisting of N, O, and S. Examples of heterocycloalkenyls include one or more selected from dihydropyridinyl, dihydropyranyl, dihydrothiopyranyl, etc., but are not limited thereto.

[0088] In the present invention, "heterocycloalkenylene" means a divalent functional group derived from heterocycloalkenyl as defined above, unless otherwise noted.

[0089] In the present invention, "aryl" means a monocyclic or polycyclic aromatic ring group having one or more fused or unfused aromatic rings, unless otherwise noted. Examples of aryls include, but are not limited to, one or more selected from phenyl, naphthalenyl, indenyl, and anthraceneyl.

[0090] In the present invention, "arylene" means a divalent functional group derived from an aryl as defined above, unless otherwise noted. In the present invention, "heteroaryl" means, unless otherwise noted, a monocyclic or polycyclic aromatic heterocyclic group having at least one heteroatom selected from the group consisting of N, O, and S within the ring and one or more fused or non-fused aromatic rings. Examples of heteroaryls include pyridinyl, thiophenyl, triazoleyl, tetraazoleyl, benzothiazolyl, benzothiophenyl, quinolineyl, indoleyl, isoindoleyl, benzofuranyl, benzopyrolyl, furanyl, pyrroleyl, thiazolyl, isothiazolyl, imidazoleyl, pyrazolyl, oxazolyl, isooxazolyl, pyrazineyl, pyridazineyl, pyrimidinyl, isoquinolineyl, benzoxazolyl, benzomidazoleyl, dihydrobenzothiophenyl, purineyl, indolyzineyl, chromenyl, pyrrolopyridinyl, pyrazolopyridinyl, thiadiazolopyridinyl, One or more selected from triazine yl, triazolopyrimidine yl, triazolopyrimidine yl, triazolopyridazine yl, indazol yl, imidazopyrimidine yl, imidazopyridazine yl, oxadiazolopyrimidine yl, benzothiadiazol yl, benzotriazole yl, benzoxadaizol yl, thiadizol yl (e.g., 1,3,4-thiadizolyl(1,3,4)), etc.) may be cited, but are not limited thereto.

[0091] In the present invention, "heteroarylene" means a divalent functional group derived from a heteroaryl defined as above, unless otherwise noted.

[0092] In the present invention, "halogen" may be -F, -Cl, -Br, or -1 unless otherwise noted. In the present invention, the statement that one or more complements may each be independently substituted with a halogen means that the complements are each independently -F, -Cl, -Br, or -1, and when two or more complements are each independently substituted with a halogen, the complements are each independently -F, -Cl, -Br, or -1, and the two or more halogens may be the same or different from each other.

[0093] OO

[0094]

[0095] In the present invention, C II can be represented as CO, C=0, or C(=0), etc., and s II 0 Cheon' Lee Woo

[0096] It can be expressed as SO, S=0, or S(=0), etc., and is S02, S=02, S(=0)2 o II

[0097] It can be indicated as S(=02), etc., and

[0098]

[0099] P may be represented as P=o or P(=0), etc. In addition, terms and abbreviations used in this specification have their original meanings unless otherwise defined.

[0100] In one embodiment of the present invention, the compound of formula I may exclude the compound of the following formula.

[0101]

[0102] In the embodiments of the present invention, Ai in Formula I is

[0103]

[0104] The complements of Ai may not be substituted, or one or more complements may each be independently substituted with -Ofe, -F, or -C1.

[0105]

[0106] In addition, the complements of Ai may not be substituted, or one or more complements may each be independently substituted with -CH3, -F, or -C1.

[0107] 5 In embodiments of the present invention, Ri in Formula I is -S(=0hNH2, -NO2, -OCH3, -S(=0)2CF3, -CF 3 I -S(=0)2NHCH3, -S(=0)2NHCH2CH3, - S(=0)2- N(CH3)2, -S(=O)2- NHCH2C(CH3)20H, -C(=O)-NH2, -C(=O)-NHCH3, -C(=O)-NHNH2, -C(=O)OH, -C(=O), -NH2,

[0108]

[0109] It may not be substituted or one or more be independently substituted with a straight-chain or branched-chain -Cl-C6 alkyl, a straight-chain or branched-chain -Cl-C6 alkoxy, -OH, or a halogen (-F, -Cl, -Br, or -1).

[0110] Specifically, in the above chemical formula I, Ri is - S(=0)HNH2 , - NO2 , - S(=0)2CF3, - 5 S(=0)2NHCH3, - S(=0)2NHCH2CH3, - S(=0)2-F , - S(=0)2-NHCH2C(CH3)20H , - C(=0)-NH2 , > C(=o)-NHCH3, - C(=O)-NHNH2,

[0111]

[0112] One or more bees may each be independently substituted with a straight-chain or branched-chain -Cl-C6 alkyl, a straight-chain or branched-chain -Cl-C6 alkoxy, -0H, or a halogen (-F, -Cl, -Br, or -1).

[0113] In embodiments of the present invention, Li in the formula I may be a single molecule, -CH2-, -(CH2)2-, -(CH2)4-, or -CH2CHOH-, and when L1 is -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, or -CH2CH0H-, the parts of L1 may not be substituted, or one or more parts may each be independently substituted with a straight-chain or branched-chain -Cl- C6 alkyl, halogen (-F, -Cl, -Br, or -I), or -0H. Specifically, in the above formula I, Li may be a single bond, -CH2-, -(CH2)2-, -(CH2)3-, or -(CH2)4-, and when L1 is -CH2-, -(CH2)2-, -(CH2)3-, or -(CH2)4-, the bosons of L1 may not be substituted, or one or more bosons may each independently be substituted with straight-chain or branched-chain -Cl-C6 alkyl, halogen (-F, -Cl, -Br, or -I), or -0H.

[0114] In the embodiments of the present invention, in Formula I

[0115] R2 is - H, - CH3, -CH2CH3 , - (CH2)2CE(3, - (CH2)3CE(3, - CH(CE(3)2, - CH2C(CEb)3, - C(CH3)20H, -CH2C(CH3)20H, -(CH2)2C(CH3)2OH, -CHF2, - CF3, -CH2CHF2, -CN, - 0CH2C(=0)NH2, -CH2CF3, -(CH2)2CF3, -(CH2)3CF3, -(CH2)4CH3, -(CH2)5CH3, -0CH(CH3)2,CH2CH2P(=0) (0CH20C(=0)C(CH3)3)2,

[0116]

[0117] Used ; and R3 can be - H, - CH3, - CH2CH3, - (CH2)2CH3, - (CH2)3CH3, - F, - CF3, - CH2CHF2, - (CH2)3CF3, or - CH(CH3)2, and ,

[0118] Here, the complements of R2 and R3 may not be substituted, or one or more complements may each be independently substituted with a straight-chain or branched-chain Cl-C6 alkyl or a halogen (-F, -Cl, -Br, or -1).

[0119] Specifically, in the above chemical formula I

[0120] R2 is - H, - CH3, - CH2CH3, - (CH2)2CH3, - (CH2)3CH3, - CH(CH3)2, - CH2C(CH3)3, - C(CH3)20H, -CH2C(CH3)20H, -(CH2)2C(CH3)20H, -CHF2, -CF3, -CH2CHF2 , -CN , -0CH2C(=0)NH2, -CH2CF3, -(CH2)2CF3, -(CH2)3CF3, -0CH(CH3)2, -S(=0)2CH3, -OCH2CH2CH3,

[0121]

[0122] R3 can be -H, -CH3, or -F, and

[0123] Here, the complements of R2 and Rs may not be substituted, or one or more complements may each be independently substituted with a straight-chain or branched-chain Cl-C6 alkyl or halogen (-F, -Cl, -Br, or -1).

[0124] In the embodiments of the present invention, R2 and R3 may not be simultaneously.

[0125] In embodiments of the present invention, A2 is also

[0126]

[0127] It may be. In embodiments of the present invention, in the above formula I

[0128] Ai is

[0129]

[0130] and, the inner part of A1 may not be substituted or each independently one or more inner parts may be substituted with -CH3, -F, or -C1; and

[0131] Ri is -S(=0)2NH2 , -S(=O)2NHCH3, -NO2,

[0132]

[0133] The celestial bodies may not be substituted, or one or more celestial bodies may each be independently substituted with a straight-chain or branched-chain -Cl-C6 alkyl, a straight-chain or branched-chain -Cl-C6 alkoxy, -OH, or a halogen (-F, -Cl, -Br, or -1).

[0134] In the embodiments of the present invention, in the above formula I,

[0135] L1 is a unitary combination, -CH2-, -(CH2)2-, -(CH2)3- or -(CH2)4-;

[0136] R2 and R3 are each independently -H, -CH3, -CD3, -CH2CH3, -C(CH3)20H, CH2C(CH3)20H, -(CH2)2C(CH3)2OH, -CF 3 I -CH2CF3, - (CH2KF3, - (CH2KF3, -CH2CHF2, -

[0137] CH(CH3)2, -OCH2CH2CH3, -CN,

[0138]

[0139] 匕2 is a single bond, -CH2-, -CH2CH2-, -C(=O)NH-, -NCH3- or -C(=o)-;

[0140] R4 is -C(CH3)20H, -CF 3 I -CH2CF3, -(CH2)2CF3, -(CH2)3CF3, -CH2CN,

[0141] - CH(CH3)2 or -OH; wherein R2 and R3 may not be -H simultaneously. In the embodiments of the present invention, in the above formula I

[0142] Ri is -S(=0)2NH2, -S(=O)2NHCH3,

[0143]

[0144] L1 is a single bond, -CH2 -, - (CH2)2-, - (CH2)3 - or - (CH2)4 -;

[0145] R2 and R3 are each independently -H, -CH3, -CD3, -CH2CH3, -C(CH3)20H, - CH2C(CH3)20H, -(CH2)2C(CH3)2OH, -CF 3 I-CH2CF3, -(CH2)2CF3, -(CH2)3CF3, -CH2CHF2, -L2 is a single bond, -Ofc-, -CH2CH2-, -C(=O)NH-, -NCH3- or -C(=0)-; R4 is -C(CH3)20H, -CF 3 I -CH2CF3, -(CH2)2CF3, -(CH2)3CF3

[0146] - CH(CH3)2 or -OH; and in the embodiments of the present invention, in the above Formula I

[0147]

[0148] each independently may be substituted with one or more of -CH3, -F, or -C1; and Ri is -S(=0)2W -S(=0)2NH(CH2C(CH3)20H), -S(=0)2NH(CH2CH3),

[0149] In the embodiments of the present invention, in the above Formula I, Li is a single bond; R2 and R3 are each independently -H, -CH3, -CD3, -CH2CH3, -CH(CH3)2, -CH2CF3 or -CH2CHF2;

[0150]

[0151] 1 is a single bond, -C(=0)-, -C(=O)NH-, -C(=0)N(CH3)-, -NHC(=O)-, -N(CH3)C(=0)-, -CH2, -CH2CH2-, -NH-, or -N(CH3)-; R4 is -CH3, -C(CH3)20H, -CH2C(CH3)20H, -CH2CF3, -CH2CH3, -CH(CH3)2, -CH2CN,

[0152]

[0153] -CH2OH, - (CH2)20H, -(CH2)2CF3, -CH2NH2, -N(CH3)2, -N(CH2C(CH3)20H)2, - NH2, - S(=0)2CH3 or -OH and ;

[0154] In the above, R2 and R3 may not be - H simultaneously.

[0155] In the embodiments of the present invention, in the formula I

[0156] Whoo

[0157]

[0158] O "neu / +- or nyas, and the -H of Ai may not be substituted or may each independently be substituted with one or more -CH3, -F, or -C1;

[0159] Ri is -S(=0)2NH2, -S(=0)2NH(CH2C(CH3)20H), -S(=0)2NH(CH2CH3), _

[0160] S(=0)2NH(CH3), -S(=O)2F -C(=O)NH2,

[0161]

[0162] Li is a unitary compound; R2 and R3 are each independently -H, -CH3, -CDS, -CH2CH3, -CH(CH3)2, -CH2CF3, or -CH2CHF2;

[0163]

[0164] L2 is a single bond, -C(=0)-, -C(=O)NH-, -C(=0)N(CH3)-, -NHC(=O)-, -N(CH3)C(=0)-, -CH2, -CH2CH2-, -NH-, or -N(CH3)- and ;

[0165] R4 is -CH3, -C(CH3)20H, -CH2C(CH3)20H, -CH2CF3, -CH2CH3, -CH(CH3)2, -CH2CN,

[0166]

[0167] -CH2OH ,(CH2)20H , -(CH2)2CF3, -CH2NH2 , -N(CH3)2 , -N(CH2C(CH3)20H)2 , -NH2 , -S(=0)2CH3 or -OH and ; and

[0168] R5 can be -H or -CH3, and

[0169] In the above, R2 and R3 may not be simultaneously I.

[0170] In the embodiments of the present invention, the substituents represented in the following chemical formulas 1-1 to 1-8 as identical to those in chemical formula I are substantially identical to those defined in chemical formula I unless otherwise defined, so a redundant description thereof is omitted. In the embodiments of the present invention, L2 in chemical formula I is a single bond and can be represented by the following chemical formula 1-1.

[0171] [Chemical Formula 1-1]

[0172] R4 is -H, — CH2CF3, -(CH2)2CF3, — CH3, CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, — (CH2)2CH(CH3)2, - N(CH=CH2)2, -(CH2)2S(=0)2CH3, -CH2CH2OH, - CH2CH2NH2, -C(CH3)2OH,

[0173] -

[0174]

[0175] CH2C(CH3)20H, -(CH2)2C(CH3)2OH, -CH2CF3, -NH2, -CH2NH2, -OH, CH2OH, -CH2NHCH3, -CH2N(CH3)2, - (CH2)NHC(=0)0H, _(CH2)2NHC(=0)0H ,(CH2)NHC(=0)C(CH3)3, -(CH2)N(CH2C(CH3)20H)2, -NHCH2C(CH3)20H, -NHCH2CH2C(CH3)20H, -N(CH2CH20H)2, -NHCH2CH2NH2 or -(CH2)2NHC(=0)C(CH3)3;

[0176] R5 can be -H or -CH3.

[0177] Specifically, in the above chemical formula 1-1,

[0178]

[0179] R4 is -H, -CH2CF3, -(CH2)2CF3, -N(CH=CH2)2, -(CH2)2S(=0)2CH3, -CH2CH2OH, -CH2CH2NH2, -C(CH3)20H, -CH2C(CH3)20H, -(CH2)2C(CH3)2OH, -CH2NH2, -CH2OH, -CH2NHCH3, -CH2N(CH3)2 or -(CH2)N(CH2C(CH3)20H)2;

[0180] R5 can be -H or -CH3.

[0181] In embodiments of the present invention, L2 in Formula I is a C1-C3 alkylene and can be represented by the following Formula 1-2.

[0182] [Chemical Formula 1-2]

[0183]

[0184] ni is 1, 2, or 3, and ;

[0185] R4 is - CH2CF3, - CH3, - CH2CH3, -C(CH3)20H, - (CH2)NHC(=0)0H, - (CH2)NHC(=0)C(CH3)3, - (CH2)2NHC(=0)0H, -OH, -CH2OH, -CH2CH2OH, -(CH2)CH(CH3)2 ,-(CH2)C(CH3)20H , -CF 3 I -S(=0)2CH3, -CH2S(=0)2CH3, -CH2NH2, -CH2CH2NH2, -NHCH2CF3,

[0186] -NHCH3 , -N(CH3)2 , -N(CH2C(CH3)20H)2 , o - It can be NH2.

[0187] Specifically, in the above chemical formula 1-2, ni is 1, 2, or 3; and R4 is -CF3, -CH2CF3, -OH, -CH2OH, -C(CH3)20H, -(CH2)C(CH3)2OH, -S(=O)2CH3, -CH2S(=0)2CH3, -CH2NH2, -NH2, -N(CH3)2, -N(CH2C(CH3)20H)2,

[0188] It can be o or o. In the above chemical formula I, L2 can be represented as -C(=o)- and can be expressed by the following chemical formula 1-3.

[0189] [Chemical Formula 1-3]

[0190]

[0191] In the above chemical formula 1-3,

[0192]

[0193] 5 - OWH, - (CH2)2CH3, - (CH2KF3, -CH2CH(CH3)2, or - CH2C(CH3)20H.

[0194] Specifically, in the above chemical formula 1-3,

[0195]

[0196] It may be -CH2NH2, -CH2OH, or -(CH2)2CF3. In embodiments of the present invention, L2 in Formula I may be represented as -C(=o)-NRai-, and [7] Formula 1-4.

[0197] [Chemical Formula 1-4]

[0198] Rai is -H, -CH3, -CH2CH3 or -CH2CH2CH3; R4 is -H, -OH, -Ofe, -CH2CH3, -CH2CH2OH, -CH(CH3)2, -CH2C(=0)NH2,

[0199]

[0200] CH2C(=0)NHCH3, _(CH2)2C(=0)NH2, _(CH2)2C(=0)0CH3, >-CH2CF3, -(CH2)2CH3, -CH2CF3, -(CH2)2CF3, -C(CH3)2CH2CH3, -C(CH3)2CH20H,

[0201] , - (CH2)3CH3 , - (CH2)4NH2 or - CH2CH2S(=0)2CH3.

[0202] Specifically, in the above chemical formula 1-4,

[0203]

[0204] Yu2 is and Rai is -H or -CH3 and ;

[0205] R4 is -H, -0H, -CH3, -CH2CH2OH, -CH(CH3)2, -CH2C(=0)NH2, -CH2C(=0)NHCH3,_(CH2)2C(=0)NH2, _(CH2)2C(=0)0CH3, _(CH2)2C(=0)0H, >

[0206] NH

[0207] , -CH2CH2NH2 , -CH2CF3 , -(CH2)2CF3 , -

[0208] -(CH2)4NH2 or -CH2CH2S(=0)2CH3. In embodiments of the present invention, L2 in Chemical Formula I can be represented as -C(=o)-NRa5-(CH2)- and can be expressed by the following Chemical Formula 1-5.

[0209] [Chemical Formula 1-5]

[0210] In the above chemical formula 1-5,

[0211]

[0212] Yu2 is and, Ra5 is -H or -CH3; R4 is or

[0213] It may be. Specifically, in the above chemical formula 1-5,

[0214] NH

[0215]

[0216] It could be.

[0217] In the embodiments of the present invention, L2 in the above formula I can be represented as - NRa3C(=0)- and can be expressed by the following formula 1-6.

[0218] [Chemical Formula 1-6]

[0219]

[0220] A2 is and R4 can be -H, -CH3, or -CH2CH3. In embodiments of the present invention, L2 in Chemical Formula I can be represented as -NRa3C(=0)- and can be expressed as Chemical Formula 1-7.

[0221] [Chemical Formula 1-7]

[0222] Ra3 is -H or -CH3; R4 is _ H , -CHs ,

[0223]

[0224] (CH2)C(=0)NH2, -C(CH3)3,- (CH2)NHC(=0)0H, - (CH2)NHC(=0)0C(CH3)3, -CH2NH2, -NHCH2CF3,

[0225]

[0226] Ra3 is - H or - CH3 and ;R4 is _ H, -CF3, -CH2CF3, - (CH2KF3, -CH2CN, CH2OH, -CH2NH2, -NHCH2CF3, -CH2C(CH3)20H or may be.

[0227] In embodiments of the present invention, L2 in the above chemical formula I can be represented as -NRa4- and by the following chemical formula I-8.

[0228] [Chemical Formula 1-8]

[0229] Ra4 is -H or -CH3; R4 is -H, -CEb, -CF3, -CH2CH3, -CH2CF3, -(CH2)2CEb, -(CH2)2CF3, -

[0230]

[0231] (CH2)C(=0)NH2, -C(CH3)3, -C(CH3)2Br, - CH2CN, - CH2OH, HO - CH2OCH3, -CH2CH(CH3)2, -CH2C(CH3)20H,

[0232] — It can be. Specifically, in the above chemical formula 1-8,

[0233]

[0234] R4 may be -H, -CH2CF3, -(CH2)2CF3, -(CH2)C(=0)NH2, or -CH2C(CH3)20H. In embodiments of the present invention, Ai, Li, Qi, Q2, Ri, R2, and 3 in the above formulas 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, and 1-8 may each independently be identical to the above formula I. Specifically, Ai, Li, Qi, Q2, Ri, R2, and R3 in the above formulas 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, and 1-8 may each independently be as follows:

[0235] or

[0236] And, the complements of Ai are not substituted, or one or more complements may each be independently substituted with -CH3, -F, or -C1;

[0237] Ri is -S(=0hNH2, -NO2, -OCH3, -S(=O)2CF3, -CF3, -S(=O)2NHCH3, -

[0238]

[0239]

[0240] or, and the mitral group of Ri is not substituted or, or one or more mitral groups may each be independently substituted with a straight-chain or branched-chain -Cl-C6 alkyl, a straight-chain or branched-chain -Cl-C6 alkoxy, -0H, or a halogen (-F, -Cl, -Br, or -1);

[0241] L1 is a single ion, — CH2 — , — (CH2)2 — , — (CH2)3 — , — (CH2)4 — or — CH2CHOH —, and the ions in L1 are unsubstituted or one or more ions can each be independently substituted with straight-chain or branched-chain - Cl- C6 alkyl, halogen (- F, - Cl, - Br, or - I ), or - OH;

[0242] R2 is - H, - CH3, - CH2CH3, - (CH2)2CH3, - (CH2)3CH3, - CH(CH3)2, - CH2C(CH3)3, - C(CH3)20H, -CH2C(CH3)20H, -(CH2)2C(CH3)20H, -CHF2, -CF3, -CH2CHF2 , -CN , -0CH2C(=0)NH2, -CH2CF3, -(CH2)2CF3, -(CH2)3CF3, -(CH2)4CH3, -(CH2)5CH3, -0CH(CH3)2,

[0243] CH2CH2P(=0) (0CH20C(=0)C(CH3)3)2,

[0244]

[0245]

[0246] R3 is _ H, - CH3, -CH2CH3 , - (CH2)2CH3, - (CH2)3CH3, “F, - CF3, - CH2CHF2, - (CH2KF3, or - CH(CH3)2 and ;

[0247] Here, R2 and R3 may each independently not have any complement substituted, or one or more complements may each independently be substituted with a straight-chain or branched-chain Cl-C6 alkyl or a halogen (-F, -C1, -Br or -1), and R2 and R3 may not simultaneously be I.

[0248] In embodiments of the present invention, in Formula I, L2 is -NRa2C(=0)0-; Ra2 is -H or -CH3;

[0249] A2 is 乂 冬 ▼시 or 丄 사 砂^; R4 is -H, -CH3, -CF3, -CH2CH3, -CH2CF3, - (CH2)2(〕H3, - (CH2)2CF3, - *° 〕 스! (CH2)C(=0)NH2, -C(CH3)3, -C(CH3)2Br, -CH2CN, 네, 4이사, -OfeOH,

[0250] 느〜 』, - (CH2)NHC(=0)0H, - (CH2)NHC(=0)0C(CH3)3, -CH2NH2, -NHCH2CF3,

[0251]

[0252] -CH2OCH3, -CH2CH(CH3)2, -CH2C(CH3)20H,

[0253]

[0254] and may be.

[0255] In embodiments of the present invention, when L2 is -NRa2C(=0)0-, Al, L1, Q1, Q2, Ri, R2 and Cheng may each independently be the same as in Formula I above. Specifically, when L2 is -NRa2C(=0)0-, Ai, Li, Qi, Q2, Ri, R2 and R3 may each independently be as follows:

[0256]

[0257]

[0258] and the ring of Al is unsubstituted or one or more rings may each independently be substituted with -CH3, -F, or -C1;

[0259] Ri is - S(=0hNH2, -NO2, -OCH3, -S(=O)2CF3, -CF3, -S(=O)2NHCH3, -S(=0)2NHCH2CH3, -S(=0)2-N(CH3)2, -S(=0)2-NHCH2C(CH3)20H, -C(=O)-NH2, -C(=0)-

[0260] X TL

[0261]

[0262] N % y HX a t or N > and the syl is not substituted or one or more syl can each be independently substituted with a straight-chain or branched-chain -Cl-C6 alkyl, a straight-chain or branched-chain -Cl-C6 alkoxy, -0H, or a halogen (-F, -Cl, -Br, or -1);

[0263] Qi and Q2 are each independently N or N-Li-R2, wherein one of Qi and Q2 is N and the other is N-Li-R2;

[0264] L1 is a single ion, -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, or -OfeCHOH-, and Li is unsubstituted or one or more ions can each be independently substituted with a straight-chain or branched-chain -Cl- C6 alkyl, halogen (-F, -Cl, -Br, or -I), or -OH;

[0265] R2 is - H, - CH3, -CH2CH3, - (CH2)2CEb, - (CH2)3CEb, - CH(CEb)2, - CH2C(CEb)3, - C(CH3)20H, -CH2C(CH3)20H, -(CH2)2C(CH3)20H, -CHF2, - CF3, -CH2CHF2, -CN, - 0CH2C(=0)NH2, -CH2CF3, -(CH2)2CF3, -(CH2)3CF3, -(CH2)4CH3, -(CH2)5CH3, -0CH(CH3)2,CH2CH2P(=0)(0CH20C(=0)C(CH3)3)2,

[0266]

[0267] It is used;

[0268] R3 is -H, -CH3, -CH2CH3, - (CH2)2CH3, - (CH2)3CH3, _ F , -CF3, -CH2CHF2, -(CH2)3CF3, or -CH(CH3)2 and ;

[0269] Here, R2 and R3 may each independently have no complement substituted, or one or more complements may each independently be substituted with a straight-chain or branched Cl-C6 alkyl or a halogen (-F, -C1, -Br, or -1), and R2 and R3 may not simultaneously be I;

[0270] R5 is - H or - CH3.

[0271] The present invention provides a compound represented by Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof:

[0272] <Chemical Formula 1> In the above Chemical Formula I, ,

[0273]

[0274] Ai is and ;

[0275] Ri is -S(=0)2NH2, -NO2, or _C(=0)_NHCH3 and ;

[0276] Qi is N-L]-R2, and Q2 is Ni;

[0277] L1 is a single bond, -CH2-, -(CH2)2-, -(CH2)3- or -(CH2)4-;

[0278] R2 is -H, -CH3, -C(CH3)2OH, -CH2C(CH3)2OH, -(CH2)2C(CH3)2OH, -CF 3 I -CH2CF3, -(CH2)2CF3;

[0279]

[0280] Or L2 is a single bond, C1-C3 alkylene, -C(=O)-, -C(=O)-NRai-, -C(=O)-NRa5-(CH2)- or -NRa3C(=O)-;

[0281] Rai, Ra3 and Ra5 are each independently -H or -Ofe;

[0282] R

[0283]

[0284] 4 is —CH2NH2, -(CH2)2NH2, —(CH2)4NH2, —NH2, -CH2OH, or

[0285]

[0286] R5 is 41.

[0287] The present invention provides a compound represented by formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates.

[0288]

[0289] The inside of Ai may be unsubstituted or each independently may be substituted with one or more -bos by -CH3, -F, or -C1;

[0290] Ri is -S(=O)2NH2, -S(=O)2NHCH3 or

[0291]

[0292] and the phenyl of Ri is unsubstituted or each of one or more phenyls may be independently substituted with straight-chain or branched-chain -Cl-C6 alkyl, straight-chain or branched-chain -Cl-C6 alkoxy, -OH or halogen (-F, -Cl, -Br, or -I);

[0293] Qi is N-L]-R2, and Q2 is thiophene;

[0294] L1 is single bond, -CH2-, - (CH2)2-, - (CH2)3- or - (CH2)4-;

[0295] R2 and R3 are each independently -H, -CH3, -CD3, -CH2CH3, -C(CH3)2OH, -5 CH2C(CH3)2OH, -(CH2)2C(CH3)2OH, -CF 3 I -CH2CF3, - (CH2)2CF3, - (CH2)3CF3, -CH2CHF2, -

[0296] CH(CH3)2, -OCH2CH2CH3, <000188​​​​​​​​​​​​​​​​​​​​R2 and R3 are not both me at the same time.

[0304] The present invention provides a compound described in Table 1 below, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates.

[0305] [Table 1] Implementation molecule

[0306] Structure name NMR

[0307] Example amount

[0308] N—[2—(3-hydroxy—3—1H NMR (DMSO-d6): 1.12 methylbutyl)—6—[4—(2—(s, 6H), 1.99 (t, 2H), hydroxyacetyl) piperazin 2.87 (m, 4H), 3.51 (m, 0 - 1-yl]-2H-indazol-5 - 2H), 3.66 (m, 2H), 4.11 HO 」N now yl]-3-(s, 2H), 4.43 (t, 2H),

[0309] 544.

[0310] 1 sulfamoyl benz amide 4.48 (s, 1H), 4.58 (m, H2N / 써 、人 7 where OH 63 1H), 7.38 (s, 1H), 7.45

[0311] N-[2-(3-hydroxy-3-methyl [[ID=3B]]

[0312] 으 0 (s, 2H), 7.76 (t, 1H), butyl)-6-[4-(2-hydroxy

[0313] 8.01 (d, 1H), 8.15 (d, acetyl) piperazin -1-yl]-1H), 8.31 (s, 1H), 8.38 2H-indazol-5 -yl]-3 ―sulf

[0314] Moyl benzamide (s, 1H), 8.41 (s, 1H),

[0315] 9.89 (s, 1H)

[0316] N-{6 - [4-(2-aminoacetyl)piperazin- 1H NMR (DMSO-d6): 1.12

[0317] (s, 6H), 1.98 (t, 2H), 1-yl]- 2-(3-hydroxy- 3 -

[0318] methylbutyl)- 2H- 2.90 (m, 4H), 3.55 (m, O indazol-5-yl}~3~ 2H), 3.71 (m, 2H), 3.89

[0319] (q, 2H), 4.42 (t, 3H), HC1 〔 J 스 XT 5 su 1 f amoy 1 benz am i de

[0320] D셰 — / 80.

[0321] 2 h 7.37 (s, 1H), 7.49 (s,

[0322] 1 ydrochlor ide

[0323] H W d〜Q H 스V A / ^ OH 2H), 7.76 (t, 1H), 8.01

[0324] N— {6 — [4— (2—o}리노아세

[0325] (d, 1H), 8.07 (s, 3H), 틸)피페라진 -1-일]- 2-(3 - 8.16 (d, 1H), 8.33 (s, 히드 록시- 3 -메틸부틸)- 1H), 8.39 (s, 2H), 9.89 2H-인다졸- 5 -일}- 3 —술파

[0326] (s, 1H)Moyl benzamide hydrochloride

[0327] It should be noted that there are some unclear or potentially incorrect notations in the original text (such as "D셰", "히드 록시", etc.), which may affect the accuracy of the translation. It is recommended to double-check and correct the original text for a more precise translation.

[0328] N-{6-[4-(2-aminoacetyl)piperazin—

[0329] 1-yl]-2-(3-hydroxy-3—

[0330] O

[0331] H2N』methylbutyl)-2H-g indazol-5-yl}~3~

[0332] 543.su1famoy l benz am i de

[0333] H—於9 H

[0334] 0 人心』가 OH 64

[0335] 0 N—{6—[4—(2—o}리노아세

[0336] 틸)피페라진 -1-일]-2-(3 - 히드 록시- 3 -메틸부틸)-2H-인다졸- 5 -일}-4 —술파

[0337] 모일 벤 즈아 미드

[0338] N—[2—(3-hydr oxy—3 —

[0339] methylbutyl)-6-[4- 1H NMR (DMSO-d6): 1.12 (4, 4,4-(s, 6H), 1.99 (t, 2H), tr i f luorobutanoyl)piper

[0340] 2.50 (in, 2H), 2.63 (in, az i n-l-y 1 ] — 2H— i ndaz o 1 —

[0341] 으스 2H), 2.87 (d, 4H), 3.64 Ap 5-yl]-3-(s, 4H), 4.42 (t, 2H), F 으 Yy— / 610. su 1 f amoy 1 benz am i de

[0342] 4.47 (s, 1H), 7.38 (s, H2N、 S P 으 OH 65

[0343] N-[2-(3-hydroxy-3-methyl-1H)-butyl]-6-[4-(4,4,4-trifluorobutyl)-piperazin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide

[0344]

[0345] N-{6-[4-(2-aminoacetyl)piperazin-

[0346] 1H NMR (DMSO-d6): 2.10 (m, 2H), 2.24 (m, 2H),

[0347] 2.90 (s, 4H), 3.54 (s, indazol-5-yl}-3-

[0348] 0

[0349] HCl H2N、JL N 2H), 3.69 (s, 2H), 3.88 sulfamoyl benzamide

[0350] (s, 2H), 4.43 (m, 2H), 604. hydrochloride

[0351] 7.39 (s, 1H), 7.48 (s, 05

[0352] N-{6-[4-(2-aminoacetyl)piperazin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide hydrochloride: 1H NMR (DMSO-d6): 1.12 (s, 6H), 1.99 (m, 2H), 7.75 (t, 1H), 8.01 (s, 1H), 8.07 (s, 2H), 8.17 (d, 1H), 8.33 (s, 1H), 8.38 (s, 2H), 9.89 (s, 1H)

[0353] Hydrochloride

[0354] N-{6-[4-(2 - aminoacetyl)piperazin—

[0355] 1-yl]-2-(4, 4,4-trifluorobutyl)—2H—

[0356] indazol-5-yl}—3—

[0357] 567. sulfamoyl benzamide

[0358] H2N,\(^,\)—'\(F\) 59

[0359] N-{6-[4-(2 - aminoacetyl

[0360] 6 (4, 4, 4-trifluorobutyl)piperazin -1-yl]-2-(4, 4, 4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[0361] N-{6-[4-(2 - aminoethyl)piperazin -1-yl]-2-(3 - hydroxy - 3 - methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[0362] N-{6-[4-(2 - aminoethyl)piperazin -1-yl]-2-(3 - hydroxy - 3 - methylbutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide. 1H NMR (DMSO-d6): 1.12 (s, 6H), 1.99 (m, 2H), 3.27 (s, 6H), 3.60 (s, H2N,\( / ,\) NX, _ indazol-5-yl}~3~ 4H), 3.77 (s, 2H), 4.44 su 1 f amoy 1 benz am i de (m, 3H), 7.37 (s, 1H), 602.

[0363] o HN』V~ 즈- (0H dihydrochloride 7.53 (s, 2H), 7.75 (t,

[0364] 58

[0365] H 7^ o 孝 厂 1H), 8.01 (d, 1H), 8.15

[0366] N-{6 - [4-(2 -aminoethyl)

[0367] 피페라진 -1-일]- 2- (3 -히 (d, 1H), 8.26 (s, 2H),

[0368] 8.34 (s, 1H), 8.35 (s, 드 록시- 3 -메틸부틸)- 2H- 1H), 8.39 (s, 1H), 9.78 인 다졸- 5 -일}- 3-술파모일

[0369] 벤 즈아 미드 2 염산염 (s, 1H), 11.18 (s, 1H)

[0370]

[0371] N-{6 - [4-(2- aminoethyl )piperazin— 1—

[0372] yl ]— 2— (3— hydroxy— 3 —

[0373] methylbutyl )- 2H- H2N、 / 、 N / 斗 indazol-5-yl}~3~

[0374] 으 Yr— / 530. su 1 f amoy 1 benz am i de

[0375] H2N、〈9 빼 丄』 、 수 OH 64 <00,02042>

[0376] — 스 N-{6 - [4-(2 -aminoethyl)

[0377] piperazin-1-yl]-2-(3-hydroxy-

[0378] 3-methylbutyl)-2H-indazol-5-yl}-4-sulfamoyl

[0379] benzamide

[0380] N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(3-hydroxy-3-(s, 6H), 2.00 (t, 2H), methylbutyl)-2H-3.23 (m, 11H), 3.70 (m, indazol-5-yl}-3-2H), 4.44 (t, 2H), 7.36 nitrobenzamide (s, 1H), 7.85 (s, 1H), 으 YxX / 568.

[0381] O HN人은*— 义 ‘OH dihydrochloride 7.85 (t, 1H), 8.21 (s, O AQA O 50

[0382] HC1 2H), 8.29 (s, 1H), 8.35

[0383] N-{6-[4-(2-aminoethyl)(s, 1H), 8.37 (d, 1H), piperazin-1-yl]-2-(3-hydroxy-3-8.45 (d, 1H), 8.71 (s, methylbutyl)-2H-1H), 9.87 (s, 1H), 11.09 indazol-5-yl}-3-nitrobenz

[0384] amide (s, 1H)

[0385] 2 hydrochloride

[0386] N-{6-[4-(2-aminoethyl)piperazin-1-

[0387] yl]-2-(3-hydroxy-3-

[0388] (methylbutyl)-2H-indazol-5-yl}~3~

[0389] 495. nitrobenzamide

[0390] 0 HN人 5 』* 누수 / OH 58

[0391] °"外 3 人 0 N-{6-[4-(2-aminoethyl)

[0392] piperazin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-4-nitrobenz

[0393] zamide

[0394] 즈아 미드

[0395]

[0396] N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[0397] yl]-2-(4,4,4- 1H NMR (DMSO-d6): 2.12 tri fluorobutyl)-2H-(m, 2H), 2.24 (m, 2H), indazol-5-yl}-3- 3.27 (m, 8H), 3.70 (m, 4H), 4.45 (m, 2H), 7.40

[0398] 626. dihydrochloride (s, 1H), 7.52 (s, 2H), H =S' 9

[0399] 6' Y 妙서 스 그 F 52 7.75 (t, 1H), 8.02 (d, ’Y N-{6-[4-(2-aminoethyl)

[0400] l놋 0 H H C C 1 1F F 1H), 8.17 (s, 1H), 8.26 Piperazin-1-yl]-2-(m, 3H), 8.37 (s, 2H), (4, 4, 4-trifluorobut

[0401] 9.78 (s, 1H), 11.16 (s, tyl)-2H-indazol-5-yl}-3-1H)

[0402] Sulfamoyl benzenesulfonamide 2 salt

[0403] Hydrochloride

[0404] N-{6-[4-(2-aminoethyl)piperazin-1—

[0405] yl]-2-(4,4,4-trifluorobutyl)-2H—

[0406] indazol-5-yl}-3—

[0407] 553. Sulfamoyl benzamide

[0408] „ N 0 HN'人』

[0409] 매 57 6

[0410] d에' 、』우 y丁下 1

[0411] F F N-{6-[4-(2-aminoethyl)

[0412] Piperazin-1-yl]-2-(4,4,4-trifluorobut

[0413] tyl)-2H-indazol-5-yl}-3-sulfamoyl benzenesulfonamide

[0414] N—[2—(3-hydroxy—3 —

[0415] methylbutyl )-6 - [4- 1H NMR (DMSO- d6) : 1.12 (2, 2, 2- (s , 6H) , 1.99 (t , 2H) , tr if luoroethyl )piperaz i 2.50 (m, 2H) , 2.82 (s , n— 1— yl ]— 2H— indazol— 5 — 4H) , 2.90 (s , 4H) , 4.40 ☆on yl ]-3- (t , 2H) , 4.47 (s , 1H) , f “rr— / 568.

[0416] … person 7 Ga OH su 1 f amoy 1 benz am i de 7.43 (s , 1H) , 7.48 (s ,

[0417] 62

[0418] / J o 2H) , 7.77 (t , 1H) , 8.02

[0419] N-[2-(3-hydroxy-3-methyl

[0420] (d, 1H) , 8.14 (d, 1H) , butyl )— 6 - [4- (2, 2, 2 -tri

[0421] 8.30 (s , 1H) , 8.39 (s , fluoroethyl )piperazine- 1H) , 8.42 (s , 1H) , 9.87 1-yl ]- 2H-indazole- 5-yl ]- (s , 1H)

[0422] 3 - Sulpamoilben Zua Mid

[0423]

[0424] 3- sul famoyl- N-[ 2 - (4, 4,4-tr if luorobutyl )- 1H NMR (DMSO- d6) : 2.10 6 - [4-(2, 2, 2- (m, 2H) , 2.25 (m, 2H) , tr if luoroethyl ) piperaz i 2.82 (s, 4H) , 2.91 (s , n— 1— yl ]— 2H— indazol— 5 — 4H) , 3.30 (s , 2H) , 4.43 592. (d, 2H) , 7.46 (s , 1H) , yl ]benz amide

[0425] HNP Ppeonu 、 、 56 7.48 (s , 2H) , 7.76 (t , 2 d' Sx jQf^° FF F 3 —sulfamoyl- N- [2- (4, 4, 4 - 1H) , 8.02 (d, 1H) , 8.15 trifluorobutyl )- 6 - [4 - (d, 1H) , 8.32 (s , 1H) , (2, 2, 2 -trifluoroe

[0426] 8.39 (s, 1H), 8.43 (s, thyl)piperazine-1-yl]-2H-phosphorus-1H), 9.87 (s, 1H)dazole-5-yl]benzamide

[0427] 1H NMR (DMSO- d6): 1.06 N- {2 - [ (1,3-dioxo lan- 2 - (s, 6H), 1.33 (q, 1H), yl)methyl ]- 6 - [4- (2 - 1.45 (q, 2H), 1.80 (d, hydroxypropan— 2 —

[0428] 2H) , 2.64 (t , 2H) , 3.08 yl )piper idin— 1— yl ]— 2H—

[0429] (d, 2H) , 3.80 (t , 2H) , indazol-5-yl}~3~ H3.85 (t, 2H), 4.11 (s, 1H), 4.47 (s, 2H), 5.27

[0430] 1H), 4.47 (s, 2H), 5.27 64 H N ,0 으' )~O

[0431] N-{2-[(1,3-dioxolan-2-yl)methyl]-6-[4-(2-hydroxypropyl)-2-yl]piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[0432] 1H), 9.81 (s, 1H) 1H NMR (DMSO-d6): 1.06 N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-

[0433] 1.42 (m, 8H), 1.76 (m, 3H), 2.64 (t, 2H), 3.07

[0434] (m, 2H), 3.75 (m, 2H), [(oxan-2-yl)methyl]-2H-

[0435] (m, 2H), 3.75 (m, 2H), indazol-5-yl}-3-sulfamoylbenzamide

[0436] o Hf人: : >丄〜 / 즈— \ 69 2H), 7.36 (s, 1H), 7.46

[0437] N-{6-[4-(2-hydroxypropyl)piperidin-1-yl]-2-[(oxan-2-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[0438] (s, 1H), 8.43 (s, 1H), benzamide

[0439] 9.81 (s, 1H)

[0440]

[0441] 1H NMR (DMSO-d6): 1.05

[0442] N—{2—[2—(1,3—dioxan-2-yl)ethyl]-6-[4-(2-hydroxypropyl)piperidin-1-yl]-2H-indazol-5-yl}~3~sulfamoylbenzamide

[0443] 1H) , 8.43 (s , 1H) , 9.80 (s , 1H)

[0444] N-{2 -[2- 1H NMR (DMSO-d6): 1.07 (car bamoylmethoxy) ethyl

[0445] (s , 6H) , 1.43 (m, 3H) , ]-6 - [4-(2- 1.79 (m, 2H) , 2.63 (m, hydr oxypropan- 2- 2H) , 3.05 (m, 2H) , 3.76 yl )piper idin— 1— yl ]— 2H—

[0446] s (m, 2H) , 3.90 (m, 2H) , indazol-5-yl}~3~

[0447] 558. 4.12 (m, 1H) , 4.55 (m, su 1 f amoy 1 benz am i de

[0448] Te= 65 2H) , 7.19 (s , 2H) , 7.37 6 People 0 0 」 °M when° N- {2-[2-(carbamoylmethoxy(s, 1H) , 7.47 (m, 2H) , ci)ethyl]- 6-[4-(2-hydrox 7.76 (t, 1H) , 8.02 (d, cipropan-2-yl)piperidine-1H) , 8.12 (d, 1H) , 8.36 1-yl]- 2H-indazole-5-yl}-(s, 2H) , 8.46 (s, 1H) , 3-sulfamoylbenzamide 9.82 (s, 1H)

[0449]

[0450] N- {6 - [4- (2 - 1H NMR (DMSO- d6) : 0.99 hydroxypropan— 2 — (d , 6H) , 1.06 ( s , 6H) , yl )p iper idin— 1— yl ]— 2 — 1.34 (t , 1H) , 1.45 (q , [2— (propan—) 2 — 2H) , 1.80 (d, 2H) , 2.64 yloxy)ethyl ]- 2H- (t , 2H) , 3.08 (d , 2H) , indazo l-5-yl}— 3— 3.48 (m , 1H) , 3.81 (t , sul famoyl benz am i de 2H) , 4.11 ( s , 1H) , 4.46

[0451] (t , 2H) , 7.37 ( s , 1H) , N- {6 - [4- (2 -hydroxypro

[0452] 7.46 (s, 2H), 7.73 (t, pan-2-yl)piperidin-1-yl]-1H), 8.01 (d, 1H), 8.12 2-[2-(propan-2-yloxy) (d, 1H), 8.25 (s, 1H), ethyl]-2H-indazole-5-yl}- 8.36 (s, 1H), 8.44 (s, 3-sulfamoylbenzamide

[0453] 1H) , 9.81 (s , 1H) N- {6 - [4- (2 - 1H— NMR(DMSO— d6) : 1.03 hydroxypropan— 2 —

[0454] ( s , 6H) , 1.35 (m , 1H) , yl )p iper idin— 1— yl ]— 2 —

[0455] 1.44 (t, 2H), 1.77 (d, (2, 2, 2-tr if luoroethyl)- 2H), 2.62 (t, 2H), 3.11 2H— indazol — 5— yl}— 3—

[0456] (d, 2H), 4.11 (s, 1H), sul famoyl benz am i de

[0457] 5.39 (q , 2H) , 7.35 ( s , N- {6 - [4-(2-hydroxypro 1H) , 7.46 ( s , 2H) , 7.73 pan- 2-yl)piperidine- 1-yl]- (t , 1H) , 8.00 (d , 1H) , 2-(2 , 2 , 2-trifluoroe 8.11 (d , 1H) , 8.23 ​​( s , yl )- 2H-indazole- 5-yl}- 3 - 1H) , 8.35 ( s , 1H) , 8.44 sulfamoylbenzamide ( s , 1H) , 9.81 (s , 1H) N- [2-(2 , 2- 1H NMR (DMSO- d6) : 1.06 di f luoroethyl )-6 - [4- (2 - ( s , 6H) , 1.36 (m , 1H) , hydroxypropan- 2- 1.44 (m , 2H) , 1.79 (d , yl )p iper idin— 1— yl ]— 2H—

[0458] 2H) , 2.64 (t , 2H) , 3.08 indazo l-5-yl ]— 3—

[0459] (d, 2H), 4.13 (s, 1H), sul famoyl benz am i de

[0460] 4.87 (t, 2H), 6.45 (t, N-[2-(2, 2-difluoroe 1H) , 7.38 (s, 1H) , 7.46 yl )-6-[4-(2-hydroxyf(s, 2H) , 7.73 (t, 1H) , tropane-2-yl)piperidine-1- 8.02 (d, 1H) , 8.12 (d, yl]-2H-indazole-5-yl]-3-1H) , 8.34 (s, 2H) , 8.46 sulfamoylbenzamide(s, 1H) , 9.81 (s, 1H)

[0461]

[0462]

[0463] N-{6 - [4-(2- 1H NMR (DMSO-d6): 1.06 hydroxypropan-2-(s, 6H), 1.35 (m, 1H), yl)piperidin-1-yl] - 2 -

[0464] 1.46 (q, 2H), 1.79 (d, (2-HOJ 2H), 2.64 (t, 2H), 2.87 methanesulfonyl ethyl)-서 Y、] o (d, 3H), 3.08 (d, 2H),

[0465] 2H - indazol - 5 - yl}~3~

[0466] 0563. 3.80 (q, 2H), 4.11 (s, 旨 0!」sulfamoyl benz amide

[0467] 69 1H), 4.79 (q, 2H), 7.37 N - {6 - [4-(2 -히드록시프로 (s, 1H), 7.46 (s, 2H), 판-2 -일)피페리딘-1-일]- 7.73 (t, 1H), 8.01 (d, 2-(2 -메탄술포닐에틸)- 1H), 8.12 (d, 1H), 8.36 2H - 인다졸-5 -일}- 3 —술파 (s, 2H), 8.44 (s, 1H), 모일 벤즈아미드 9.80 (s, 1H)

[0468] 1H NMR (DMSO-d6): 0.75 N - {6 - [4-(2 - (t, 3H), 1.06 (s, 6H), hydroxypropan-2- 1.42 (m, 5H), 1.79 (d, yl)piperidin-1-yl] - 2 -

[0469] 2H), 2.64 (t, 2H), 3.07 (2 - propoxyethyl)- 2H—

[0470] H(d, 2H), 3.30 (m, 2H), and o indazol-5-yl}~3~

[0471] 乂』、즈、广 N. 3.81 (s, 2H), 4.11 (s,

[0472] 543. sulfamoyl benzamide

[0473] H N o m人丄애즈〜) 1H), 4.48 (s, 2H), 7.37

[0474] 68

[0475] 豐" 아 三 N-{6-[4-(2-hydroxypro (s, 1H), 7.46 (s, 2H), 판-2-yl)piperidin-1-yl]-7.73 (t, 1H), 8.03 (d, 2-(2-propoxyethyl)-2H-1H), 8.12 (d, 1H), 8.26 indazol-5-yl}-3-sulfamoyl (s, 1H), 8.36 (s, 1H), benzamide 8.44 (s, 1H), 9.81 (s,

[0476] 1H)

[0477]

[0478] 1H NMR (DMSO-d6): 1.06

[0479] N-[2-(3-cyanopropyl)—6—(s, 6H), 1.34 (m, 1H), [4—(2—hydroxypropan—2—1.45 (m, 2H), 1.79 (d, yl)piperidin—1—yl]—2H—2H), 2.18 (q, 2H), 2.53 indazol-5-yl]—3—(m, 2H), 2.64 (m, 2H), sulfamoyl benzamide 3.07 (m, 2H), 4.11 (s,

[0480] 1H), 4.42 (s, 2H), 7.38 N-[2-(3-cyanopropyl)-(s, 1H), 7.46 (s, 2H), 6-[4-(2-hydroxypropane-7.74 (t, 1H), 8.02 (d, 2-yl)piperidine-1-yl]-2H-1H), 8.12 (d, 1H), 8.31 Indazole-5-yl]-3-sulfamoyl

[0481] Benz Zua Mid ( s , 1H) , 8.36 ( s , 1H) ,

[0482] 8.45 (s, 1H), 9.81 (s, 1H)

[0483] 1H NMR (DMSO- d6): 1.05 N- {6 - [4- (2 - (s, 6H), 1.34 (m, 1H), hydr oxypropan- 2- 1.45 (m, 2H), 1.79 (d, yl)p iper idin— 1— yl ]— 2 —

[0484] 2H) , 2.10 ( s , 2H) , 2.25 (4, 4 , 4- tr if luorobutyl )- (m , 2H) , 2.64 (t , 2H) , 2H— indazol — 5— yl}— 3—

[0485] 3.07 (d, 2H), 4.13 (s, sul famoyl benz am i de

[0486] 1H), 4.43 (s, 2H), 7.39 N-{6-[4-(2-hydroxypro(s, 1H) , 7.44 (s, 2H) , pan-2-yl)piperidin-1-yl]- 7.73 (s, 1H), 8.01 (s, 2-(4, 4, 4-trifluorobutyl1H) , 8.11 (s, 1H) , 8.31 yl)-2H-indazole-5-yl}-3-(s, 1H), 8.35 (s, 1H), sulfamoylbenzamide 8.45 (s, 1H), 9.81 (s,

[0487] 1H)

[0488] N- {6 - [4- (2 - 1H— NMR(DMSO— d6) : 1.03 hydr oxypropan- 2- ( s , 6H) , 1.35 (m , 1H) , yl )p iper idin— 1— yl ]— 2 — 1.44 (t , 2H) , 1.77 (d, (oxan— 4— yl )—2H— indazol— 2H) , 2.62 (t , 2H) , 3.11 5-y 1}— 3— nitr obenz am i de (d , 2H) , 3.49 (m , 4H) ,

[0489] 3.98 (d , 4H) , 4.11 ( s , N- {6 - [4-(2-hydroxypro

[0490] Pan- 2 -il)piperidine- 1H) , 4.65 (m , 1H) , 7.38

[0491] 1-yl]- ( s , 1H) , 7.83 (t , 1H) , 2-(oxane-4-yl)-2H-indazole 8.35 ( s , 2H) , 8.41 (q, -5-yl}-3-nitrobenzami 2H) , 8.67 ( s , 1H) , 9.95

[0492] ( s , 1H)

[0493]

[0494]

[0495] 1H—NMR(DMSO—d6):1.03

[0496] N- {6 - [4- (2 - (s, 6H), 1.35 (m, 1H), hydroxypropan— 2 —

[0497] 1.44 (t , 2H) , 1.77 (d, yl )p iper idin— 1— yl ]— 2 —

[0498] 2H) , 2.62 (t , 2H) , 3.11 (oxan— 4— yl )— 2H— indazol—

[0499] (d, 2H), 3.49 (m, 4H), 5-yl}-3- 3.98 (d, 4H), 4.11 (s, sul famoyl benz am i de

[0500] 1H), 4.65 (m, 1H), 7.35 N-{6-[4-(2-hydroxypro(s, 1H) , 7.46 (s, 2H) , pan-2-yl)piperidin-1-yl]- 7.73 (t, 1H), 8.00 (d, 2-(oxane-4-yl)-2H-indazole 1H), 8.11 (d, 1H), 8.23 ​​-5-yl}- 3-sulfamoylbenza(s, 1H), 8.35 (s, 1H), mid 8.44 (s, 1H), 9.81 (s,

[0501] 1H)

[0502] N- {6 - [4- (2 - 1H NMR (DMSO- d6) : 1.05 hydroxypropan— 2 — ( s , 6H) , 1.34 (m , 1H) , yl )p iper idin— 1— yl ]— 2 — 1.44 (m , 2H) , 1.50 (d , (propan- 2- yl )- 2H- 6H) , 1.79 (d, 2H) , 2.64 indazo l-5-yl}— 3— ( s , 2H) , 3.06 ( s , 2H) , sul famoyl benz am i de 4.12 ( s , 1H) , 4.72 ( s ,

[0503] 1H) , 7.39 ( s , 1H) , 7.45 N- {6 - [4- (2 -hydroxypro

[0504] Pan- 2 -yl )piperidine- 1-yl]- ( s , 2H) , 7.73 (t , 1H) ,

[0505] 8.01 (d , 1H) , 8.11 ( s , 2-(propane- 2 -yl )- 2H-inda 1H) , 8.31 ( s , 1H) , 8.36 sol- 5 -yl}- 3 ―sulfamoylbenz

[0506] Amide ( s , 1H) , 8.44 ( s , 1H) ,

[0507] 9.82 ( s , 1H)

[0508] 1H— NMR (DMSO— d6) : l?05 N- {6 - [4- (2 - ( s , 6H) , 1.43 (m , 1H) , hydroxypropan- 2- 1.44 (m , 2H) , 1.80 (d, yl )p iper idin— 1— yl ]— 2 —

[0509] 2H) , 2.63 (t , 2H) , 3.10 methyl -2H- indazo 1— 5 —

[0510] (d , 2H) , 4.08 (s , 3H) , y 1}— 3— nitr obenz ami de

[0511] 4.11 ( s , 1H) , 7.33 ( s , N- {6 - [4- (2-hydroxypro 1H) , 7.83 (t , 1H) , 8.23 ​​pan- 2-yl)piperidine- 1-yl]- ( s , 1H) , 8.39 (d , 1H) , 2-methyl- 2H-indazole- 5-yl}- 8.42 ( s , 1H) , 8.43 (d, 3-nitrobenzamide 1H) , 8.66 ( s , 1H) , 9.93

[0512] ( s , 1H)

[0513]

[0514]

[0515] N-{6-[4-(2-Hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide 1H NMR (DMSO-d6): 1.06 (s, 6H), 1.36 (m, 1H), 1.44 (m, 2H), 1.80 (d, J 2H), 2.63 (t, 2H), 3.06 (d, 2H), 4.08 (s, 3H), 4.12 (s, 1H), 7.35 (s, 1H), 7.46 (s, 2H), 7.73 (t, 1H), 8.00 (d, 1H), 8.11 (d, 1H), 8.23 (s, 1H), 8.35 (s, 1H), 8.44 (s, 1H), 9.80 (s, 1H) N-{2-ethyl-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide 1H NMR (DMSO-d6): 1.06 (s, 6H), 1.46 (m, 6H), 2.66 (m, 4H), 3.09 (m, 2H), 4.11 (s, 1H), 4.38 (s, 2H), 7.38 (s, 1H),

[0516] '" ''O (d, 2H), 4.08 (s, 3H), '.人리 y yl}-3- 3 N — 471.

[0517] x <、 sulfamoylbenzamide 4.12 (s, 1H), 7.35 (s, f -』、三、,•☆누가 / 58

[0518] 1H), 7.46 (s, 2H), 7.73어오시、义 、 1 N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-8.11 (d, 1H), 8.23 (s, 1H), 8.35 (s, 1H), 8.44 3-sulfamoylbenzamide (s, 1H), 9.80 (s, 1H) N-{2-ethyl-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide 1H NMR (DMSO-d6): 1.06 (s, 6H), 1.46 (m, 6H), 2.66 (m, 4H), 3.09 (m, 2H), 4.11 (s, 1H), 4.38 (s, 2H), 7.38 (s, 1H), 1 1 hW

[0519] 60 N- {2-ethyl-6-[4-(2-hydro 7.46 (s , 2H) , 7.73 (t , roxypropane-2-yl )piperi 1H) , 8.03 (d, 1H) , 8.12 Vrip din-1-yl]-2H-indazole-5-(d, 1H) , 8.28 (s , 1H) , yl}-3-sulfamoylbenzami 8.36 (s , 1H) , 8.45 (s , IS 1H) , 9.82 (s , 1H)

[0520] 1H NMR (DMSO— d6): 1.77 - 1.79 (m, 2H), 1.95-1.98 N-{6 - [4-( 2— cyano— N—

[0521] (m, 2H) , 2.83 (t , 2H) , methyl acet ami do )pi per id

[0522] 3.09-3.11 (m, 2H) , 3.38 in— 1—yl ]— 2,3— dimethyl—

[0523] (s, 3H), 3.64-3.68 (m, 2H— indazol— 5— yl}~3~

[0524] 2H) , 3.74-3.76 (m, 1H) , su 1 f amoy 1 benz am i de

[0525] 523.

[0526] 3.78 (s , 3H) , 4.09 (s , 61 N- {6 - [4- (2 -cyano- N-meth H2N. S P Myoso (3H), 7.38 (s, 1H), 7.50 thylacetamidone (piperidine) (s, 2H), 7.76 (t, 1H), -1-yl]-2,3-dimethyl-2H-phosphorus 7.82 (d, 1H), 8.02 (d, dazole-5-yl}-3-sulfamoylbenzene (1H), 8.23 ​​(s, 1H), 8.34 ziamide

[0527] (s, 1H), 8.39 (s, 1H), 9.87 (s, 1H)

[0528]

[0529] 1H NMR (DMSO—d6): 1.64 —

[0530] N-(2-methyl-6-{4-1.66 (m, 2H), 1.77 - 1.79 [methyl (3, 3, 3-(m, 2H), 2.02 - 2.04 (m, trifluoropropyl) amino]p ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​N-(2-methyl-6-{4-[methyl(3,3,3-trifluoropropyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-(1H-1,2,3,4-tetrazol-5-yl)benzamide

[0540] 2.01 (m, 5H), 2.22 (s, 3H), 2.66 - 2.68 (m, 2H),

[0541] indazol - 5 - yl)-3-(1H -

[0542] 2.81 (t, 2H), 3.09 - 3.14 (m, 4H), 4.09 (s, 3H),

[0543] 527. yl)benzamide

[0544] NH HN人』 '7.39 (s, 1H), 7.67 (t,

[0545] 56 <000239s>N-(2 - methyl - 6 - {4 - [methyl(1H), 8.00 (d, 1H), 8.19 (3, 3, 3 - trifluoropropy (d, 1H), 8.24 (s, 1H), l)amino]piperidin - 1 - 8.54 (s, 1H), 8.59 (s, 1H), 9.91 (s, 1H), 10.7 (s, 1H)

[0547] yl)benzamide

[0548]

[0549] 1—[2—(s - hydroxy - 3 —

[0550] 1H NMR (DMSO - d6): 1.01 methylbutyl)—5—(3 —

[0551] (d , 6H) , 1.12 ( s , 6H) , nitr obenzam i do ) — 2H—

[0552] 1.75 (m, 4H), 1.99 (t, indazo l-6-yl]—N—

[0553] 2H) , 2.20 (m, 1H) , 2.64 (propan— 2 —

[0554] (m , 2H) , 3.09 (d , 2H) , yl )p iper idine— 4—

[0555] 3.79 (m, 1H), 4.42 (t, carboxamide

[0556] 2H), 4.48 (s, 1H), 7.32 1-[2-(3-hydroxy-3-methyl(s, 1H) , 7.58 (s, 1H) , butyl)-5-(3-nitrobenza)7.86 (t, 1H) , 8.28 (d, mido)-2H-indazole-6-yl]- 2H), 8.35 (d, 1H), 8.42 N-(propane-2-yl)piperidine (d, 1H) , 8.68 (s, 1H) , -4-7}rbox'}white]d 9.87 (s, 1H)

[0557] N—[ 2— ( 3-hydr oxy— 3 — 1H NMR (DMSO- d6) : 1.12 methylbutyl )—6 — [4— ( s , 6H) , 1.73 (m , 2H) , (morpho l ine— 4— 1.78 (q , 2H) , 1.99 (t , carbonyl )p iper i din— 1— 2H) , 2.73 (t , 3H) , 3.09 yl ]— 2H— indazol— 5— yl ]— 3 — (d , 2H) , 3.42 (m , 2H) , nitr obenzam i de 3.52 (m , 6H) , 4.40 (t ,

[0558] 2H), 4.48 (s, 1H), 7.28 N-[2-(3-hydroxy-3-methyl(s, 1H) , 7.84 (t, 1H) , butyl )-6-[4-(morpholine-4-carbonyl)piperidine- 8.26 (s, 1H), 8.29 (s,

[0559] 1- yl ]- 1H) , 8.35 (d, 1H) , 8.42 2H-indazole- 5 -yl ]- 3-nitrobenzamide (d , 1H) , 8.69 ( s , 1H) ,

[0560] 9.89 ( s , 1H)

[0561] N- (6 - {4 - 1H NMR (DMSO-d6): 1.12 [(carbamoylmethyl) carba

[0562] ( s , 6H) , 1.75 (m , 2H) , moyl ]p iper i din— 1— yl}— 2—

[0563] 1.82 (d, 2H), 1.99 (t, (3-hydr oxy-3- 2H), 2.35 (m, 1H), 2.69 methylbutyl)— 2H—

[0564] (t , 3H) , 3.06 (d , 2H) , indazo l-5-yl )—3 —

[0565] 4.42 (t, 2H), 4.47 (s, sul famoyl benz am i de

[0566] 2H), 6.97 (s, 1H), 7.23 N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl)-3-sulfamoylbenzamide

[0567] 1H), 9.79 (s, 1H)

[0568]

[0569]

[0570] N-[2-(3-hydroxy—3— [[ID=十四]]

[0571] 1H NMR (DMSO-d6): 1.12 methylbutyl)-6-(4-(s, 6H), 1.16 (d, 3H), {[(1R)-1-(methylcarbamoyl)ethyl]

[0572] 2H), 2.35 (m, 1H), 2.55 carbamoyl}piperidin-1-(s, 3H), 2.67 (t, 2H), 0 ▽ dou yl)-2H-indazol-5-yl]-3—

[0573] 3.06 (d, 2H), 4.19 (m, —N. 613. sulfamoylbenzamide

[0574] 1H), 4.42 (t, 2H), 4.48 H2N / cry에 지、 《어 73

[0575] It should be noted that there may be some unclear or incorrect notations in the original text, which may affect the accuracy of the translation. It is recommended to double-check and correct if possible for a more precise translation.N-[2-(3-hydroxy-3-methylbutyl)-6-(4-{[(methylcarbamoyl)methyl]carbamoyl}piperidin-1-yl)-2H-indazol-5-yl]-3-sulfamoylbenzamide

[0576] 1H NMR (DMSO-d6): 1.12 N—[2—(3-hydroxy—3—

[0577] (s, 6H), 1.74 (q, 2H), methylbutyl)-6-(4 - 1.82 (d, 2H), 1.98 (t, {[(methylcarbamoyl)meth

[0578] 2H), 2.56 (s, 3H), 2.68 yl]carbamoyl}piperidin—

[0579] (t, 2H), 3.07 (d, 2H), H 0 1-yl)-2H-indazo 1-5-yl]-3.62 (s, 2H), 4.41 (t, 3-sulfamoy 1 benz am i de

[0580] 599. 2H), 4.48 (s, 1H), 7.36 H °2N、 / 내쓰 n서x义 / 애 71 N-[2-(3-hydroxy-3-methyl (s, 1H), 7.49 (s, 2H), (AQ sub-butyl)—6-(4-{[(methylcarbamoyl)methyl]carbamoyl}

[0581] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide 1H NMR (DMSO-d6): 1.12 (s, 6H), 1.73 (m, 4H), 1.98 (t, 2H), 2.75 (m, 3H), 3.05 (d, 2H), 3.42 - 3.54 (m, 8H), 4.41 (t, 2H), 4.47 (s, 1H), 7.30 (s, 1H), 7.48 (s, 2H), 7.74 (t, 1H), 8.00 (d, 1H), 8.12 (d, 1H), 8.29 (s, 1H), 8.32 (s, 1H), 8.38 (s, 1H), 9.79 (s, 1H)

[0582] (s, 1H)

[0583]

[0584] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide

[0585] 3.54 (m, 8H), 4.41 (t,

[0586] 598. sulfamoylbenzamide 2H), 4.47 (s, 1H), 7.30 H2N、 S P H心 人 N \<OH 72 (s, 1H), 7.48 (s, 2H),

[0587] N-[2-(3-hydroxy-3-methyl

[0588] d s butyl)- 7.74 (t, 1H), 8.00 (d,

[0589] 6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide 1H), 8.12 (d, 1H), 8.29

[0590] 1-(s, 1H), 8.32 (s, 1H), -[2H-indazol-5-yl]-3-sulfamoylbenzamide (s, 1H), 8.38 (s, 1H), 9.79

[0591] 1H)

[0592] 1H NMR (DMSO-d6): 1.12 (s, 6H), 1.66 (q, 2H), N-{1-[2-(3-hydroxy-3-1.85 (d, 2H), 1.99 (t, methylbutyl)-5-(3-2H), 2.76 (t, 2H), 3.02 sul famoylbenzamido)-2H-indazol-6-yl]piperidin- H 6-yl]piperidin—

[0593] 3.25 (s, 2H), 3.52 (s, 4-yl Imorpholine—4—

[0594] 4H), 3.62 (s, 1H), 4.06 613. carboxamide

[0595] (s, 1H), 4.40 (t, 2H), H2N、° S P 으 H세心스브 \< / OH 73

[0596] / 아 N-{1-[2-(3-hydroxy-3-4.48 (s, 1H), 6.14 (s, methyl butyl)-5-(3-sul famoyl benzamido)-2H-indazol- (s, 1H), 7.40 (s, 1H), 7.47 6-yl]piperidin-4-yl}morpholine-4-carboxamide (s, 2H), 7.77 (t, 1H), 8.02 (d, 1H), 8.15 (d, 1H), 8.29 (s, 1H), 8.36

[0597] (s, 1H), 8.40 (s, 1H), 9.89 (s, 1H)

[0598]

[0599] 1H NMR (DMSO-d6): 1.14

[0600] N- { 1- [ 2- ( 3-hydr oxy- 3 - (s , 6H) , 1.79 (q, 2H) , methylbutyl )-5- (3 - 1.99 (m, 4H) , 2.85 (t , sul f amoylbenzamido)-2H- 2H) , 3.10 (d, 2H) , 4.00 indazol-6-yl ]piper idin—

[0601] r] H (m, 1H) , 4.43 (t , 2H) ,

[0602] 4-yl}pyr idine— 3 —

[0603] 4.48 (s , 1H), 7.42 (s , ° 605). carboxamide

[0604] Yr— / 1H) , 7.47 (m, 3H) , 7.77 H2N S P 71

[0605] Yu, N- {1- [2- (3 -hydroxy- 3 - (t , 1H) , 8.01 (d, 1H) ,

[0606] 0 Methylbutyl )-5-(3-sulfamoyl 8.17 (t , 2H) , 8.30 (s , benzamido)-2H-indazole- 1H) , 8.36 (s , 1H) , 8.42 6-yl ]piperidin- 4-yl}pyri (s , 1H) , 8.45 (s , 1H) , din- 3-carboxamide 8.68 (d, 1H) , 9.00 (s ,

[0607] 1H) , 9.89 (s , 1H) 1H NMR (DMSO- d6) : 1.12 N— [ 2— ( 3-hydr oxy— 3 —

[0608] (s , 6H) , 1.75 (q, 2H) , methylbutyl )-6 - [4- (2 - 1.81 (m, 2H) , 1.98 (t , hydroxyacet ami do )piper i

[0609] 2H), 2.81 (t, 2H), 3.01 din—1—yl]—2H—indazol—5—

[0610] (d, 2H), 3.79 (s, 1H), yl]-3-HoV、p 3.83 (m, 2H), 4.40 (t, 558. su 1 f amoy 1 benz am i de 0 으 rY— / 2H), 4.48 (s, 1H), 5.45 H2K S P 心—4OH 65

[0611] N-[2-(3-hydroxy-3-methyl (s, 1H), 7.42 (s, 1H),朴 Q人 o

[0612] butyl)—6-[4-(2-hydroxy 7.47 (s, 2H), 7.57 (d,

[0613] 1H), 7.78 (t, 1H), 8.02 acetamido)piperidin-1-yl]-2H-indazol-5-yl]-(d, 1H), 8.13 (d, 1H), 3-sulfamoylbenzene amide 8.30 (s, 1H), 8.41 (s,

[0614] 2H), 9.87 (s, 1H)

[0615]

[0616] 1H NMR (DMSO-d6): 1.12

[0617] (2S)-N-{1-[2-(3-(s, 6H), 1.60 (q, 2H), hydroxy—3—methylbutyl)-1.85 (d, 3H), 1.99 (m, 5-(3- 2H), 2.06 (m, 1H), 2.11 sulfamoylbenzamideLHffl- (m, 1H), 2.21 (m, 1H), indazol—6—yl]piperidin—

[0618] 2.77 (t, 2H), 3.04 (d, 4-yl}—5—oxopyrrolidine - 2H), 3.72 (m, 1H), 3.96 611. 2-carboxamide

[0619] (d, 1H), 4.41 (t, 2H), 빠丄」斗 011 72

[0620] (2S)-N-{1-[2-(3 -히드록4.48 (s, 1H), 7.38 (s, 싸 시 - 3 -메틸부틸)-5-(3 ―술1H), 7.50 (s, 2H), 7.74 파모일벤즈아미도)-2H -인 (m, 2H), 7.87 (t, 1H), 다졸 - 6 -일]피페리딘 - 4 - 8.02 (d, 1H), 8.14 (d, 일}-5 -옥소피롤리딘 - 2 -카1H), 8.29 (s, 1H), 8.33 르복사미드 (s, 1H), 8.39 (s, 1H),

[0621] 9.81 (s, 1H)

[0622] N-{6 -[4-(2 - 1H NMR (DMSO - d6): 1.12 aminoacetaini do)p iper i di

[0623] (s, 6H), 1.62 (m, 2H), n—1—yl]—2—(3—hydroxy—3 —

[0624] 1.89 (m, 2H), 1.99 (m, methylbutyl)-2H - 2H), 2.80 (t, 2H), 3.06 indazol - 5 - yl}~3~

[0625] (d, 2H), 3.52 (q, 2H), su 1 famoy 1 benz am i de

[0626] 3.79 (m, 1H), 4.42 (t, 594. hydrochloride

[0627] 3H), 7.38 (s, 1H), 7.50 13

[0628] H N ° 0 으 I flat n시r' 7 —,느 / N-{6 - [4-(2- heart}linoacet (s, 2H), 7.75 (t, 1H), 7 suss HC! ° H amido) piperidine-1-yl ] - 7.96 (m, 3H), 8.03 (d,

[0629] 2- (3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-(m, 2H), 8.30 til)-2H-indazol-5-yl}-3-(m, 2H), 8.33 (m, 1H), sulfamoylbenzenesulfonamide hydrochloride 8.40 (s, 1H), 9.82 (s, salt 1H)

[0630]

[0631] N-{6 -[4-(2- aminoacetaini do)p iper i di

[0632] n—1—yl ]—2—(3—hydroxy—3 —

[0633] methylbutyl )-2H- H2NV 으 indazol-5-yl}~3~

[0634] ° 으 Yr— / 557. sulfamoyl benzamide

[0635] 띠 S朴' 9 Q 1 서쪼이~ — 0H 67 ​​​​​​​​​​1H NMR (DMSO-d6): 1.12 N-{6-[4-(2-(s, 6H), 1.58 (q, 2H), cyanoacetamido)piperidi

[0640] 1.87 (d, 2H), 1.99 (t, n—1—yl]—2—(3—hydroxy—3—

[0641] 2H), 2.78 (t, 2H), 3.02 methylbutyl)-2H-(d, 2H), 3.60 (s, 2H), indazol-5-yl}~3~

[0642] ▽

[0643] H 으 으 3.71 (m, 1H), 4.40 (t,

[0644] 567. sulfamoyl benzamide

[0645] W於 1 心세 011 2H), 4.47 (s, 1H), 7.36 Q 67

[0646] 서 N-{6-[4-(2-cyanoacet (s, 1H), 7.49 (s, 2H), amidopiperidin-1-yl]-7.75 (t, 1H), 8.01 (d, 2-(3-hydroxy-3-methylbu 1H), 8.14 (d, 1H), 8.20 til)-2H-indazol-5-yl}-3-(d, 1H), 8.29 (s, Sulfamoyl benzamide 1H), 8.32 (s, 1H), 8.39 (s,

[0647] 1H), 9.79 (s, 1H)

[0648]

[0649] 1H NMR (DMSO-d6): 1.11

[0650] N-(6-{4-[(s,6H),1.49(m,2H),[(carbamoylmethyl)amino

[0651] 1.89(d,2H),1.98(t,]piperidin-1-yl}-2-(3-

[0652] 2H),2.55(m,1H),2.69hydroxy-3-methylbutyl)-(t,2H),3.02(d,2H),H2J?내Y今2H-indazol-5-yl)-3-

[0653] 3.09(d,2H),4.41(t,sulfamoylbenzamide

[0654] 557.2H),4.47(s,1H),7.05H2N、 S P으HY广r-—、《 / OH67N-(6-{4-[(카르바모일메(s,1H),7.31(s,1H),

[0655] 0 틸)아미노]피페리딘-1-7.37(s,1H),7.52(s,일}-2-(3-히드록시-3-메2H),7.77(t,IH),8.01틸부틸)-2H-인다졸-5-(d,1H),8.12(d,1H),일)-3—술파모일벤즈아미8.29(s,1H),8.38(s,IS1H),8.40(s,1H),9.85

[0656] (s,1H)

[0657] 1H-NMR (DMSO-d6): 1.11 N-[2-(3-hydroxy-3-(s,6H)), 1.58 (m, 1H), methylbutyl)-6-[4-(2-1.70 (m, 2H), 1.82 (m, hydroxyacetamido)piper i2H), 1.97 (t, 2H), 2.77 din-1-yl]-2H-indazol-5-(m, 2H), 3.04 (m, 2H), HO now Ap yl]~3~nitrobenz amide 3.77 (d, 2H), 4.41 (t, 0 으 Ty— / 524.

[0658] 0 HN, 스 으 (OH 2H), 4.47 (s, 1H), 5.42

[0659] 58 N-[2-(3-hydroxy-3-methyl

[0660] (AQ 人 o (t, 1H), 7.38 (s, 1H), butyl)-6-[4-(2-hydroxy 7.55 (d, 1H), 7.86 (t, acetamido) piperidine-1H), 8.29 (s, 1H), 8.33 1-yl]-2H-indazol-5-yl]-(s, 1H), 8.36 (d, 1H), 3-nitrobenzamide

[0661] 8.44 (d, 1H), 8.71 (s, 1H), 9.92 (s, 1H)

[0662]

[0663] N—[2—(3-hydroxy—3—1H NMR (DMSO-d6): 1.12 methylbutyl)-6-[4-(s, 6H), 1.58 (q, 2H), (4, 4,4- 1.85 (d, 2H), 1.98 (t, trifluorobutanamido)pip 2H), 2.33 (t, 2H), 2.49 eridin—1—yl]-2H—(m, 2H), 2.76 (t, 2H), Fsj H indazol-5-yl]-3—3.03 (d, 2H), 3.72 (s, 0 히 v- (OH 624. su 1 famoy 1 benz am i de 1H), 4.43 (t, 2H), 4.47 Q HN&人 7 68 (s, 1H), 7.37 (s, 1H),

[0664] N-[2-(3-hydroxy-3-methyl

[0665] 쎠'' 0 凡 7.49 (s, 2H), 7.75 (t, butyl)-6-[4-(4, 4, 4-tri

[0666] 1H), 7.93 (d, 1H), 8.02 fluoro butanamido) pip

[0667] (d, 1H), 8.15 (d, 1H), ridin-1-yl]-2H-indazol-5- 8.29 (s, 1H), 8.33 (s, yl]-3 —sulfamoylbenzami

[0668] IS 1H), 8.39 (s, 1H), 9.81

[0669] (s, 1H)

[0670] N-[2-(3-hydroxy—3 —

[0671] methylbutyl)-6-{4- 1H NMR (DMSO-d6): 1.11 [(2, 2, 2-(s, 6H), 1.96 (m, 5H), trifluoroethyl)amino]pi 2.26 (m, 1H), 2.60 (m, 이』佔peridin-l-yl}—2H—2H), 2.69 (t, 2H), 3.02 indazol-5-yl]—3—(d, 2H), 4.41 (t, 2H), 582. su1famoy1 benz amide 4.48 (s, 1H), 6.60 (s, 띠少셰妙스、《° H 64 1H), 7.15 (s, 1H), 7.36

[0672] N-[2-(3-hydroxy-3-methyl

[0673] (s, 1H), 7.49 (s, 2H), butyl)—6-{4-[(2, 2, 2-trifluoroethyl)amino]pi

[0674] 7.77 (t, 1H), 8.02 (d, peridin-1-yl}-2H-indazole- (s, 1H), 8.13 (d, 1H), 8.29 페리딘-1-일}-2H-인다졸- (s, 1H), 8.38 (s, 2H), 5-일]-3 —술파모일벤즈아

[0675] 1H), 8.13 (d, 1H), 8.29 페리딘-1-일}-2H-인다졸-5-일]-3 —술파모일벤즈아미드 9.84 (s, 1H)

[0676] 미드 9.84 (s, 1H)

[0677]

[0678] 1H NMR (DMSO-d6): 1.10

[0679] N-[2-(3-hydroxy—3—

[0680] (s, 6H), 1.53 - 1.57 (m, methylbutyl)-6 - [4 - 2H), 1.86 - 1.88 (m, 2H), (3, 3,3 - 1.99 - 2.00 (m, 2H), trifluoropropanamido)pi 2.75 - 2.77 (m, 2H), peridin - l - yl]— 2H—

[0681] 3.01 - 3.08 (m, 2H), indazol - 5 - yl]— 3—

[0682] 3.71 - 3.72 (m, 2H), f ° / 576. nitrobenzamide

[0683] O HN시、』 " 4.05 - 4.06 (m, 1H),

[0684] 58

[0685] o - 斗 Q 人 o N - [2 - (3 - hydroxy - 3 - methyl 4.41 - 4.42 (m, 2H), 4.48 butyl)— 6 - [4 - (3, 3, 3 - tri (s, 1H), 7.34 (s, 1H), fluoropropanamido)pi 7.84 (d, 1H), 8.23 - 8.26 peridin - 1 - yl] - 2H - indazole - (m, 2H), 8.29 (s, 1H), 5 - yl]— 3 - nitrobenzami 8.38 (s, 1H), 8.43 (s, IS 1H), 8.71 (s, 1H), 9.91

[0686] [[ID=二十]](s, 1H)

[0687] It should be noted that there may be some inaccuracies or unclear parts in the original text, especially some notations that seem not to conform to standard chemical or language expressions. This translation is done as accurately as possible based on the given text.N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3,3,3-trifluoropropanamido)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide 1H NMR (DMSO-d6): 1.11 (s, 6H), 1.55 - 1.57 (m, 2H), 1.85 - 1.87 (m, 2H), 1.96 - 1.98 (m, 2H), 2.77 (t, 2H), 3.01 - 3.02 (m, 2H), 3.78 - 3.80 (m, 2H), 4.39 - 4.41 (m, 2H), 4.48 (m, 1H), 7.36 (s, 1H), 7.49 (s, 2H), 7.74 (t, 1H), 8.01 (s, 1H), 8.18 (d, 1H), 8.20 (d, 1H), 8.29 (s, 1H), 8.31 (s, 1H), 8.69 (s, 1H), 9.79 (s, 1H) f 610. sulfamoylbenzamide 4.39 - 4.41 (m, 2H), 4.48 °C N m / z 65 (s, 1H), 7.36 (s, 1H), H2N— S PH—M—, <OH N-[2-(3-hydroxy-3-methyl

[0688] 7.49 (s, 2H), 7.74 (t, butyl)-6-[4-(3,3,3-tri

[0689] 1H), 8.01 (s, 1H), 8.18 fluoro propanamido)pi

[0690] (d, 1H), 8.20 (d, 1H), peridin-1-yl]-2H-indazol- 8.29 (s, 1H), 8.31 (s, 5-yl]-3 —sulfamoylbenz

[0691] amide 1H), 8.69 (s, 1H), 9.79

[0692] (s, 1H)

[0693]

[0694] 1H NMR (DMSO-d6): 1.11

[0695] N-[2-(3-hydroxy-3 —

[0696] (s, 6H), 1.53-1.57 (m, methylbutyl)-6 - [4- 2H), 1.84-1.90 (m, 2H), (3, 3,3- 1.97-2.00 (m, 2H), 2.40 tr if luor opr ​​opan amido)pi (s, 3H), 2.77 (t , 2H) , per idin-l-yl ]— 2H—

[0697] 3.02-3.04 (m, 2H) , H indazol-5-yl ]~3~

[0698] 3.71-3.74 (m, 2H) , (methyl sul famoyl) benz am

[0699] 624. 4.03-4.05 (m, 3H) , ide

[0700] A 9 ”1= o = OH 68 4.39-4.43 (m, 2H) , 4.48

[0701] N- [2- (3-hydroxy- 3-methyl (s , 1H) , 7.36 (s , 1H) , butyl )— 6- [4- (3, 3 , 3-tri 7.59 (br . s , 1H) , 7.77 fluoropropanamido) p (t , 1H) , 7.97 (d, 1H) , peridin- 1-yl]- 2H-indazole- 8.18-8.20 (m, 2H) , 8.29 5-yl]- 3-(methylsulfamoyl ) (s , 1H) , 8.31 (d, 1H) , benzamide 8.64 (s , 1H) , 9.82 (s ,

[0702] 1H)

[0703] 1H NMR (DMSO- d6): 1.11 N- { 1- [ 2- ( 3-hydr oxy- 3 - (s , 6H) , 1.81-1.84 (m, methylbutyl )- 5 - [3- (1H- 2H) , 1.95-2.01 (m, 4H) , imidazol-5- 2.84 (t , 2H) , 3.12 (d, yl )benzamido]— 2H—

[0704] 2H) , 3.98-3.99 (m, 1H) , indazol-6-yl ]piper idin—

[0705] 4.40-4.42 (m, 2H) , 4.48 f『、] H

[0706] N A N 4-yl}pyr idine— 3 —

[0707] n (s , 1H) , 7.43 (s , 1H) ,

[0708] 592. carboxamide

[0709] 7.46-7.48 (m, 2H) , 7.52 ° 으 Yy— / 사' NH mr、^* V 4-OH 70

[0710] N- {1- [2- (3 -hydroxy- 3 - (t , 1H) , 7.68 (s , 1H) ,ni g o methylbutyl )-5-[3-(1H-imi 7.71 (d, 1H) , 7.98 (d, dazole-5-yl)benzamido]-1H) , 8.15 (d, 1H) , 8.29 2H-indazole-6-yl]piperidine (s , 1H) , 8.39 (s , 1H) , -4-yl}pyridine-3-carboxa 8.45 (s , 1H) , 8.52 (d, mid 1H) , 8.67 (d, 1H) , 8.96

[0711] (d, 1H) , 9.69 (s , 1H)

[0712]

[0713] N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(4-methyl-3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidin-4-yl}pyridine-3-carboxamide

[0714] 619. (m, 2H), 4.47 (s, 1H), 0 amide

[0715] H2K S 7.43 (s, 1H), 7.47 - 7.49

[0716] N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(4-methyl-3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidin-4-yl}pyridine-3-carboxamide

[0717] 1H), 8.68 (d, 1H), 8.99

[0718] (s, 1H), 9.82 (s, 1H) 1H NMR (DMSO-d6): 1.11 N-{6-[4-(3-hydroxy—3—

[0719] (s, 12H), 1.58 (m, 2H), methyl butanamido)piper i

[0720] 1.85 (m, 2H), 1.97 (m, din—1—yl]—2—(3—hydroxy—

[0721] 2H), 2.17 (m, 2H), 2.753 - methylbutyl)-2H-(s, 2H), 3.02 (s, 2H), indazol - 5 - yl}~3~

[0722] H(?『'丁 N '''에 3.76 (s, 1H), 4.41 (s, su 1 f amoy 1 benz am i de

[0723] 600.으 IT— / 2H), 4.48 (s, 1H), 4.80 74 N-{6 - [4 - (3 -히드록시 - 3 - H2N、 / 妙스가OH (s, 1H), 7.38 (s, 1H), 메틸부탄아미도)피페리딘 6 "0人 0 7.49 (s, 2H), 7.75 (m, - 1 - 일]-2 - (3 -히드록시 - 3 - 2H), 8.02 (d, 1H), 8.13 메틸부틸)-2H - 인다졸 - 5 - (d, 1H), 8.29 (s, 1H), 일}-3 - 술파모일벤즈아미

[0724] 8.35 (s, 1H), 8.39 (s, IS

[0725] 1H), 9.82 (s, 1H)

[0726]

[0727] 1H NMR (DMSO—d6): 1.74 —

[0728] N-{6 -[4-(2 - 1.76 (m, 2H), 1.93 - 1.95 cyanoacetami do)p iper i di (m, 2H), 2.81 (t, 2H), n—1—yl]—2—methyl—2H—3.07 - 3.09 (m, 2H), NS Ao indazo l-5-yl}~3~ 3.62-3.64 (m, 2H), o 461. nitrobenzami de 3.95-3.93 (m, 1H), 4.06 O HN人』 으 48 (s, 3H), 7.34 (s, 1H), (AQ 人 o N- {6 - [4- (2 -시아노아세트

[0729] amido) piperidine-1-yl ]- 7.84 (t, 1H), 8.23-8.25

[0730] (m, 2H), 8.37-8.38 (m, 2 -methyl- 2H-indazole- 5 -yl}- 1H), 8.40 (s, 1H), 8.41- 3 -nitrobenzamide 8.42 (m, 1H), 8.71 (s,

[0731] 1H), 9.91 (s, 1H) 1H NMR (DMSO— d6): 1.77 - 1.79 (m, 2H), 1.95-1.98 N- {1- [2- methyl- 5- (3 - (m, 2H), 2.83 (t, 2H), sul famoylbenzamidecLHffl- 3.09-3.11 (m, 2H), indazol— 6— yl ]piperidin—

[0732] 3.97-3.98 (m, 1H), 4.09 斗 p 4-yl}pyridine-3- (s, 3H), 7.41 (s, 1H), 533. carboxamide

[0733] 7.47-7.50 (m, 3H), 7.78 61

[0734] H2N(、세 SP wonderful N-{1-[2-methyl-5-(3-sulfamoyl(t,1H),8.01(d,1H),moyl benzimidazole)-2H-indazole 8.16(d,2H),8.24(s,zol-6-yl]piperidin-4-yl}1H),8.36(s,1H),8.41-pyridine-3-carboxamide 8.42(m,2H),8.67(d,

[0735] 1H),8.98(s,1H),9.87(s,lH)

[0736] 1H NMR (DMSO—d6): 1.57 — N-{6-[4-(2-1.59(m,2H),1.87-1.89 cyanoacetamido)piperidi(m,2H),2.76(t,2H),H n—1—yl]—2—methyl—2H—3.02-3.04(m,2H),3.59 indazol-5-yl}~3~(s,2H),3.60-3.62(m, N New heart = N—495.sulfamoyl benzamide 1H),4.09(s,3H),7.35 o HN人人56(s,1H),7.49(s,2H),때》"、O 승 N-{6-[4-(2-cyanoacet

[0737] amido)piperidin-1-yl]-7.74(t,1H),8.00(d,

[0738] 1H),8.20(d,1H),8.21 2-methyl-2H-indazol-5-yl}-(d,1H),8.23(s,1H),3-sulfamoylbenzimidazole 8.32(s,1H),8.38(s,

[0739] 1H),9.79(s,1H)

[0740]

[0741] It should be noted that the original text seems to have some unclear or incorrect chemical structure expressions and notations, which may affect the accurate understanding and translation. It is recommended to double-check and correct the original text for more accurate translation and interpretation.1H NMR (DMSO—d6): 1.40—

[0742] N-{6-[4-(2- 1.47 (m, 2H), 1.83 (d, cyanoacetamido)piperidi

[0743] 2H), 2.64 (s, 3H), 2.71 n—1—yl]—2—methyl—2H—

[0744] (t, 2H), 3.02 (d, 2H), indazol-5-yl}—4—methyl—

[0745] 3.57 (s, 2H), 3.64 - 3.68 o〔、』、으N_3-sulfamoyl benzamide

[0746] 509. (m, 1H), 4.08 (s, 3H), 0呼'으스59 N-{6-[4-(2 -시아노아세트7.28 (s, 1H), 7.45 (t, 세아미도)piperidin - 1 - yl]- 1H), 7.51 (s, 2H), 7.64

[0747] 2 -메틸- 2H -인다졸- 5 -일}-(d, 1H), 7.97 (d, 1H), 4 -메틸- 3 —술파모일벤즈아8.22 - 8.24 (m, 1H), 8.30 미드(s, 1H), 8.49 (s, 1H),

[0748] 9.29 (s, 1H)

[0749] N-{6-[4-(2- 1H NMR (DMSO—d6): 1.54 — cyanoacetamido)piperidi

[0750] 1.56 (m, 2H), 1.86 - 1.88 n—1—yl]—2—methyl—2H—

[0751] (m, 2H), 2.75 (t, 2H), indazol-5-yl}—4—fluoro—

[0752] 3.02 (d, 2H), 3.60 (s, 1 3-sulfamoylbenzamide

[0753] 513. 2H), 3.64 - 3.69 (m, 1H), H2N / 心妙: 0스 유 55 N-{6-[4-(2-cyanoacet 4.08 (s, 3H), 7.33 (s, 서 amido)piperidine-1-yl]-1H), 7.58 (t, 1H), 7.82

[0754] 2-methyl-2H-indazol-5-yl}-(s, 2H), 8.20 - 8.24 (m, 4-fluoro-3 —sulfamoylben 2H), 8.32 (s, 1H), 8.50 즈아 mid (s, 1H), 9.78 (s, 1H) 4-chloro-N-{6-[4-(2 - 1H NMR (DMSO—d6): 1.54 — cyanoacetamido)piperidi 1.56 (m, 2H), 1.86 - 1.88 n—1—yl]—2—methyl—2H— (m, 2H), 2.75 (t, 2H), H

[0755] 스 indazol-5-yl}~3~ 3.03 (d, 2H), 3.60 (s, 0 Y 心 yy N _ sulfamoylbenzamide 2H), 3.69 - 3.73 (m, 1H),

[0756] 530.

[0757] 4.08 (s, 3H), 7.34 (s, H2N、 S P 쓰서 00 4-chloro-N-{6-[4-(2 - 시

[0758] 아노아 세트 아미 도)피 페리 1H), 7.75 (s, 2H), 7.80

[0759] (s, 1H), 7.82 (d, 1H), din-1-yl]-2 -methyl-2H-ind

[0760] 8.12 (d , 1H) , 8.23 ​​( s , zol- 5 -il}- 3 —sulfamoylbenz

[0761] Amid 1H), 8.26 ( s , 1H) , 8.51

[0762] ( s , 1H) , 9.83 ( s , 1H)

[0763]

[0764] 1H NMR (DMSO—d6): 1.57 — N- {6 - [4- (2 - 1.59 (m, 2H), 1.88-1.89 cyanoacetami do)p iper i di

[0765] (m, 2H), 2.65 (s, 3H), n—1—yl]—2—methyl—2H—

[0766] 2.76 (t , 2H) , 3.02 (d , indazo l-5-yl}— 2— methyl—

[0767] 2H) , 3.60 ( s , 2H) , 3.72- 3- sul famoyl benz ami de

[0768] 3.75 (m, 1H), 4.08 (s, N-{6-[4-(2-cyanoacetate 3H), 7.36 (s, 1H), 7.52 amido)piperidin-1-yl]-(s, 2H), 7.53-7.55 (m, 2-methyl-2H-indazole-5-yl}-1H), 8.02 (d, 1H), 8.20-2-methyl-3-sulfamoylbenzoa 8.21 (m, 1H), 8.22 (s, mid 1H), 8.34 (s, 1H), 8.43

[0769] ( s , 1H) , 9.73 ( s , 1H) 1H NMR (DMSO— d6) : 1.60— N- {6 - [4- (2 - 1.62 (m , 2H) , 1.88-1.97 cyanoacetami do)p iper i di

[0770] (m, 4H), 2.80 (t, 2H), n—1—yl]—2—methyl—2H—

[0771] 3.00 (d, 2H), 3.62 (s, indazo l-5-yl}— 2—f luoro—

[0772] 2H) , 3.70-3.72 (m, 1H) , 5-sul f amoy 1 benz ami de

[0773] 4.09 ( s , 3H) , 7.45 ( s , N- {6 - [4- (2-cyanoacet 1H) , 7.55 ( s , 2H) , 7.56-amido)piperidin-1-yl ]- 7.58 (m , 1H) , 8.02-8.03 2-methyl-2H-indazole-5-yl}- (m , 1H) , 8.25 ( s , 1H) , 2-fluoro-5-sulfamoylben 8.31 ( s , 1H) , 8.58 (d , zamide 1H) , 8.63 ( s , 1H) , 10.0

[0774] ( s , 1H)

[0775] N- {2 - [2- (morpho l in- 4- yl )ethyl ]- 6 - [4- 1H NMR (DMSO- d6) : 1.76 (morpho l ine— 4— (m, 4H), 2.40 (s, 4H), carbonyl)p iper i din— 1— 2.78 (m, 5H), 3.07 (d , yl ]— 2H— indazol— 5— yl}— 3— 1H) , 3.52 (m , 13H) , 4.46 sul famoyl benz am i de (t , 2H) , 7.30 ( s , 1H) ,

[0776] 7.48 ( s , 2H) , 7.75 (t , N- {2 - [2-(morpholine- 4 -il ) ) )

[0777] 1H), 8.01 (d, 1H), 8.13 ethyl]-6-[4-(morpholine-4-carbonyl)piperidin-(d, 1H), 8.30 (s, 1H),

[0778] 1-8.32 (s, 1H), 8.38 (s, yl]-2H-indazol-5-yl}-3-1H), 9.79 (s, 1H) sulfamoylbenzamide

[0779]

[0780] 1H NMR (DMSO—d6): 1.73 —

[0781] N-(6-{4-1.75 (m, 2H), 1.81-1.83 [(carbamoylmethyl)carba

[0782] (m, 2H), 1.92-1.98 (m, moyl]piperidin-1-yl}~2~

[0783] 2H), 2.34-2.36 (m, 4H), [2—(morpholin—4—

[0784] 2.69 (t, 2H), 3.07 (d, yl)ethyl]-2H-indazol-5-2H), 3.50-3.51 (m, 4H), 0 yl)-3-3.61 (d, 2H), 4.00-4.01 H2 Y / p 612. sulfamoylbenzamide

[0785] o 너、uv그j)(m, 1H), 4.45-4.46 (m,

[0786] 71

[0787] N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-(s, 1H), 7.23 o H스 人 스 틸)carbamoyl]piperidin-(s, 1H), 7.36 (s, 1H),

[0788] 1-Ethyl}-2-[2-(morpholin-4-yl)ethyl]-2H-indazole-5-sulfamoylbenzamide: 7.50 (s, 2H), 7.75 (t, 1H), 8.01 (d, 2H), 8.13 (d, 1H), 8.30 (s, 1H), 8.34 (s, 1H), 8.38 (s, 1H), 9.79 (s, 1H) N-methyl-1-[5-(3-sulfamoylbenzamido)-1-(2, 2, 2-trifluoroethyl)-1H-indazol-6-yl]piperidine-4-carboxamide

[0789] 1H NMR (DMSO-d6): 1.76 (m, 4H), 2.25 (m, 1H), 2.55 (d, 3H), 2.65 (m, 1H), 3.12 (d, 2H), 5.38 (q, 2H), 7.50 (s, 2H), 538. carboxamide

[0790] 2H), 3.12 (d, 2H), 5.38 (q, 2H), 7.50 (s, 2H), 538. carboxamide

[0791] (q, 2H), 7.50 (s, 2H), 538. carboxamide

[0792] H N [[ID=​​​​​​​​​​​​​

[0797] N-[2-(2,2-difluoroethyl)-6-[4-(4-hydroxypiperidine-1-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-

[0798] (t,1H),3.65(t,1H), H0 sulfamoylbenzamide

[0799] J0's汝J-590.3.84(d,1H),3.92(m,

[0800] 65 N-[2-(2,2-difluoroethyl)-6-[4-(4-hydroxypiperidine-1-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide

[0801] 9.81(s,1H)

[0802] N-[2-(2, 2- 1H NMR (DMSO- d6) : 1.00 di f luoroethyl )-6 - {4- [4- (s , 6H) , 1.09 (m, 2H) , (2— hydroxypropan— 2 — 1.38 (t , 1H) , 1.63-1.83 yl )piper idine— 1— (m, 6H) , 2.37 (t , 1H) , carbonyl ]piper idin— 1— 2.77 (m, 3H) , 2.90 (t , 0 yl}— 2H— indazol— 5— yl ]— 3 — 1H) , 3.05-3.08 (d, 2H) , ho> Number 632. su 1 f amoy 1 benz am i de 4.02 (d, 1H) , 4.09 (s ,

[0803] 0g N > 73 1H) , 4.47 (d, 1H) , 4.88

[0804] N- [2- (2, 2-difluoro(td, 2H) , 6.34- 6.47(tt , / isertyl)- 6 - {4 - [4- (2-hydroxy 1H) , 7.32 (s , 1H) , 7.49 propane- 2-yl )piperidine- 1-carbonyl] piperidine- (s , 2H) , 7.74 (t , 1H) ,

[0805] 1- yl}- 8.00 (d, 1H) , 8.14 (d, 2H-indazole- 5 -yl]- 3 - sulfamo ylben zua mid 1H) , 8.34 (s , 1H) , 8.39

[0806] (d, 2H) , 9.81 (s , 1H)

[0807]

[0808] l-[2-(2, 2- 1H NMR (DMSO-d6): 1.72 di f luoroethyl)-5- (3 - (d, 2H), 1.81 (m, 2H), sul f amoylbenzamido)-2H- 2.14 (m, 1H), 2.67 (t,

[0809] 2H), 3.05 - 3.08 (d, 2H), O indazol - 6 - yl]—N—

[0810] 으 H human n F hydroxypiperidine—4—3.58 (m, 1H), 4.88 (td, heart 그、)-F 522. carboxamide 2H), 6.34 - 6.47(tt, 1H), 2N、서 OHN〕」 N 53 7.37 (s, 1H), 7.52 (s,

[0811] 1 - [2 - (2, 2 - difluoroethyl

[0812] 2H), 7.74 (t, 1H), 8.00til)-5-(3 —sulfamoylbenzamide d "C广 0 (d, 1H), 8.14 (d, 1H), 미도)-2H - indazol - 6 - yl]-8.34 (s, 1H), 8.39 (d, N - hydroxy piperidine - 4 - ca 2H), 8.74 (s, 1H), 9.81riboxamide

[0813] (s, 1H), 10.50 (s, 1H) 1H NMR (DMSO - d6): 1.12 (s, 6H), 1.30 (m, 1H), 1 - {1 - [2 - (3 - hydroxy—3 —

[0814] 1.41 (m, 1H), 1.72 (m, methylbutyl)-5-(3 - 6H), 1.99 (t, 2H), 2.31 sulfamoylbenzamidecLHgH - (t, 1H), 2.55 (m, 1H), indazol—6 —

[0815] 2.74 (m, 1H), 2.77 (m, yl]piperidine—4—

[0816] 2H) , 3.01 (m, 1H) , 3.07 carbonyl}pi per idine— 3 — 0 0 (m, 2H) , 3.97 (d, 1H) , 639. carboxamide

[0817] 4.33 (d, 1H) , 4.42 (t , 77

[0818] 1- {1- [2- (3-hydroxy- 3- 2H) , 4.47 (s , 1H) , 6.75 u / o H-phosphorus (OH methylbutyl )- 5- (3-sulfamoyl (s , 1H) , 7.24 (s , 1H) , benzamido) - 2H-indazole- 7.31 (s , 1H) , 7.47 (s , β 0 FU

[0819] 6 -il]piperidine- 4-carbo (2H) , 7.75 (t , 1H) , 8.01 nil}piperidine- 3-carboxa (d, 1H) , 8.12 (d, 1H) , mid 8.28 (s , 1H) , 8.34 (s ,

[0820] 1H) , 8.40 (s , 1H) , 9.79 (s , 1H)

[0821]

[0822] 1H NMR (DMSO-d6): 1.10 l-[2-( 3-hydr oxy— 3 —

[0823] (s, 6H), 1.76 (m, 4H), methylbutyl)-5- (3 - 1.97 (m, 2H), 2.29 (m, sul f amoylbenzamido)-2H- 1H), 2.68 (m, 2H), 3.08 indazol-6-yl]- N- (2 - (m, 4H) , 3.42 (m, 2H) , * s / 0— hydroxyethyl )piper idine

[0824] 4.40 (s, 2H), 4.47 (s, 572. —4—carboxamide

[0825] 1H) , 4.60 (s , 1H) , 7.36 68 H / 1- [2- (3-hydroxy- 3-methyl (s , 1H) , 7.52 (s , 2H) , band S' 9 “v ^ 0H Butyl )- 5- (3 —sulfamoylbenz 7.77 (t , 1H) , 7.83 (s , amido) -2H-indazole- 6 - 1H) , 8.01 (d, 1H) , 8.13 6 ]- N- (2-hydroxyethyl ) (d, 1H) , 8.29 (s , 1H) , piperidine- 4-carboxamide 8.37 (s , 2H) , 9.80 (s ,

[0826] 1H)

[0827] N- (2- aminoethyl )-1 - [2 - 1H NMR (DMSO- d6) : 1.10 (3— hydroxy— 3 —

[0828] (s, 6H), 1.75 (m, 2H), methylbutyl)-5- (3 - 1.84 (m, 2H), 1.99 (t, sul f amoylbenzamidcLHgH- 2H), 2.33 (m, 1H), 2.70 indazol— 6 — 0

[0829] (t, 2H), 2.84 (q, 2H), H2N〜 N Ag yl ]piper idine— 4—

[0830] 3.10 (m, 2H) , 3.28 (q, carboxamide

[0831] 608.

[0832] 2H) , 4.42 (t , 3H) , 7.36 hydrochloride

[0833] 16 HA / T^ ^ 0H (s, 1H), 7.51 (s, 2H), d'"QP 0HCl N- (2-aminoethyl )- 1- [2- 7.78 (m, 4H) , 8.01 (d, (3-hydroxy- 3-methylbutyric)

[0834] 1H) , 8.05 (t , 1H) , 8.15 thil )- 5- (3 —sulfamoylbenzua

[0835] (d, 1H) , 8.30 (s , 1H) , mi do)- 2H-indazole- 6 -il ]pi

[0836] 8.34 (s , 1H) , 8.38 (s , peridin- 4-carboxamide

[0837] 1H) , 9.79 (s , 1H) 03sa eo u 12 u

[0838]

[0839] N- (2- aminoethyl )-1 - [2 - (3— hydroxy— 3 —

[0840] methylbutyl )-5- (3-0 sul f amoylbenzamidcLHgH- H2N〜 N J^ indazol— 6 —

[0841] yl ]piper idine— 4—

[0842] carboxamide

[0843] w 뿌 0<세 N- (2-aminoethyl)- 1- [2- (3-hydroxy- 3-methylbutyric)

[0844] Til)- 5- (3 —Sulpamoilbenzua

[0845] Mi Do)- 2H-Indazole- 6-il ]P

[0846] Peridin- 4 - Carboxamide

[0847] N-hydr oxy- 1- [ 2- ( 3- 1H NMR (DMSO- d6) : 1.11 hydr oxy-3-methy 1 butyl )- (s , 6H) , 1.72 (m, 2H) , 5-(3- 1.79 (m, 2H) , 1.98 (m, sul f amoylbenzamidcLHgH- 2H) , 2.13 (m, 1H) , 2.69 0 indazol— 6 — (t , 2H) , 3.06 (d, 2H) , HO 'N〜 yl ]piper idine— 4— 4.41 (t , 2H) , 4.47 (s ,

[0848] 544.

[0849] carboxamide 1H) , 7.36 (s , 1H) , 7.53 63

[0850] H2N / 』 \ 《OH (s , 2H) , 7.47 (t , 1H) , 6 N-hydroxy- 1- [2- (3 - hydride

[0851] … 8.01 (d, 1H) , 8.13 (d, roxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-1H) , 8.29 (s , 1H) , 8.34

[0852] 2H-Indazole-6-yl]piperidine-(s, 1H), 8.38(s, 1H),

[0853] 4-Carboxamide 8.74 (s , 1H) , 9.81 (s ,

[0854] 1H) , 10.50 (s , 1H)

[0855]

[0856] N— (1— hydroxy— 2 —

[0857] 1H NMR (DMSO- d6): 1.12 methylpropan— 2— yl )—1 —

[0858] (s, 6H), 1.15 (s, 6H), [2-(3-hydroxy—3—

[0859] 1.73 (m, 4H), 1.98 (m, methylbutyl)-5-(3 - 2H), 2.28 (m, 1H), 2.65 sul famoylbenzamidcLHgH- (m, 2H), 3.05 (m, 2H), indazol—6 —

[0860] *,乂 \ / — 0 3.35 (m, 2H), 4.40 (t, yl ]piperidine—4—

[0861] 600. 2H), 4.47 (s, 1H), 4.80 누〕— / carboxamide

[0862] 74 (s, 1H), 7.27 (s, 1H), H2N세、 / N-(1-hydroxy-2 -methylpr 7.35 (s, 1H), 7.50 (s, 로 판-2 -일)-1-[2-(3 -히드 2H), 7.74 (t, 1H), 8.01 록시-3 -methylbutyl)-5-(3 - (d, 1H), 8.13 (d, 1H), 술 파모 일벤 즈아 미도)-2H- 8.29 (s, 1H), 8.35 (s, 인다 졸-6 -일]piperidine-4 - 1H), 8.38 (s, 1H), 9.79 카르 복사 미 드 (s, 1H)

[0863] 1H NMR (DMSO-d6): 1.10 1-[2-(3-hydroxy—3—

[0864] methylbutyl)-5-(3 - (s, 6H), 1.30 (m, 1H), sul famoylbenzamido)-2H- 1.40 (m, 1H), 1.57 (m, indazol-6-yl ]—N— 2H), 1.75 (m, 5H), 1.90

[0865] (m, 1H) , 1.99 (m, 2H) , [ (1R, 2R)- 2 - .OH hydr oxy eye 1 opent y 1 ]pipe 2.27 (m, 1H) , 2.66 (m,

[0866] 612. 2H) , 3.05 (m, 2H) , 3.75 r idine— 4— carboxamide

[0867] 75 (m, 2H) , 4.40 (t , 2H) , H Z 1-[2-(3-hydroxy-3-methyl

[0868] Band 4.48 (s , 1H) , 4.65 (s , S' 9 1 Heart Book ' 《 0H Butyl )- 5- (3 —sulfamoylbenz

[0869] 1H), 7.36 (s, 1H), 7.52 (amido) -2H-indazole- 6 - (s, 2H), 7.73 (m, 2H), yl]- N- [ (1R, 2R)- 2 -hydroxyhydroxylase 8.01 (d, 1H), 8.15 (d, cyclopentyl]piperidin- 1H), 8.29 (s, 1H), 8.37 4— 7} [input h-gide]

[0870] (d, 2H) , 9.81 (s , 1H)

[0871]

[0872] l-[2-( 3-hydr oxy— 3 —

[0873] methylbutyl )-5- (3 - 1H NMR (DMSO- d6) : 1.12 sul f amoylbenzamido)-2H- (s , 6H) , 1.56 (m, 1H) , indazol-6-yl ]— N— 1.79 (m, 4H) , 1.97 (m, 0 [ (pyrrol idin— 3 — 1H) , 1.99 (m, 2H) , 2.68 yl )methyl ]piper idine— 4— (m, 2H) , 2.77 (m, 2H) , HNT—

[0874] N - / carboxamide 3.09 (in, 6H), 3.20 (in,

[0875] 648.

[0876] hydrochloride 2H), 4.41 (m, 3H), 7.36 HA / 22

[0877] d - mannitol HCl hydroxy (s, 1H), 7.51 (s, 2H),

[0878] 1 - [2 - (3 - - 3 - methyl

[0879] 7.75 (t, 1H), 8.03 (m, butyl)-5 - (3 - sulfamoylbenz 2H), 8.15 (m, 1H), 8.30 amido)-2H - indazole - 6 - (s, 1H), 8.34 (s, 1H), one]-N - [(pyrrolidin - 3 - yl) 8.38 (s, 1H), 8.74 (s, methyl] piperidine - 4 - carbox

[0880] 2H), 9.81 (s, 1H) samide hydrochloride

[0881] 1 - [2 - (3 - hydroxy—3 —

[0882] methylbutyl)-5 - (3 - sulfamoylbenzamido)-2H - indazol - 6 - yl]—N—

[0883] 0 [(pyrrolidin—3 —

[0884] HN 7 se yl)methyl]piperidine—4—

[0885] 611. carboxamide

[0886] H2N、 S P H heart) H 76

[0887] 1 - [2 - (3 - hydroxy - 3 - methyl

[0888] J 0 butyl)-5 - (3 —sulfamoylbenz It should be noted that the original text seems to have some unclear or incorrect chemical structure - related expressions, which may lead to difficulties in accurate understanding and translation. This translation is done based on the best effort to maintain the original content as much as possible.

[0889] (amido)-2H-indazol-6-yl]-N-[(pyrrolidin-3-yl)

[0890] methyl]piperidine-4-carbox

[0891] amide

[0892]

[0893] N-(4-aminobutyl)-1-[2-1H NMR (DMSO-d6): 1.11 (3-hydroxy-3-

[0894] (s, 6H), 1.43 (m, 2H), methylbutyl)-5-(3-1.49 (m, 2H), 1.77 (m, sulfamoylbenzamide.C8H-4H), 1.98 (m, 2H), 2.27 indazol-6-

[0895] (m, 1H), 2.75 (m, 4H), yl]piperidine-4-

[0896] 0 3.04 (m, 4H), 4.01 (q, tyk / x / dou carboxamide

[0897] 636. 1H), 4.42 (m, 2H), 7.35 hydrochloride

[0898] HCl ear heart jie li 11 21 (s, 1H), 7.53 (s, 2H),

[0899] N-(4-amino-butyl)-1-[2-7.69 (s, 2H), 7.75 (t, o,P sha ren (3-hydroxy-3-methylbut 2H), 7.90 (s, 1H), 8.01 h It should be noted that the original text seems to be rather fragmented and contains some unclear or potentially incorrect notations, which may make the translation a bit challenging to fully understand in a coherent context.N- (4-aminobutyl )-1 - [2 - (3— hydroxy— 3 —methylbutyl )-5- (3 -sulfamoylbenzamido)-2H-indazol- 6 -yl ]piperidine— 4 -carboxamide, δH (DMSO-d6): 1.20 (m, 2H), 1.40 (m, 2H), 1.50 (m, 2H), 1.60 (m, 2H), 2.30 (t, 2H), 3.20 (m, 2H), 3.50 (m, 2H), 3.80 (m, 2H), 6.70 (d, 1H), 8.13 (d, 1H), 8.30 (s, 1H), 8.34 (s, 1H), 8.38 (s, 1H), 9.81 (s, 1H)

[0900] N- (4- aminobutyl )-1 - [2 - (3— hydroxy— 3 —

[0901] methylbutyl )-5- (3 - 0 sul f amoylbenzamidcLHgH- ^Nvx / 斗 / y斗 indazol— 6 —

[0902] <{ H (这里原标签似乎有误,推测是 H ,按推测翻译) L^y^yN. 厂 (0H yl ]piper idine— 4—

[0903] 599.<{ (这里原标签似乎有误,推测是 ,按推测翻译)<{

[0904] (这里原标签似乎有误,推测是

[0904] ,按推测翻译) carboxamide <000313{6>(这里原标签似乎有误,推测是

[0905] ,按推测翻译) 75 [[ID=2{1]]

[0906] (这里原标签似乎有误,推测是

[0906] ,按推测翻译) N- (4 -amino butyl )- 1- [2 - (3 -hydroxy- 3 -methylbut

[0907] 틸 )- ********** (这里原内容似乎不完整,推测是틸 )- 5- (3 —술파모일벤즈아미도)- 2H-인다졸- 6 -일 ]피페리딘- 4 -카르복사미드,按推测翻译)

[0908] 미 도)- 2H-인다졸- 6 -일 ]피

[0909] 페리 딘- 4 -카르복사미드

[0910]

[0911] 请注意,原文中部分标签可能存在错误,我已按照推测进行翻译,如果实际标签有准确信息,请根据准确信息进行调整。1— [ 2— ( 3-hydr oxy— 3 — 1H NMR (DMSO- d6) : 1.12 methylbutyl )—5— (3 — ( s , 6H) , 1.80 (m , 4H) , sul famoylbenzaini dcLHffl- 1.99 (t , 2H) , 2.38 (m , indazo l-6-yl ]-N-(2, 2, 2- 1H), 2.69 (t, 2H), 3.07 tr if luoroethyl)p iper i di (d, 2H), 3.87 (m, 2H), ne— 4— carboxami de 4.42 (t, 2H), 4.48 (s,

[0912] 1H) , 7.35 ( s , 1H) , 7.47 1- [2-(3-hydroxy- 3-methyl )

[0913] ( s , 2H) , 7.74 (t , 1H) , butyl )- 5-(3 ―sulfamoylbenz

[0914] 8.01 (d , 1H) , 8.13 (d , amido ) -2H-indazole- 6 - 1H) , 8.29 ( s , 1H) , 8.33 il ]- N-(2 , 2 , 2 -trifluoride

[0915] ( s , 1H) , 8.38 ( s , 1H) , rhoethyl )piperidine- 4-car

[0916] Copy Mid 8.52 (t , 1H) , 9.78 ( s ,

[0917] 1H)

[0918] 1— [ 2— ( 3-hydr oxy— 3 — 1H NMR (DMSO- d6) : 1.12 methylbutyl )—5— (3 — ( s , 6H) , 1.79 (m , 5H) , sul famoylbenzami dcLHffl- 1.97 (t , 3H) , 2.28 (m , indazo l- 6- yl ]- N- (2 - 1H) , 2.69 (t , 2H) , 2.97 methanesul fonyl ethyl )pi ( s , 3H) , 3.06 (d , 2H) , per i dine— 4— carboxami de 3.45 (q , 2H) , 4.42 (t ,

[0919] 2H), 4.48 ( s , 1H) , 7.36 1- [2- (3-hydroxy- 3-methyl

[0920] ( s , 1H) , 7.50 ( s , 2H) , butyl )- 5- (3 ―sulfamoylbenz

[0921] 7.75 (t, 1H), 8.01 (d, amido) -2H-indazole-6 -1H), 8.12 (m, 2H), 8.29 ]-N-(2-methanesulfonyl

[0922] ( s , 1H) , 8.35 ( s , 1H) , thyl )piperidine- 4-carboxa

[0923] Mid 8.37 ( s , 1H) , 9.79 ( s ,

[0924] 1H)

[0925]

[0926]

[0927] 1H NMR (DMSO- d6) : 1.20

[0928] N- {6 - [4- (4 - (d, 1H), 1.31 (d, 1H), hydroxyp iper idine-1- 1.71-1.74 (m, 6H), 2.10 c ar bony 1)p iper i din— 1—

[0929] (m, 2H), 2.23 (m, 3H), yl]-2-(4, 4, 4- 2.77 (t, 3H), 2.95 (t, tr if luorobutyl)— 2H—

[0930] 0 1H) , 3.05-3.08 (d, 2H) , indazo l-5-yl}~3~

[0931] 3.18 (t , 1H) , 3.65 (t , 636. su 1 f amoy 1 benz am i de

[0932] 1H) , 3.75 (m, 1H) , 3.90 Ho^ 으 Yy— 69

[0933] N- {6 - [4- (4 -hydroxypife (m , 1H) , 4.42 (t , 2H) , 0 IQA

[0934] 2 Enter

[0935] s"v 、XV lithin- 1-carbonyl )piperi 4.70 (d , 1H) , 7.33 ( s , o' XT f f din- 1-yl ]- 2- (4, 4, 4-tri 1H) , 7.49 ( s , 2H) , 7.74 fluorobutyl )- 2H-indazole (t , 1H) , 8.00 (d , 1H) , -5 -yl}- 3 —sulfamoylbenzoa 8.14 (d , 1H) , 8.31 ( s , mid 1H) , 8.35 (d, 2H) , 9.80

[0936] ( s , 1H)

[0937] N-{6-[4-(4-aminopiperidine-1-carbonyl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide (1H NMR (DMSO—d6): 1.38—1.40 (q, 2H), 1.65 - 1.82 (m, 6H), 2.10 (m, 2H), 2.25 (m, 3H), 2.58 - 2.82 (m, 4H), 3.05 - 3.08 (d, 4H), 3.68 (m, 1H), 4.43 (t, 2H), 7.03 (t, 1H), 7.33 (s, 1H), 7.39 (s, 2H), 7.44 - 7.68 (m, 2H), 7.74 (t, 1H), 7.88 (d, 1H), 8.00 (d, 1H), 8.14 (d, 1H), 8.31 (s, 1H), 8.35 (d, 2H), 9.80 (s, 1H))

[0938] 635. sulfamoylbenzamide (t, 2H), 7.03 (t, 1H), mV

[0939] H2N.乂시 — 71 7.33 (s, 1H), 7.39 (s, 《

[0940] N-{6-[4-(4-aminopiperidine-1-carbonyl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide (1H NMR (DMSO—d6): 1.38—1.40 (q, 2H), 1.65 - 1.82 (m, 6H), 2.10 (m, 2H), 2.25 (m, 3H), 2.58 - 2.82 (m, 4H), 3.05 - 3.08 (d, 4H), 3.68 (m, 1H), 4.43 (t, 2H), 7.03 (t, 1H), 7.33 (s, 1H), 7.39 (s, 2H), 7.44 - 7.68 (m, 2H), 7.74 (t, 1H), 7.88 (d, 1H), ꜛ.00 (d, 1H), 8.14 (d, 1H), 8.31 (s, 1H), 8.35 (d, 2H), 9.80 (s, 1H))

[0941] o HN人人스\\ 2H), 7.44 - 7.68 (m, 2H), "에 1 F din-1-carbonyl)piperidin-7.74 (t, 1H), 7.88 (d, 1- yl]-2-(4,4,4-trifluoro

[0942] 1H), 8.00 (d, 1H), 8.14 butyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[0943] IS 8.35 (d, 2H), 9.80 (s,

[0944] 1H)

[0945] [[ID=z7]]

[0946] N-hydr oxy— 1— [ 5— ( 3- 1H NMR (DMSO- d6) : 1.72 sul famoylbenzaini dcLHB- (d , 2H) , 1.81 (m , 2H) , (4, 4 , 4- tr if luorobutyl )- 2.09 (m , 2H) , 2.15 (m , 2H— indazol — 6 — 1H) , 2.23 (m, 2H) , 2.67 yl ]p iper idine— 4— (t , 2H) , 3.05 (d , 2H) , carboxamide 4.43 (t , 2H) , 7.38 ( s ,

[0947] 1H), 7.53 ( s , 2H), 7.74 N-hydroxy- 1- [5- (3 ―sulfa

[0948] (t , 1H) , 8.00 (d , 1H) , moyl benzo' mido)- 2 - 8.14 (d , 1H) , 8.31 ( s , (4, 4 , 4 -trifluorobu)

[0949] 1H), 8.35 (d, 2H), 8.74 thyl )- 2H-indazole- 6 -yl ]piphe

[0950] ( s , 1H) , 9.81 ( s , 1H) , Ri Din-il 4— 7}Reubok-in FWhite]d

[0951] 10.5 ( s , 1H)

[0952] N- (6- {4 - [4- (2 - 1H) NMR (DMSO- d6) : 0.99 hydroxypropan— 2 — ( s , 6H) , 1.09 (m , 1H) , yl )p iper idine— 1— 1.38 (t , 1H) , 1.50 (d , carbonyl ]p iper i din— 1— 6H) , 1.65-1.82 (m, 6H) , yl}- 2- (propan- 2- yl )- 2H- 2.36 (t , 1H) , 2.77 (t , indazo l-5-yl )—3 — 3H) , 2.90 (t , 1H) , 3.08 sul famoyl benz am i de (d , 2H) , 4.04 (d , 1H) ,

[0953] 4.09 ( s , 1H) , 4.46 ( , N- (6- {4 - [4- (2 -hydroxy

[0954] 1H), 4.73 (q, 1H), 7.34 propane-2-yl)piperidin-1-(s, 1H), 7.49 (s, 2H), carbonyl]piperidin-1- 7.74 (t, 1H), 8.00 (d, yl)}-2-(propane-2-yl)-2H- 1H), 8.13 (d, 1H), 8.31 indazole-5-yl)-3-sulfamoyl

[0955] Benz Zua Mid ( s , 1H) , 8.35 (d , 2H) ,

[0956] 9.81 ( s , 1H)

[0957] 1- [2- methyl- 5- (3 - 1H— NMR(DMSO— d6): 1.74 sul famoylbenzaini dcLHffl- (t, 2H), 1.76 (t, 2H), indazo l-6-yl]-N-(2, 2, 2- 2.39 (m, 1H), 2.69 (t , tr if luoroethyl )p iper i di 2H) , 3.08 (d, 2H) , 3.88 ne— 4— carboxami de (m , 2H) , 4.08 ( s , 3H) ,

[0958] 7.34 ( s , 1H) , 7.47 ( s , 1- [2-methyl- 5- (3 ―sulfamoyl

[0959] 2H) , 7.73 (t , 1H) , 8.00 Benzamido)- 2H-indazole- (d , 1H) , 8.15 (d , 1H) , 6 -yl ]- N- (2, 2 , 2 -triflu

[0960] 8.23 ( s , 1H) , 8.34 ( s , oroe ethyl )piperidine- 4-car

[0961] 1H) , 8.38 ( s , 1H) , 8.51 Le Bocca Mid

[0962] (m , 1H) , 9.77 ( s , 1H)

[0963]

[0964] N- {2- methyl- 6 - [4 - 1H— NMR(DMSO— d6): 1.75

[0965] (morpho l ine— 4— (m , 4H) , 2.74 (m , 3H) , carbonyl )p iper i din— 1— 3.06 (d , 2H) , 3.40-3.60 yl ]— 2H— indazol— 5— yl}— 3— (m , 8H) , 4.08 (s, 3H), sul famoyl benz am i de 7.29 (s, 1H), 7.48 (s,

[0966] 2H), 7.74 (t, 1H), 8.00 N-{2-methyl-6-[4-(morphol){2-methyl-6-[4-(morphol){2-methyl-6-[4-[4-]{4-methyl-6

[0967] Lin- 4 -carbonyl)piperidine- (d , 1H) , 8.11 (d , 1H) ,

[0968] 8.23 ( s , 1H) , 8.33 ( s , 1-yl]- 2H-indazole- 5 -yl}- 1H) , 8.37 ( s , 1H) , 9.78 3 -sulfamoylben zua mid ( s , 1H)

[0969] 1- [2- methyl- 5- (3 - 1H— NMR(DMSO— d6) : 1.01 sul famoylbenzami do)-2H- (d , 6H) , 1.75 (d , 4H) , indazo l-6-yl ]— N— 2.21 (t , 1H) , 2.67 (m, (propan— 2 — 2H) , 3.06 (d , 2H) , 3.80 yl )p iper idine— 4— (q , 1H) , 4.08 (s , 3H) , carboxamide 7.35 ( s , 1H) , 7.50 ( s ,

[0970] 2H), 7.68 (d, 1H), 7.74 1-[2-methyl-5-(3―sulfamoyl

[0971] Benzamido )- 2H-Indazole- (t , 1H) , 8.00 (d , 1H) ,

[0972] 8.11 (d , 1H) , 8.23 ​​( s , 6 -il]- N-(propane- 2 -il)pi

[0973] 1H), 8.36 (s, 2H), 9.80 peridin-4-carboxamide (s, 1H)

[0974] N- (2-hydr oxyet hy 1)—N—

[0975] 1H— NMR (DMSO— d6) : 1.75 methyl— l— [ 2— methyl— 5 —

[0976] (m , 4H) , 2.73 (m , 3H) , ( 3— su 1 f amoy 1 benz am i do ) —

[0977] 2.80 (m, 2H), 3.06 (s, 2H—indazol—6—

[0978] 3H) , 3.40 (m , 2H) , 3.52 yl ]p iper idine— 4—

[0979] (d, 2H), 4.08 (s, 3H), carboxamide

[0980] 5.72 (s, 1H), 7.31 (s, N-(2-hydroxyethyl)-N-methyl 1H), 7.51 (d, 2H), 7.74 tyl-1-[2-methyl-5-(3-sulfa(t, 1H), 8.00 (d, 1H), moylbenzamido)-2H-inda 8.11 (d, 1H), 8.23 ​​(s, sol-6-yl]piperidin-4-car 1H), 8.33 (s, 1H), 8.37 boxamid (s, 1H), 9.81 (d, 1H)

[0981]

[0982]

[0983] N-hydr oxy— 1- [ 2-methy 1 — 1H- NMR(DMSO- d6): 1.75

[0984] 5-(3- (m, 4H) , 2.15 (m, 1H) , 0 sul f amoylbenzamidcLHgH- 2.69 (d, 2H) , 3.06 (d, indazol— 6 — 2H) , 4.08 (s , 3H) , 7.34 H ° o yl ]piper idine— 4— (s , 1H) , 7.52 (s , 2H) ,

[0985] 472.

[0986] carboxamide 7.74 (t, 1H), 8.00 (d, 52

[0987] H2N, / 호 妙 스 1H), 8.11 (d, 1H), 8.23

[0988] N-hydroxy-1-[2-methyl-5-(s, 1H), 8.34 (s, 1H), (3 — sulfamoylbenzamido)-8.37 (s, 1H), 8.73 (s, 2H-indazol-6-yl]piperidine

[0989] 1H), 9.79 (s, 1H), 10.50 - 4 - 7}르복入 h기드

[0990] (s, 1H)

[0991] N, N-dimethyl-1-[2-methyl—5—(3 — 1H-NMR(DMSO-d6): 1.74 0 sulfamoylbenzamidcLHgH-(m, 4H), 2.77 (m, 6H), indazol—6 — 3.02 - 3.04 (m, 5H), 4.08 yl]piperidine—4—(s, 3H), 7.31 (s, 1H), 484.

[0992] 人 』 7 carboxamide 7.50 (s, 2H), 7.74 (t, o HN 58

[0993] 1H), 8.00 (d, 1H), 8.12 N, N-dimethyl-1-[2-methyl-5-(d, 1H), 8.23 (s, 1H), (3 — sulfamoylbenzamido)-8.34 (s, 1H), 8.37 (s, 2H-indazol-6-yl]piperidine

[0994] 1H), 9.80 (s, 1H) - 4 - 7}르복入 h기드<000个3322>

[0995] 1H NMR (DMSO-d6): 1.38 N-{6-[4-(2-(m, 4H), 1.55 (m, 1H), hydroxyethyl)piperidin— It should be noted that there are some unclear or incorrect notations in the original text (such as "르복入 h기드"), which may affect the accuracy of the overall understanding and translation.

[0996] 1.76 (d, 2H), 2.10 (m, l-yl]-2-(4, 4,4- 2H), 2.25 (m, 2H), 2.68 trifluorobutyl)—2H—

[0997] (t, 2H), 3.00 (d, 2H), indazol-5-yl}—3—

[0998] 3.45 (s, 2H), 4.32 (s, 553. sulfamoyl benz amide

[0999] 1H), 4.43 (s, 2H), 7.40 60

[1000] N-{6-[4-(2-hydroxyethyl)piperidin- 1-yl]-2-methyl-2H-

[1001] H2N、 S [[and others, 'Three companies']-1-yl]-2-7.78 (t, 1H), 8.02 (d, (outside 0 people 0 FF (4, 4, 4-trifluorobutyl)-2H-indazol-5-yl}-3-(s, 1H), 8.31 trifluorobutyl)-2H-indazole-5-yl}-3-(s, 1H), 8.36 (s, 1H), sulfamoylbenzamide 8.46 (s, 1H), 9.87 (s,

[1002] 1H)

[1003]

[1004] 1H NMR (DMSO-d6): 1.42

[1005] N-{6-[4-(2-(m, 4H), 1.52 (m, 1H), hydroxyethyl)piperidin—

[1006] 1.76 (m, 2H), 2.68 (m, 1-yl]—2—methyl—2H—

[1007] It should be noted that there seem to be some unclear or incorrect parts in the original text, especially in the "얘 、 '三 社 틸 )피페리딘-1-일" part which is difficult to accurately understand and translate. This translation is based on the best attempt to make sense of the available text.2H), 2.99 (m, 2H), 3.44 indazol-5-yl}—3—(t, 2H), 4.09 (s, 3H), 457. sulfamoyl benzamide

[1008] 0 number HN人Y人'N- 4.32 (s, 1H), 7.37 (s,

[1009] 55

[1010] N-{6-[4-(2-hydroxyethyl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoyl benzamide

[1011] (s, 1H), 9.86 (s, 1H) N-{6-[4-(hydroxymethyl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoyl benzamide

[1012] o HN人人 7 丄 3.32 (d, 2H), 4.43 (t,

[1013] 57 3H), 7.41 (s, 1H), 7.47 s才N-{6-[4-(hydroxymethyl)

[1014] o 1 F (s, 2H), 7.77 (t, 1H), piperidin-1-yl]-2-(4,4,4-trifluorobutyl)

[1015] 1H), 8.30 (s, 1H), 8.37 (t)-2H-indazol-5-yl}-3-(s, 1H), 8.45 (s, 1H), sulfamoyl benzamide

[1016] 9.87 (s, 1H)

[1017] 1H NMR (DMSO-d6): 1.34 N-{6-[4-(m, 2H), 1.51 (m, 1H), (hydroxymethyl)piperidino

[1018] 1.77 (m, 2H), 2.68 (m, H( / 、[今n—1—yl]—2—methyl—2H—

[1019] 2H), 3.01 (m, 2H), 3.35 Uy dou_indazol-5-yl}~3~

[1020] (m, 2H), 4.07 (s, 3H), 443. sulfamoyl benzamide

[1021] U H K N T TTXT ^、z으 / 4.44 (s, 1H), 7.36 (s,, / o HN

[1022] 2 L、스52[[ID=2,9]]

[1023] N-{6-[4-(hydroxymethyl) 1H), 7.45 (s, 2H), 7.76 / J piperidin-1-yl]-2-methyl-(t, 1H), 8.02 (d, 1H),

[1024] 2H-indazol-5-yl}-3 —sulfamoyl benzamide 8.22 (t, 1H), 8.36 (s, 1H), 8.37 (s, 1H), 8.43

[1025] (s, 1H), 9.85 (s, 1H)

[1026]

[1027] 1H NMR (DMSO—d6): 1.26 —

[1028] N-{6 -[4-(aminomethyl)piperidin-

[1029] (m, 1H), 1.78 (d, 2H), l-yl]-2-methyl-2H- 2.67-2.72 (m, 4H), indazol-5-yl}-3-

[1030] l ,,,N,y, Y ,N 3.11-3.13 (m, 2H), 4.12 sulfamoyl benzamide

[1031] |ii N — 515. (s, 3H), 7.35 (s, 1H), n 0 HN''' w hydrochloride

[1032] 45 7.46 (s, 2H), 7.75 (t, 忌厂人 HC1 N-{6 - [4-(aminomethyl)pi 1H), 7.88 (brs, 3H), 으W peridine-1-yl]- 2 -methyl-2H- 8.03 (d, 1H), 8.13 (d, indazol-5-yl}-3-sulfamoyl 1H), 8.24 (s, 1H), 8.38 benzamide hydrochloride (s, 1H), 8.46 (s, 1H),

[1033] 9.87 (s, 1H)

[1034] 1H NMR (DMSO-d6) 6: 1.20 1.35 (m, 2H), 1.55- N- {6 - [4 - (aminomethyl)p iper idin— 1.70 (m, 1H), 1.75- 1. 82 l-yl]-2-methyl-2H- (in, 2H), 2.35-2.55 (in, indazo l-5-yl}~3~ 2H) , 2. 60-2.75 (m, 4H) , 442. 3.05-3.15 (m, 2H) , 4.07 su 1 f amoy 1 benz am i de

[1035] H2N、 / Wash 」 54 ( s , 3H) , 7.34 ( s , 1H) ,

[1036] N- {6 - [4-(aminomethyl)pi / se 7.45-7.55 (br s , 2H) , peridin-1-yl]-2-methyl-2H-7.73 (t , 1H) , 7.95-8.05 indazole-5-yl}-3-sulfamoyl

[1037] (in , 2H) , 8.20-8.25 (in, benzamide

[1038] 2H) , 8.38 ( s , 1H) , 9.85 ( s , 1H) .

[1039] 1H- NMR (DMSO- d6): 1.11 N-{6 - [ (35)-3- (s, 6H), 1.65 (m, 2H), [ (carbamoylmethyl) carba

[1040] 1.95 (m , 2H) , 2.00 (t , moyl ]p iper i din— 1— yl ]— 2 —

[1041] 2H) , 2.69 (m , 2H) , 2.91 (3— hydroxy— 3 —

[1042] (m , 2H) , 3.08 (d , 1H) , methylbutyl )- 2H- 3.52 (m , 2H) , 4.42 (t , indazo l-5-yl}~3~

[1043] 551. 2H), 4.47 (s, 1H), 6.91 nitrobenzamide-based —보 z 60 (s, 1H), 7.16 (s, 1H), N-{6 - [(3S)-3 - [(carbamoyl 0 ° HN시아义 OH 7.38 (s, 1H), 7.84 (t, 1H), 7.93 (t, 1H), 8.30 methyl)carbamoyl]piperidine-1-yl]-2-(3-hydroxy °"幻스 (s, 1H), 8.33 (d, 1H), 시-3-methylbutyl)-2H-indazole-5-yl}-3-nitrobenzamide

[1044] (s, 1H)

[1045]

[1046] 1H NMR (DMSO-d6): 1.09

[1047] N-{6 - [4-(2-hydroxy—2—

[1048] (s, 6H), 1.20 (s, 2H), methylpropyl)piperidin—

[1049] 1.36 (m, 3H), 1.85 (d, l-yl]-2-methyl-2H- 2H), 2.67 (t, 2H), 2.98 indazol-5-yl}-3-

[1050] (d, 2H), 4.04 (m, 1H), 으 sulfamoyl benzamide

[1051] 485. 4.08 (s, 3H), 7.35 (s, „ XT 0 T HTXNT* 1 으、느스 / 저느厂

[1052] 6-N-{6-[4-(2-hydroxy-2-1H), 7.46 (broad s, 2H), methylpropyl)piperidin-1-, 7.78 (t, 1H), 8.01 (d, ...]-2-methyl-2H-indazol-5-1H), 8.13 (d, 1H), 8.22,}-3-sulfamoylbenzamide, 8.36 (s, 1H), IS 8.44 (s, 1H), 9.84 (s,

[1053] 1H)

[1054] N-{6-[4-(aminomethyl)piperidin-2.10 (m, 2H), 2.20 - 2.30 l-yl]-2-(4, 4, 4-(in, 2H), 2.50 - 2.60 (in, trifluorobutyl)-2H-2H), 2.65 (t, 2H), 2.80 H2NY indazol-5-yl}-3-, sulfamoylbenzamide 3.10 (d, 2H), 4.50 (t, 611.

[1055] 2dihydrochloride 2H), 7.35 (s, 1H), 7.46 HN / '9少 1 义 X HC; '丁方F 51

[1056] (broad s, 2H), 7.60 (t, N-{6-[4-(aminomethyl)pi

[1057] piperidin-1-yl]-1H), 7.80 (broad s, 3H),

[1058] 2-(4, 4, 4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenz

[1059] Zua mid 2 hydrochloride (s, 1H), 8.45 (s, 1H),

[1060] 9.80 (s, 1H)

[1061] 1H NMR (DMSO-d6): 1.55 - N-{6-[4 - 1.70 (m, 3H), 1.75 - 1.85 (aminomethyl)piperidin—

[1062] (m, 2H), 1.95 - 2.10 (m, l-yl]-2-(4, 4, 4 - 2H), 2.20 - 2.35 (m, 4H), trifluorobutyl)-2H~

[1063] H2N"Y^ 2.45 - 2.55 (m, 2H), 으 indazol-5-yl}-3~

[1064] 2.60 - 2.75 (m, 2H), 538. sulfamoyl benzamide

[1065] 2.90 - 3.05 (m, 2H), 4.45 59

[1066] :min V ' three v N-{6-[4-(aminomethyl)pi (t, 2H), 7.34 (s, 1H), peridine - 1-yl]-2-(4, 4, 4 - 7.45 - 7.55 (br s, 2H), trifluoro butyl)-2H-indazole - 5 - yl}-3-sulfamoylbenzene (in, 2H), 8.20 - 8.25 (in, zua mid 2H), 8.38 (s, 1H). 9.82

[1067] (s, 1H).

[1068]

[1069] 1H NMR (DMSO-d6): 1.06

[1070] N-[6-(3 - { [bis(2-(s,12H),1.21(s,6H),hydroxy-2-1.52 - 1.63(m,2H),methylpropyl)amino]meth1.75 - 1.84(m,2H),yllpiperidin - l - yl) - 2 - 1.86 - 1.90(m,1H),HO人methyl - 2H - indazo1 - 5 - 2.10 - 2.14ppm(in,1H), f N^k° H y1] - 3 - [(2 - hydroxy - 2 - 2.54(d,2H),2.62(t,2H),2.75(d,4H),2.93658.

[1071] benzamide(d,2H),3.11ppm(d,86

[1072] 2H),4.08(s,3H),4.12HljjW N - [6 - (3 - { [bis(2 - hydroxy(2 - methylpropyl)amino]

[1073] methyl}piperidin - 7.35(s,1H),7.46(br1 - yl)-2 - methyls,1H),7.61(t,1H), - 2H - indazol - 5 - yl] - 3 - 7.94(s,1H),8.03(d,[ (2 - hydroxy - 2 - methylpro

[1074] pyl)sulfamoyl]benzamide1H),8.15(d,1H),8.35

[1075] (s,1H),8.45(s,1H),9.83(s,1H)

[1076] 1H NMR (DMSO- d6): 1.06 (s, 6H), 1.10 (t, 3H), 3 - (ethyl sul f amoyl) - N- 1.52 1.63 (m, 2H), (6-{3-[ (2-hydr oxy— 2~ 1.75-1.84 (m, 2H), methylpropyl )amino]pipe 1.85-1.93 (m, 1H) , r idin—l—yl}— 2— methyl — 2.10-2.15 (m, 1H) , 2.53 2H— indazol— 5 — (br s , 1H) , 2.65 (t , 528. yl ) benz am ide 2H) , 2.75 (d, 2H) , 2.95 o 67 (q, 2H) , 3.13 (d, 2H) ,

[1077] 3-(ethylsulfamoyl)-N-(6-4.08(s, 3H) , 4.12(s, {3-[(2-hydroxy-2-methyl

[1078] propyl) amino]piperidine- 1H), 7.35 (s, 1H), 7.46

[1079] (br s , 1H ) , 7.60 (t , 1-yl}- 2-methyl- 2H-indazole- 1H) , 7.94 (s , 1H) , 8.01 5 -yl )benzamide (d, 1H) , 8.15 (d, 1H) ,

[1080] 8.35 (s, 1H), 8.45 (s, 1H), 9.81 (s, 1H)

[1081]

[1082] 1H NMR (DMSO- d6) : 1.45

[1083] N-(6 -{4- (m, 2H), 1.85 (m, 3H), [ (methyl amino)methyl ]pi

[1084] 2.10 (m, 2H), 2.22 (m, per idin-l-yl}-2-(4, 4,4-2H), 2.52 (s, 3H), 2.71'm…trifluorobutyl)-2H-indazol-5-yl)-3—

[1085] 3.04 (m, 2H), 3.30 (s, — Yi Jiang 7 ' Heritage 552. sulfamoyl benzamide

[1086] 1H), 4.43 (s, 2H), 7.44 62

[1087] O' ^Qp 0 F F N-(6-{4-[(methylamino)meth (s, 1H), 7.54 (br s, til]piperidin-1-yl}-2-2H), 7.88 (m, 1H), 8.03 (4, 4, 4-trifluorobutyl)-2H-indazol-5-yl)-3-8.32 (s, 1H), 8.38 (s, sulfamoyl benzamide 1H), 8.44 (s, 1H), 9.89

[1088] (s, 1H).<000�515>

[1089] N-(6-{4-1H NMR (DMSO-d6): 1.45 [(dimethyl amino)methyl]

[1090] (m, 2H), 1.89 (m, 3H), piperidin-l-yl}~2~

[1091] 2.10 (m, 2H), 2.24 (m, (4, 4,4-trifluorobutyl)-2H), 2.75 (m, 7H), 3.05 2H-indazol-5-yl)-3—

[1092] (m, 4H), 4.44 (m, 2H), uh 566. sulfamoyl benzamide It should be noted that there may be some inaccuracies or unclear parts in the original text which might affect the precision of the translation. If possible, it would be beneficial to have a more accurate or clarified original text for a more accurate translation.

[1093] H 7 Arts 64 7.40 (s , 1H) , 7.54 (s ,

[1094] N- (6-{4-[(dimethylamino)2H) , 7.79 (m, 1H) , 8.04 methyl]piperidin-1-yl}-2-(m, 1H) , 8.17 (m, 1H) , (4,4,4-trifluorobutyric 8.33 (s , 1H) , 8.38 (s , yl)-2H-indazole-5-yl )-3-1H) , 8.44 (s , 1H) , 9.67 sulfamoylbenzamide (s , 1H) , 9.88 (s , 1H) .

[1095] 1H NMR (DMSO-d6): 0.81 N-[2-(2, 2- (s, 9H), 1.06 (s, 6H), dimethylpropyl)—6—[4—

[1096] 1.33 (m, 1H) , 1.44 (m, (2— hydroxypropan— 2 —

[1097] 2H) , 1.80 (m, 2H) , 2.64 yl )piper idin-l-yl ]-2H- (m, 2H) , 3.10 (m, 2H) , indazol-5-yl ]— 3— H It p

[1098] 527. 4.11 (m, 1H) , 4.30 (m, su 1 f amoy 1 benz am i de

[1099] 68 2H) , 7.37 (s , 1H) , 7.45 H2N、 / N- [2- (2, 2-dimethylprop (s , 2H) , 7.73 (m, 1H) , phil)- 6 - [4- (2-hydroxyp o' "Qs' 08.01 (m, 1H), 8.12 (m, 2H), piperidin-1-yl), 8.29 (s, 1H), 8.35 (s, 1H), 8.44 (s, 1H), sulfamoylbenzamide

[1100] 9.81 (s, 1H).

[1101]

[1102] 1H NMR (DMSO-d6): 0.39

[1103] N-[2-(m, 2H), 0.52 (m, 2H), (cyclopropylmethyl)-6-

[1104] 1.06 (s, 6H), 1.33 (m, [4-(2-hydroxyprop-2-yl)piperidin-1-yl]-2H-

[1105] 2H), 1.44 (m, 2H), 1.80 (m, 2H), 2.64 (m, 2H), [4-(2-hydroxyprop-2-yl)piperidin-1-yl]-2H-

[1106] HO [4-(2-hydroxyprop-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-

[1107] 3.10 (m, 2H), 4.11 (m, 1H), 4.19 (m, 2H), 7.37

[1108] 1H), 4.19 (m, 2H), 7.37 H W <외 Q꺼人人 o 人 7 스 64

[1109] N-[2-(Cyclobutylmethyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide

[1110] 1H).

[1111] 1H NMR (DMSO-d6): 1.06 N-[2-(s, 6H), 1.35 (m, 1H), (cyclobutylmethyl)—6 —

[1112] 1.44 (m, 2H), 1.79 (m, [4-(2-hydroxyprop an—2~

[1113] 6H), 1.95 (m, 2H), 2.64 yl)piperidin—1—yl]—2H—

[1114] ga (m, 2H), 2.84 (m, 1H), indazol-5-yl]—3—

[1115] 3.07 (m, 2H), 4.11 (s, 525. sulfamoyl benzamide

[1116] 1H), 4.36 (m, 2H), 7.37 67

[1117] N-[2-(Cyclobutylmethyl)-(s, 1H), 7.46 (s, 2H), <AQ 人 o 니 6-[4-(2-hydroxypropane-7.73 (m, 1H), 8.02 (m,

[1118] 2 - {6 - [4 - (2 - hydroxypropan - 2 - yl)piperidin - 1 - yl] - 5 - (3 - sulfamoylbenzamido)-2H - indazol - 2 - yl}ethyl diethyl phosphonate

[1119] 1H).

[1120]

[1121] 1H NMR (DMSO - d6): 1.06 (s, 6H), 1.16 (s, 6H), 1.35 (m, 1H), 1.45 (m, 2H), 1.80 (m, 2H), 2.64 (m, 2H), 3.07 (m, 2H),

[1122] 2H), 3.31 (m, 2H), 3.95 (m, 4H), 4.11 (m, 1H), 4.52 (m, 2H), H (3 - sulfamoylbenzamido)-

[1123] 2H - indazol - 2 - yl

[1124] o HN〕父 N 『 4H), 4.11 (m, 1H), 4.52 (m, 2H),

[1125] Diethyl (2 - {6 - [4 - (2 - hydroxypropan - 2 - yl)piperidin - 1 - yl] - 5 - (3 - sulfamoylbenzamido)-2H - indazol - 2 - yl}ethyl)phosphonate

[1126] 1H), 9.81 (s, 1H). 1H NMR (DMSO-d6): 1.06 N-[2-(difluoromethyl)-(s, 6H), 1.36 (m, 1H), 6 - [4-(2-hydroxypropan—

[1127] 1.46 (m, 2H), 1.80 (m, 2-yl)piperidin-l-yl]-2H), 2.65 (m, 2H), 3.13 2H—indazol—5—yl]—3 —

[1128] (m, 2H), 4.13 (s, 1H), H isopropyl sulfamoyl benzamide

[1129] δ 507. 7.43 (s, 1H), 7.46 (s,... T o T HT​​​​​​​​​​​​​​​​​​​​1.82 (d, 2H), 2.71 (t, yl}-3-(2-methyl-2H-2H), 3.14 (d, 2H), 3.99 H It p

[1135] “YTN—1, 2, 3, 4-1 etrazol -5 - 474. (s, 3H), 4.11 (s, 1H), N=N HN^、人'''' 7 yl) benz amide

[1136] 569 4.42 (s, 3H), 7.45 (s, N-{6-[4-(2-hydroxypro 1H), 7.73 (t, 1H), 7.96 * N Four spane - 2 - yl)piperidin - 1 - yl]-(s, 1H), 8.07 (d, 1H), 2 - methyl - 2H - indazole - 5 - yl}-8.23 (s, 1H), 8.48 (s, 3-(2 - methyl - 2H - 1, 2, 3, 4 - tetra 1H), 8.57 (s, 1H), 9.78 triazole - 5 - yl)benzamide (s, 1H)

[1137]

[1138] 1H NMR (DMSO - d6): 0.96

[1139] N-{6-[4-(2-(s, 6H), 1.21 - 1.33 (m, hydroxypropan—2 —

[1140] 1H), 1.33 - 1.39 (q, 2H), yl)piperidin—1—yl]—2 —

[1141] 1.81 (d, 2H), 2.66 (t, methyl - 2H - indazo 1 - 5 - 2H), 3.13 (d, 2H), 3.99 yl}—3—(1H—imidazol—1—

[1142] (s, 3H), 4.08 (s, 1H), yl) benz amide

[1143] 7.10 ( s , 1H) , 7.41 ( s , N- {6 - [4-(2-hydroxypro 1H) , 7.67 (t , lh) , 7.83 pan- 2-yl)piperidine- 1-yl]- ( s , 1H) , 7.86-7.89 (m, 2-methyl- 2H-indazole- 5-yl}- 2H) , 7.94 ( s , 1H) , 8.33 3-(1H-imidazole- 1-yl)benz ( s , 1H) , 8.37 ( s , 1H) , zamide 8.46 ( s , 1H) , 9.71 ( ,

[1144] 1H)

[1145] N- {6 - [4- (2 - 1H NMR (DMSO- d6) : 0.99 hydroxypropan- 2- ( s , 6H) , 1.28-1.37 (m, yl )p iper idin— 1— yl ]— 2 — 1H) , 1.40-1.43 (m, 2H) , methyl -2H- indazo 1—5 — 1.79 (d , 2H) , 2.66 (t , yl}-3-( lH-l , 2, 4- 2H) , 3.13 (d, 2H) , 3.99 tr i azo ll-yl )benzami de ( s , 3H) , 4.10 ( s , 1H) ,

[1146] 7.43 ( s , 1H) , 7.72 (t , N- {6 - [4-(2-hydroxypro

[1147] Pan- 2 -yl)piperidin- 1-yl]- 1H) , 7.83 ( s , 1H) , 7.97

[1148] (s, 1H) , 8.08 (d, 1H) , 2-methyl-2H-indazole-5-yl}- 8.23 ​​(s, 1H) , 8.41 (d, 3-(1H-1, 2, 4-triazole-1-yl)benzamide 1H) , 9.39 (s, 1H) , 9.73

[1149] ( s , 1H) .

[1150] N- {6 - [4- (2 - 1H NMR (DMSO- d6) : 1.07 hydroxypropan— 2 —

[1151] ( s , 6H) , 1.32-1.42 (m, yl )p iper idin— 1— yl ]— 2 —

[1152] 1H) , 1.46-1.48 (m, 2H) , methyl -2H- indazo 1-5- 1.80 (d , 2H) , 2.60 ( s , yl}— 4— methyl— 3 —

[1153] 3H) , 2.63 (t , 2H) , 3.10 sul famoyl benz am i de

[1154] (d , 2H) , 3.99 ( s , 3H) , N- {6 - [4- (2-hydroxypro 4.14 ( s , 1H) , 7.34 ( s , pan- 2-yl )piperidin- 1-yl]- 1H) , 7.44 ( s , 2H) , 7.70 2-methyl- 2H-indazole- 5-yl}- (d , 1H) , 7.94 ( s , 1H) , 4-methyl- 3-sulfamoylbenza 7.96 (d , 1H) , 8.43 ( s , mid 2H) , 9.69 (s . 1H) .

[1155]

[1156]

[1157] 4-f luoro-N-{6 - [4-(2- 1H NMR (DMSO- d6) : 1.06 hydr oxypropan- 2- (s, 6H) , 1.36-1.43 (m, yl)piper idin— 1— yl ]— 2 —

[1158] 1H) , 1.44-1.46 (m, 2H) , that methyl— 2H—indazo 1—5 —

[1159] 1.80 (d, 2H), 2.66 (t, yl}-3- 2H), 3.13 (d, 2H), 3.98 ^ N TTN-489. sulfamoyl benzamide

[1160] (s, 3H), 4.11 (s, 1H), o HN人人' 7 57

[1161] 4-Fluoro-N-{6-[4-(2- 7.41 (s, 1H), 7.59 (t, — O hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H- (s, 1H), 7.77 (s, 2H), 7.94 indazol-5-yl}-3-sulfamoyl 8.23 (s, 1H), 8.32 (s. 1H), 9.75 (s, benzamide 1H)

[1162] 4-chloro-N-{6 - [4-(2- 1H NMR (DMSO-d6): 1.06 hydroxypropan-2- (s, 6H), 1.36-1.41 (m, yl)piperidin—1—yl]—2 —

[1163] 1H), 1.43-1.45 (m, 2H), H 잇 p methyl—2H—indazo1—5 —

[1164] 1.78 (d, 2H), 2.66 (t, yl}-3- 2H), 3.12 (d, 2H), 3.98 506. sulfamoyl benzamide

[1165] (s, 3H), 4.12 (s, 1H), H2N、 / 妙스02

[1166] 4-chloro-N-{6-[4-(2-hyp 7.41(s, 1H) , 7.71(s, 0sdroxypropane-2-yl)pipe 2H) , 7.81(d, 1H) , 7.94ridin-1-yl]-2-methyl-2H-phosph (s, 1H) , 8.12(d, 1H) ,dazole-5-yl}-3-sulfamoylben 8.34(s, 1H) , 8.51(s, zamide 1H) , 9.80(s, 1H) . N-{6 - [4-(2- 1H NMR (DMSO- d6) : 1.06 hydr oxypropan- 2- (s , 6H) , 1.36 (m, 1H) , yl )piper idin— 1— yl ]— 2 —

[1167] 1.44 (m, 2H) , 1.80 (d, ( 2 H3)methyl-2H- 2H) , 2.63 (t , 2H) , 3.05 indazol-5-yl}~3~

[1168] HN o bOH D (d, 2H) , 4.12 (s , 1H) ,

[1169] 474. su 1 f amoy 1 benz am i de

[1170] 7.35 (s , 1H) , 7.46 (s , 59

[1171] N- {6 - [4- (2 -hydroxypro 2H) , 7.73 (t , 1H) , 8.01 「 A pan- 2 -yl )piperidine- 1-yl]- (d, 1H) , 8.11 (d, 1H) ,

[1172] 2-( 2 H3)methyl-2H-indazole 8.23 ​​(s , 1H) , 8.35 (s , -5 -yl}-3—sulfamoylbenzoate 1H) , 8.44 (s , 1H) , 9.80 mid (s , 1H) .

[1173]

[1174] N- {6 - [4- (2 - 1H NMR (DMSO- d6) : 0.99 hydroxypropan— 2 — (s , 6H) , 1.28 (m, 1H) , yl )piper idin— 1— yl ]— 2 — 1.39 (m, 2H) , 1.74 (d, [2— (thiophen— 2 — 2H) , 2.59 (t , 4H) , 3.03 yl )ethyl ]- 2H- indazol- 5 - (d, 2H) , 4.04 (s , 1H) , yl}-3- 4.52 (m, 2H) , 6.72 (m, sul famoyl benz am i de 1H) , 6.82 (m, 1H), 7.20

[1175] (m, 1H) , 7.31 (s , 1H) , N- {6 - [4- (2 -hydroxypro

[1176] 7.39 (s , 2H) , 7.67 (m, pan- 2 -yl )piperidine- 1-yl]- 1H) , 7.94 (m, 1H) , 8.04 2 - [2-(thiophene- 2 -yl )e (m, 1H) , 8.13 (s , 1H) , tyl]- 2H-indazole- 5 -yl}- 3 - sulfamoylbenzamide 8.28 (s , 1H) , 8.33 (s ,

[1177] 1H) , 9.72 (s , 1H) .

[1178] N- {6 - [4- (2 - 1H NMR (DMSO- d6) : 1.06 hydroxypropan— 2 — (s , 6H) , 1.35 (m, 1H) , yl )piper idin— 1— yl ]— 2 — 1.44 (m, 2H) , 1.79 (d, [ 2 - ( lH-pyr az o 1 - 1- 2H) , 2.64 (t , 2H) , 3.08 yl )ethyl ]- 2H- indazol- 5 - (d, 2H) , 4.11 (s , 1H) , yl}-3- 4.64 (m, 2H) , 4.77 (m, sul famoyl benz am i de 2H) , 6.11 (s , 1H) , 7.36

[1179] (s , 1H) , 7.39 (s , 1H) , N- {6 -[4- (2 -hydroxypro

[1180] 7.41 (s , 1H) , 7.45 (s , pan- 2 -yl )piperidin- 1-yl ]- 2H) , 7.73 (t , 1H) , 7.95 2 - [2-( 1H-pyrazole- 1-yl )e (s , 1H) , 8.00 (s , 1H) , tyl ]- 2H-indazole- 5 -yl}- 3 - sulfamoylbenzamide 8.10 (s , 1H) , 8.35 (s ,

[1181] 2H) , 9.78 (s , 1H) .

[1182] 1H NMR (DMSO-d6): 1.20 N- (2- methyl- 6- {4 - [2 - (s, 2H), 1.36 (m, 3H), oxo— 2— (piper idin— 1—

[1183] 1.52-1.58 (m, 6H) , 1.85 yl )ethyl ]piper idin— 1—

[1184] (d, 2H) , 2.67 (t , 2H) , yl}- 2H- i nd az o 1 - 5-y 1 )—3 —

[1185] 2.98 (d, 2H), 3.55 - 3.57 sulfamoyl benzamide

[1186] (m, 4H), 4.08 (s, 3H), N-(2 - methyl - 6 - {4 - [2 - oxo - 7.35 (s, 1H), 7.46 (br s, 2H), 7.78 (t, 1H), 8.01 (d, 1H), 8.13 (d, 1H), 8.22 (s, 1H), 8.36 (s, 1H), 8.44 (s, 1H),

[1187] 9.84 (s, 1H)

[1188]

[1189] N-(2 - methyl - 6 - {4 - [2 - oxo - 2 - (pyrrolidin - 1 - yl)ethyl]piperidin - 1 - yl}-2H - indazol - 5 - yl)-3 - sulfamoyl benzamide 1H NMR (DMSO - d6): 1.20 (s, 2H), 1.36 (m, 3H), 1.85 (d, 2H), 2.07 - 2.25 (m, 8H) 2.67 (t, 2H), 2.98 (d, 2H), 4.08 (s,

[1190] 524.

[1191] 3H), 7.35 (s, 1H), 7.46 H2N、 / 妙스 64 N-(2 - methyl - 6 - {4 - [2 - oxo - (br s, 2H), 7.78 (t, d'〜Q 人 0 2 - (pyrrolidin - 1 - yl)ethyl]

[1192] piperidin - 1H), 8.01 (d, 1H), 8.13 1 - yl}-2H - indazol

[1193] (d, 1H), 8.22 (s, 1H), (5 - yl)-3 - sulfamoylbenz

[1194] amide 8.36 (s, 1H), 8.44 (s,

[1195] 1H), 9.84 (s, 1H) N-{6 - [4-(2 - hydroxypropan - 2 - yl)piperidin - 1 - yl]-2 - (1,3 - thiazol - 2 - yl)-2H - indazol - 5 - yl}-3 - sulfamoylbenzamide 7.36 (s, 1H), 7.46 (br s, 2H), 7.66 (m, 1H), 1.06 (s, 6H), 1.36 (m, 1H), 1.45 (m, 2H), 1.85 (d, 2H), 2.67 (t, 2H), 2.98 (d, 2H), 4.04 (m, 1H),

[1196] 540. sulfamoylbenzamide 7.36 (s, 1H), 7.46 (br s, 2H), 7.66 (m, 1H), U H 2 X N T '«? o HN L 、스 卜

[1197] <AQ number N-{6 - [4-(2 - hydroxypro

[1198] pan - 2 - yl)piperidin - 7.78 (t, 1H), 7.93 (s,

[1199] 1 - yl]-1H), 8.03 (d, 1H), 8.14 (d, 1H), 8.36 (s, 1H), 8.51 (s, 1H), 9.04 (s, N-{6 - [4-(2 - hydroxypropan - 2 - yl)piperidin - 1 - yl]-2 - (1,3 - thiazol - 2 - yl)-2H - indazol - 5 - yl}-3 - sulfamoylbenzamide

[1200] 1H), 9.80 (s, 1H) N—[2—(3-hydroxy—3— 1H NMR (DMSO-d6): 1.12 methylbutyl)-6 - [4- (s, 6H), 1.35 (q, 2H),

[1201] 1.52 (m, 1H), 1.80 (d, (hydroxymethyl)piperidi

[1202] HC<、厂斗 n— 1— yl]—2H—indazol—5 — 1H), 1.99 (m, 2H), 2.68

[1203] (t, 2H), 3.05 (d, 2H),丁세_ / yl] ~3~nitrobenz amide

[1204] O丁 7 481.

[1205] ' “(OH 3.36 (m, 2H), 4.40 (t,

[1206] 553 N-[2-(3 -히드록시- 3 -메틸 2H), 4.48 (d, 2H), 7.37 (AQ人 0 부틸)—6 - [4-(히드록시메 (s, 1H), 7.86 (t, 1H), 틸) 피페리딘- 1-일]- 2H-인

[1207] 8.29 (s, 1H), 8.37 (m,다졸- 5 -일]- 3 -니트로벤즈

[1208] 2H), 8.43 (d, 1H), 8.69아미드

[1209] (s, 1H), 10.00 (s, 1H)

[1210]

[1211] 3-({1-[2-(3-hydroxy- 3 - 1H—NMR(DMSO—d6):

[1212] methylbutyl )—5— (3 — l . ll( s , 6H) , 1.73(m , nitr obenzam i do ) — 2H— 4H) , 1.98(t , 2H) , indazo l-6-yl ]p iper i din— 2.23(m , 1H) , 2.33(t ,

[1213] 2H) , 2.64(m , 2H) , HO 4- yl}forinami do)propano ic 3.08(d , 2H) , 3.20(q , 566.

[1214] aci d 2H) , 4.40(t , 2H) , 615

[1215] 4.47( s , 1H) , 7.31( s , 3- ({1- [2- (3-hydroxy- 3 - 1H) , 7.84(t , 2H) , methylbutyl )- 5- (3-nitroben 8.26(d , 2H) , 8.29(d , zumido)- 2H-indazole- 6 - 1H) , 8.41(d , 1H) , yl] piperidine- 4 -yl}forma

[1216] Mido) Pro Pano Iksan 8.68( s , 1H) , 9.87( s ,

[1217] 1H)

[1218] 1H- NMR(DMSO- d6) : N- (6- {4 - [ (2 - l . ll( s , 6H) , 1.73(m , carbamoylethyl ) carbamoy 4H) , 2.00(t , 2H) , 1 ]p iper i din- 1-yl}— 2— (3 — 2.18(t , 2H) , 2.64(m , hydr oxy-3-methy 1 butyl )- 2H) , 3.08(d , 2H) , 2H— indazol — 5— yl )—3 — 3.19(t , 2H) , 3.25( s , nitr obenzam i de 1H) , 4.42(t , 2H), 565.

[1219] 4.47( s , 1H) , 6.75( s , 63 N- (6- {4 - [ (2 -carbamoyl

[1220] ethyl )carbamoyl ]piperidium 1H) , 7.25(s , 1H) ,

[1221] 7.31(s, 1H), 7.79(t, din-1-yl}-2-(3-hydroxy-1H), 7.84(t, 1H), 3-methylbutyl)-2H-indazole-8.26(d, 2H), 8.29(d, 5-yl)-3-nitrobenzami

[1222] 1H) , 8.41(d , 1H) , 8.68( s , 1H) , 9.87( s ,

[1223]

[1224] 1H NMR (DMSO- d6) : 1.12

[1225] N-{6 -[4- (s, 6H), 1.98 (m, 5H), (di ethenyl am ino)pi per id

[1226] 2.10 (m, 2H) , 2.89 (m, in— 1— yl ]— 2— (3— hydroxy—

[1227] 2H) , 3.13 (m, 2H) , 4.43 3-methylbutyl )- 2H- (t , 2H) , 4.48 (s , 1H) , 4 indazol-5-yl}~3~¬

[1228] Yu 5.98 (s , 2H) , 6.63 (s ,

[1229] 552. su 1 f amoy 1 benz am i de

[1230] HJ (OH 1H), 6.88 (s, 2H), 7.14

[1231] 69

[1232] N- {6 - [4-(diethynylami (s , 1H) , 7.43 (s , 1H) , 6"O people 0 No) Piperidine-1-yl]-2-(3-7.47 (s, 2H), 7.79 (t, hydroxy-3-methylbutyl)-1H), 8.03 (d, 1H), 8.20 2H-indazole-5-yl}-3-sulfa(d, 1H), 8.31 (s, 1H), moylbenzamide 8.40 (s, 1H), 8.45 (s,

[1233] 1H) , 9.85 (s , 1H) 1- [3- f luoro- 2- (3 - hydroxy— 3— methylbutyl )- 1H NMR (DMSO- d6) : 1.13 5-(3- (s , 6H) , 1.79 (m, 4H) , sul famoylbenzainidcLHffl- 2.00 (t, 3H), 3.10 (s, 0 indazol-6-yl]-N-(2, 2, 2- 4H), 3.89 (m, 2H), 4.47 tr if luoroethyl)piper idi

[1234] g 0H (t , 2H) , 4.49 (s , 1H) ,

[1235] 628. ne— 4— carboxamide

[1236] H N ,0 H / X—7.48 (s, 2H), 7.75 (t,

[1237] 64

[1238] H 7 ah o F 1-[3-fluoro-2-(3-hydro 1H) ,8.03 (d, 1H) ,8.11 roxy-3-methylbutyl )-5-(3-s (d, 1H) ,8.32 (s , 1H) , sulfamoylbenzamido )-2H- 8.36 (s , 1H) ,8.45 (s , indazole-6-yl ]-N-(2,2,2-1H) ,8.51 (t , 1H) ,10.05 tripluoroethyl )piperi(s , 1H)

[1239] Din-4-carboxamide

[1240]

[1241] N-[2-(3-hydroxy—3—1H-NMR(DMSO-d6): 1.12 methylbutyl)-6-{4-[4-(s, 6H), 1.38 (t, 1H), (2—hydroxypropan—2—1.99 (t, 2H), 2.37 (t, yl)piperidine—1—1H), 2.47 (s, 1H), 2.76 0

[1242] carbonyl]piperidine—1—(d, 3H), 2.90 (t, 1H),乂yl}—2H—indazol—5—yl]—3—3.05 (m, 4H), 3.54 (s,

[1243] N.

[1244] 654. sulfamoyl benzamide 2H), 4.01 (d, 1H), 4.13 HO \

[1245] H 2 N

[1246] N 、 C O HNXX^OH

[1247] " 83 (s, 1H), 4.39 (t, 2H), i \

[1248] 6 才 0 N-[2-(3-hydroxy-3-methyl

[1249] 4.50 (s, 1H), 7.32 (s, butyl)-6-{4-[4-(2-hydroxy<00038 empat 7><00038 empat 8>1H), 7.52 (s, 2H), 7.74 cipropan-2-yl)piperidine-(t, 1H), 8.01 (d, 1H), 1-carbonyl]piperidine-1-8.12 (d, 1H), 8.29 (s, yl}-2H-indazole-5-yl]-3-1H), 8.37 (d, 2H), 9.34 sulfamoylbenzuad

[1251] (s, 1H), 9.81 (s, 1H) 1H NMR (DMSO- d6): 1.11 N- { 1- [ 2- ( 3-hydr oxy- 3 - (s, 6H), 1.78-1.82 (m, methylbutyl)-5- (3 - 2H), 1.92-1.98 (m, 2H) , sul f amoylbenzamido)-2H- 1.99-2.00 (m, 2H) , 2.83 indazol-6-yl ]piper idin— (t , 2H) , 3.12-3.23 (m, 4-yl}-5- 2H) , 3.37 (s , 3H) , 3.93- -KMp methanesul fonyl fur an— 2 — 3.95 (m, 1H) , 4.41-4.43

[1252] 672. carboxamide (m, 2H) , 4.48 (s , 1H) , W-se Simseo' < 0H 77 7.34 (d, 1H) , 7.36 (d,

[1253] N- {1- [2- (3-hydroxy- 3- 1H) , 7.41 (s , 1H) , 7.50 methylbutyl )- 5- (3-sulfamoyl

[1254] (s , 2H) , 7.76 (t , 1H) , benzamido) - 2H-indazole- 8.02 (d, 1H) , 8.16 (d, 6 -yl]piperidine- 4 -yl}- 5 - 1H) , 8.30 (s , 1H) , 8.32 methanesulfonyl furan- 2-carboxyl

[1255] (s , 1H) , 8.41 (s , 1H) , Samid D

[1256] 8.50 (s, 1H), 9.85 (s, 1H)

[1257]

[1258] methyl 3 - ({1 - [2 - (3 - 1H - NMR (DMSO - d6):

[1259] hydroxy - 3 - methylbutyl)-1,11(s, 6H), 1.74(m, 5 - (3 - nitrobenzamido)-4H), 1.98(t, 2H), 2H - indazol - 6 - 2.23(m, 1H), 2.33(t, 、시」g夕斗yl]piperidin - 4 - 2H), 2.64(m, 2H), 으 N Y~N. 厂~(OH yl}forinamido)propanoate 3.08(d, 2H), 3.20(q,

[1260] 580.

[1261] 2H), 3.54(s, 3H), 0HA〕—642 methyl 3 - ({1 - [2 - (3 - 히드록

[1262] o計어A o 4.40(t, 2H), 4.47(s, 시 - 3 - methylbutyl)-5 - (3 - 니

[1263] 1H), 7.31(s, 1H), 트로벤즈아미도)-2H - 인다

[1264] 7.84(m, 2H), 8.26(d, 졸 - 6 - 일]피페리딘 - 4 - 일}

[1265] 2H), 8.29(d, 1H), 포름아미도)프로파노에이

[1266] 8.4l(d, 1H), 8.68(s, 트

[1267] 1H), 9.87(s, 1H) N—[2—(3 - hydroxy—3 —

[1268] methylbutyl )- 6 - [ (3S)- 3 - 1H NMR (DMSO- d6): 1.08 (2- (s, 6H), 1.72 (m, 1H), hydr oxyacet amido) pyr ro 1 1.81 (t, 2H), 2.00 (t, idin—l—yl]—2H— indazol—2H) , 2.78 (t , 2H) , 3.04 HO 0

[1269] 5-yl ]-3- (d, 2H) , 3.78 (d, 2H) , su 1 f amoy 1 benz am i de 4.41 (t , 2H) , 4.48 (s , 617.

[1270] 0 HN'VU N ^4OH dihydrochloride 1H) , 5.43 (t , 1H) , 7.38 H2 Yes, filial piety 54

[1271] (s , 1H) , 7.49 (s , 2H) , N- [2- (3-hydroxy- 3-methyl

[1272] 7.75 (t , 1H) , 8.02 (d, butyl )- 6 - [ (3S)- 3- (2 -hydro

[1273] 1H), 8.12 (d, 1H), 8.25 Roxy aceto-mido) pirrolili

[1274] (s , 1H) , 8.38 (s , 1H) , din- 1-yl ]- 2H-indazole- 5 - 8.47 (s , 1H) , 8.71 (s , yl ]- 3 —sulfamoylbenzami

[1275] 1H), 9.82 (s, 1H) dihydrochloride

[1276]

[1277] N-[2-( 3-hydr oxy— 3 —

[1278] methylbutyl )- 6 - [ (3S)- 3 - (2- hydr oxyacet amido) pyr ro 1

[1279] HO P idin— 1— yl ]— 2H— indazol—

[1280] 5-yl ]-3- 544. su 1 f amoy 1 benz am i de

[1281] 63

[1282] ☆t 소 ' > N- [2- (3 -hydroxy- 3 -methyl

[1283] J butyl )- 6 - [ (3S)- 3- (2 -hyd

[1284] oxy acetamido) pyrrolidino

[1285] din- 1-yl]- 2H-indazol- 5 - yl]- 3 —sulfamoylbenzami

[1286] IS

[1287] 6]]1H NMR (DMSO- d6) : 1.11 (s, 6H), 1.80-1.81 (m, N- {1- [2- (3-hydroxy- 3 - 2H), 1.95-2.00 (m, 4H), methylbutyl)- 5 - [3- (1H- 2.84 (t, 2H), 3.04-3.06 imidazol-1- (m, 2H), 3.99-4.00 (m, yl)benzamido]— 2H—

[1288] 1H), 4.39-4.41 (m, 2H), 1『斗 H indazol-6-yl ]piperidin—

[1289] N A N P 4.57 (s, 1H), 7.09 (s,

[1290] 4-yl}pyridine— 3 —

[1291] 1H), 7.48 (t, 1H), 7.38 0 / 592. carboxamide

[1292] 門 (s, 1H), 7.46-7.48 (m, HN」으스 丄 (0H 704

[1293] 《Day. N-{1-[2-(3-hydroxy-3-1H), 7.69 (t, 1H), 7.83 methyl butyl)-5-[3-(1H-imidazole-1-yl)benzamido]-8.02-8.05 (m, 1H), 8.19 2H-indazol-6-yl]piperidine (d, 1H), 8.30 (s, 1H), -4-yl}pyridine-3-carboxamide

[1294] 8.67 - 8.68 (m, 1H), 8.99 (s, 1H), 9.87 (s, 1H)

[1295]

[1296] N1-{6-[4-(aminomethyl)piperidin—

[1297] 1H NMR (DMSO-d6): 1.12 1-yl]—2—(3-hydroxy—3—

[1298] (s, 6H), 1.52 (m, 2H), methylbutyl)-2H-1.80 (m, 2H), 1.90 (m, indazol-5-yl}—N3—

[1299] H2N^今2H), 1.99 (t, 2H), 2.81 methyl benzene-1, 3~

[1300] (d, 7H), 3.11 (s, 2H), 사Of— / dicarboxamide

[1301] 529. 4.43 (t, 3H), 7.46 (s, 0人'' 7 hydrochloride

[1302] 08 1H), 7.65 (t, 1H), 7.95 시人0 서 hciN1-{6-[4-(aminomethyl)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-N3-methylbenzene-1,3-dicarboxamide hydrochloride salt

[1303] N1-{6-[4-(aminomethyl)piperidin—

[1304] 1-yl]—2—(3—hydroxy—3 —

[1305] methylbutyl)-2H-indazol-5-yl}—N3 —

[1306] ethyl Y— / methyl benzene—1,3~

[1307] 0 HN人』*、수 OH 492.

[1308] dicarboxamide

[1309] 624

[1310] N1-{6-[4-(aminomethyl)pi

[1311] peridin-1-yl]-2-(3 -hid

[1312] roxy-3 -methylbutyl)-2H-in

[1313] dazol-5-yl}-N3-methylbenzene-1,3-dicarboxamide

[1314]

[1315] 1H NMR (DMSO-d6): 1.11

[1316] N-{1-[2-(3-hydroxy-3-(s,6H),1.89 - 1.90(m,methylbutyl)-5-[3-(1H-2H),1.95 - 2.01(m,4H),pyrazol-1-4-2.82(t,2H),3.13(d,yl)benzamido]-2H-2H),3.98 - 4.00(m,1H),fT서]H indazol-6-yl]piperidin—4.40 - 4.42(m,2H),4.48 N A N 、O 4-yl}pyridine—3—(s,1H),7.41(s,1H), 0 으 XT— / 592.carboxamide 7.44 - 7.46(m,1H),州 HN人 5 으^ 7 WOH 704 7.53 - 7.55(m,2H),7.72 "七 승 그 N-{1-[2-(3 -히드록시-3-(d,1H),7.81 - 7.82(m,메틸 부틸)-5-[3-(1H-피라

[1317] 2H),7.99(s,1H),8.15 졸-4 -일)benzamido]-2H-(s,1H),8.27(d,1H),인다 졸-6 -일]piperidin-4 - 8.28(s,1H),8.39(s,일}pyridine-3 -카르복사미

[1318] 1H),8.58(d,1H),8.96 IS

[1319] (s,1H),9.62(s,1H),10.0(d,1H)

[1320] 1H NMR (DMSO-d6): 1.05 N-{6-[4-(2-(s,6H),1.34(m,1H),hydroxypropan-2-1.44(m,2H),1.79(d,yl)piperidin—1—yl]—2 —

[1321] 2H), 2.62 (t, 2H), 3.07 [(pyridin-3-yl)methyl]—

[1322] H It (d, 2H), 4.10 (s, 1H),

[1323] 2H—indazol—5—yl}~3~

[1324] 5.62 (s, 2H), 7.35 (d, 548. sulfamoyl benzamide

[1325] o 으 HN人』 ▽ 3>= \ 1H), 7.36 (s, 1H), 7.46

[1326] 66

[1327] H 7J o 0 N-{6-[4-(2-hydroxypro (s, 2H), 7.66 (d, 1H), pan-2-yl)piperidin-1-yl]- 7.73 (t, 1H), 8.01 (d, 2 - [(pyridin-3-yl)methyl]- 1H), 8.12 (t, 1H), 8.35 2H-indazol-5-yl}-3 —sulf (s, 1H), 8.47 (s, 2H), moil benzamide 8.48 (d, 1H), 8.57 (s,

[1328] 1H), 9.80 (s, 1H).

[1329]

[1330] 1H NMR (DMSO-d6): 1.11

[1331] N-{l-[5-(4-fluoro-3- (s, 6H), 1.68-1.72 (m, sulfamoylbenzamido)-2- 2H), 1.95-2.01 (m, 4H), (3—hydroxy—3 —

[1332] 2.81 - 2.83 (m, 2H), 『now methylbutyl)-2H - H 3.09 - 3.10 (m, 2H), indazol - 6 - yl]piperidin—

[1333] N A N 3.95 - 3.99 (m, 1H), n 4 - yl}pyridine—3—

[1334] 4.40 - 4.42 (m, 2H), 4.50 623. carboxamide

[1335] (s, 1H), 7.40 (s, 1H), H쑤 9 사 斗 0 H 7

[1336] N - {1 - [5 - (4 - fluoro - 3 - 7.46 - 7.49 (m, 1H), 7.60 才 0 sulfamoylbenzenesulfonamido)-2 - (t, 1H), 7.84 (s, 2H),

[1337] (3 - hydroxy - 3 - methylbut 8.16 (td, 1H), 8.21 - til)-2H - indazole - 6 - yl]piperidine - 4 - yl}pyridine - 3 - carbo 8.27 (m, 1H), 8.27 - 8.28 lidine - 4 - yl}pyridine - 3 - carboxamide 2H), 8.38 - 8.40 (m, 2H), 8.67 (d, 1H), 8.98

[1338] (d, 1H), 9.86 (s, 1H) N—[2—(3 - hydroxy—3—

[1339] methylbutyl)-6 - [4 - 1H NMR (DMSO - d6): 1.12 (2, 2, 2 - (s, 6H), 1.75 (m, 2H), trifluoroacetamido)pipe 1.86 (m, 2H), 1.98 (m, F、J H ridin - l - y 1] — 2H—indazol—3H), 2.79 (t, 2H), 3.07 Ar Np 5-yl ]-3- (d, 2H), 4.40 (t, 2H), ° 으 yr— / 596. su 1 f amoy 1 benz am i de 4.48 (s, 1H), 7.38 (s, H W 妙 스' < 0H 63 1H), 7.50 (s, 2H), 7.76

[1340] N-[2-(3 -히드록시- 3 -메틸

[1341] (t, 1H), 8.02 (d, 1H), 부틸 )— 6 - [4-(2, 2, 2 -트리

[1342] 8.15 (d, 1H), 8.30 (s, 플루오 로아 세트 아미도) 피

[1343] 1H), 8.32 (s, 1H), 8.40 페리 딘- 1-일 ]- 2H-인다졸- (s, 1H), 9.27 (s, 1H), 5 -일 ]- 3 —술파모일벤즈아

[1344] 9.81 (s, 1H) 미드

[1345]

[1346] 1H NMR (DMSO - d6): 1.11

[1347] N-(l-{5 - [3-(s, 6H), 1.84 - 1.87 (m, (hydraz inecarbonyl )benz 2H), 2.85 (t, 2H), 1.97 - am i do ] — 2— (3~hydr oxy— 3 — 2.01 (m, 4H), 3.08 - 3.09

[1348] (d, 2H), 4.01 - 4.04 (m, methylbutyl )- 2H- 『今 H indazol-6-yl}piper idin— 1H), 4.40 - 4.43 (t, 2H), N 4.49 (s, 1H), 4.51 (d, A N n 4-yl )pyr idine— 3 — It seems there are some non-standard or unclear notations in this text which might be errors in the original. If possible, it would be beneficial to have a more accurate original for a more precise translation.

[1349] 584. 2H) , 7.44 (s , 1H) , 7.47- : son carboxamide

[1350] o— > H 681 7.49 (m, 1H) , 7.64 (t ,

[1351] N- (1- {5 - [3- (hydrazine ka H s . 1H) , 8.01 (d, 1H) , 8.07 levonyl )benzamido]- 2 - (d, 1H) , 8.21-8.23 (td, (3-hydroxy- 3-methylbuty

[1352] 1H), 8.29 (s, 1H), 8.40 thyl)- 2H-indazole- 6-yl}piphetamine

[1353] (s , 1H) , 8.43-8.45 (m, pyridin-4-yl)pyridin-3-car

[1354] 2H) , 8.47 (s , 1H) , 8.68 Copy Mid

[1355] (d, 1H) , 9.03 (d, 1H) , 9.90 (s, 1H)

[1356] 1H NMR (DMSO-d6): 1.11 (s, 6H), 1.82-1.86 (m, N- { 1- [2- (3-hydr oxy- 3 - 2H), 1.96-1.98 (m, 2H), methylbutyl)-5 - [3 - 1.98-2.01 (m, 2H) , 2.43 (methyl sul famoyl ) benz am

[1357] (s , 3H) , 2.83 (t , 2H) , i do ] -2H- i ndazo 1 —6 —

[1358] 3.12-3.14 (m, 2H) , 3.37 yl ]p iper idin— 4— y 1}— 5—

[1359] W p (s, 3H) , 3.92-3.97 (m, methanesul fonyl fur an— 2 —

[1360] 686. 1H), 4.40 - 4.41 (m, 2H), carboxamide 0 Division /

[1361] 8 4.48 (s, 1H), 7.28 (d, X? 11 Heart세 N - {1 - [2 - (3 - hydroxy - 3 - 1H), 7.34 (d, 1H), 7.40 쓰 methylbutyl)-5 - [3 - (methylsulf

[1362] (s, 1H), 7.61 (br.s, pamoyl)benzamido]-2H - 1H), 7.80 (t, 1H), 7.98 indazole - 6 - yl]piperidine - 4 - (d, 1H), 8.20 (d, 1H), one}-5 - methanesulfonylfuran - 2 - 8.30 (d, 2H), 8.34 (s, carboxamide

[1363] 1H), 8.46 (d, 1H), 9.87 (s, 1H)

[1364]

[1365] N - {6 - [4 - (2 - 1H NMR (DMSO - d6): 1.00 hydroxypropan—2 — (s, 6H), 1.36 - 1.42 (m, yl)piperidin—1—yl]—2 — 1H), 1.44 - 1.47 (m, 2H),

[1366] 1.81 (d, 2H), 2.65 (t, methyl - 2H - indazo 1—5 —

[1367] H It p yl}-3-(lH - l, 2, 4 - 2H), 3.09 (d, 2H), 4.08

[1368] 459. triazol - 5 - yl)be (s, 3H), 4.12 (s, 1H), etc - nzamide

[1369] N~NH 554 7.41 (s, 1H), 7.71 (s,

[1370] N-{6-[4-(2-hydroxypro

[1371] 1H), 7.81 (d, 1H), 7.94 propan-2-yl)piperidin-1-yl]- N thios 0 (s, 1H), 8.12 (d, 1H), 2-methyl-2H-indazol-5-yl}-8.34 (s, 1H), 8.51 (s, 3-(1H-1, 2, 4-triazol-5-1H), 8.66 (s, 1H), 9.80 yl)benzamide

[1372] (s, 1H), 12.9 (s, 1H). N-{6-[4-(2-hydroxypropan-2-

[1373] (s, 6H), 1.35 (m, 1H), yl)piperidin-1-yl]-2-

[1374] 1.44 (m, 2H), 1.79 (d, [(1-methyl-1H-pyrazol-1-

[1375] 2H), 2.62 (t, 2H), 3.06 4-yl)methyl]-2H-

[1376] (d, 2H), 3.76 (s, 3H), indazol-5-yl}~3~

[1377] 4.11 (s, 1H), 5.39 (s, 551. sulfamoyl benzamide

[1378] 2H), 7.35 (s, 1H), 7.43 Q Hg人 己=\ 67

[1379] N-{6-[4-(2-hydroxypro (d, 1H), 7.45 (s, 2H), ☆ s It should be noted that there are some unclear or potentially incorrect chemical structure-related parts in this text which might need further clarification for a more accurate and meaningful translation in the context of a complete and correct chemical description."Li 0 V - plate - 2 - day) piperidin - 1 - yl] - 7.70 (s, 1H), 7.73 (d, 2 - [(1 - methyl - 1H - pyrazol - 4 - 1H), 8.01 (d, 1H), 8.11 day) methyl] - 2H - indazole - 5 - (d, 1H), 8.27 (s, 1H), day} - 3 - sulfamoylbenzami 8.35 (s, 1H), 8.42 (s, IS 1H), 9.80 (s, 1H).

[1380]

[1381] 1H NMR (DMSO - d6): 1.11

[1382] (s, 6H), 1.88 - 1.90 (m, N1 - [2 - (3 - hydroxy—3 —

[1383] 2H), 1.99 - 2.01 (m, 4H), methylbutyl) - 6 - [4 - 1.97 - 1.99 (m, 2H), 2.77 (pyridine - 3 - (d, 3H), 2.98 (t, 2H), ami do) piperidin - 1 - yl] - 3.08 - 3.09 (m, 2H), 2H - indazol - 5 - yl] - N3 - 『dou H 4.01 - 4.03 (m, 1H), N A N n methyl benzene - 1, 3~

[1384] 583. 4.40 - 4.42 (m, 2H), 4.49 ° / dicarboxamide

[1385] 693 (s, 1H), 7.44 (s, 1H), O HN시、스 ^ - ^OH

[1386] , / 0 승 Nl- [2- (3 -hydroxy- 3 -methylbutyl )- 6 - [4-(pyridin- 3 -amido) piperidin- 1 -yl ]- 8 -indazol- 5 -yl ] -N3 -methylbenzene- 1, 3 -dicarboxamide 7.47-7.49 (m, 2H), 7.65 (t, 1H), 8.01 (d, 1H), 8.10 (d, 1H), 8.18 (td, 1H), 8.29 (s, 1H), 8.41 - 8.46 (m, 3H), 8.66-8.67 (m, 2H), 9.03 (s, 1H), 9.92 (s, 1H)

[1387] (m, 2H), 9.03 (s, 1H), 9.92 (s, 1H)

[1388] 1H NMR (DMSO-d6): 1.06 N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2 -

[1389] 1.44 (m, 2H), 1.79 (d, 2H), 2.63 (t, 2H), 3.07 (d, 2H), 3.37 (m, 2H), 4.11 (s, 1H), 4.74 (s, 2H), 7.18 (m, 2H), 7.36

[1390] 2H), 7.46 (s, 2H), 7.64 (m, 1H), 7.73 (m, 1H), 7.69 (s, 1H) 0 Y - sulfamoylbenzamide

[1391] 69 (s, 1H), 7.46 (s, 2H), 2N、 S P 買」

[1392] N-{6 - [4-(2-hydroxypropy 7.64 (m, 1H), 7.73 (m, / ^Qr°

[1393] Pan- 2-yl )piperidin- 1-yl]- 1H) , 8.01 (m, 1H) , 8.10 2- [2-(pyridin- 2-yl )e (m, 1H) , 8.17 (s , 1H) , tyl]- 2H-indazole- 5-yl}- 3- 8.35 (s , 1H) , 8.39 (s , sulfamoylbenzumide 1H) , 8.49 (s , 1H) , 9.79

[1394] (s , 1H) .

[1395]

[1396] 1H NMR (DMSO- d6): 1.12 l-[2-( 3-hydr oxy— 3 —

[1397] (s, 6H), 1.81 (m, 5H), methylbutyl)-5- (3 - 1.96 (t, 2H), 2.09 (m, sul f amoylbenzamido)-2H- 1H), 2.28 (m, 1H), 2.71 indazol-6-yl]- N- [(3S)- (m, 2H) , 2.97 (m, 1H) , pyrrol idin— 3 —

[1398] 1 Ze〜 1 0 3.08 (m, 2H) , 3.18 (m, yl ]piper idine— 4—

[1399] Si YY、1H) , 3.31 (m, 3H) , 4.26 carboxamide

[1400] 634. (q, 1H) , 4.42 (t , 2H) , hydrochloride

[1401] H2N / 19 7.37 (s, 1H), 7.50 (s, 6'Xr° 따 1-[2-(3-hydroxy-3-methyl 2H), 7.75 (t, 1H), 8.01 butyl)-5-(3 —sulfamoylbenz (d, 1H), 8.15 (d, 1H), amid o)-2H-indazol-6 - 8.20 (d, 1H), 8.30 (s, 1H), 8.33 (s, 1H), 8.38 (s, 1H), 8.87 (s, 1H), 8.99 (s, 1H), 9.79 (s,

[1402] 1H)

[1403] 1-[2-(3-hydroxy—3 —

[1404] methylbutyl)-5-(3 - sulfamoylbenzamido)-2H- indazol-6-yl]-N-[(3S)- 10

[1405] 〈人 人 今 pyrrolidin—3 —

[1406] Y

[1407] yl]piperidine—4— <000417​​​​​​​​​​​​​​​​​​​​​​​3-sulfamoyl-N-[2-(4,4,4-trifluorobutyl)-1H NMR (DMSO-d6): 2.12 6-[4-(3,3,3-(m,2H), 2.25 (m,2H), trifluoropropyl)piperaz 2.55 (in,2H), 2.60 (in,in—1—yl]—2H—indazol—5—6H), 2.90 (m,4H), 4.43 사606. yl]benzamide (m,2H), 7.43 (s,1H), 人Of—

[1415] 0 HN 人' 7 \ 八 39 7.46 (s,2H), 7.77 (m, H 2 N '<丄 、入 / V F 3 —sulfamoyl-N-[2-(4,4,4 - 0' Yj ° F F 1H), 8.03 (m,1H), 8.15 trifluorobutyl)-6-[4-(m,1H), 8.32 (s,1H), (3,3,3-trifluoropro

[1416] 8.37 (s,1H), 8.45 (s, 필) piperazin -1-yl]-2H-ind

[1417] 1H), 9.85 (s,1H). dazol—5 -yl]benzamide

[1418] N—[2—(3-hydroxy—3 —

[1419] 1H NMR (DMSO-d6): 1.12 methylbutyl)-6-(4-(s,6H), 1.54 (m,2H), {[(2,2,2- 1.89 (m,2H), 1.99 (m, trifluoroethyl)carbamoy

[1420] 3H), 2.78 (t,2H), 2.99 FJ H H 1 ]amino}piperidin—1—

[1421] (d, 2H), 3.79 (m, 2H), 스 Vp z yl )— 2H— indazol— 5— yl ]— 3 —

[1422] o ‘、세 N V— (OH 4.42 (t, 2H), 4.48 (s,

[1423] 625. su 1 f amoy 1 benz am i de

[1424] 1H), 6.17 (s, 1H), 6.39 H2N、 S P 1 에스 67

[1425] N-[2-(3 -hydroxy-3 -methyl (s, 1H), 7.38 (s, 1H), butyl)—6-(4 - {[(2, 2, 2 -trifluoroethyl)carbamoyl]amino}piperidine-1-yl)-2H-indazol-5-yl]-3 -sulfamoylbenzamide N-{6 - [4-(2 -aminoethyl)piperazin-1-yl]-2 -methyl-2H-3.70 (m, 2H), 4.11 (s, H2N^^

[1426] (m, 8H), 3.34 (m, 2H), yl ]- 2 -methyl-2H- 3.70 (m, 2H), 4.11 (s, H2N^^ N ^ indazol-5-yl}~3~ [[ID=,25]]

[1427] 3H), 7.36 (s, 1H), 7.55 sulfamoylbenzamide

[1428] 으 YTN— 530. (s, 2H), 7.76 (t, 1H), o HN人 人' \ 7 dihydrochloride

[1429] 47 8.01 (d, 1H) , 8.18 (d, H 7 Yu o - N- {6 - [4- (2-aminoethyl ) 1H) , 8.29 (s , 1H) , 8.34 piperazine-1-yl]- 2-methyl- (m, 3H) , 8.40 (m, 2H) , 2H-indazole- 5-yl}- 3 —sulfa 9.78 (s , 1H) , 11.31 (s , moyl benzamide dihydrochloride 1H) .

[1430]

[1431] N-{6 - [4-(2-aminoethyl)piperaz in— 1—

[1432] yl ]- 2- methyl- 2H- indazol-5-yl}~3~

[1433] eww N m — su 1 f amoy 1 benz am i de

[1434] H2N, S P ppe“ N- {6 - [4- (2 -aminoethyl)

[1435] Park 0 zu 0 Piperazine -1-yl]- 2-methyl- 2H-indazole- 5-yl}- 3-sulfa

[1436] Moil Ben Zua Mid

[1437] N— [ 2— ( 3-hydr oxy— 3 —

[1438] 1H NMR (DMSO-d6): 1.12 methylbutyl)-6 - [4-(2- (s, 6H), 1.99 (t, 2H), methanesul fonyl ethyl)pi

[1439] 2.65 (m, 6H) , 2.78 (t , 、perazin-l-yl]— 2H—

[1440] s'

[1441] / 9

[1442] 'Three'! 2H), 2.89 (s, 4H), 3.03 indazol-5-yl]—3—

[1443] (s, 3H), 4.40 (t, 2H), 으592.

[1444] YT— / sulfamoyl benzamide

[1445] 4.48 (s, 1H), 7.41 (s, H2N / 쩌“° H 73

[1446] 於Q 스N-[2-(3-hydroxy-3-methyl 1H), 7.47 (s, 2H), 7.78 butyl)-6-[4-(2-methanesulfo (t, 1H), 8.02 (d, 1H), nil ethyl)piperazin-1-yl]-8.15 (d, 1H), 8.30 (s, 2H-indazol-5-yl]-3—sulfamoyl benzamide (s, 1H), 8.38 (s, 1H), 8.42 (s, 1H), 9.85 (s, 1H)

[1447] 1H NMR (DMSO-d6): 1.12 N-(6-{4-(s, 6H), 1.75 (m, 2H), [(carbamoylmethyl) carba

[1448] 1.81 (m, 2H), 1.99 (m, moyl]piperidin-l-yl}~2~

[1449] 2H), 2.34 (m, 1H), 2.67 0 (3-hydroxy-3-methylbutyl)-2H-3.10 (d, 2H), 3.59 (d, 2H), 4.40 (t, 0 indazol-5-yl)—3—

[1450] 心 / 551. 2H), 4.48 (s, 1H), 6.96 0 HN시세주—⑭ nitrobenzamide

[1451] 60 (s, 1H), 7.21 (s, 1H), o』石서 N-(6-{4-[(카르바모일메 7.33 (s, 1H), 7.84 (t, 틸) 카르 바모 일]피 페리 딘-1H), 7.92 (t, 1H), 8.27 1-일}-2-(3-히드록시-3-(s, 1H), 8.29 (s, 1H), 메틸 부틸)-2H-인다졸-5- 8.33 (d, 1H), 8.41 (d, 일)-3-니트로벤즈아미드 1H), 8.69 (s, 1H), 9.89

[1452] (s, 1H)

[1453]

[1454] N—[2—(3-hydr oxy—3 — 1H-NMR(DMSO-d6):

[1455] methylbutyl)-6-[4-(2- l.ll(s, 6H), 2.00(t, 0 hydroxyacetyl)piperaz in 2H), 2.91(m, 4H), HO 』N今-l-yl]-2H-indazol-5- 3.52(m, 4H), 4.11(d, 으 / yl ]~3~n i t r obenz am i de 2H), 4.42(t, 2H),

[1456] 510.

[1457] o m / V …义 OH 4.47(s, 1H), 7.38(s,

[1458] 55 N-[2-(3-히드록시-3-메틸

[1459] 1H), 7.85(t, 1H), 0-牛Q승 부틸)—6-[4-(2-히드록시

[1460] 8.31(s, 1H), 8.33(s, 아세 틸)피페라진 -1-일]-1H), 8.38(d, 1H), 2H-인다졸-5-일]-3-니트

[1461] 8.42(d, 1H) , 8.72(s , low Benzah mid

[1462] 1H) , 10. OKs , 1H) N-{6 - [4-(2- 1H NMR (DMSO- d6) : 0.96 hydr oxypropan— 2 —

[1463] (s, 6H), 1.39 (m, 3H), yl)piper idin— 1— yl ]— 2 —

[1464] 1.79 (m, 2H) , 2.64 (m, methyl -2H~indazo 1-5- 2H) , 3.07 (m, 2H) , 4.07 yl}— 3— (1H— pyrazol— 3 —

[1465] (m, 4H) , 6.79 (d, 1H) , 458. yl ) benz am ide

[1466] 7.36 (d, 1H) , 7.56 (t , 566

[1467] ☆Ah. N- {6 - [4- (2-hydroxypro 1H) , 7.74 (br s , 1H) , pan- 2-yl )piperidin- 1-yl]- 7.81 (s , 1H) , 7.99 (s , 2-methyl- 2H-indazole- 5-yl}- 1H) , 8.22 (s , 1H) , 8.33 3- (1H-pyrazole- 3-yl )benz (s , 1H) , 8.50 (s , 1H) , amid 9.74 (s , 1H) .

[1468] N—[2—(3-hydroxy—3—1H NMR (DMSO-d6): 1.12 methylbutyl)-6-{4-[(2S)—5—oxopyrrolidine-1.97 (m, 1H), 1.99 (t, 2H), 2.07 (t, 2H), 2.31 (m, 1H), 2.88 N—.」丄스斗 yl}—2H—indazol—5—yl]—3—(m, 4H), 3.66 (m, 4H), 〜〔{今 N.sulfamoyl benzamide 4.41 (t, 2H), 4.48 (s,

[1469] 597.

[1470] 1H), 4.55 (d, 1H), 7.41 빼 (外义 Q서 요 69 N-[2-(3 -히드록시- 3 -메틸

[1471] (s, 1H), 7.54 (s, 2H), 부틸)—6 - {4 - [(2S)- 5 -옥소

[1472] 7.69 (s, 1H), 7.77 (t, 피롤리딘- 2 -카르보닐]피

[1473] 1H), 8.01 (d, 1H), 8.16 페 라진- 1-일}- 2H-인다졸- (d, 1H), 8.32 (s, 1H), 5 -일]- 3 —술파모일벤즈아

[1474] 8.38 (s, 1H), 8.41 (s, 미드

[1475] 1H), 9.91 (s, 1H)

[1476]

[1477] 1—[2—(3-hydroxy—3 —

[1478] 1H—NMR(DMSO—d6): 1.11 methylbutyl)-5 —[3 —

[1479] ( s , 6H) , 1.76 (m , 2H) , (methyl sul f amoy 1 )benz am

[1480] 2.00 (t , 2H) , 2.25 (m , i do]— 2H— indazo l— 6— yl ]- 1H) , 2.38 (m, 2H) , 2.43 N-(2 , 2 , 2- (m , 2H) , 2.68 (t , 2H) , tr if luoroethyl )p iper i di

[1481] 3.08 (d, 2H), 3.26 (d, ne— 4— carboxami de

[1482] 3H), 4.41 (t, 2H), 4.47 1-[2-(3-hydroxy-3-methyl(s, 1H) , 7.30 (d, 1H) , butyl)-5-[3-(methylsulfamo 7.35 (s, 2H) , 7.57 (m, yl)benzamido]- 2H-indahnda 1H), 7.78 (t, 1H), 7.98 sol-6-yl]- N-(2,2,2-tri(d, 1H) , 8.17 (d, 1H) , fluoroethyl)piperidine- 8.29 (s, 1H) , 8.33 (s, 4— 7}Leboc People}White]De 1H) , 9.79 (s , 1H)

[1483] N- (6 - {4 - [ (carbamoylmethyl) carba 1H NMR (DMSO- d6) : 1.12 moyl ]p iper i din— 1— yl}— 2— ( s , 6H) , 1.75 (m , 2H) , ( 3-hydr oxy-3- 1.81 (m , 2H) , 1.99 (m , methylbutyl )— 2H— 2H) , 2.34 (m, 1H) , 2.67 indazo l-5-yl )—3 — (t , 2H) , 3.10 (d , 2H) , tr if luoromethanesul fony 3.59 (d , 2H) , 4.39 ( s , 1 benz am i de 1H) , 4.40 (t , 2H) , 6.96

[1484] ( s , 1H) , 7.21 ( s , 1H) , N-(6-{4 -[(carbamoylme )

[1485] 7.33 (s, 1H), 7.84 (t, yl)carbamoyl]piperidine-1H), 7.92 (t, 1H), 8.29 1-yl}-2-(3-hydroxy-3-(m, 2H), 8.43 (m, 1H), methylbutyl)-2H-indazole-5-8.47 (m, 1H), 8.48 (s, yl)-3-trifluoromethane

[1486] 1H), 9.97 (s, 1H) Sulfonyl Benzia Mid

[1487]

[1488] l-[2-( 3-hydr oxy— 3 — 1H NMR (DMSO- d6) : 1.10 methylbutyl )-5- (3 - (s , 6H) , 1.42 (q, 1H) , sul f amoylbenzamido)-2H- 1.61 (m, 1H) , 1.80 (m, indazol-6-yl ]— N— 6H) , 1.99 (t , 2H) , 2.30 (piper idin-3- (t , 1H) , 2.62 (m, 3H) , A o

[1489] yl )piper idine— 4— 2.78 (m, 1H) , 3.09 (m, [sha <p carboxamide 3H) , 3.19 (d, 1H) , 3.87

[1490] 648.

[1491] hr 、 / hydrochloride (m, 1H) , 4.42 (t , 3H) ,

[1492] 22

[1493] H2N '9 X Z- (0H 7.38 (s , 1H) , 7.51 (s ,

[1494] 1-[2-(3-hydroxy-3-methyl

[1495] o'Yj 0 HC1 2H), 7.75 (t, 1H), 8.02 butyl )- 5- (3 —sulfamoylbenz

[1496] (m, 2H) , 8.15 (m, 1H) , amido) -2H-indazole- 6 - 8.31 (s , 1H) , 8.34 (s , yl ]- N- (piperidin- 3 -yl )pi

[1497] 1H), 8.38 (s, 1H), 8.70 peridin-4-carboxamide

[1498] (m, 1H) , 8.82 (d, 1H) , 0 u3sa 12 ueo

[1499] 9.80 (s , 1H)

[1500] 1-[2-( 3-hydr oxy— 3 —

[1501] methylbutyl )-5- (3-sul f amoylbenzamido)-2H- indazol-6-yl ]— N—

[1502] (piper idin-3- yl )piper idine— 4—

[1503] 611.

[1504] … 우 carboxamide

[1505] OH 76

[1506] In QA 1 - [2 - (3 - hydroxy - 3 - methyl

[1507] butyl) - 5 - (3 — sulfamoylbenz

[1508] amido) - 2H - indazol - 6 - yl] - N - (piperidin - 3 - yl)pi

[1509] peridine - 4 - carboxamide <于

[1510]

[1511] 1H NMR (DMSO - d6): 1.11

[1512] N - {1 - [2 - (3 - hydroxy - 3 - (s, 6H), 1.78 - 1.80 (m, methylbutyl) - 5 - (3 - 2H), 1.97 - 1.99 (m, 2H), nitrobenzamido) — 2H—

[1513] 1.99 - 2.01 (m, 2H), 3.13 indazol - 6 - yl]piperidin—

[1514] (t, 2H), 3.27 - 3.29 (m, W p 4 - yl} - 5 - 2H), 3.37 (s, 3H), 3.88 - methanesulfonyl furan—2 —

[1515] : — 3.90 (m, 1H), 4.40 - 4.42

[1516] 638. carboxamide

[1517] (m, 2H), 4.48 (s, 1H), 7

[1518] °"XJ N - {1 - [2 - (3 - hydroxy - 3 - 7.28 (d, 1H), 7.33 (d, 人 0 It should be noted that there may be some unclear or incorrect chemical structure and naming expressions in the original text, which may affect the accuracy of the translation. It is recommended to double - check with the original chemical knowledge and context for a more accurate understanding.(Methylbutyl)-5-(3-nitrobenzo[b][1,7]naphthyridin-6-yl)-2H-indazole-6-carboxylic acid {4-[4-(trifluoromethyl)piperidine-1-carbonyl]piperidin-1-yl}-5-methylfuran-2-carboxamide: 7.34 (s, 1H), 7.86 (t, 1H), 8.24 (s, 1H), 8.30 (s, 1H), 8.39 (d, 1H), 8.42 (d, 1H), 8.57 (d, 1H), 8.72 (s, 1H),

[1519] 9.92 (s, 1H)

[1520] 1H-NMR (DMSO-d6): 1.12 (s, 6H), 1.19 (m, 1H), 1.36 (m, 1H), 1.73 (s, 3H), 1.81 (m, 3H), 1.99 (m, 2H), 2.57 (m, 2H), 2.76 (m, 3H), 3.05 (s, 3H), 4.08 (d, 1H), 4.42 (t, 2H),

[1521] 4.47 (s, 1H), 4.52 (s, 1H), N-[2-(3-hydroxy-3-methylbutyl)-6-{4-[4-(trifluoromethyl)piperidine-1-carbonyl]piperidin-1-yl}-2H-indazol-5-yl]-3-sulfamoylbenzamide: 7.30 (s, 1H),

[1522] 7.48 (s, 2H), 7.74 (t, 1H),

[1523] 8.00 (d, 1H),

[1524] 8.12 (d, 1H), 8.29 (s, 1H),

[1525] 1H) , 8.34(s , 1H) , Moil Ben Zua Mid

[1526] 8.37(s , 1H) , 9.79(s , 1H)

[1527]

[1528] N- {6 - [4- (2 - 1H NMR (DMSO-d6): 2.65 methanesul fonyl ethyl)pi (m, 6H), 2.78 (t, 2H), peraz in— 1—yl]— 2— methyl— 2.89 (s, 4H), 3.03 (s, 2H— indazol — 5— yl}— 3— 3H) , 4.11 ( s , 3H) , 7.41 sul famoyl benz am i de ( s , 1H) , 7.47 ( s , 2H) ,

[1529] 7.78 (t , 1H) , 8.02 (d , N-{6-[4-(2-methanesulfonyl)

[1530] 1H) , 8.15 (d, 1H) , 8.30 til) piperazine -1-yl ]- 2 -meth

[1531] ( s , 1H) , 8.38 ( s , 1H) , thyl- 2H-indazole- 5 -yl}- 3 ―sul

[1532] 8.42 ( s , 1H) , 9.85 ( s , Pamo Il Benzia Mid

[1533] 1H) .

[1534] N- {6 - [4- (2 - 1H NMR (DMSO- d6) : 1.06 hydroxypropan— 2 —

[1535] ( s , 6H) , 1.36 (m , 1H) , yl )p iper idin— 1— yl ]— 2 —

[1536] 1.45 (m, 2H), 1.81 (d, [(5-methyl-1, 2—oxazo 1—

[1537] 2H) , 2.32 ( s , 3H) , 2.63 3-yl )methyl ]- 2H- (t , 2H) , 3.08 (d , 2H) , indazo l-5-yl}— 3—

[1538] 4.11 ( s , 1H) , 5.61 ( s , sul famoyl benz am i de

[1539] 2H), 6.08 (s, 1H), 7.36 N-{6-[4-(2-hydroxypro(s, 1H), 7.46 (s, 2H), pan-2-yl)piperidine-1-yl]-7.73 (t, 1H), 8.02 (d, 2-[(5-methyl-1, 2-oxazole-1H), 8.12 (d, 1H), 8.36 3-yl)methyl]-2H-indazole-5-(s, 1H), 8.41 (s, 1H), yl}-3-sulfamoylbenzami 8.45 (s, 1H), 9.81 (s,

[1540] 1H) .

[1541] N— (2— hydroxy— 2 —

[1542] methylpropyl )-1 - [2-(3- 1H NMR (DMSO-d6): 1.01 hydr oxy-3-methy 1 butyl)- (s, 6H), 1.12 (s, 6H), 5-(3- 1.78 (m, 4H), 1.99 (t, sul famoylbenzami) dcLHffl- 2H) , 2.40 (m, 1H) , 2.68 indazo l— 6 — (m , 2H) , 3.01 (d , 2H) , yl ]p iper idine— 4— 3.07 (d , 2H) , 4.40 (m , carboxamide 3H) , 4.48 ( s , 1H) , 7.36

[1543] ( s , 1H) , 7.50 ( s , 2H) , N-(2-hydroxy- 2-methylph

[1544] 7.73 (m, 2H), 8.00 (d, rhophyl)-1-[2-(3-hydroxy-1H) , 8.12 (d, 1H), 8.29 3-methylbutyl)-5-(3-sulfamo

[1545] ( s , 1H) , 8.35 ( s , 1H) , ylbenzamido )- 2H-indazole

[1546] 8.38 ( s , 1H) , 9.80 ( s , -6 -il)piperidine- 4-carboxyl

[1547] 1H)

[1548] Sami de

[1549]

[1550]

[1551] N-[2-( 3-hydr oxy— 3 —

[1552] 1H NMR (DMSO- d6): 1.12 methylbutyl)- 6 - [ (3S)- 3 - (s, 6H), 1.56 (m, 1H), (morphol ine— 4—

[1553] 1.77 (m, 3H) , 2.00 (d, carbonyl )piper idin— 1—

[1554] 2H) , 2.68 (m, 1H) , 2.86 yl ]— 2H— indazol— 5— yl ]— 3 — OyOyg (m, 1H) , 2.97 (m, 3H) ,

[1555] 564. nitrobenzamide

[1556] 3.28 (t , 4H) , 3.36 (t , 643

[1557] °"、3 people 0N-[2-(3-hydroxy-3-methyl-4H)-4,41(t,2H),4.48 butyl)-6-[(3S)-3-(morpho (s,1H),7.36(s,1H), lin-4-carbonyl)piperidine-7.84(t,1H),8.30(s,1- yl]-2H-indazol-5-yl]-1H),8.42(m,3H),8.70 3-nitrobenzamide (s,1H),10.20(s,1H). N-{6-[4-(2-hydroxypropan—2—1H NMR (DMSO-d6): 1.06 yl)piperidin—1—yl]—2—(s,6H),1.43-1.45(m, methyl-2H-indazo 1—5—2H),1.77(d,2H),1.95- yl}-5-1.96(m,1H),2.59-2.61 H It p

[1558] sulfamoylthiophene-2-(m,2H),3.06(d,2H), heart YTN—477.

[1559] carboxamide 4.07(s,3H),.4.11 HN、 스6

[1560] (s,lH),7.28(s,1H), N-{6-[4-(2-hydroxypro

[1561] 미4~ 7.58(s,1H),7.77(s,0 서는 ~丁이 人° 판-2-yl)piperidin-1-yl]-1H),7.84(s,2H),8.18 2-methyl-2H-indazol-5-yl}-(s,1H),8.21(s,1H),5 ―sulfamoylthiophene-2-car

[1562] 9.72(s,1H) copy mid

[1563] N-{6-[4-(2- 1H NMR (DMSO-d6): 1.06 hydroxypropan—2—

[1564] (s , 6H) , 1.33 (m, 1H) , yl )piper idin— 1— yl ]— 2 —

[1565] 1.42-1.45 (m, 2H) , 1.80 methyl— 2H— indazol— 5 —

[1566] (d, 2H), 2.42 (s, 3H), sa yl}-3- 2.62 (t, 2H), 3.08 (d, (methyl sul famoyl) benz am

[1567] Eu 485. 2H) , 4.09 (m, 4H) , 7.34 YT_ ide

[1568] g ,9 HIJ 』 6 (s , 1H) , 7.55 (s , 1H) ,

[1569] N- {6 - [4- (2-hydroxypro 7.77 (t , 1H) , 7.97 (d, pan- 2-yl )piperidine- 1-yl]- 1H) , 8.15 (d, 1H) , 8.23 ​​2-methyl- 2H-indazole- 5-yl}- (s , 1H) , 8.29 (s , 1H) , 3-(methylsulfamoyl )benza 8.42 (s , 1H) , 9.82 (s , mid 1H) .

[1570]

[1571] N- {2- methyl- 6 - [4 - (2, 2, 2- 1H NMR (DMSO- d6) : 2.82 tr if luoroethyl ) piperaz i

[1572] (m, 4H) , 2.90 (m, 4H) , n— 1— yl ]— 2H— indazol— 5 —

[1573] 3.20 (m, 2H) , 4.09 (s , yl}-3- F 으에 우 3H) , 7.42 (s , 1H) , 7.48

[1574] 496. su 1 f amoy 1 benz am i de

[1575] (s, 2H), 7.77 (t, 1H), 0 HN people 乂으 51

[1576] N-{2-methyl-6-[4-(2, 2, 2 - 8.03 (d, 1H), 8.14 (d, 스 〕 0 trifluoroethyl)piperazin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide, 8.24 (s, 1H), {8.38 (s, 1H), 8.42 (s, 1H), 9.86 (s, 1H).

[1577] IS

[1578] N-(2-methyl-6-{4-[(2, 2, 2- 1H NMR (DMSO-d6): 1.47 trifluoroethyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide, 1.94 (m, 2H), 2.25 (m, 1H), 2.70 (m, 5H), 3.03 (m, 2H), per idin-l-yl}-2H-indazol-5-yl}-3- 5H), 4.08 으라 510. su 1 f amoy 1 benz am i de (s, 3H), 7.36 (s, 1H), o HN people 7 54 7.49 (s, 2H), 7.77 (t,

[1579] N-(2-methyl-6-{4-[(2, 2, 2 - 1H), 8.02 (d, 1H), 8.14 으 0 trifluoroethyl)amino

[1580] (d, 1H), 8.23 (s, 1H), 노] piperidin-1-yl}-2H-ind

[1581] 8.38 (s, 1H), 8.41 (s, 1H), 1H), 9.84 (s, 1H). 즈아 mid

[1582] 1H), 9.84 (s, 1H). 즈아 mid

[1583] It should be noted that there are some unclear or incorrect notations in the original text (such as "0 HN人 乂으 51", "스 〕", "즈아 미드", etc.), which may affect the accurate understanding and translation. The translation is done as accurately as possible based on the existing content.N-{2-methyl-6-[4-(3,3,3-trifluoropropyl)piperaz

[1584] (m, 6H), 2.89 (m, 4H), in—1—yl]—2H—indazol—5—

[1585] 3.41 (m, 2H), 4.09 (s, ☆义〜 으 yl}-3- 3H), 7.39 (s, 1H), 7.47 510. sulfamoyl benz amide

[1586] 으 YB-(s, 2H), 7.78 (t, 1H),

[1587] 54

[1588] … «心스 N-{2-methyl-6-[4-(3, 3, 3- 8.01 (d, 1H), 8.15 (d, trifluoropropyl)piper 1H), 8.24 (s, 1H), 8.37 6 X)人 0

[1589] lazin-1-yl]-2H-indazol-5-(s, 1H), 8.44 (s, 1H), 일}-3―sulfamoylbenzami 9.84 (s, 1H).

[1590] IS

[1591]

[1592] ZI4

[1593] K>-jyK> 三 T [n ■[乂

[1594] (HI ‘s) 08' 6 ‘ (HI

[1595] 눕 言'仏-下- B ta低 |互 [ B血

[1596] X) 99 ’ 8 ‘ (HI ‘s) 8£' 8

[1597] ( @>- £- B ta低뇨)]- N-[루

[1598] ‘(HI‘s) flower: ’8‘(HZ‘s)

[1599] - 9 -롲 EiR>- HZ-(五 [너 o

[1600] OS'S‘(HI‘P) £U8‘(HZ

[1601] * 順 @>五世롱- £)- 9-(Bi누

[1602] X) TO'8‘(HI‘1)呈L'L

[1603] B lla- £-스눌三 [으- £)- Z]- 1

[1604] ‘(HZ‘s) I9’Z‘(HI‘s)

[1605] 9Z

[1606] LZ'L‘(H£ X) Iff‘(H£ spj JojipojpXq

[1607] •ggg

[1608] X) £T'£‘(H£ X) 8O'£ SpjllIBXOqjBO

[1609] ‘(HZ X) OO'£‘(H£‘in) — p— sujpj J3djd[ iXqj3iu(

[1610] OZ’Z‘(HI‘1) 6Z’Z‘(HZ -g-ujpj jsdjd) ]

[1611] X) 86’I‘(HZ X) 8Z'I - N-[ I으- 9- lozBpuj

[1612] ‘(HI X) £9’I‘(H9‘s) — pg— (opjureztraqptourej pis

[1613] II’I :(9P- OSWQ) HWN HI —으)一 9— (i x i n qi Xi u 9 미

[1614] — g— XxcupXq— g)— g]— T

[1615] (HI

[1616] Three [i너'『눕豆 ■仏 -R- ‘ s) £F0I ‘ (HI ‘ s) Z8 ’ 6

[1617] 匕 臣低 1互 [ @>-9-롲七1心>-1正

[1618] ‘ (HZ ‘ s) 89 ‘8 ‘ (HI ‘P)

[1619] - (五 [너 o玄傾'끄 Hh- 9)

[1620] IF8 ‘ (HI ‘P) 9£’8 ‘ (HI

[1621] - 9-宣血- Z]- 1- [v눌三기으 - N

[1622] ‘ s) £Z ’ 8 ‘ (HI ‘ 1) 987,

[1623] ‘ (HI ‘ s) 0£‘Z ‘ (H下 ‘ s) apiUIEXOqJEO .ggp

[1624] 80千 ‘ (HZ ‘P) SO T ‘ (HZ — p— 9U|p| j9d|d[ {X

[1625] X) WZ ‘ (HI X) £I ’Z — 9— lozEpuj— HZ

[1626] ‘ (HZ ‘ 1) 8Z ’I ‘ (HZ ‘P) _ ( op piiE zusqo J ) I u_g ) _g

[1627] ZZ ’ I : (9P- OSWQ) HWN HI - 1 Xq )9Ui_g ] -X -Xxo JpXq—N

[1628] ’ (HI ‘ s) I6’ 6 ‘ (HI ‘ s)

[1629] 三기너 o玄

[1630] IF8 ‘ (HI ‘ s) 8£’8 ‘ (HI

[1631] 順 @>五世롱- £- ( @>- 9 -롲七1

[1632] ‘ s) Z£’ 8 ‘ (HI ‘P) 9U 8

[1633] R>- HZ- { ft>- 1- 1어호低 hr [ pi

[1634] ‘ (HI ‘P) T0 ‘8 ‘ (HI ‘ 1)

[1635] TT言' U- Z- B ta룰 tffT눙

[1636] LL 'L ‘ (HI ‘ s) 697, ‘ (HZ

[1637] — 9— (SZ) ]—꼬}— 9— Blla— Z)— N 89

[1638] ‘ s) re ’Z ‘ (HI ‘ s) IFZ gzi ■ggg

[1639] ‘ (HI ‘P) 99千 ‘ (H£ ‘ s) sp i uiE zusq { XouiE j { ns

[1640] IF下 ‘ (H下 X) 99 T ‘ (H下 - ( I소- 9- lowpuj— HZ- { IX

[1641] X) 88 ’Z ‘ (HI X) I£’Z — X— u| ZEJ9d|d[ {XuoqjEO

[1642] ‘ (HZ ‘ 1) ZO ’Z ‘ (HI ‘ 1) -g.auipi pojjXdoxo— g

[1643]

[1644] 66 ‘ T : (9P- OSWQ) HWN HI - (SZ) ]-꼬}- 9- 1스 U3UJ- z)- N

[1645] E17E9O / SZOZSI / 丄 3d ST66ET / 9Z0Z OMl-[2-( 3-hydr oxy— 3 —

[1646] methylbutyl )-5- (3 - sul f amoylbenzamido)-2H- indazol-6-yl ]— N—

[1647] 0

[1648] [(piperidin-3-yl)methyl]piperidine—4—

[1649] yl)methyl]piperidine—4—

[1650] hexyl H o tri 625. carboxamide

[1651] ^OH 79

[1652] 1-[2-(3-hydroxy-3-methyl

[1653] 《V 0 butyl)-5-(3-sulfamoylbenz

[1654] amido)-2H-indazol-6-yl]-N-[(piperidin-3-yl)

[1655] methyl]piperidine-4-carbox

[1656] amide

[1657] N-{6-[4-(2-1H NMR (DMSO-d6): 1.06 hydroxypropan-2-yl (s, 6H), 1.14 (m, 1H), yl)piperidin-1-yl]-2-1.26 (m, 1H), 1.37 (m, methyl-2H~indazol-5-1H), 1.55 (m, 1H), 1.64 아 yl}-N-methyl-3-(m, 1H), 2.07-2.12 (m, 으 N 〕485. sulfamoylbenzamide 2H), 3.02 (m, 1H), 3.45 r 5—

[1658] 유 6 (s, 3H), 4.06 (m, 5H),

[1659] y N-{6-[4-(2-hydroxypro

[1660] 6.83 (s, 1H), 7.10 (m, 6 外판-2-yl)piperidin-1-yl]-0 스 0 It should be noted that there are some unclear or potentially incorrect chemical formula and text fragments in the original, which may affect the full understanding and accurate translation. It is recommended to double-check and clarify the source content for more precise translation.1H), 7.14 (m, 1H), 7.22

[1661] {2-Methyl-2H-indazol-5-yl}-(m, 2H), 7.58 (m, 1H), N-Methyl-3-sulfamoylbenz

[1662] 7.78 (s, 1H), 7.95 (s, mid

[1663] 1H), 8.22 (s, 1H). N-{6-[4-(2-hydroxy-2-

[1664] 1H NMR (DMSO-d6): 1.10 methylpropyl)piperaz in—

[1665] (s, 6H), 2.26 (m, 2H), l-yl]-2-methyl-2H- 2.72 (m, 4H), 2.88 (m, indazol-5-yl}-3-

[1666] H ⑦厂 1 厂우 ]리 4H), 4.10 (m, 4H), 7.38 su 1 f amoy 1 benz am i de

[1667] 486. (s, 1H), 7.48 (s, 2H), 59 N-{6-[4-(2-hydroxy-2- 7.77 (t, 1H), 8.02 (d, methylpropyl)piperazin-1- 1H), 8.14 (d, 1H), 8.24 ''J

[1668] yl]-2-methyl-2H-indazol-5-(s, 1H), 8.38 (s, 1H), yl}-3-sulfamoylbenzami 8.42 (s, 1H), 9.81 (s, IS 1H).

[1669]

[1670] N—(2—hydroxy—2—

[1671] methylpropyl)—1—[2—1H NMR (DMSO - d6): 1.00 methyl—5—(3—(s, 6H), 1.77 (m, 4H), nitrobenzamido)—2H—2.34 (m, 1H), 2.64 (m, O

[1672] indazol - 6 - 2H), 3.00 (d, 2H), 3.08 yl]piperidine—4—(d, 2H), 4.08 (s, 3H), 으 亡 494.

[1673] Y N—carboxamide 4.40 (s, 1H), 7.30 (s, o mi人 丄 人 '으 552

[1674] 1H), 7.61 (t, 1H), 7.83 o<Q 人 o N-(2 -히드록시- 2 -메틸프

[1675] (t, 1H), 8.23 (s, 1H), 로 필)- 1 - [2 -메틸- 5 - (3 -니

[1676] 8.28 (s, 1H), 8.35 (d, 트로 벤 즈아 미도)- 2H -인다

[1677] 1H), 8.41 (d, 1H), 8.68 졸- 6 -일]피페리딘- 4 -카르

[1678] (s, 1H), 9.87 (s, 1H) 복사 미드

[1679] It should be noted that the original text seems to be quite fragmented and contains some unclear or potentially incorrect notations, which may affect the comprehensibility of the overall meaning.1H NMR (DMSO-d6): 1.12 1-{1-[2-(3-hydroxy-3-(s, 6H), 1.30 (m, 1H), methylbutyl)-5-(3-1.44 (m, 1H), 1.72 (m, sulfamoylbenzamidcLHgH-6H), 1.99 (t, 2H), 2.31 indazol-6-(t, 1H), 2.55 (m, 1H), 0 yl]piperidine-4-2.76 (m, 3H), 3.05 (m, 베 人 > 人 〜 carbonyl}piperidine-4-3H), 3.97 (d, 1H), 4.33

[1680] X N

[1681] 639. carboxamide (d, 1H), 4.42 (t, 2H), V S P HP丄OH 77 4.47 (s, 1H), 6.75 (s,

[1682] 1-{1-[2-(3-hydroxy-3-1H), 7.24 (s, 1H), 7.31 J methyl butyl)-5-(3 — sulfamoyl

[1683] (s, 1H), 7.49 (s, 2H), benzamide)-2H-indazole-7.75 (t, 1H), 8.01 (d, 6 -yl]piperidine-4-carbo

[1684] 1H), 8.12 (d, 1H), 8.29 nil}piperidine-4-carboxa

[1685] (s, 1H), 8.34 (s, 1H), mid

[1686] 8.38 (s, 1H), 9.80 (s, 1H)

[1687]

[1688] l-[2-(3-hydroxy—3—1H NMR (DMSO-d6): 1.11 methylbutyl)-5-(3-(s, 6H), 1.78 (s, 4H), sulfamoylbenzamido)-2H-1.99 (t, 2H), 2.25 (m, indazol-6-yl]-N-(3, 3,3-1H), 2.38 (m, 2H), 2.40 trifluoropropyl)piperid(m, 2H), 2.69 (m, 2H), H ine—4—carboxamide 3.05 (d, 2H), 4.42 (t, 斗 n 서 J 0H 624.

[1689] 2H), 4.47 (s, 1H), 7.36 o HN人人 스 68 1-[2-(3-hydroxy-3-methyl

[1690] (s, 1H), 7.50 (s, 2H), butyl)-5-(3—sulfamoylbenz

[1691] 7.75 (t, 1H), 8.03 (m, amid o)-2H-indazol-6-2H), 8.12 (d, 1H), 8.29 일]-N-(3, 3, 3-trifluo

[1692] (s, 1H), 8.35 (s, 1H), ropropyl)piperidine-4-ca[[ID=十七]]

[1693] 8.37 (s, 1H), 9.79 (s, le copy mid

[1694] 1H)

[1695] 1-[2-(3-hydroxy—3— [[ID=2二十七]]

[1696] 1H NMR (DMSO-d6): 1.11 methylbutyl)-5-[3-(s, 6H), 1.77 (m, 4H), (methyl sulfamoyl) benz am

[1697] It should be noted that there seem to be some unclear or incorrect notations in the original text which might affect the overall comprehensibility and accuracy of the translation. If possible, it would be beneficial to have a more clearly formatted and error-free original text for a more precise translation.2.00 (t , 2H) , 2.25 (m, ido]— 2H— indazol— 6— yl ]- 1H) , 2.38 (m, 2H) , 2.43 N-(3 ,3 , 3- (m, 2H) , 2.68 (t , 2H) , tr if luoropropyl )piper id

[1698] H kzNy^N. r-bOH 3.08 (d, 2H) , 3.26 (d,

[1699] 638. ine— 4— carboxamide

[1700] 3H) , 4.41 (t , 2H) , 4.47 eu 71

[1701] 1-[2-(3-hydroxy-3-methyl(s, 1H) , 7.30(d, 1H) , butyl )-5-[3-(methylsulfamo 7.35(s, 2H) , 7.57(m, yl )benzamido]-2H-indahnda 1H) , 7.78(t, 1H) , 7.98 sol-6-yl ]-N-(3,3,3-tri(d, 1H) , 8.17(d, 1H) , fluoropropyl )piperidine 8.29(s, 1H) , 8.33(s, -4-garbock hydroxyl group 1H) , 9.79(s, 1H)

[1702]

[1703] 1H NMR (DMSO- d6) : 1.11

[1704] N— {1 — [5— (4— chloro— 3 —

[1705] (s, 6H), 1.88-1.92 (m, sul f amoylbenzamido)-2- 2H), 1.95-2.00 (m, 4H), (3— hydroxy— 3 —

[1706] 2.82 (t, 2H), 3.02-3.04 methylbutyl)-2H-so (m, 2H), 4.00-4.01 (m, H indazol-6-yl]piper idin—

[1707] 1H) , 4.41-4.43 (m, 2H) , N A N p 4-yl}pyr idine— 3 —

[1708] ° 4.48 (s , 1H) , 7.41 (s , Yr— / 640. carboxamide

[1709] 1H), 7.46-7.49 (m, 1H), w f X u ~ ' 《 0H 16

[1710] N- {1- [5- (4-chloro- 3-sulfur 7.50 (s , 2H) , 7.82 (d, 0 surfamoyl benzamide)- 2- (3- 2H) , 8.00-8.01 (d, 2H) , hydroxy- 3-methylbutyl)- 8.19-8.21 (m, 2H) , 8.29 2H-indazole- 6-yl]piperidine (s , 1H) , 8.32 (s , 1H) , -4-yl}pyridine- 3-carboxa 8.58 (s , 1H) , 8.67 (d, 1H) , 9.00 (s , 1H) , 9.94

[1711] (s , 1H)

[1712] 1H NMR (DMSO-d6): 1.11 N- {1- [5- (2- f luoro- 5 - (s , 6H) , 1.80-1.81 (m, sul f amoylbenzamido)-2- 2H) , 1.96-1.98 (m, 4H) , (3— hydroxy— 3 — 2.82-2.84 (m, 2H) , methylbutyl )- 2H- 3.11-3.12 (m, 2H) , if 1 H indazol-6-yl ]piper idin— 4.01-4.04 (m, 1H) ,

[1713] 4.41-4 A N 4-yl}pyr idine— 3 — .52 (m, 2H) , 4.52 n

[1714] 623. carboxamide (s, 1H), 7.43 (s, 1H), Jo Sun 7 7.46-7.47 (m, 2H),

[1715] N- {1- [5- (2-fluoro- 5- 8.70-8.71 (m, 1H) , sulfamoylbenzamido )- 2- 8.16-8.17 (m, 2H) , 8.29 (3-hydroxy- 3-methylbuty

[1716] (d, 1H) , 8.40 (s , 1H) , thyl )-2H-indazole- 6 -yl]piphe

[1717] 8.53 (s , 1H) , 8.60-8.62 pyridine-4-yl pyridine-3-car

[1718] (m, 2H) , 8.67 (d, 1H) , radiated mid

[1719] 8.89 (s, 1H), 9.93 (s, 1).

[1720]

[1721] 1H NMR (DMSO- d6) : 1.11

[1722] N- { 1- [ 2- ( 3-hydr oxy- 3 - (s , 6H) , 1.63-1.65 (m, methylbutyl )-5- (2 - 2H) , 1.93-1.95 (m, 2H) , methyl-3- 1.97-1.99 (m, 2H) , 2.65 sul f amoylbenzamido)-2H- (s, 3H), 2.78 (t, 2H), small H indazol-6-yl]piper idin— 3.12 (d, 2H), 3.92-3.98 N A Nn 4-yl}pyr idine— 3 — (m, 1H) , 4.40-4.42 (m, ° e / 619. carboxamide 2H) , 4.48 (s , 1H) , 7.34 0 1 HA human M-OH 74 (s , 1H) , 7.45-7.47 (m, H2N、 S 9 1 I \ N- {1- [2-(3-hydroxy-3-2H) ,7.51 (s ,2H) ,7.67 methylbutyl )-5-(2-methyl-3-(d,1H) ,7.95 (d,1H) , sulfamoylbenzamido)-2H- 8.16 (d,1H) ,8.28 (s , indazole-6-yl]piperidine-4-1H) ,8.32 (s ,1H) ,8.50 yl}pyridine-3-carboxymi

[1723] (s , 1H) , 8.66 (d, 1H) , IS

[1724] 8.96 (d, 1H) , 9.26(s , 1H) .

[1725] 1H NMR (DMSO- d6) : 1.11 N- { 1- [ 2- ( 3-hydr oxy- 3 - (s , 6H) , 1.74-1.76 (m, methylbutyl )-5 - [3 - 2H) , 1.98-2.00 (m, 4H) , (pyr idin— 4—

[1726] 2.81 (t , 2H) , 3.14 (d, yl )benzamido]— 2H—

[1727] 2H) , 3.99-4.00 (m, 1H) , indazol-6-yl ]piper idin—

[1728] if [Average Temperature] H 4.41-4.42 (m, 2H) , 4.48

[1729] 4-yl}pyr idine— 3 —

[1730] N A Nn (s , 1H) , 7.39 (d, 1H) , o Our 603. carboxamide

[1731] IT、, HN"" 1 ,this, 7 ^-^OH 7.41 (s, 1H) , 7.71-7.72

[1732] 727

[1733] Oj o The N- {1-[2-(3-hydroxy-3-(m, 2H) , 7.76-7.78 (m, methylbutyl )-5-[3-(pyridine-3H) , 8.02 (d, 1H) , 8.11 4-yl )benzamido]-2H-phosphorus(s , 1H) , 8.29 (d, 1H) , dazole-6-yl ]piperidine-4-8.34 (d, 1H) , 8.51 (s , yl}pyridine-3-carboxami (1H) , 8.62-8.65 (m, 3H) , IS 8.95 (s , 1H) , 9.76 (s ,

[1734] 1H)

[1735]

[1736] N- {6 - [4- (2 - 1H NMR (DMSO- d6) : 0.98 hydroxypropan— 2 —

[1737] (s, 6H), 1.34-1.41 (m, yl)piper idin— 1— yl ]— 2 —

[1738] 3H) , 1.77 (d, 2H) , 2.63 methyl -2H- indazo 1— 5 —

[1739] (t , 2H) , 3.08 (d, 2H) , H It p yl}-3-(lH-l, 2, 3 , 4- Neu Nra 4.08 (s , 3H) , 4.12 (s ,

[1740] 460. tetrazol— 1—yl ) benz am ide

[1741] 1H), 7.34 (s, 1H), 7.81 N=N HN^으 〜542

[1742] N-{6-[4-(2-hydroxypro (t, 1H), 8.08 (d, 1H), N -jo

[1743] phenyl-2-yl)piperidin-1-yl]-8.12 (d, 1H), 8.23 (s, 2-methyl-2H-indazol-5-yl}-1H), 8.42 (s, 1H), 8.64 3-(1H-1, 2, 3, 4-tetrazol-(s, 1H), 9.83 (s, 1H), 1-yl)benzamide 10.2 (s, 1H).

[1744] 1H NMR (DMSO-d6): 0.97 N-{6-[4-(2-(s, 6H), 1.34-1.37 (m, hydroxypropan—2—

[1745] 1H), 1.34-1.40 (m, 2H), yl)piperidin—1—yl]—2—

[1746] 1.77 (d, 2H), 2.63 (t, methyl-2H-indazo 1—5—

[1747] H잇 p 2H), 3.08 (d, 2H), 4.07 yl}-3-(lH-l, 2, 3- 으 (s, 3H), 4.31 (s, 1H),

[1748] 459. triazol-l-yl)benzamide

[1749] 7.34 (s, 1H), 7.75 (t, N=N HN디、人'' 7 554

[1750] N-{6-[4-(2-hydroxypro 1H), 7.81 (s, 1H), 7.98 V石 스

[1751] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-(s, 1H), 8.01 (d, 1H), 2-methyl-2H-indazol-5-yl}-8.11 (d, 1H), 8.23 (s, 3-(1H-1,2,3-triazol-1-yl), 8.34 (d, 1H), 8.41 (s, 1H), 8.93 (s, 1H),

[1752] 9.82 (s, 1H).

[1753] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5-sulfamoyl furan-2-carboxamide 1H NMR (DMSO-d6): 1.01 (s, 6H), 1.37 - 1.45 (m, 2H), 1.56 - 1.58 (m, 2H), 1.79 (d, 2H), 2.63 (t, 2H), 3.06 (d, 2H), 4.07 - 54 (s, 3H), 4.33 (s, 1H), N ~54 (s, 3H), 4.33 (s, 1H),

[1754] N-{6-[4-(2-hydroxypro

[1755] H2N K 人 0 7.12 (s, 1H), 7.34 (s, N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-2H), 7.96 (s, 2H), 8.23 (s, 1H), 8.45 (s, 1H), 5-sulfamoyl furan-2-carbox

[1756] 9.59 (s, 1H). samide

[1757]

[1758] N2 - {6 - [4-(2- 1H NMR (DMSO- d6) : 1.06 hydr oxypropan- 2- (s, 6H) , 1.36-1.42 (m, yl) pipe idin— 1— yl ]— 2 —

[1759] 1H) , 1.44-1.49 (m, 2H) , methyl— 2H—indazo 1—5 —

[1760] H It p 1.80 (d, 2H) , 2.63 (t , yl lthi ophene-2 ​​, 5- 2H) , 3.06 (d, 2H) , 4.08 441. dicarboxamide

[1761] (s , 3H) , 4.12 (s , 1H) , 55

[1762] N2 - {6 - [4- (2-hydroxyf 7.35 (s , 1H) , 7.50 (br lopane-2-yl )piperidine-1- s , 2H) , 7.60 (d, 1H) , yl]- 2-methyl-2H-indazole-5 - 7.80 (d, 1H) , 8.23 ​​(s , yl}thiophene- 2, 5-dicarboxyl 1H) , 8.35 (s , 1H) , 9.80 samid (s , 1H)

[1763] N-{6 - [4-(2- hydr oxypropan- 2- 1H NMR (DMSO- d6) : 1.06 yl )piper idin— 1— yl ]— 2 — (s , 6H) , 1.37-1.45 (m, methyl -2H~indazo 1-5- 1H) , 1.49-1.51 (m, 2H) , yl}— 1— (pyr idin— 4— yl )- 1.77 (d, 2H) , 2.60 (t , 1H— pyrazole— 4— 2H) , 3.10 (d, 2H) , 4.07

[1764] 459.

[1765] carboxamide (s, 3H), 4.10 (s, 1H), 554

[1766] ON dou 7.27 (s, 1H), 7.92 (d,

[1767] N-{6-[4-(2-hydroxypro

[1768] 2H), 8.20 (s, 1H), 8.23 pan-2-yl)piperidin-1-yl]-(s, 1H), 8.32 (s, 1H), 2-methyl-2H-indazol-5-yl}-8.67 (d, 2H), 9.32 (s, 1-(pyridin-4-yl)-1H-pyra

[1769] 1H), 9.82 (s, 1H). zol-4-carboxamide

[1770] N-{6-[4-(2-1H NMR (DMSO-d6): 0.95 hydroxypropan-2-(s, 6H), 1.37 (m, 3H), yl)piperidin-1-yl]-2-

[1771] 1.79 (d, 2H), 2.63 (t, methyl-2H~indazo1-5-2H), 3.08 (d, 2H), 4.08 H it factory yl}-3-(1H-pyrazol-1-4-

[1772] (m, 4H), 7.34 (s, 1H), 458. yl)benzamide

[1773] bone bo-7.49 (t, 1H), 7.70 (d,

[1774] 566

[1775] HN AQA N-{6-[4-(2-hydroxypro 1H), 7.79 (d, 1H), 7.93- pan-2-yl)piperidin-1-yl]-8.31 (br s, 2H), 8.10 2-methyl-2H-indazol-5-yl}-(s, 1H), 8.22 (s, 1H), 3-(1H-pyrazol-4-yl)benz 8.48 (s, 1H), 9.69 (s, amide 1H).

[1776]

[1777] N—{ 6 — [4— (3— hydroxy— 3 — 1H NMR (DMSO- d6) : 1.08 methylbutyl )piperaz in— ( s , 6H) , 1.53 (t , 2H) , 1— yl ]— 2— methyl— 2H— 2.49-2.60 (m, 6H) , 2.88 indazo l-5-yl}— 3— (m, 4H), 4.09 (s, 3H), sul famoyl benz am i de 4.62 (br s, 1H), 7.37

[1778] ( s , 1H) , 7.47 ( s , 2H) , N- {6 - [4- (3 -hydroxy- 3 - 7.77 (t , 1H) , 8.02 (d , methylbutyl )piperazine -1- 1H) , 8.14 (d, 1H) , 8.24 yl ]- 2 -methyl- 2H-indazole- 5 - ( s , 1H) , 8.37 ( s , 1H) , yl}- 3 ―sulfamoylbenzami

[1779] 8.42 (s, 1H), 9.81 (s, 1H).

[1780] 2- f luoro- N- {6 - [4- (2 - hydroxypropan— 2 — 1H NMR (DMSO- d6) : 1.08 yl )p iper idin— 1— yl ]— 2 — ( s , 6H) , 1.35 (t , 1H) , methyl -2H- indazo 1— 5 — 1.44 (q , 2H) , 1.77 (d , yl}-5- 2H) , 2.64 (t , 2H) , 3.03 sul famoyl benz am i de (d , 2H) , 4.08 ( s , 4H) ,

[1781] 7.38 (t , 1H) , 7.51 (t , 2 -fluoro- N- {6 - [4- (2 - 1H) , 7.54 ( s , 2H) , 7.95 hydroxypropane- 2 -yl)p

[1782] (d , 1H) , 8.24 ( s , 1H) , peridin- 1-yl]- 2-methyl- 2H- 8.44 (d , 1H) , 8.64 ( s , indazole- 5-yl}- 5 ―sulfamoyl

[1783] 1H) , 10.14 (d, 1H) Benz Zua Mid

[1784] 3- ({6 - [4- (2 - hydroxypropan— 2 —

[1785] 1H NMR (DMSO-d6): 1.03 yl)p iper idin— 1— yl ]— 2 —

[1786] ( s , 6H) , 1.33-1.41 (m, methyl -2H- indazo 1-5- 3H) , 1.78 (d, 2H) , 2.60 yl Icarbamoyl )benzene— 1—

[1787] (t , 2H) , 3.10 (d , 2H) , sul fonyl f luor i de

[1788] 4.09 (m, 4H), 7.31 (s, 3-({6-[4-(2-hydroxyf 1H) , 7.95 (s, 1H) , 8.23 ​​rhopanet-2-yl)piperidin-1-(s, 1H) , 8.34 (m, 2H) , yl ]-2-methyl-2H-indazole-5- 8.44 (s, 1H) , 8.53 (s, yl} carbamoyl )benzene-1—sulfur 1H) , 9.94 (s, 1H). phonyl fluoride

[1789]

[1790]

[1791] N-{6 - [4-(2- 1H NMR (DMSO-d6): 1.06 hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-2-(3-sulfamoylphenyl)acetamide

[1792] (s, 6H), 1.24 - 1.33 (m, yl)piperidin-1-yl]-2-

[1793] 3H), 1.67 (d, 2H), 2.44 methyl-2H-indazo-1-5-

[1794] (m, 2H), 2.95 (d, 2H), 그 yl}-2-(3- 3.86 (s, 2H), 4.04 (s, ▽라 sulfamoylphenyl)acetami

[1795] 485. 3H), 4.09 (s, 1H), 7.17 198 스 HN丄、스 de

[1796] 6 (s, 1H), 7.31 (s, 2H), 오이 』。 N-{6 - [4-(2-hydroxypro 7.52 (t, 1H), 7.57 (d, pan-2-yl)piperidin-1-yl]-1H), 7.70 (d, 1H), 7.79 2-methyl-2H-indazol-5-yl}- (s, 1H), 8.13 (s, 1H), 2-(3 —sulfamoylphenyl)acet 8.18 (s, 1H), 8.92 (s, 트아 mid 1H).

[1797] N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-2-(4-sulfamoylphenyl)acetamide 1H NMR (DMSO-d6): 1.07 (s, 6H), 1.27 (m, 1H), methyl-2H-indazol-5-yl}-2-(4- 2H), 2.44 (s, 2H), 2.94 sulfamoylphenyl)acetami (d, 2H), 3.85 (s, 2H), H 잇厂 485.

[1798] 199 H2N. P Sa 05 - de 4.04 (s , 3H) , 4.17 (s ,

[1799] 6

[1800] 1H) , 7.17 (s , 1H) , 7.27 N- {6 - [4- (2 -hydroxypro

[1801] (s , 2H) , 7.51 (d, 2H) , pan- 2 -yl )piperidine- 1-yl ]- 7.77 (d, 2H) , 8.13 (s , 2 -methyl- 2H-indazole- 5 -yl}- 1H) , 8.16 (s , 1H) , 8.89 2- (4 —sulfamoylphenyl)ace

[1802] (s , 1H) .

[1803] TIA Mid

[1804]

[1805] Compounds represented by the formulas I, 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8 of the present invention, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof exhibit IRAK-4 or IRAK-1 inhibitory activity.

[1806] Compounds represented by the formulas I, 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8 of the present invention, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof can effectively inhibit IRAK-4 or IRAK-1 at low concentrations and can effectively prevent or treat IRAK-4 or IRAK-1-related diseases. Compounds represented by the formulas I, 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8 of the present invention, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof can effectively inhibit the secretion of inflammatory cytokines.

[1807] Compounds represented by the formulas I, 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8 of the present invention, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof may have few or no side effects and may exhibit excellent pharmacokinetic properties. For example, compounds represented by the above chemical formulas I, 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof may exhibit excellent absorption rates (e.g., high bioavailability), be appropriately distributed to each tissue upon administration to exhibit desired pharmacological effects in each tissue (e.g., preventive or therapeutic effects for diseases that can be treated by inhibiting IRAK-4 or IRAK-1), and may be effectively metabolized in the body.

[1808] Compounds represented by the formulas I, 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8 of the present invention, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof can exhibit excellent anti-inflammatory effects on an animal model of systemic inflammation induced by LPS.

[1809] In the present invention, isomers include structural isomers and stereoisomers, stereoisomers include diastereomers and optical isomers, and optical isomers include not only enantiomers but also mixtures of enantiomers and racemics.

[1810] In the present invention, "pharmaceutically acceptable" may mean physiologically acceptable and, when administered to an individual, not typically cause allergic reactions such as gastrointestinal disorders or dizziness or similar reactions.

[1811] In the present invention, "pharmaceuticalally acceptable salt" means a salt commonly used in the pharmaceutical industry, and includes, for example, an inorganic ionic salt prepared from calcium, potassium, sodium, or magnesium; an inorganic salt prepared from hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid, or sulfuric acid; an organic acid salt prepared from acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, spartic acid, ascorbic acid, carboxylic acid, or vanillic acid; and a sulfonate prepared from methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, or naphthalenesulfonic acid. Amino acid salts prepared with glycine, arginine, or lysine, etc.; and amine salts prepared with trimethylamine, trithylamine, ammonia, pyridine, or picolin, etc., but the types of salts referred to in the present invention are not limited by these listed salts.

[1812] The pharmaceutically acceptable salt of the present invention can be prepared by conventional methods known to those skilled in the art.

[1813] The “hydrate” of the present invention is a compound represented by the chemical formula I or a pharmaceutically acceptable salt thereof in which water is bonded by non-covalent intermolecular forces, and may contain stoichiometric or non-chemical stoichiometric amounts of water. Specifically, the hydrate may contain water in a ratio of about 0.25 moles to about 10 moles based on 1 mole of active ingredient, and more specifically, may contain about 0.5 moles, about 1 mole, about 1.5 moles, about 2 moles, about 2.5 moles, about 3 moles, about 5 moles, etc.

[1814] The "solvated product" of the present invention is a compound represented by Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a solvent other than water are bonded by non-covalent intermolecular forces, and may contain the solvent in stoichiometric or non-chemical stoichiometric amounts. Specifically, the solvated product may contain solvent molecules in a ratio of about 0.25 moles to about 10 moles based on 1 mole of active ingredient, and more specifically, may contain about 0.5 moles, about 1 mole, about 1.5 moles, about 2 moles, about 2.5 moles, about 3 moles, about 5 moles, etc.

[1815] Method for preparing a compound

[1816] The present invention provides a method for preparing compounds represented by the formula I, 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof.

[1817] The compounds represented by the formulas I, 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8 of the present invention, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof may be prepared, for example, according to the method of Reaction Scheme 1 below, but are not limited thereto.

[1818] <Reaction Equation 1>

[1819] Step 1 Compound 1-1

[1820] R r Y Step 4

[1821] Step 5-1

[1822] Compound 4-1

[1823] Step 5-2

[1824] Compound 5-2

[1825] Step 1 Step 3-2 Step 6-3 Starting Material Compound 1-2

[1826] Step 4 U

[1827] .Aplti

[1828]

[1829] As shown in FIG. 1, Ri, R3, R4, L2, AI, A2, QI, and Q2 in the above reaction scheme 1 are each the same as those defined in the compound item represented by the above chemical formula I. The chloride (C1) in the above reaction scheme I may be a bromide (Br), iodide (I), 4-methylbenzene sulfonate, etc., the carboxylic acid may be an acyl chloride, etc., and the reactive halide may be an acyl halide, carboxylic acid, etc., for example, the chloride may be an acyl chloride or a carboxylic acid.

[1830] [Step 1] Coupling Reaction

[1831] Step 1 above is a step of preparing the compound 1-1 or compound 1-2 by using an excess amount of cyclic amine from a starting material in the presence of a base and stirring under heating conditions for 12 to 48 hours. Specifically, the compound 1-1 or compound 1-2 can be prepared by stirring at 120 °C to 150 °C for 12 to 36 hours.

[1832] In embodiments of the present invention, step 1 may be performed in the presence of a solvent, and the solvent is not particularly limited as long as it is inert to the reaction, but may use methanol, ethanol, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, water, N,N-dimethylformamide, dimethyl sulfoxide, benzene, toluene, xylene, or mixtures thereof.

[1833] In the embodiments of the present invention, both organic and inorganic bases may be used as the base, for example, organic bases such as triethylamine, diisopropylethylamine, 1,8-diazabicyclo[5.4.di-7-undecene (DBU) or 1,5-diazabicyclo[4.3.di-5-nonene (DBN)]; or inorganic bases such as potassium bicarbonate, sodium bicarbonate, potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, potassium phosphate, or sodium phosphate may be used.

[1834] [Step 2] Coupling reaction

[1835] Step 2 above is a step of preparing a 1- or 2-substituted indazole derivative (compound 2-1) from compound 1-1 (see Reaction Scheme 1 above).

[1836] In the embodiments of the present invention, step 2 can be performed using a solvent inert to the reaction, R3-X (such as chloride (C1), bromide (Br), iodide (I), 4-methylbenzene sulfonate, etc.) and a base, and compound 2-1 can be prepared by stirring for 0.5 to 48 hours at room temperature (10 to 25 °C) to 60 °C.

[1837] In the embodiments of the present invention, optionally, in the case where R3-X is an ogacloride or bromide, an alkali metal iodide, such as potassium iodide or sodium iodide, may be added.

[1838] In the embodiments of the present invention, both organic bases and inorganic bases may be used as the base, and for example, the inorganic base may be potassium carbonate, cesium carbonate, sodium hydride, etc.

[1839] In the embodiments of the present invention, when the R3-X base is a reactive halide (Cl, Br, or I), N-cyclohexyl-N-methylcyclohexaneamine may be used as the organic base.

[1840] In the embodiments of the present invention, the solvent may be, for example, 1-methylpyrrolidin-2-one, DMF, DMSO, THF, etc.

[1841] [Steps 3-1 and 3-2] Reduction reaction

[1842] Steps 3-1 and 3-2 above are steps for preparing compound 3-1 or compound 3-2 by stirring compound 2-1 or compound 1-2 for 3 to 96 hours under cooling or heating using hydrogen gas in a solvent with palladium / charcoal.

[1843] In embodiments of the present invention, the compound 3-1 or compound 3-2 can be prepared by stirring for 0.5 to 48 hours at room temperature (10 to 25 °C) to 60 °C in steps 3-1 and 3-2.

[1844] In the embodiments of the present invention, steps 3-1 and 3-2 may be performed under a solvent, and the solvent is not specifically limited as long as it is a solvent that does not inhibit the reaction, but methanol, ethanol, tetrahydrofuran, ethyl acetate, dichloromethane, or a mixture thereof may be used.

[1845] [Steps 4 and 6-1] Amide reaction

[1846] Step 4 is a step of preparing the compound 4-1 or compound 6-3 by stirring the compound 3-1 or compound 3-3 with an equal or excess amount of the corresponding Ri-Y (Y is a carboxylic acid or acyl chloride) in a solvent inert to the reaction, using a condensing agent and a base, for 1 to 24 hours under cooling or heating.

[1847] Step 6-1 can prepare the compound 6-1 using an amine (R4-NH2) per-combination agent, under the same conditions as Step 4, as the compound 5-1.

[1848] In embodiments of the present invention, the above step may produce the compound 4-1, compound 6-3, or compound 6-1 by stirring at room temperature to 120°C for 1 to 8 hours.

[1849] In the embodiments of the present invention, step 4 / step 6-1 may be performed in the presence of a solvent, and the solvent may be N,N-dimethylformamide, dimethylacetamide, dichloromethane, 1,2-dichloroethane, chloroform, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile, or a mixture thereof, provided that it is inert to the reaction.

[1850] In embodiments of the present invention, the condensation agent may be pentafluorophenyl trifluoroacetate, dicyclocarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), 1,1'-carbonyldiimidazole, etc. In embodiments of the present invention, an additive or base may be additionally used in the reaction.

[1851] In the embodiments of the present invention, the additive may include N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), etc.

[1852] In the embodiments of the present invention, the base may be an organic base such as trithylamine, diisopropylthylamine, etc.; or an inorganic base such as potassium carbonate, sodium carbonate, potassium hydroxide, or sodium hydroxide.

[1853] [Step 5-1] Hydrolysis reaction

[1854] Step 5-1 is a step of preparing compound 5-1 by stirring compound 4-1 in a solvent, using an equal or excess amount of aqueous base solution, under cooling or heating for 3 to 96 hours.

[1855] In embodiments of the present invention, the compound 5-1 can be prepared by stirring for 3 to 48 hours at room temperature (10 to 25 °C) to 60 °C in step 5-1.

[1856] In the embodiments of the present invention, the solvent is not particularly limited as long as it is a solvent that does not inhibit the reaction, but methanol, ethanol, tetrahydrofuran, dimethoxyethane, acetonitrile, or a mixture thereof may be used. As the base, an inorganic base such as lithium hydroxide, sodium hydroxide, or potassium hydroxide may be used. [Step 5-2] Detachment reaction

[1857] Step 5-2 above is a step of preparing compound 5-2 by stirring compound 4-1 in a solvent, using an equal or excess amount of acid solution, under cooling or heating for 3 to 96 hours.

[1858] In embodiments of the present invention, the compound 5-2 can be prepared by stirring for 3 to 48 hours at room temperature (10 to 25 °C) to 60 °C in step 5-2.

[1859] In the embodiments of the present invention, the solvent may be dichloromethane, 1,4-dioxane, methanol, ethanol, tetrahydrofuran, dimethoxyethane, acetonitrile, or a mixture thereof, which are inert to the reaction. The acid may be hydrochloric acid, sulfuric acid, trifluoroacetic acid, etc.

[1860] [Steps 6-2 and 6-3] Coupling reaction

[1861] Steps 6-2 and 6-3 above are steps for preparing compound 6-2 or compound 3-3 by stirring compound 5-2 or compound 3-2 for 3 to 96 hours under cooling or heating using R4-Z or R5-Z (Z is a reactive halide, acyl halide, or carboxylic acid), a solvent and a base that do not inhibit the reaction.

[1862] In embodiments of the present invention, the halide may be F, Cl, Br, or I. In embodiments of the present invention, steps 6-2 and 6-3 may be carried out under substantially the same conditions as step 2, or step 4 and step 6-1 to produce compound 6-2 or compound 3-3.

[1863] The above reaction scheme 1 represents a representative method for preparing the compounds of the present invention, and includes manufacturing methods modified to a level obvious to those skilled in the art. For example, those skilled in the art may prepare the compounds of the present invention based on the above reaction scheme 1 by partially changing, adding, or deleting each step and reaction condition.

[1864] A composition comprising a compound represented by Chemical Formula I, a method using a compound represented by Chemical Formula I, and a use of a compound represented by Chemical Formula I

[1865] The present invention provides a pharmaceutical composition comprising, as an active ingredient, a compound represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7, or Formula 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof.

[1866] The present invention provides a health functional food composition comprising a compound represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7 or Formula 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof.

[1867] Compounds represented by the above formulas I, 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof, and pharmaceutical compositions comprising these as active ingredients exhibit IRAK-4 and / or IRAK-1 inhibitory activity and may be used for the prevention, treatment, or improvement of IRAK-4 or IRAK-1 related diseases.

[1868] In the present invention, "IRAK-4 or IRAK-1 related disease" may be an autoimmune disease, an inflammatory disease, or a tumor.

[1869] In one embodiment of the present invention, the IRAK-4 or IRAK-1 related disease may be rheumatoid arthritis, spondylosis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, psoriasis, atopic dermatitis, vitiligo, multiple sclerosis, myasthenia gravis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, cutaneous lupus erythematosus, Sjögren's syndrome, or Behcet's disease. The pharmaceutical composition of the present invention may additionally include one or more pharmaceutically acceptable carriers in addition to compounds represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7, or Formula 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof.

[1870] At this time, the pharmaceutically acceptable carrier is one or more commonly used in the industry when preparing the formulation, selected from lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, but is not limited thereto.

[1871] In addition, the pharmaceutical composition of the present invention may further include, in addition to the above components, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, or a preservative.

[1872] The present invention provides a method for preventing or treating IRAK-4 or IRAK-1 related diseases, comprising the step of administering to an individual a compound represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7 or Formula 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof, or a pharmaceutical composition containing the same.

[1873] The method for preventing or treating IRAK-4 or IRAK-1 related diseases according to the present invention may comprise administering a therapeutically effective amount of a compound represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7, or Formula 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof, or a pharmaceutical composition containing the same.

[1874] In the present invention, "prevention" means any act of suppressing or delaying the onset of IRAK-4 or IRAK-1 related diseases by administering a compound represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7, or Formula 1-8 of the present invention, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof.

[1875] In the present invention, "treatment" means any act in which symptoms of IRAK-4 or IRAK-1 related diseases are improved or beneficially altered by the administration of a compound represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7, or Formula 1-8 of the present invention, compounds 1 to 199 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof. The present invention relates to a compound represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7, or Formula 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, and their for the prevention or treatment of IRAK-4 or IRAK-1 related diseases. The present invention provides a use of a pharmaceutically acceptable salt, or a hydrate or solvate thereof, or a pharmaceutical composition comprising the same. The present invention provides a use of a compound represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7, or Formula 1-8, compounds 1 to 199 of Table 1, stereoisomers thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, or a pharmaceutical composition comprising the same, for the manufacture of a drug for the prevention or treatment of IRAK-4 or IRAK-1 related diseases.

[1876] In addition, the present invention comprises the following items (1) to (31) relating to a novel compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, a pharmaceutical composition comprising the same, a method of prevention or treatment comprising administering the same, and the use thereof.

[1877] (1) The present invention provides a compound represented by Chemical Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof:

[1878] <Chemical Formula 1>

[1879]

[1880] In Chemical Formula I above,

[1881]

[1882] and X1 and X2 are each independently C or N, Y1 is C, N, O or S (wherein when Y1 is O or S, X2 is C), and the ring A1 is unsubstituted or one or more rings may each independently be substituted with a straight-chain or branched-chain -C1-C6 alkyl or a halogen (-F, -Cl, -Br or -I);

[1883] Ring A2 is a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of a straight-chain or branched-chain -C1-C6 alkyl, -CF3, -NO2, -S(=O)2-NRaRb, -S(=O)2CF3, -S(=O)2F, -ORc, N and O in the ring, a 6- to 10-membered aryl, -C(=O)NRdRe, -C(=O)OH, -C(=O)OCH3 or -CN, wherein Ra, Rb, Rc, Rd and Re are each independently -H, a straight-chain or branched-chain -C1-C6 alkyl, -CF3, -CH2C(CH3)2OH or -NH2, and at this time, the H of ring A2 is unsubstituted or one or more rings may each independently be substituted with a straight-chain or branched-chain -C1-C6 alkyl, a straight-chain or branched-chain -C1-C6 alkoxy, -OH or a halogen (-F, -Cl, -Br, or -I);

[1884] Q1 and Q2 are each independently -N- or -N(Li-R2)-, where one of Q1 and Q2 is _new_ and the other is _new(1丄1—1?2)_;

[1885] Li is a single bond or C1-C8 alkylene. When Li is C1-C8 alkylene, the H of Li is unsubstituted or one or more of the substituents may each independently be a straight-chain or branched-chain -Cl-C6 alkyl, halogen (-F, -Cl, -Br or -I) or -OH;

[1886] R2 is -H, a straight-chain or branched-chain -Cl-C8 alkyl, a straight-chain or branched-chain -Cl-C6 alkyl-OH, a straight-chain or branched-chain -Cl-C6 alkoxy, a 4- to 6-membered heterocycloalkyl containing 1 to 4 heteroatoms independently selected from the group consisting of N and O in the ring, -CN, -OCH2C(=O)NRfRg, -S(=O)2Rh, -CH2CH2P(=O)(OCH2CH3)2, -CD3, -CH2CH2P(=O)(OCH2OC(=O)C(CH3)3)2, a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S in the ring, a C3-C6 cycloalkyl or a 6- to 10-membered aryl, where Rf, Rg and Rh are each independently H or a straight-chain or branched-chain -C1-C6 alkyl, and at this time the substituents of R2 are unsubstituted or one or more of the substituents may each independently be a straight-chain or branched-chain -Cl-C6 alkyl or halogen (-F, -Cl, -Br, or -I);

[1887] R3 is -H, a straight-chain or branched-chain -Cl-C6 alkyl or a halogen (-F, -Cl, -Br, or -I), where R3 is unsubstituted or one or more complements may each be independently substituted with a straight-chain or branched-chain -Cl-C6 alkyl or a halogen (-F, -Cl, -Br, or -I);

[1888] A2 is a quintoidal to hexavalent heterocyclic alkylene containing 1 to 4 N atoms in the ring;

[1889] L2 is a homogeneous, C1-C6 alkylene, -C(=0)-NRai-, -C(=0)0-, -C(=0)-, -NRa2C(=0)0-, -NRa3C(=0)-, -NRa4-, or -C(=0)-NRa5-CH2-, where Rai, Ra2, Ra3, Ra4, or Ra5 are each independently -H, straight-chain or branched-chain -C1-C6 alkyl, and the complement of L2 is unsubstituted or one or more complements may each independently be substituted with straight-chain or branched-chain -Cl-C6 alkyl or halogens (-F, -Cl, -Br, or -1);

[1890] R4 is a 3- to 8-membered heterocycloal kyle containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of -H, straight-chain or branched -Cl-C6alkyl, N, and O, C3-C8 cycloal kyle, -(CH2)mC(=0)NRbiRb2(m is an integer from 1 to 6), -(CH2)pC(=0)0Rb3(p is an integer from 1 to 6), a 5- to 6-membered heterocycloal kyle containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of N, O, and S, -NRb4Rb5, -N(CH=CH2)2, -(CH2)qNRb6C(=0)0H(q is an integer from 0 to 6), -(CH2)rOH(r is (integer from 1 to 6), - (CH2)sNH2(s is an integer from 1 to 6), - (CH2)tCN(t is an integer from 1 to 6), straight-chain or branched-chain -C1-C6 alkoxy, -C(CH3)20H, -CH2CF3, -(CH2)2CF3, -CF 3 I — NH2 , phenyl , -C(CH3)2Br , —OH , -CH2C(CH3)20H , -S(=0)2CH3,

[1891]

[1892] 0 or 0 and, where Rbi, Rb2, Rb3, Rb4, Rb5, and Rb6 are each independently H, straight-chain or branched-chain -Cl-C6alkyl,

[1893]

[1894] -CH2C(CH3)20H , -CH2CH2C(CH3)20H , -C(CH3)20H , -CH2CH2OH , -OH , C3-C8 cycloal kill , -CH2CF3 , -(CH2)2CF3 or -CF3 and ,

[1895] The R4 complement is unsubstituted or one or more complements each independently contain 1 to 4 heterocyclic alkyls in the ring independently selected from the group consisting of straight-chain or branched -Cl-C6alkyl, halogen (-F, -Cl, -Br, or -I), -C(=0)NH2, -S(=0)2NH2, -OH, -NH2, -CH(CH3)0H, CH2OH, -C(=0)0C(CH3)3, straight-chain or branched -Cl-C6 alkoxy, -CN, -OH, N, and 0, -S(=0)2CH3,

[1896] -C(CH3)20H, -CF3, or -S(=0hCF3) can be substituted;

[1897] R5 is -H or a straight-chain or branched-chain -Cl- C6 alkyl. (2) In the above (1), Ai in the above formula I is

[1898]

[1899] (3) In the above (1) or (2), the H of Ai in the above formula I may not be substituted, or one or more complements may each be independently substituted with -CH3, -F, or -C1.

[1900] (4) In any one of (1) to (3) above, Ri in the above formula I is -S(=0)2NH2, -NO2, -OCH3, -S(=0)2CF3, -CF3, -S(=0)2NHCH3, -S(=0)2NHCH2CH3, -5S(=0)2-F, -S(=0)2-N(CH3)2, -S(=0)2-NHCH2C(CH3)20H, -C(=O)-NH2, -C(=o)-NHCH3, >

[1901]

[1902]

[1903] " , N, and the valence may not be substituted, or one or more valence may each be independently substituted with a straight-chain or branched-chain -Cl-C6 alkyl, a straight-chain or branched-chain -Cl-C6 alkoxy, -OH, or a halogen (-F, -Cl, -Br, or -1).

[1904] (5) In any one of (1) to (4) above, Li is a single ion, -CH2-, -(CH2)2-, -(CH2)4-, or -CH2CHOH-, and L1 is -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, or -CH2CH0H-, the ion of L1 may not be substituted, or one or more ion may each be independently substituted with a straight-chain or branched-chain -Cl- C6 alkyl, halogen (-F, -Cl, -Br, or -1) or -0H.

[1905] (6) In any one of the above (1) to (5), in the above formula I

[1906] R2 is - H, - CH3, - CH2CH3, - (CH2)2CH3, - (CH2)3CH3, - CH(CH3)2, - CH2C(CH3)3, -C(CH3)20H, -CH2C(CH3)20H, -(CH2)2C(CH3)2OH, -CHF2, -CF3, -CH2CHF2, -CN, - 0CH2C(=0)NH2, -CH2CF3, -(CH2)2CF3, -(CH2)3CF3, -(CH2)4CH3, -(CH2)5CH3, -0CH(CH3)2,

[1907] R3 is -H, -CH3, -CH2CH3, -(CH2)2CH3, -(CH2)3CH3, -F, -CF3, -CH2CHF2, (CH2)3CF3, or -CH(CH3)2;

[1908] Here, R2 and R3 are each independently unsubstituted or one or more H7s, each independently straight-chain or branched-chain Cl-C6 alkyl, or halogens (-F, -C1, -

[1909]

[1910] Or it may be something that can be replaced with - 1).

[1911] (7) In any one of the above (1) to (6), R2 and R3 may not be simultaneously me.

[1912] (8) In any one of (1) to (7) above, A2 in the above formula I is (9) In any one of (1) to (8) above, L1 is a single bond, -CH2-, -(CH2)2-, -(CH2)3- or -(CH2)4-;

[1913] R2 and R3 are independently - H , - CH3 , - CD3 , - CH2CH3 , - C(CH3)20H , - CH2C(CH3)20H , - (CH2)2C(CH3)2OH , - CF 3 I -CH2CF3, -(CH2)2CF3, -(CH2)3CF3, -CH2CHF2, -

[1914] CH(CH3)2 , -OCH2CH2CH3 ,

[1915] L2 is a unitary combination, -Ofc-, -CH2CH2-, -C(=O)NH-, -NCH3-, or -C(=0)- and ;

[1916] R4 is - C(CH3)20H, -CF 3 I -CH2CF3, -(CH2)2CF3, -(CH2)3CF3

[1917]

[1918] - CH(CH3)2 or -OH and ;

[1919] R2 and R3 may simultaneously be things that are not me. (10) In any one of the above (1) to (9), in the above formula I

[1920] (11) In any one of the above (1) to (10), Li is a single compound; R2 and R3 are each independently -H, -CH3, -CD3, -CH2CH3, -CH(CH3)2, -CH2CF3 or -CH2CHF2;

[1921]

[1922] L2 is a single bond, -C(=0)-, -C(=O)NH-, -C(=0)N(CH3)-, -NHC(=O)-, -N(CH3)C(=0)-, -CH2, -CH2CH2-, -NH-, or -N(CH3)- and ;

[1923] R4 is -CH3, -C(CH3)20H, -CH2C(CH3)20H, -CH2CF3, -CH2CH3, -CH(CH3)2, -CH2CN,

[1924]

[1925] -CH2OH, -(CH2)20H, -(CH2)2CF3, -CH2NH2, -N(CH3)2, -N(CH2C(CH3)20H)2, -NH2, -S(=0)2CH3 or -OH; R2 and R3 may simultaneously be non-I.

[1926] or , and the inner part of A1 is not substituted or each independently can be substituted with one or more inner parts -CH3, -F, or -C1; and Ri are -S(=0)2W -S(=0)2NH(CH2C(CH3)20H), -S(=0)2NH(CH2CH3), ,

[1927]

[1928] (13) In any one of (1) to (12) above, L2 in Chemical Formula I may be a single compound and represented by the following Chemical Formula 1-1:

[1929] [Chemical Formula 1-1]

[1930] In the above chemical formula 1-1,

[1931] R4 is -H, — CH2CF3, -(CH2)2CF3, — CH3, CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, — (CH2)2CH(CH3)2, - N(CH=CH2)2, -(CH2)2S(=0)2CH3, -CH2CH2OH, -CH2CH2NH2, -C(CH3)2OH,

[1932] -

[1933]

[1934] CH2C(CH3)20H, -(CH2)2C(CH3)2OH, -CH2CF3, - NH2, -CH2NH2, -OH, -CH2OH, -CH2NHCH3, -CH2N(CH3)2, _(CH2)NHC(=0)0H, _(CH2)2NHC(=0)0H, _(CH2)NHC(=0)C(CH3)3, — (CH2) N ( CH2C (CH3) 2OH) 2, -NHCH2C (CH3) 2OH, -NHCH2CH2C (CH3) 2OH, -N (CH2CH2OH)2, - NHCH2CH2NH2 or - (CH2)2NHC(=0)C(CH3)3;

[1935] R5 is -H or -CH3; in the above formula I-1, Ai, Li, Qi, Q2, RI, R2 and R3 may each independently be the same as any one of (1) to (13).

[1936] (14) In any one of the above (1) to (13), L2 in the above formula I may be a C1-C3 alkylene and may be represented by the following formula 1-2:

[1937] 5 [Chemical Formula 1-2]

[1938]

[1939] ni is 1, 2, or 3, and ;

[1940] 0 R4 is - CH2CF3, - CH3, - CH2CH3, -C(CH3)20H, - (CH2)NHC(=0)0H, - (CH2)NHC(=0)C(CH3)3, - (CH2)2NHC(=0)0H, -OH, -CH2OH, -CH2CH2OH, -(CH2)CH(CH3)2, -(CH2)C(CH3)20H, -CF3, -S(=0)2CH3, -CH2S(=0)2CH3, -CH2NH2, -CH2CH2NH2, -NHCH2CF3,

[1941] -NHCH3, -N(CH3)2, -N(CH2C(CH3)20H)2,

[1942]

[1943] - It is NH2 and ;

[1944] 5 In the above chemical formula I-2, Al, L1, Q1, Q2, R1, R2 and R3 may each be independently identical to any one of (1) to (13).

[1945] (15) In any one of the above (1) to (13), L2 in Chemical Formula I can be represented as -C(=0)- and can be expressed by the following Chemical Formula 1-3: [Chemical Formula 1-3]

[1946]

[1947]

[1948] -OH , -CH2NH2 , -CH2OH , - (CH2)2CH3 , - (CH2KF3 , -CH2CH(CH3)2 , or - CH2C(CH3)20H ;

[1949] In the above chemical formula I-3, Al, L1, Q1, Q2, R1, R2 and R3 may each be independently identical to any one of (1) to (13).

[1950] (16) In any one of the above (1) to (13), L2 in the above chemical formula I can be represented as -C(=0)-NRai- and the following chemical formula 1-4:

[1951] [Chemical Formula 1-4]

[1952] Rai is -H, -CH3, -CH2CH3, or -CH2CH2CH3; R4 is -H, -OH, -Ofe, -CH2CH3, -CH2CH2OH, -CH(CH3)2, -CH2C(=0)NH2, -

[1953] C

[1954]

[1955] H2C(=0)NHCH3, _(CH2)2C(=0)NH2, _(CH2)2C(=0)0CH3, >- CH2CF3, -(CH2)2CH3, -CH2CF3, -(CH2)2CF3, -C(CH3)2CH2CH3, -C(CH3)2CH20H, -

[1956]

[1957] C(CH3)2CH2CH20H , - (CH2)3CE(3 , - (CH2)4NH2 or - CH2CH2S(=0)2CH3 and ;

[1958] In the above chemical formula I-4, Al, L1, Q1, Q2, RI, R2 and R3 may each be independently identical to any one of (1) to (13).

[1959] (17) In any one of the above (1) to (13), L2 in the above chemical formula I can be represented as -C(=0)-NRa5-(Ofc)- and the following chemical formula 1-5:

[1960] [Chemical Formula 1-5] Ras In the above Chemical Formula I-5, A s

[1961] Ra5 is - H or - CH3 and ;

[1962]

[1963] In the above chemical formulas 1-5, Ai, Li, Qi, Q2, Ri, R2 and R3 can each independently be the same as any one of (1) to (13).

[1964] (18) In any one of (1) to (13) above, L2 in Chemical Formula I can be represented as -C(=0)0- and can be represented by the following Chemical Formula 1-6:

[1965] [Chemical Formula 1-6]

[1966]

[1967] R4 is -H, -CH3, or -CH2CH3;

[1968] In the above chemical formula I-6, Ai, Li, Qi, Q2, RI, R2 and R3 may each be independently identical to any one of (1) to (13).

[1969] (19) In any one of (1) to (13) above, L2 in Chemical Formula I can be represented as - NRa3C(=0)- and can be represented by the following Chemical Formula 1-7:

[1970] [Chemical Formula 1-7]

[1971]

[1972] In the above chemical formulas 1-7, Ra3 is -H or -CH3; and R4 is -H, -CH3, -CF3, -CH2CH3, -CH2CF3, -(CH2)2(〕H3, -(CH2)2CF3, -

[1973]

[1974]

[1975] In the above chemical formula I-7, Ai, Li, Qi, Q2, RI, R2 and R3 may each be independently identical to any one of (1) to (13).

[1976] (20) In any one of (1) to (13) above, L2 in Chemical Formula I can be represented as - NRa4 - and can be represented by the following Chemical Formula 1-8:

[1977] [Chemical Formula 1-8]

[1978] In the above chemical formula 1-8, Ra4 is -H or -CH3;

[1979] R4 is -H, -CH3, -CF3, -CH2CH3, -CH2CF3, -(CH2)2CEb, -(CH2)2CF3, -

[1980] (CH2)C(=0)NH2, -C(CH3)3, -C(CH3)2Br, -CH20H,

[1981]

[1982] _(CH2)NHC(=0)0H, _(CH2)NHC(=0)0C(CH3)3, -CH2NH2, -NHCH2CF3,

[1983]

[1984] In the above chemical formula I-8, Ai, Li, Qi, Q2, RI, R2 and R3 may each be independently identical to any one of (1) to (13).

[1985] (21) In any one of (1) to (13) above, in Formula I, L2 is -NRa2C(=O)O-;

[1986] Each Ra2 is independently -H or -CH3;

[1987]

[1988] R4 is -H, -C2H5, -CF3, -CH2CH3, -CH2CF3, -(CH2)2C2H5, -(CH2)2CF3, -(CH2)C(=O)NH2, -C(CH3)3, -C(CH3)2Br, -CH2CN,

[1989] -(CH2)NHC(=O)OH, -(CH2)NHC(=O)OC(CH3)3, -CH2NH2, -NHCH2CF3,

[1990] -CH2CH(CH3)2, -CH2C(CH3)2OH,

[1991] —

[1992]

[1993] and may be.

[1994] (22) The present invention provides a compound represented by Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof:

[1995] <Formula 1>

[1996]

[1997] R1 is -S(=O)NH2, -NO2 or -C(=O)-NHCH3;

[1998] Q1 is N-L1-R2, Q2 is phenyl;

[1999] L1 is a single bond, -CH2-, -(CH2)2-, -(CH2)3- or -(CH2)4-;

[2000] R2 is -H, -CH3, -C(CH3)2OH, -CH2C(CH3)2OH, - (OfehCXOfehOH, -CF3, -CH2CF3, - (CH2)2CF3;

[2001] R3 is -H;

[2002]

[2003] L2 is a single bond, C1-C3 alkylene, -C(=O)-, -C(=O)-NRai-, -C(=O)-NRa5-(CH2)- or -NRa3C(=O)-;

[2004] The above Rai, Ra3 and Ra~ are each independently -H or -Ofe;

[2005] R

[2006]

[2007] R4 is -CH2NH2, - (CH2)2NH2, - (CH2)4NH2, -NH2, -CH2OH, or

[2008]

[2009] ;

[2010] R5 is — 보이다.

[2011] (23) The present invention provides a compound represented by formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates:

[2012] <Formula I>

[2013] N、、、

[2014] In the above formula I,

[2015]

[2016] Ai may be unsubstituted or each independently one or more - 보 may be substituted with -CH3, -F, or -C1;

[2017] N 〜〜 N It should be noted that there are some unclear or incorrect expressions in the original text (such as "- (OfehCXOfehOH" and "—보이다"), which may affect the accuracy of the translation, but the translation is carried out according to the rules as much as possible..

[2018] Ri is -S(=0)2NH2, -S(=O)2NHCH3, -NO2, N

[2019]

[2020] And, the bolsters of Ri may be unsubstituted or one or more bolsters may each be independently substituted with a straight-chain or branched-chain -Cl-C6 alkyl, a straight-chain or branched-chain -Cl-C6 alkoxy, -OH, or a halogen (-F, -Cl, -Br, or -I); Qi is N-Li-Q2, and Q2 is Si;

[2021] L1 is a unitary sum, -CH2 - , - (CH2)2- , - (CH2)3 - or - (CH2)4 - and ;

[2022] R2 and R3 are independently - H, - CH3, - CD3, - CH2CH3, -C(CH3)20H, CH2C(CH3)20H, -(CH2)2C(CH3)2OH, -CF 3 I -CH2CF3, - (CH2KF3, - (CH2KF3, -CH2CHF2, -

[2023] CH(CH3)2, -OCH2CH2CH3, -CN,

[2024] L2 is a unitary combination, - Ofc- , - CH2CH2- , - C(=O)NH- , -NCH3- or - C(=0)- and;

[2025] R4 is -C(CH3)20H, -CF3, -CH2CF3, -(CH2)2CF3, -(CH2)3CF3

[2026]

[2027] - CH(CH3)2 or -OH and ;

[2028] I?5 is - H and;

[2029] R2 and R3 are not me at the same time.

[2030] (24) The present invention provides a compound shown in the following table, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates: Example

[2031] Structural name

[2032] Example

[2033] O N-[2-(3-hydroxy—3—methylbutyl)-6 - [4-(2- HO 、 hydroxyacetyl)piperazin—1—yl]—2H—indazol—5 —A^

[2034] yl]-3-sulfamoylbenzamide

[2035] 1

[2036] N- [2-(3 -hydroxy-3 -methylbutyl)-6 - [4-(2 -hydroxy… righteousness" right 011 acetyl)piperazin-1-yl]-2H-indazol-5-yl]-3 -cAQ sulfamoylbenzamide

[2037] N—{6 —[4—(2—aminoacetyl)piperazin—1—yl]—2 —0

[2038] H2N、A N (3-hydroxy-3-methylbutyl)—2H—indazol—5—yl}-HCl 〔ssss、 T 3-sulfamoylbenzamide hydrochloride 2

[2039] N-{6 - [4-(2 -aminoacetyl)piperazin-1-yl]-2 - H2N、〈9H heart』ka OH

[2040] d ~Q song (3 -hydroxy-3 -methylbutyl)-2H-indazol-5-yl}-3 -sulfamoylbenzamide hydrochloride

[2041] N— {6 — [4— (2— aminoacetyl )piperazin— 1— yl ]— 2— 0

[2042] H2N』g ( 3-hydr oxy-3-methyl butyl )— 2H— indazol— 5— yl}- 3- su 1 f amoylbenzamide

[2043] 3

[2044] N- {6 - [4- (2-aminoacetyl)piperazine -1-yl]- 2 - H W Myos ' U 011 (3-hydroxy-3-methylbutyl)-2H-indazole-5-yl}-4- 6 Outside 0° Alcohol Famo Ilvenza Mid

[2045] 0 N- [ 2- ( 3-hydr oxy-3-methyl butyl ) - 6 - [ 4- ( 4 , 4 , 4 - gs trif l uor obut anoy 1 ) pi per az in— 1-y 1 ] — 2H— Ap

[2046] i ndazo 1 -5-yl ] — 3— su 1 f amoy 1 benz am i de

[2047] 4 f “n 、 / N- [2- (3-hydroxy- 3-methylbutyl)- 6 - [4- (4, 4, 4-t H2N / sasuga OH

[2048] Difluorobutane (noyl)piperazine -1-yl]- 2H-indazole -5 -yl]- 3 —sulfamoylbenzamide

[2049]

[2050] N— {6 — [4— (2— aminoacetyl )piperazin— 1— yl ]— 2— 0

[2051] HCl H2N of N-{6-[4-(2-aminoacetyl)piperazin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide hydrochloride

[2052] 0 N-{6-[4-(2-aminoacetyl)piperazin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3- 2 才 〕 Qf^° F sulfamoylbenzamide hydrochloride

[2053] o N—{6 — [4—(2—aminoacetyl)piperazin—1—yl]—2 — H2N、Ag (4,4,4-trifluorobutyl)-2H-indazol-5-yl}~3~sulfamoylbenzamide

[2054] 背 Of—

[2055] o HN人니 〜 7 、 己 N-{6-[4-(2-aminoacetyl)piperazin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3- H 7 「 o >

[2056] sulfamoylbenzamide

[2057] N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(3 - H2N^^ N ^

[2058] hydroxy—3—methylbutyl)—2H—indazol—5—yl}~3~sulfamoylbenzamide dihydrochloride N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(3 - H—9 = 0H

[2059] N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide 2 hydrochloride

[2060] N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(3- H2N^^ N ^ hydroxy—3—methylbutyl)—2H—indazol—5—yl}~3~ sulfamoylbenzamide

[2061] Y〕5 A /

[2062] H2N、〈9 Hf 」 7 '수 011 N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(3-<AQ 수 hydroxy-3-methylbutyl)-2H-indazol-5-yl}-4-sulfamoylbenzamide

[2063]

[2064] N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(3- H2N、F N ^

[2065] hydroxy—3—methylbutyl)—2H—indazol—5—yl}~3~ nitrobenzamide dihydrochloride

[2066] /

[2067] O HN< 스 (OH N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(3- 0求^ 人 0 HC1 hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-nitrobenzamide 2 hydrochloride

[2068] N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-(3- H2N^^ N ^

[2069] {6 - [4 - (2 - aminoethyl)piperazin - 1 - yl] - 2 - (3 - hydroxy - 3 - methylbutyl)- 2H - indazol - 5 - yl}- 3 - nitrobenzamide

[2070] O HN、— 으- ( / OH N- {6 - [4 - (2 - aminoethyl)piperazin - 1 - yl] - 2 - (3 - hydroxy - 3 - methylbutyl)- 2H - indazol - 5 - yl}- 4 - nitrobenzamide

[2071] N— {6 — [4— (2— aminoethyl )piperazin— 1— yl]— 2 — H2N^^ N ^

[2072] (4,4,4 - trifluorobutyl)- 2H - indazol - 5 - yl}- 3 - sulfamoylbenzamide dihydrochloride H2N、&9 1 义 、 '丄 F N- {6 - [4 - (2 - aminoethyl)piperazin - 1 - yl] - 2 - (4,4,4 - trifluorobutyl)- 2H - indazol - 5 - yl}- 3 - d' Y^il 0 HC1 F F

[2073] HC1 sulfamoylbenzamide 2 hydrochloride

[2074] N— {6 — [4— (2— aminoethyl )piperazin— 1— yl]— 2 — H2N^^ N ^ (4,4,4 - trifluorobutyl)- 2H - indazol - 5 - yl}- 3 - sulfamoylbenzamide

[2075] “ : Of—

[2076] o HN人 丄 으 '己 N- {6 - [4 - (2 - aminoethyl)piperazin - 1 - yl] - 2 - 머 人 '으、스 三 V F

[2077] 6' TjP° F F (4,4,4 - trifluorobutyl)- 2H - indazol - 5 - yl}- 3 - sulfamoylbenzamide

[2078]

[2079] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-2H-indazol-

[2080] 5-yl]-3-sulfamoylbenzamide

[2081] H2N. S P 빠" 수 OH N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2,2,2-tri 6 fluoroethyl)piperazin-1-yl]-2H-indazol-5-「 ° yl]-3-sulfamoylbenzamide

[2082] 3-sulfamoyl-N-[2-(4,4,4-trifluorobutyl)-6-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-F 으 紀 ]2H-indazol-5-yl]benzamide H2N、 S P 妙스 三 야 3-sulfamoyl-N-[2-(4,4,4-trifluorobutyl)-6- / 유 0 서 [4-(2,2,2-trifluoroethyl)piperazin-1-yl]-2H-indazol-5-yl]benzamide

[2083] 『잇아 N—{2 —[(1,3-dioxolan-2-yl)methyl]-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazo1-5-yl}~3~sulfamoylbenzamide N-{2 -[(1,3-dioxolan-2-yl)methyl]-6-[4-(2-hydroxy H N '° mg、 스 7 ^~0

[2084] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(oxan-2-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2085] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(oxan-2-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2086] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(oxan-2-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide S N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(oxan-2-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2087]

[2088] N-{2-[2-(1,3-dioxan-2-yl)ethyl]-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide H N-{2-[2-(1,3-dioxan-2-yl)ethyl]-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide 7 N-{2-[2-(1,3-dioxan-2-yl)ethyl]-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2089] N-{2-[2-(carbamoylinethoxy)ethyl]-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2090] N-{2-[2-(carbamoylmethoxy)ethyl]-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol- H W I V A / -5-yl}-3-sulfamoylbenzamide 6 XJ ° NH2 5-yl}-3-sulfamoylbenzamide

[2091] N-{6-[4-(2-hydroxypropane-2-yl)piperidin-1-yl]-2-[2-(propane-2-yloxy)ethyl]-2H-indazol- N -5-yl}-3-sulfamoylbenzamide

[2092] H N O HNXX N N-{6-[4-(2-hydroxypropane-2-yl)piperidin-1-yl]-2-[2-(propane-2-yloxy)ethyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2093] HOJ N-{6-[4-(2-hydroxypropane-2-yl)piperidin-1-yl]-2-(2,2,2-trifluoroethyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide „ x T o T H TX N T >、

[2094] H N 、스> 으 / N-{6-[4-(2-hydroxypropane-2-yl)piperidin-(-ol)-1-yl]-2-(2,2,2-trifluoroethyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2095]

[2096] It should be noted that there may be some unclear or incorrect chemical structure descriptions in the original text, which may affect the accuracy of the translation. It is recommended to double-check with the source document for a more precise understanding.N-[2-(2,2-difluoroethyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide N- [2- (2, 2-difluoroethyl)- 6 - [4- (2-hydroxy d 广 0 3-sulfamoylbenzamide

[2097] N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1- H yl]-2-(2-methanesulfonylethyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2098] o HN人 』 7 N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(2-methanesulfonyl-ethyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2099] N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(2-propoxyethyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2100] XT—

[2101] N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1- … '° 느 yl]-2-(2-propoxyethyl)-2H-indazol-5-yl}-3 —sulf — 人 0 느 sulfamoylbenzamide

[2102] N-[2-(3-cyanopropyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2103] HN o 「, / N-[2-(3-cyanopropyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2104] / piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2105] Pamo-ylbenzamide

[2106]

[2107] HO J N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2108] IL N’”-\

[2109] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2110] 1-1i N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(oxan-4-yl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2111] yl]-2-(oxan-4-yl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2112] 소,>..<N / — \ nitrobenzamide

[2113] 『 >--< 0

[2114] o i-ir 스'' 〜’ N- {6 - [4- (2 -hydroxypropan-2-yl)piperidin-1-yl]-2-(oxan-4-yl)-2H-indazol-5-yl}-3-nitro 0* 、厂 『스0 benzamide

[2115] 으丄

[2116] IICL | N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(oxan-4-yl)-2H-indazol-5-yl}~3~ 易''、스 7 / —、、 sulfamoyl benzamide

[2117] tw X X , N 그 P N- {6 - [4-(2 -hydroxypropan-2-yl)piperidin-1-I-LM. / ?

[2118] yl]-2-(oxan-4-yl)-2H-indazol-5-yl}-3 —sulfamoyl 「 广 ylbenzamide

[2119] 'V'

[2120] HOJ N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(propan-2-yl)-2H-indazol-5-yl}~3~ 、丄 ''弓 :스、、广』、 I / sulfamoyl benzamide

[2121] N— (

[2122] TT AT N- {6 - [4-(2 -hydroxypropan-2-yl)piperidin-1- 0 HN 〜' ■

[2123] yl]-2-(propan-2-yl)-2H-indazol-5-yl}-3 —sulfao : ( u moyl benzamide

[2124] %,

[2125]

[2126] HO J N-{6 - [4-(2-hydroxyprop-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-nitrobenzamide

[2127] [L N —

[2128] O SA' Dou''’" N-{6 - [4-(2-hydroxyprop-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-nitrobenzamide

[2129] 〔''는.,

[2130] HO、 J N-{6 - [4-(2-hydroxyprop-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-

[2131] I、.•소、— 、 ◎. sulfamoyl benzamide

[2132] Se N —

[2133] HN'、"' 」 N-{6 - [4-(2-hydroxyprop-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2134] yl]-2-methyl-2H-indazol-5-yl}-3 —sulfamoylbenzamide

[2135] amide

[2136] 는 。

[2137] HOj N-{2-ethyl-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2138] L. L N----』

[2139] 0 IN" 人'저'' N-{2-ethyl-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2140] N-{6-[4-(2-cyano-N-

[2141] methylacetamido)piperidin-1-yl]-2,3-dimethyl-2H-indazol-5-yl}-3-

[2142] sulfamoylbenzamide

[2143] N-{6-[4-(2-cyano-N-methylacetamido)piperidin-1-yl]-2,3-dimethyl-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2144] d幻 승 딘-1-yl]-2,3-dimethyl-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2145]

[2146] N-(2-methyl-6-{4-[methyl(3,3,3-trifluoropropyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide N-(2-methyl-6-{4-[methyl(3,3,3-trifluoropropyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3- o^Qr^ S P 필 )amino]piperidin-1-yl}-2H-indazol-5-yl)-3- o^Qr^0 Sulfa Parmo Iben Zua Mid

[2147] N-(2-methyl-6-{4-[methyl(3,3,3-trifluoropropyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-(1H-1,2,3,4-tetrazol-5-yl)benzamide

[2148] yl)benzamide

[2149] N'NH N-(2-methyl-6-{4-[methyl(3,3,3-trifluoropropyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-(1H-1,2,3,4-tetrazol-5-yl)benzamide 101-[2-(3-hydroxy-3-methylbutyl)-5-(3-A』Y斗nitrobenzamido)-2H-indazol-6-yl]-N-(propan-

[2150] 2-yl)piperidine-4-carboxamide

[2151] H u rr NA /

[2152] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-nitrobenz 0 HN스스\&0H

[2153] zamid)-2H-indazol-6-yl]-N-(propan-2-yl)pi o'서Q승piperidine-4-carboxamide

[2154] 0 N—[2—(3-hydroxy—3—methylbutyl)—6—[4—

[2155] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide

[2156]

[2157] N-(6-{4-0

[2158] [(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy—3-methylbutyl)-2H-indazol—

[2159] 5-yl)-3-sulfamoylbenzamide

[2160] H2N、 S PH心』가OH

[2161] N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin d 「°din-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl)-3-sulfamoylbenzamide

[2162] N-[2-(3-hydroxy-3-methylbutyl)-6-(4-{[(1R)-U-01-'外(methylcarbamoyl)ethyl]carbamoyl}piperidin—06^0心Yg1-yl)-2H-indazol-5-yl]-3-sulfamoylbenzamideH2N. S P떠』가OHN-[2-(3-hydroxy-3-methylbutyl)-6-(4-{[(1R)-1- d{[(methyl carbamoyl)ethyl]carbamoyl}piperidin-1-yl)-2H-indazol-5-yl]-3-sulfamoylbenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-(4-H0

[2163] {[(methyl carbamoyl)methyl]carbamoyl}piperidin-1-yl)-2H-indazol-5-yl]-3-

[2164] sulfamoylbenzamide

[2165] N-[2-(3-hydroxy-3-methylbutyl)-6-(4-{[(methylcarbamoyl)methyl]carbamoyl}piperidin-1-yl)-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2166] d s 、Q 스) 011 {[(methylcarbamoyl)methyl]carbamoyl}piperidin-1-yl)-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2167] 0 N-[2-(3-hydroxy-3-methylbutyl)-6-[4-

[2168] (morpholine-4-carbonyl)piperidin-1-yl)-2H-indazol-(-5-yl]-3-sulfamoylbenzamide

[2169] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(morpholine-4-carbonyl)piperidin-1-yl)-2H-indazol-5-yl]-3-sulfamoylbenzamide 7 percarbonyl)piperidin-1-yl)-2H-indazol-5-yl]-o

[2170] 3-sulfamoylbenzamide

[2171]

[2172] 今 hN—{1 — [2— (3— hydroxy— 3— methylbutyl )—5— (3 — sulfamoyl benzamido ) — 2H— indazol—6 — yl ]piperidin—4— yl} morpholine—4— carboxamide N-{1- [2- (3 -hydroxy- 3 -methylbutyl)- 5- (3 —sulfamoyl benzamido ) — 2H— indazol—6 — yl ]piperidin—4— yl} morpholine—4— carboxamide

[2173] <에 0 일벤즈아미도)- 2H-인다졸- 6 -일]피페리딘- 4 -일} 모르폴린- 4 -카르복사미드

[2174] N—{1 — [2— (3— hydroxy— 3— methylbutyl )—5— (3 — [『今 H sulfamoyl benzamido ) — 2H— indazol—6 — N A N 으 yl ]piperidin—4— yl}pyridine—3— carboxamide o 으 세 幻

[2175] N-{1- [2- (3 -hydroxy- 3 -methylbutyl)- 5- (3 —sulfamoyl % N / 'S' 9 세 1 오" 우 011 일벤즈아미도)- 2H-인다졸- 6 -일]피페리딘- 4 -일} 피리딘- 3 -카르복사미드

[2176] N— [ 2— ( 3-hydroxy— 3— methylbutyl )-6 - [4-(2- H

[2177] hydroxyacetamido )piperidin-1-yl ]— 2H— HO"YY 、I

[2178] indazol -5-yl ] — 3— sulfamoyl benzamide N- [2- (3 -hydroxy- 3 -methylbutyl)- 6 - [4- (2 -히드록시아세트아미도)피페리딘- 1 -일]— 2H— 인다졸- 5 -일] — 3— sulfamoyl 벤즈아미드 011(2S)-N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidin-4-yl}-5-oxopyrrolidine-2-carboxamide 6 「 ° yl]-3-sulfamoylbenzamide

[2179] (2S)-N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidin-4-yl}-5-oxopyrrolidine-2-carboxamide 0 p느』 乂 、 广 N carboxamide

[2180] (2S)-N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidin-4-yl}-5-oxopyrrolidine-2-carboxamide S X 广 0

[2181] (2S)-N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidin-4-yl}-5-oxopyrrolidine-2-carboxamide

[2182]

[2183] N-{6-[4-(2-aminoacetamido)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide hydrochloride N-{6-[4-(2-aminoacetamido)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide hydrochloride

[2184] yl}-3-sulfamoylbenzamide hydrochloride N-{6-[4-(2-aminoacetamido)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide hydrochloride XT o HN

[2185] H u N '&' JL OH yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide hydrochloride 0 HC1 yl}-3-sulfamoylbenzamide hydrochloride

[2186] N-{6-[4-(2-aminoacetamido)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2187] 으 YT— /

[2188] … “f 7 = ° H N-{6-[4-(2-aminoacetamido)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2189] N—{6—[4—(2—cyanoacetamido)piperidin—1—yl]—H

[2190] 2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide N 「yl}-3-sulfamoylbenzamide

[2191] H2N / H心 스 가 OH N-{6-[4-(2-cyanoacetamido)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2192] N-(6-{4-[(carbamoylmethyl)amino]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-H2N쓰"^ 스

[2193] indazo1—5—yl)-3-sulfamoylbenzamide 으 Y〕、 N-(6-{4-[(carbamoylmethyl)amino]piperidin-1- H W 빠 』 서 4 OH1-{2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2194]

[2195] N—[2—(3-hydroxy—3—methylbutyl)-6-[4-(2-H

[2196] hydroxyacetamido)piperidin-1-yl]—2H—HO今o 으 紀 ]indazol—5-yl]~3~nitrobenzamide

[2197] 0 HN丄으으 、-(OHN-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2-hydroxy o'牛 Q 승 시 acetamido)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide

[2198] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(4,4,4-trifluorobutanamido)piperidin-1-yl]-2H-흐 스 Apindazol-5-yl]—3—sulfamoylbenzamide O 〔VyYq 으오 011

[2199] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(4,4,4-트 H2N、 S P妙스 리플 루오로 부탄아미도)피 페리 딘-1-일]-2H-인다 d "O 人 0 졸-5-yl]-3 —sulfamoylbenzamide

[2200] N—[2—(3—hydroxy—3—methylbutyl)—6—{4—[(2, 2, 2-trifluoroethyl)amino]piperidin-1-yl}-2H-indazol-5-yl]—3—sulfamoylbenzamide 으Yy— / N-[2-(3-hydroxy-3-methylbutyl)-6-{4-[(2, 2, 2-H2N、〈9 므세 … '수 011 tri fluor o ethyl )amino]piperidin-1-yl}-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2201] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3, 3, 3-H

[2202] trifluoropropanamido)piperidin—1—yl]—2H—:>nr N Y dou i ndaz o 1 —5—yl]~3~nitrobenzamide f ° 0 」n

[2203] HN丄으 、* 으- / (OHN-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3, 3, 3-tr °"牛 Q 人 0 rifluoropropanamido)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide

[2204]

[2205] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3, 3, 3-H

[2206] 드trifluoropropanamido)piperidin—1—yl]—2H—nr—

[2207] i ndazo 1 -5-yl] — 3—sulfamoylbenzamide

[2208] F 0 /

[2209] H2N. S P as OH N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3,3,3-trifluoropropanamido)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2210] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3,3,3-H

[2211] s — trifluoropropanamido)piperidin—1—yl]—2H— f indazol—5—yl]—3—(methylsulfamoyl)benzamide ° 心 N rr_ /

[2212] H o HN人느 으、-(OH N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3,3,3-trifluoropropanamido)piperidin-1-yl]-2H-indazol-5-yl]-3-(methylsulfamoyl)benzamide

[2213] N—{1—[2—(3—hydroxy—3—methylbutyl)—5—[3—(1H—imidazol—5—yl)benzamido]—2H—indazol—6—yl]piperidin—4—yl}pyridine—3—carboxamide o 으

[2214] 次' NH ^-COH N-{1-[2-(3-hydroxy-3-methylbutyl)-5-[3-(1H-imidazol-5-yl)benzamido]-2H-indazol-6-yl]pipe N ^Q 셔 ridin-4-yl}pyridine-3-carboxamide

[2215] N—{1 — [2— (3— hydroxy— 3— methylbutyl )—5— (4— methyl— 3— sulfamoylbenzamido ) — 2H— indazol—6 — yl ]piperidin— 4— yl}pyridine— 3— carboxamide 0 으 / N-{1- [2- (3 -hydroxy- 3 -methylbutyl)- 5- (4 -methyl- % N 'S P 뿌 」 가 OH

[2216] 3 —sulfamoylbenzamido)- 2H-indazol- 6 -yl]piperi / j o

[2217] din- 4 -yl}pyridine- 3 -carboxamide

[2218]

[2219] N-{6 - [4-( 3-hydroxy— 3 —

[2220] methyl butanamido )piperidin-l-yl ]— 2— (3 — H(? > r''g N '{『''s hydroxy— 3— methylbutyl )— 2H— indazol— 5— yl}~3~ sulfamoylbenzamide

[2221] H2N、〈9 H Y 、’人 7 가 011 N- {6 - [4- (3 -hydroxy- 3 -methylbutanamido)piperidi d s xr o din- 1-일]- 2- (3 -hydroxy- 3 -methylbutyl)- 2H-indazol- 5 -일}- 3 —sulfamoylbenzamide

[2222] N—{6 — [4—(2—cyanoacetamido)piperidin—1—yl]—2—methyl—2H—indazol—5—yl}—3—nitrobenzamide

[2223] N-{6 - [4- (2 - cyanoacetamido)piperidin-1-yl] -2 -methyl- 2H-indazol- 5 -yl}- 3 -nitrobenzamide

[2224] °'牛 Q 人 0

[2225] N-{1- [2-methyl -5 - (3-sulfamoylbenzamido)- 2H-indazol- 6 -yl]piperidin- 4 -yl}pyridine-3-carboxamide

[2226] N-{1- [2 -methyl- 5- (3 —sulfamoylbenzamido)- 2H-indazol- 6 -yl]piperidin- 4 -yl}pyridine-3-carboxamide

[2227] Ay 。

[2228] HN—{6 — [4—(2—cyanoacetamido)piperidin—1—yl]—2-methyl — 2H—indazol-5-yl}—3—

[2229] 0 - sulfamoylbenzamide

[2230] U XT UAT 乂丄 乂 처느 / N-{6 - [4- (2 - cyanoacetamido)piperidin-1-yl] -2 -methyl- 2H-indazol- 5 -yl}- 3 -sulfamoylbenzamide

[2231] —yl]- 2 -methyl- 2H-indazol- 5 -yl}- 3 —sulfamoylbenzamide

[2232]

[2233] H N— {6 — [4— (2— cyanoacetamido)piperidin— 1— yl] —

[2234] 2— methyl— 2H— indazol-5— yl}— 4— methyl— 3 — sulfamoyl benzamide

[2235] „ XT o HN 、스 N- {6 - [4- (2 - cyanoacetamido)piperidin- 1- H 2 N ''义 L 일 ] -2 -methyl- 2H- indazol- 5 -yl}- 4 -methyl- 3 —sulfamoyl…

[2236] benzamide

[2237] N— {6 — [4— (2— cyanoacetamido)piperidin— 1— yl] — — c 2-methyl — 2H— indazol-5-yl}— 4— fluoro— 3 —sulfamoyl benzamide

[2238] H N O H N XX N - N- {6 - [4- (2 - cyanoacetamido)piperidin- 1- yl]- 2 -methyl- 2H- indazol- 5 -yl}- 4 -fluoro- 3 —sulfamoyl benzamide

[2239] H 4-chloro-N-{6 - [4-(2- xv 斗 cyanoacetamido)piperidin- 1- yl ]- 2- methyl-2H- o i indazol- 5-yl}— 3— sulfamoyl benzamide u 、 T 0 T H TXNT人、느 / 스''스느 / 4 -chloro- N- {6 - [4- (2 - cyanoacetamido)piperidin- 1- yl]- 2 -methyl- 2H- indazol- 5 -yl}- 3 —sulfamoyl benzamide w °

[2240] N—{6—[4—(2—cyanoacetamido)piperidin—1—yl]—2—methyl—2H—indazol—5—yl}—2—methyl—3—sulfamoylbenzamide

[2241] In Jiang CO - N - {6 - [4 - (2 - cyanoacetamido)piperidin - 1 - yl] - 2 - methyl - 2H - indazol - 5 - yl}-2 - methyl - 3 - sulfamoylbenzamide

[2242] - 2 - methyl - 2H - indazol - 5 - yl}-2 - methyl - 3 - sulfamoylbenzamide

[2243] ☆ day 0

[2244]

[2245] N—{6—[4—(2—cyanoacetamido)piperidin—1—yl]—

[2246] 2 - methyl - 2H - indazol - 5 - yl}-2 - fluoro - 5 - sulfamoylbenzamide

[2247] 애 U XT 0 어 T CC N

[2248] H TX N T 人

[2249] H N - N - {6 - [4 - (2 - cyanoacetamido)piperidin - 1 - yl] - 2 - methyl - 2H - indazol - 5 - yl}-2 - fluoro - 5 - sulfamoylbenzamide

[2250] 0

[2251] N—{2—[2—(morpholin-4-yl)ethyl]—6—[4—(morpholine-4-carbonyl)piperidin-1-yl]—2H—([1,2]indazol-5-yl)}—3—sulfamoylbenzamide N-{2-[2-(morpholin-4-yl)ethyl]-6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2252] N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-1- H2N yl}-2-[2-(morpholin-4-yl)ethyl]-2H-indazol-

[2253] o〔" YW N으—p 5-yl)—3—sulfamoylbenzamide H2N—、 S P妙스스 N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-[2-(morpholin-4-yl)ethyl]-2H-indazol-5-yl)-3—sulfamoylbenzamide

[2254] N—methyl—1—[5—(3—sulfamoylbenzamido)—1—?F

[2255] (2,2,2-trifluoroethyl)—1H—indazol—6—스 CW昌 yl]piperidine—4—carboxamide

[2256] N-methyl-1-[5-(3—sulfamoylbenzamido)-1-20 JO

[2257] H N. P 허 (2,2,2-trifluoroethyl)-1H-indazol-6-yl]피 / 에 페리딘-4-carboxamide

[2258]

[2259] N-[2-(2,2-difluoroethyl)-6-[4-(4-0

[2260] hydroxypiperidine-1-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide H(」三 1 서 三 弓 令 새 汝스- 旦

[2261] 0 HN人 人 7 N-[2-(2,2-difluoroethyl)-6-[4-(4-hydroxy piperidine-1-carbonyl)piperidin-1-yl]-2H-indas s sol-5-yl]-3-sulfamoylbenzamide

[2262] N-[2-(2,2-difluoroethyl)-6-{4-[4-(2- O hydroxy propan-2-yl)piperidine—1—

[2263] carbonyl]piperidin-1-yl}-2H-indazol-5-yl]~ 才 O 人 수 F 3-sulfamoylbenzamide

[2264] HoT H2N._P O H 1 쪼NXX N N-[2-(2,2-difluoroethyl)-6-{4-[4-(2-hydroxy d斗 Q 스 ) cyclopropan-2-yl)piperidine-1-carbonyl]piperidin-1-yl}-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2265] 1—[2—(2,2—difluoroethyl)—5—(3 —

[2266] <000.org / 10.1007 / s10600-015-1207-9°'N 牛 F sulfamoylbenzamido)—2H—indazol—6—yl]—N— H 心N Y i : >=N. S-oxo hydroxypiperidine-4-carboxamide

[2267] 1-[2-(2,2-difluoroethyl)-5-(3-sulfamoylbenz O HNX

[2268] H2N Pm〕e

[2269] , S-s amido)-2H-indazol-6-yl]-N-hydroxypiperidine-4-carboxamide

[2270] 1-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3-O 0 sulfamoyl benzamido)-2H-indazol-6-

[2271] yl]piperidine-4-carbonyl}piperidine-3-carboxamide [[ID=2,0]]

[2272] % yield 9 heart Sugaa! 1-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamo 6 X wide 0 yl benzamido)-2H-indazol-6-yl]piperidine-4-carboxyl bonyl}piperidine-3-carboxamide

[2273]

[2274] l-[z-(3-hydroxy-3-methylbutyl)-5-(3-0

[2275] sulfamoyl benzamido)-2H-indazol-6-yl]-N-(2-hydroxyethyl)piperidine-4-carboxamide H2N、 S PH heart』—OH 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl benz amido)-2H-indazol-6-yl]-N-(2-hydroxyethy d s It should be noted that there may be some unclear or incorrect chemical names and notations in the original text, which may affect the accuracy of the translation. It is recommended to double-check with the original source for a more precise understanding.xr° til) Piperidine-4-carboxamide

[2276] N-(2-aminoethyl)-1-[2-(3-hydroxy-3-0 methylbutyl)-5-(3-sulfamoylbenzaniido)-2H-H2N〜 N 1-indazol-6-yl]piperidine-4-carboxamide H hydrochloride

[2277] YT— /

[2278] H V 써 、 人 7 가 0 h N-(2-aminoethyl)-1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide hydrochloride 0 HCI 틸)-5-(3 —술파모일벤즈아미도)-2H-인다졸-6 - 일]피 페리 딘-4 -카르복사미드 염산염

[2279] N-(2-aminoethyl)-1-[2-(3-hydroxy-3-0<00​​​​​​​​​​​​​​​​​%v dou yl]piperidine—4—carboxamide

[2284] H “n, / N-hydroxy-1-[2-(3-hydroxy-3-methylbutyl)-5-H2N、〈9'shu 0 H (3 —sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide

[2285]

[2286] N—(1-hydroxy—2-methylpropan—2-yl)-1-[2-(3-hydroxy—3-methylbutyl)—5—(3 —

[2287] 또,乂 \ / ° su 1 famoy 1 benz am i do)-2H-indazo l—6 — H 心 / yl]piperidine—4—carboxamide

[2288] HW 妙스, 》 N-(l-hydroxy-2-methylpropan-2-yl)-1-[2-(3-hydroxy-3-methylbutyl)-5-(3 —sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide

[2289] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3 - .OH su 1 famoy 1 benz am i do)-2H-indazol-6-yl]—N—어 'N午[(1R, 2R)—2-hydroxycyclopentyl]piperidine—4— H 으 N 、스 ^N. carboxamide

[2290] O HA丄少、4OH 1-[2-(3-hydroxy-3-methylbutyl)-5-(3 —sulfamoyl H 2 N 才 X \

[2291] d Benzo[h]imidazo[2,1-b][1,3]thiazol-2-yl]-N-[(1R,2R)-2-hydroxycyclopentyl]piperidine-4-carboxamide

[2292] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-

[2293] [(pyrrolidin-3-yl)methyl]piperidine-4-carboxamide

[2294] u 1 -carboxamide hydrochloride

[2295] H2N / -=~OH 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl 6 , XJ ° HC1 Benzo[h]imidazo[2,1-b][1,3]thiazol-2-yl]-N-[(pyrrolidin-3-yl)methyl]piperidine-4-carboxamide hydrochloride

[2296] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-

[2297] [(pyrrolidin-3-yl)methyl]piperidine-4-HNVYY 、!

[2298] carboxamide

[2299] 心 Yr— /

[2300] H2N、 / 妙 스가 OH 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl 6 X 〕人 0Benzo[h]imidazol-6-yl]-N-[(pyrrolidin-3-yl)methyl]piperidine-4-carboxamide

[2301]

[2302] N—(4—aminobutyl)—1 —[2—(3—hydroxy—3 —

[2303] methylbutyl)—5—(3—sulfamoylbenzaniido)-2H-

[2304] indazol—6—yl]piperidine—4—carboxamide HCI H 느』 수 011 hydrochloride

[2305] (스 / 妙 人 7 N-(4 -aminobutyl)- 1-[2-(3 -hydroxy- 3 -methylbut HZ0 人 o tyl)- 5-(3 —sulfamoylbenzamido)- 2H-indazol- 6 - yl]piperidine- 4 -carboxamide hydrochloride

[2306] N—(4—aminobutyl)—1 —[2—(3—hydroxy—3 — o methylbutyl)—5—(3—sulfamoylbenzaniido)-2H- 日2向、 / 、 N 」k丁 / 斗

[2307] indazol—6—yl]piperidine—4—carboxamide H 心 N 'f 스 y己 — ( OH

[2308] (상 9 妙스 N-(4 -aminobutyl)- 1-[2-(3 -hydroxy- 3 -methylbut HZQ 人 0 tyl)- 5-(3 —sulfamoylbenzamido)- 2H-indazol- 6 - yl]piperidine- 4 -carboxamide

[2309] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N—

[2310] (2,2,2-trifluoroethyl)piperidine-4-carboxamide

[2311] F —

[2312] carboxamide

[2313] H2N、 S PH heart is OH 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyld'outside Q heart 0 benzamido)-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide

[2314] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-o0sulfamoylbenzamido)-2H-indazol-6-yl]-N-(2~three gAp methanesulfonylethyl)piperidine-4—

[2315] 1 carboxamide

[2316] N A /

[2317] %

[2318] d 、 /

[2319] SQ 1 heart so'shi 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl 승 benzamido)-2H-indazol-6-yl]-N-(2-methanesulfonyl ethyl)piperidine-4-carboxamide

[2320]

[2321] N-{6-[4-(4-hydroxypiperidine-1-carbonyl)piperidin-1-yl]-2-(4,4,4—

[2322] trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2323] 0 HN

[2324] H 2 N 人 』… 、 己

[2325] '<v 、入 〉V F N-{6-[4-(4-hydroxy piperidine-1-carbonyl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2326] N—{6 — [4—(4—aminopiperidine—1—

[2327] o carbonyl)piperidin—1—yl]—2—(4,4,4—

[2328] trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2329] 바 人 느 。오스 广 朱 sulfamoylbenzamide

[2330] H2N^P ™^、 '조 F N-{6-[4-(4-aminopiperidine-1-carbonyl)piperidin 6 Xj ° F din-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2331] N-hydroxy—1—[5—(3-sulfamoylbenzamido)-2-0

[2332] HO、 NA s (4,4,4- tr if luorobutyl )- 2H- indazol- 6 - yl ]piper idine— 4— carboxamide

[2333] H “ 〕o 、

[2334] o HN people people' 7 N-hydroxy- 1- [5- (3 —sulfamoylbenzamido)- 2 - 2 S'^xAn VF (4, 4,4-trifluorobutyl)- 2H-indazole- 6 -il]pi o' 〕3T° f f Peridin- 4 - Carboxamide

[2335] N— ( 6 — { 4— [ 4— ( 2-hydr oxyprop an— 2 —

[2336] 0 yl )p iper idine— 1— carbonyl ]p iper idine— 1—yl}~2~

[2337] (propan-2-yl)—2H— indazol— 5— yl )~3~ su 1 f amoy 1 benz am i de

[2338] H ^°? Uh OH

[2339] H2N, S P H ? N- (6 - {4 - [4- (2-hydroxypropane- 2-yl )piperidine- (se 0 1-carbonyl ]piperidine- 1-yl}- 2-(propane- 2-yl )- 2H-indazole- 5-yl )- 3 —sulfamoylbenzamide

[2340]

[2341] 0 1- [ 2— met hy 1 — 5— ( 3— su 1 f amoy 1 benz am i do ) — 2H— indazol-6-yl ]-N-(2,2, 2- four numbers

[2342] tr if luoroethyl )piper i dine— 4— carboxamidef - 1-[2-Methyl-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide XT 0 HN, S

[2343] - 1-[2-Methyl-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide

[2344] N-{2-Methyl-6-[4-(morpholine-4-

[2345] 0

[2346] carbonyl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2347] 0 mA, J ~ N-{2-Methyl-6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2348] 1-[2-Methyl-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(propan-2-yl)piperidine-4-carboxamide

[2349] H 으 N r〕fv

[2350] 1-[2-Methyl-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(propan-2-yl)piperidine-4-carboxamide S P 1 妙* 우

[2351] 1-[2-Methyl-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(propan-2-yl)piperidine-4-carboxamide

[2352] N-(2-Hydroxyethyl)-N-methyl-1-[2-methyl-5-O-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide

[2353] 1 斗- w 、 T o T H T 、NT느느〜、〜**느 =누 / N-(2-Hydroxyethyl)-N-methyl-1-[2-methyl-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine- 6 X 广 0 4-carboxamide

[2354]

[2355] o

[2356] N-hydroxy—1-[2-methyl—5—(3 — H0 / n sulfamoylbenzamido)—2H-indazol—6-yl]piperidine—4-carboxamide

[2357] T TXT

[2358] o HN 人 、느으스스느구乂 N-hydroxy-1-[2-methyl-5-(3-sulfamoylbenzami H 2 N 、才 L

[2359] do)-2H-indazol-6-yl]piperidine-4-carboxamide 6 幻 0 스 0

[2360] N,N-dimethyl-1-[2-methyl-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide

[2361] _〕 Ding Xz—

[2362] H2N、 S P N,N-dimethyl-1-[2-methyl-5-(3-sulfamoylbenzami 6 Xx people 0 do)-2H-indazol-6-yl]piperidine-4-carboxamide

[2363] N—{6—[4—(2-hydroxyethyl)piperidin—1—yl]—2—H°,—,T*,S(4,4,4-trifluorobutyl)-2H-indazol-5-yl}~3~sulfamoylbenzamide

[2364] H2N^9 ™^,'三 VF N-{6-[4-(2-hydroxyethyl)piperidin-1-yl]-2- 6 ° F (4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2365] HO、 / ,T* N—{6—[4—(2-hydroxyethyl)piperidin—1—yl]—2—methyl—2H—indazol—5—yl}~3~ LN YT N—sulfamoylbenzamide

[2366] T TXT TJ XT o HN people,느스 / 人건그 /

[2367] N-{6-[4-(2-hydroxyethyl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3—sulfamoylbenzamide d s "아

[2368]

[2369] It should be noted that there seem to be some unclear or incorrect parts in the original text which might affect the accuracy of the translation.N-{6-[4-(Hydroxymethyl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2370] N-{6-[4-(히드록시메틸)피페리딘-1-일]-2-(4,4,4-트리플루오로부틸)-2H-인다졸-5-일}-3-술파모일벤즈아미드

[2371] HO^다 斗 N-{6-[4-(Hydroxymethyl)piperidin-1-yl]-2-메틸—2H—인다졸—5—일}-3—

[2372] sulfamoylbenzamide

[2373] 0 H수 」、 人으

[2374] N-{6-[4-(히드록시메틸)피페리딘-1-일]-2-메틸 W 。 -2H-인다졸-5-일}-3 —술파모일벤즈아미드

[2375] 쟈,&"'' 、 厂' 斗 N—{6 — [4—(Aminomethyl)piperidin—1—yl]~2~

[2376] 1 、스'—메틸 — 2H—인다졸 — 5—일}-3~

[2377] 1 XJ-sulfamoylbenzamide hydrochloride O. P 으 띠 UP| N-{6-[4-(아미노메틸)피페리딘-1-일]-2-메틸- 、 、弓:슈 、,** 、泊 11C1

[2378] H,N r 사 ° 2H-인다졸-5-일}-3 —술파모일벤즈아미드 염산염 오 M

[2379] H2N『Y Dou N-{6 - [4-(aminomethyl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2380] „ XT 0 T HJXNTssss、、ssss는느人

[2381] H 2 N 、必 L N-{6 - [4-(aminomethyl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide <外0人 0

[2382]

[2383] N-{6 -[(35)-3-[(carbamoylmethyl)carbamoyl]piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-nitrobenzamide

[2384] 0 ° HN」、」으 (OH

[2385] o Dou Q people o N-{6 - [(3S)-3 - [(carbamoylmethyl)carbamoyl]piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-nitrobenzamide

[2386] N-{6 - [4-(2-hydroxy-2 -

[2387] methylpropyl)piperidin-1-yl]-2-methyl-2H- 으 indazol-5-yl}-3-sulfamoylbenzamide TTXT : 05 —

[2388] 스스丄 / 느 느 /

[2389] o HN, * N-{6-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2390] N—{6—[4—(aminomethyl)piperidin—1—yl]~2~H2N"Y、I(4,4,4-trifluorobutyl)-2H-indazol-5-yl}~3~sulfamoylbenzamide dihydrochloride H2N. S P 义」고 F N-{6-[4-(aminomethyl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide 2 hydrochloride

[2391] N-{6-[4-(aminomethyl)piperidin—1—yl]~2~H2N^^(4,4,4-trifluorobutyl)-2H-indazol-5-yl}~3~으 Y亡―sulfamoylbenzamide

[2392] o HN人人' 7 즈己 N-{6-[4-(aminomethyl)piperidin-1-yl]-2- H 7 아 아>(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2393]

[2394] N-[6-(3-{[bis(2-hydroxy-2-H乂methylpropyl)amino]inethyl}piperidin—1—yl)-2—methyl—2H—indazol—5—yl]~3 - [(2—hydroxy—2 — f l>? H

[2395] methylpropyl )sulfamoyl ]benzamide % N- [6- (3-{[bis(2-hydroxy-2-methylpropyl)amino]methyl}piperidin-1-yl )-2-methyl-2H-indazole-5-yl]-3-[(2-hydroxy-2-methylpropyl)sulfamoyl]benzamide

[2396] 3-(ethylsulf amoy 1 ) — N— (6 - {3-[( 2-hydr oxy— 2 — methylpropyl ) amino] piper id in-l-yl}— 2— H methyl -2H- indazo 1 -5-yl ) benz am i de °r / s >- 3-(ethylsulfamoyl )- N- (6 - {3 - [ (2 -hydroxy- 2 -methyl d s [Athylpropyl )amino]piperidine-1-yl}-2-methyl-2H-indazole—5-yl)benzamide

[2397] N-(6-{4-[(methylamino)methyl]piperidin-l- yl}- 2- (4, 4, 4- 1 rif 1 uorobutyl ) - 2H- i ndazol -5 - yl ) -3 - su 1 f amoy 1 benz am i de

[2398] “

[2399] 6 s' 9 N- (6 - {4 - [(methylamino)methyl]piperidine- 1-yl}- 2 - 「0 「s 0 (4,4,4-trifluorobutyl)-2H-indazole-5-yl)-3-sulfamoylbenzamide

[2400] N— (6 — {4— [(dimethylamino)methyl]piper idin-1- 'Y u yl}- 2- (4, 4, 4- 1 rif 1 uorobutyl ) - 2H- i ndazol -5 - sa o , yl ) -3 - su 1 f amoy 1 benz am i de

[2401] H2N d, &9 black 0 、'즈 F v FF N-(6-{4-[(dimethylamino)methyl]piperidin-1-yl}-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl)-3-sulfamoyl benzamide

[2402]

[2403] N-[2-(2,2-dimethylpropyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoyl benzamide

[2404] N-[2-(2,2-dimethylpropyl)-6-[4-(2-hydroxyprop H2N、 S P wonderful people factory V lopane-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-d' S You 0

[2405] sulfamoyl benzamide

[2406] N-[2-(cyclopropylmethyl)-6-[4-(2-a hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoyl benzamide

[2407] N-[2-(cyclopropylmethyl)-6-[4-(2-hydroxyprop H2N、 S P subtract people people 7 lopane-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoyl benzamide

[2408] Ah N- [2- ( cycl obutylmethyl )-6 - [4-( 2 - hy dr oxyp r op an- 2-y 1 )piper idin— 1— yl ]— 2H— i ndazo 1 -5-yl ] — 3— su 1 f amoy 1 benz am i de

[2409] N- [2-(cyclobutylmethyl)- 6 - [4- (2 -hydroxypro H2N. P 』 7 7 Pan- 2 -il)piperidine- 1-il]- 2H-indazole- 5 -il]- 3 —sulfamoylbenzimide

[2410] diethyl (2 - {6 - [4-( 2— hydr oxypr op an— 2 — yl )piper idin— 1— yl ]— 5— (3 —

[2411] beep su 1 f amoy 1 benz am i do ) — 2H— i ndazo 1 ~2~ Q 1 yl}ethyl )phosphonate

[2412] H N O JO Le 、?— 0g dietyl (2 - {6 - [4- (2 -hydroxypropane- 2 -yl)piphe H 7 「 o 0 Lidin- 1-yl]- 5- (3 —sulfamoylbenzamido)- 2H-indazole- 2-yl}ethyl )phosphonate

[2413]

[2414] N-[2-(di f luoromethyl )-6 - [4-(2- hy dr oxyp r op an- 2-y 1 )piper idin— 1— yl ]— 2H— ugh yy M F i ndazo 1-5-yl ] — 3— su 1 f amoy 1 benz am i de o HN 、s F N- [2-(difluoromethyl)- 6 - [4- (2-hydroxypropan- 2-yl)piperidine- 1-yl]- 2H-indazole- 5-yl]- 3 —sulfamoylbenzamide

[2415] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1- H yl]-2-methyl-2H-indazol-5-yl}-3-(2-methyl-

[2416] 2H-1,2,3,4-tetrazol-5-yl)benzamide N=N ➡ HN* 5 。 ➡ N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1--N N <Q into]-2-methyl-2H-indazol-5-yl}-3-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)benzamide

[2417] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1- H yl]-2-methyl-2H-indazol-5-yl}-3-(1H- ➡ y _ _ imidazol-1-yl)benzamide

[2418] N ➡ HNH 』 N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-VN ➡ s yl]-2-methyl-2H-indazol-5-yl}-3-(1H-imidazol-1-yl)benzamide

[2419] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1- H yl]-2-methyl-2H-indazol-5-yl}-3-(1H-1,2,4-triazol-1-yl)benzamide

[2420] ➡ YTN—

[2421] / 그 N mr" 1 、• 人 〜 7 N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-N N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H-1,2,4-triazol-1-yl)benzamide

[2422]

[2423] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-4-methyl-3- H it p

[2424] “TY sulfamoyl benzamide

[2425] 人、 / 」수으

[2426] u XT OHN N—N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-4-methyl-3-sulfamoylbenzamide

[2427] yl}-2-methyl-2H-indazol-5-yl}-4-methyl-3-sulfamoylbenzamide <00063xx0>4-fluoro-N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5- H V

[2429] yl}-3-sulfamoylbenzamide

[2430] 으 Y 丁 v

[2431] 리느 b丄극구 /

[2432] 4-fluoro-N-{6-[4-(2-hydroxypropan-2-yl)u XT 0HN、스

[2433] <x000576>2 N ''才L piperidin- l-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoyl O It seems there are some unclear or incorrect parts in the original text (such as "잇 p", "人 、 / 」수으", "으 Y 丁 v", "리느 b 丄극구 / ", "0HN 、스", "''才L 피 페리 딘- 1-일]" which might be encoding or input errors). The translation is done as accurately as possible based on the recognizable parts.

[2434] Parmo Ivenzamid

[2435] 4-chloro-N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5- H0 丄

[2436] yl}-3-sulfamoylbenzamide

[2437] TTXT乂丄스으 / '''느극 / 4-chloro-N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5- XT 0 HN 、스

[2438] piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide w °

[2439] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-( 2 H3)methyl-2H-indazol-5-yl}~3~아

[2440] sulfamoylbenzamide

[2441] 으 N :O5 오

[2442] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-( D

[2443] yl]-2-( 2 H3)methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide 6 「 °

[2444]

[2445] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1- HN-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[2-(thiophen-2-yl)ethyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2446] 心 으 幻

[2447] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[2-(thiophen-2-yl)ethyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide S P 1 心서

[2448] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[2-(thiophen-2-yl)ethyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide 0}-3-sulfamoylbenzamide

[2449] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[2-(1H-pyrazol-1-yl)ethyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide H N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[2-(1H-pyrazol-1-yl)ethyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide 2}-3-sulfamoylbenzamide

[2450] N-(2-methyl-6-{4-[2-oxo-2-(piperidin-1-yl)ethyl]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide

[2451] N-(2-methyl-6-{4-[2-oxo-2-(piperidin-1-yl)ethyl]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide X T TXT

[2452] „ T o HN乂 、으스丄으人

[2453] Til] Peperidine-1-yl}-2H-indazol-5-yl)-3-sulfamoyl 0 Isobenzene amide

[2454] N-(2-methyl-6-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoyl benzamide

[2455] ° 으 VYV

[2456] N-(2-methyl-6-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoyl benzamide

[2457] Til] Peperidine-1-yl}-2H-indazol-5-yl)-3-sulfamoyl benzamide

[2458] w °

[2459]

[2460] N-{6-[4-(2-hydroxyprop-ane-2-yl)piperidin-1-yl]-2-(1,3-thiazol-2-yl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2461] „ XT o 三 HN o 、: S 〕 N-{6-[4-(2-hydroxypropane-2-yl)piperidin-1-yl]-2-(1,3-thiazol-2-yl)-2H-indazol-5-yl}-3-sulfamoylbenzamide 0 -2-(1,3-thiazol-2-yl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2462] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(hydroxymethyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide

[2463] O HN~ people 흐 우 OH

[2464] N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(hydroxy o斗 Q people o methyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide

[2465] 3-({1-[2-(3-hydroxy—3—methylbutyl)—5—(3—O 0 nitrobenzamido)-2H-indazol-6-yl]piperidin—I』~N 义 Y、!

[2466] H 느』 f、广 4-yl}formainido)propanoic acid

[2467] N. / —(OH

[2468] o HNXX N 3-({1-[2-(3-hydroxy-3-methylbutyl)-5-(3-nitro °"X) people 0 benzamide)-2H-indazol-6-yl]piperidin-4-yl}formamido)propanoic acid

[2469] N-(6-{4-[(2-carbamoyl ethyl)carbamoyl]piperidin—1—yl}—2—o o

[2470] (3-hydroxy-3-methylbutyl)-2H—indazol-5-yl)-H2N스

[2471] “YYW shu'a

[2472] 0 HN、 스 1 3-nitrobenzamide

[2473] N-(6-{4-[(2-carbamoylethyl)carbamoyl]piper o'斗 Q people o

[2474] It should be noted that there are some unclear or potentially incorrect chemical structure notations in the original text which might lead to less accurate translation in some parts.N-{6-[4-(diethylamino)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2475]

[2476] N-{6-[4-(diethenylamino)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2477] H* I 〉 1 ,-N-{6-[4-(diethylamino)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2478] 1-[3-fluoro-2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide

[2479] (2,2,2-trifluoroethyl)piperidine-4-carboxamide

[2480] H N pHfXX—1-[3-fluoro-2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide F (3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide

[2481] N—[2-(3-hydroxy-3-methylbutyl)-6-{4-[4-(2-hydroxypropan-2-yl)piperidine-1-carbonyl]piperidin-1-yl}-2H-indazol-5-yl]~

[2482] 0 carbonyl]piperidin-1-yl}-2H-indazol-5-yl]~

[2483] 3-sulfamoylbenzamide

[2484] Herl N

[2485] 0 mA. —,즈 4 / OH N-[2-(3-hydroxy-3-methylbutyl)-6-{4-[4-(2-hydroxypropan-2-yl)piperidine-1-carbonyl]piperidin-1-yl}-2H-indazol-5-yl]-3 —sulfamoylbenzamide

[2486] N—{1 —[2—(3—hydroxy—3—methylbutyl)—5—(3 —sulfamoyl benzamido)—2H—indazol—6 —

[2487] -HVpyl]piperidin—4—yl}—5—methanesulfonyl furan—

[2488] 2-carboxamide

[2489] H2N. S P 씨 』 가 OH N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3 —sulfamoylbenzimido)-2H-indazol-6 -yl]piperidin-4 - yl}-5-methanesulfonylfuran-2 -carboxamide

[2490]

[2491] methyl 3-({1 - [2-(3-hydroxy-3-methylbutyl)-5 - (3-nitrobenzamido)—2H—indazol—6 — 、0人〜 저义丁 己 yl]piperidin—4—yl}formamido)propanoate '、"•午刀、广 N. 『〈OH

[2492] o HA〕☆ D-methyl 3-({1-[2-(3-hydroxy-3-methylbutyl)-5-(3-o=Q people 0 nitrobenzamido)-2H-indazol-6-yl]piperidin-4-yl}formamido)propanoate

[2493] N—[2—(3-hydroxy—3—methylbutyl)—6—[(3S)—3—(2-hydroxyacetamido)pyrrolidin-1-yl]—2H—HO P

[2494] indazo1-5-yl]—3—sulfamoylbenzamide 매。—』.dihydrochloride

[2495] 0 HA』- N 、4OH N-[2-(3-hydroxy-3-methylbutyl)-6-[(3S)-3-(2- H 7x广0 J

[2496] hydroxyacetamido)pyrrolidin-1-yl]-2H-indazol-5-yl]-3—sulfamoylbenzamide 2hydrochloride

[2497] N—[2—(3-hydroxy—3—methylbutyl)—6—[(3S)—3—HO P(2-hydroxyacetamido)pyrrolidin-1-yl]—2H—『-Gy、广N.indazo1-5-yl]—3—sulfamoylbenzamide 떼 / 心N-[2-(3-hydroxy-3-methylbutyl)-6-[(3S)-3-(2-hydroxyacetamido)pyrrolidin-1-yl]-2H-indazo於0广 0 zol-5-yl]-3—sulfamoylbenzamide

[2498] N—{1 — [2— (3— hydroxy— 3— methylbutyl )— 5 — [3— (1H—imidazol-1-yl) benzamido]-2H-indazol-6-yl]piperidin—4—yl}pyridine—3—carboxamide N N n yl]piperidin—4—yl}pyridine—3—carboxamide 0 으 Yy— /

[2499] 쓰 HN人으 브 丄- (OH N- {1- [2- (3 -hydroxy- 3 -methylbutyl)- 5 - [3- (1H-이 스 Q\ imidazol-1-yl)benzamido]-  2H-indazol- 6 -yl]piperidin- 4 -yl}pyridine- 3 -carboxamide

[2500]

[2501] Nl-{6 - [4-(aminomethyl)piperidin-1-yl]-2-(3-hydroxy—3—methylbutyl)—2H—indazol—5—yl}—N3—H2N『Y 斗 methyl benzene-1,3~dicarboxamide 으 Yy N hydrochloride

[2502] O HN人이 으 느- (OH

[2503] Nl- {6 - [4-(아미노메틸)piperidin- 1-yl]- 2-(3 -히 ' 砂 0 人° hci 드 록시- 3 -methylbutyl)- 2H-indazol- 5 -yl}-N3 -methyl benzene-1,3 -dicarboxamide hydrochloride

[2504] Nl-{6 - [4-(aminomethyl)piperidin-1-yl]-2-(3-hydroxy—3—methylbutyl)—2H—indazol—5—yl}—N3—HX'Y'l

[2505] methyl benzene-1,3~dicarboxamide

[2506] o mT 흐흐 ( / OH

[2507] Nl- {6 - [4-(Aminomethyl)piperidin-1-yl]-2-(3 -hi ' 斗 O 人 0 droxy-3-methylbutyl)-2H-indazol-5-yl}-N3-methyl benzene-1,3-dicarboxamide

[2508] N— {1 — [2—(3— hydroxy— 3— methylbutyl)— 5 — [3—(1H— pyrazol-4-yl) benzamido ] — 2H— indazol-6 — N 『、져A수1 『N H 、p

[2509] yl ]piperidin—4—yl}pyridine—3—carboxamide ° /

[2510] HN ■、人… 느- (OH N- {1- [2-(3 -hydroxy-3 -methylbutyl)-5 - [3-(1H-py "j o razol—4 -yl)benzamido]-2H-indazol-6 -yl]piperidine-4 -yl}pyridine-3 -carboxamide

[2511] N-{6 - [4-(2-hydroxyprop an—2—yl)piperidin—1—yl ]-2-[(pyridin-3-yl)methyl ] - 2H-indazol -5 - yl}-3-sulfamoylbenzamide

[2512] o HN^^ 7 ^=\ N- {6 - [4-(2 -hydroxypropan-2 -yl)piperidin-1- 2 / 豆 人 o D yl]-2 - [(pyridin-3-yl)methyl]-2H-indazol-5 -yl}-3 -sulfamoyl benzamide

[2513]

[2514] N—{1—[5—(4—fluoro—3—sulfamoylbenzamido)~2~if주은]H(3—hydroxy—3—methylbutyl)—2H—indazol—6— N N nyl]piperidin—4—yl}pyridine—3—carboxamide N-{1- [5- (4 -fluoro- 3 —sulfamoylbenzamido)- 2- (3 -hydroxy- 3 -methylbutyl)- 2H-indazol- 6 -yl]piperidin- 4 -yl}pyridine- 3 -carboxamide

[2515] N- [2- (3- hydroxy- 3- methylbutyl )-6 - [4- (2, 2, 2 -F三H trifluoroacetamido)piperidin—1—yl ]—2H— F V、o

[2516] O丁세幻indazo1 -5-yl ] — 3—sulfamoylbenzamide HW "广』 7 '우 011 N- [2- (3 -hydroxy- 3 -methylbutyl)- 6 - [4- (2, 2, 2 -trifluoroacetamido)piperidin- 1-일]- 2H-인 d 「 °다졸- 5 -일]- 3 -sulfamoylbenzamide

[2517] N-(l-{5 - [3-(hydrazinecarbonyl)benzamido ] — 2 —『저은|H(3—hydroxy—3—methylbutyl)—2H—indazol—6 — N A N 、O yl}piperidin—4—yl)pyridine—3—carboxamide 0 으Y]fN A /

[2518] 0 *人: :』~'' COH N-(l- {5 - [3-(hydrazine carbonyl)benzamido]- 2 - (3-hydroxy- 3-methylbutyl)- 2H-indazole- 6-yl}pipe H VO S Ridin- 4 -il )Pyridin- 3 -Carboxamide

[2519] N—{1 — [2— (3— hydroxy— 3— methylbutyl )—5 — [3— (methyl su 1 famoyl ) benz am i do] — 2H— indazo 1 —6 — yl ]piper idin— 4— yl}— 5— methanesul fonyl fur an— -HVp

[2520] 2-carboxamide

[2521] ; o be—

[2522] N-{1- [2- (3-hydroxy- 3-methylbutyl)- 5 - [3- (methyl ce o

[2523] Sulfamoil )benzamido]-2H-indazole-6-yl]piperidine-4-yl}-5-methanesulfonylfuran-2-carboxamide

[2524]

[2525] N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) pi per idin— 1— yl]-2-methyl-2H-indazol-5-yl}-3-(lH-l,2,4-

[2526] eu tr iazol-5-yl ) benzamide

[2527] N~NH N- {6 - [4- (2-hydroxypropane- 2-yl )piperidine- 1-yl]- 2-methyl- 2H-indazole- 5-yl}- 3- (1H- 1,2,4-triazole- 5-yl)benzamide N S 0S°

[2528] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(1-methyl-1H-pyrazol-4-yl)methyl]- H it p

[2529] 2H-indazol-5-yl}-3-sulfamoylbenzamide snf—

[2530] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(1-methyl-1H-pyrazol-4-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide S 'nong samui, su cha

[2531] yl]-2-[(1-methyl-1H-pyrazol-4-yl)methyl]-2H-indazol-5-yl}' 0 N '

[2532] zol-5-yl}-3-sulfamoylbenzamide

[2533] N1-[2-(3-hydroxy-3-methylbutyl)-6-[4-(pyridine-3-amido)piperidin-1-yl]-2H-

[2534] N,A{N,p indazol-5-yl]-N3-methylbenzene-1,3-

[2535] dicarboxamide

[2536] ° “rtx /

[2537] OHN^,'(OH

[2538] N1-[2-(3-hydroxy-3-methylbutyl)-6-[4-(pyridine-3-amido)piperidin-1-yl]-2H-indazol-5-yl]-N3-methylbenzene-1,3-dicarboxamide 0

[2539] methylbenzene-1,3-dicarboxamide

[2540] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[2-(pyridin-2-yl)ethyl]-2H-indazol-5- H Yes, / ,

[2541] yl}-3-sulfamoylbenzamide

[2542] Ding〕Vyw Stone

[2543] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[2-(pyridin-2-yl)ethyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide S P Myosins

[2544] yl]-2-[2-(pyridin-2-yl)ethyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2545] yl}-3-sulfamoylbenzamide

[2546]

[2547] l-[2-(3-hydroxy-3-methylbutyl)-5-(3-O sulfamoylbenzamido)-2H-indazol-6-yl]-N-〈丄 / y" 斗[(3S)-pyrrolidin-3-yl]piperidine-4-

[2548] carboxamide hydrochloride

[2549] H2N / 써" 〒 OH 1-[2-(3-hydroxy-3-methylbutyl)-5-(3 — sulfamoyl d "O people 0 hci benzamido)-2H-indazol-6-yl]-N-[(3S)-pyrrolidin-3-yl]piperidine-4-carboxamide hydrochloride

[2550] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-[(3S)-pyrrolidin-3-yl]piperidine-4-

[2551] carboxamide

[2552] H ,

[2553] H W I X VU ^ OH 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl

[2554] benzamido)-2H-indazol-6-yl]-N-[(3S)-pyrrolidin-3-yl]piperidine-4-carboxamide

[2555] 3-sulfamoyl-N-[2-(4,4,4-trifluorobutyl)-6-[4-(3,3,3-trifluoropropyl)piperazin-1-yl]-2H-indazol-5-yl]benzamide

[2556] 3-sulfamoyl-N-[2-(4,4,4-trifluorobutyl)-6- 2 수 XJ 人 0 f pF [4-(3,3,3-trifluoropropyl)piperazin-1-yl]-2H-indazol-5-yl]benzamide

[2557] N-[2-(3-hydroxy-3-methylbutyl)-6-(4-{[(2,2,2-trifluoroethyl)carbamoyl]amino}piperidin-1-

[2558] p

[2559] 0-yl)-2H-indazol-5-yl]-3-sulfamoylbenzamide H2N、 S P 心스 N-[2-(3-hydroxy-3-methylbutyl)-6-(4-{[(2, 2, 2- d "O 人 0 trifluoromethyl)carbamoyl]amino}piperidin-1-yl)-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2560]

[2561] N—{6—[4—(2—aminoethyl)piperazin—1—yl]—2—H2N으、自今 methyl—2H—indazol—5—yl}~3~

[2562] sulfamoylbenzamide dihydrochloride “라

[2563] o HN&丄〜 7 N-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-methyl H 2 N '〒 / 、 X HC1

[2564] -2H-indazol-5-yl}-3-sulfamoylbenzamide 2hydrochloride 0' Xj ° HC1

[2565] salt

[2566] N—{6—[4—(2—aminoethyl)piperazin—1—yl]—2—methyl—2H—indazol—5—yl}~3~

[2567] 으 sulfamoylbenzamide

[2568] … T o T H TXNT丄스

[2569] H 、으스스느구 /

[2570] 2 N, lead LN- {6 - [4- (2 -aminoethyl)piperazin-1-yl]- 2 -methyl cAQ west

[2571] -2H-indazol-5-yl}- 3 —sulfamoylbenzamide

[2572] N— [ 2— ( 3-hydroxy— 3— methylbutyl )-6 - [4-(2 -methanesulfonylethyl )piperazin— 1— yl ]— 2H— / ,세 〕

[2573] indazo 1 -5-yl ] — 3— sulfamoy 1 benz am i de N- [2- (3 -hydroxy- 3 -methylbutyl)- 6 - [4- (2 -methanesulfonyl H2N. P 푀 广 」 'water 0 H

[2574] / 으 ) 人 0 ponylethyl)piperazin-1-yl]- 2H-indazol-5-yl]- 3 - sulfamoylbenzamide

[2575] N- (6 - {4 - O [(carbamoylmethyl ) carbamoyl ]piperidin-l- 베 乂 y 1}-2 - ( 3-hydroxy— 3— methylbutyl ) ~2H~ indazol —

[2576] o

[2577] 5-y 1 ) ~3~nitrobenzamide

[2578] ° “rr— /

[2579] 0 HN人』 이 우수 0H

[2580] N- (6 - {4 - [(carbamoylmethyl)carbamoyl]piperidine (#0 人 0 )

[2581] ) din-1-yl}- 2- (3 -hydroxy- 3 -methylbutyl)- 2H-indazol- 5 -yl )-3 -nitrobenzamide

[2582]

[2583] It should be noted that there may be some unclear or incorrect chemical structure representations in the original text, which may affect the accuracy of the translation. It is recommended to double-check with the original chemical research materials for more accurate understanding.N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2-O

[2584] hydroxyacetyl)piperazin-1-yl]-2H-indazol-5-"-Ar、!

[2585] yl]-3-nitrobenzamide “rr— /

[2586] OHN人 으스 으 (OHN-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2-hydroxy (#0人O 시 아세틸)피페라진-1-yl]-2H-indazol-5-yl]-3-nitro 벤즈아미드

[2587] N-{6-[4-(2-hydroxyprop an-2-yl)piperidin-1-가 yl]-2-methyl-2H-indazol-5-yl}-3-(1H-

[2588] pyrazol~3~yl)benzamide

[2589] 으 N TT_

[2590] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-매 臥 心 승 일]-2-methyl-2H-indazol-5-yl}-3-(1H-pyrazol-3-yl)benzamide

[2591] N—[2—(3-hydroxy—3—methylbutyl)—6—{4—[(2S)—u ° 5-oxopyrrolidine—2—carbonyl]piperazin-1— 0 리 0夕 今 』. yl}-2H-indazo1—5—yl]—3—sulfamoylbenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-{4-[(2S)-5--☆쏘" 그011 {[Oxopyrrolidin-2-carbonyl]piperazin-1-yl}-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2592] 1-[2-(3-hydroxy-3-methylbutyl)-5-[3-(methylsulfamoyl)benzamido]-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4- f u n5 A / carboxamide

[2593] H o 印才 〜스 으- (OH

[2594] " / J O 1-[2-(3-hydroxy-3-methylbutyl)-5-[3-(methylsulfamoyl)benzamido]-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide <舍

[2595]

[2596] N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol-° H 、广 N 5— y 1 )—3—trifluoromethanesulfonylbenzamide 义 p 베 가 OH

[2597] F It should be noted that there are some unclear or seemingly incorrect expressions in the original text (such as "H o 印才 〜스 으- (OH", etc.), which may affect the accuracy of the translation. The translation is done as accurately as possible based on the existing text.Talent Gong's N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl)-3-trifluoromethanesulfonylbenzamide 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-Ao

[2598] (piperidin-3-yl)piperidine-4-carboxamide with o hydrochloride

[2599] U :O

[2600] o HN、

[2601] H2N, people ☆으 으 - $ / OH 1-[2-(3-hydroxy-3-methylbutyl)-5-(3

[2602] 1 \ —sulfamoylbenzamido)-2H-indazol-6-yl]-N-(piperidin-3- d , Xj ° HC1

[2603] yl)piperidine-4-carboxamide hydrochloride

[2604] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N- 으(piperidin-3-yl)piperidine-4-carboxamide Vo

[2605] H / 1-[2-(3-hydroxy-3-methylbutyl)-5-(3 —sulfamoyl H2N、 S P wonderful s with OH

[2606] benzamido)-2H-indazol-6-yl]-N-(piperidin-3-yl)piperidine-4-carboxamide

[2607] N—{1 — [2—(3—hydroxy—3—methylbutyl)—5—(3—nitrobenzamido)—2H—indazol—6—yl]piperidin—4-yl}-5-methanesulfonyl furan—2-carboxamide; ho—N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3-nitrobenzamido)-2H-indazol-6-yl]piperidin-4-yl}-5-methanesulfonyl furan-2-carboxamide

[2608]

[2609] N-[2-(3-hydroxy—3-methylbutyl)—6—{4—[4—(trifluoromethyl)piperidine—1-carbonyl]piperidin-1-yl}-2H-indazol-5-yl]~3-sulfamoylbenzamide

[2610] H2N. PH心人 / 가OH

[2611] 세N—[2-(3-hydroxy-3-methylbutyl)-6—{4—[4-(트리0

[2612] 플루오로메틸)piperidine-1-carbonyl]piperidin-1-yl}-2H-indazol-5-yl]-3—sulfamoylbenzamide

[2613] 、'9N—{6—[4—(2-methanesulfonylethyl)piperazin—

[2614] 1-yl]—2—methyl—2H—indazol—5-yl}~3~으Y亡sulfamoyl benz amide

[2615] N—

[2616] o to N-{6-[4-(2-methanesulfonylethyl)piperazin-1-yl]-2- 2 (methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2617] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(5-methyl-1,2-oxazol-3-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide 0 HgK to to E N-{6-[4-(2-hydroxypropan-2-yl)piperidine-1- 2 d j o yl]-2-[(5-methyl-1,2-oxazol-3-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2618] N-(2-hydroxy-2-methylpropyl)-1-[2-(3-hydroxy-3-methylbutyl)-5-(3-

[2619] sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide<​​​​​​​​​​​​​​​​N-[(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide

[2624] N-[2-(3-hydroxy-3-methylbutyl)-6-[(3S)-3-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide 0 N-[(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide

[2625] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5-sulfamoylthiophene-2-carboxamide 1 (乱码,无法准确翻译) 0 -2-carboxamide

[2626] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(methylsulfamoyl)benzamide

[2627] N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(methylsulfamoyl)benzamide 0 benzamide

[2628] N-{2-methyl-6-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide O HNXX N -H2N. P is N-{2-methyl-6-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2629]

[2630] N-(2-methyl-6-{4-[(2,2,2-trifluoroethyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide 으 YD-N-(2-methyl-6-{4-[(2,2,2-trifluoroethyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide H2N、 S P is sulfamoyl benzamide 0 sulfamoyl benzamide

[2631] N-{2-methyl-6-[4-(3,3,3-trifluoropropyl)piperazin-1-yl]-2H-indazol-

[2632] 5-yl}-3-sulfamoylbenzamide

[2633] N-{2-methyl-6-[4-(3,3,3-trifluoropropyl)piperazin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide H2N、 / 1 piperazin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenz 0 amide

[2634] „ 0 N-(2-methyl-6-{4-[ (2S)-5-oxopyrrolidine-2-N斗.、、'1 L - carbonyl - piperazin - 1 - yl - 2H - indazol - 5 - yl 0== o 0 나 back 3 - sulfamoyl benzamide

[2635] H N o

[2636] H 2 N ' HN XX

[2637] 6L N - N - (2 - methyl - 6 - {4 - [(2S) - 5 - oxopyrrolidine - 2 - carbo

[2638] yl]piperazin - 1 - yl} - 2H - indazol - 5 - yl) - 3 — sulfamoyl benzamide

[2639] oyl benzamide

[2640] [[ID=V29]]N - hydroxy — 1 - [2 - methyl - 5 - (3 - nitrobenzamido) - H0 / n 2H - indazol — 6 — yl]piperidine — 4 — carboxamide 0 HN人^ 스 N - hydroxy - 1 - [2 - methyl - 5 - (3 - nitrobenzamido) - 2H - indazol - 6 - yl]piperidine - 4 - carboxamide o쓰 Q 人 o

[2641] [[ID=3!]]

[2642] 1 - [2 - (3 - hydroxy - 3 - methylbutyl) - 5 - (3 - sulfamoyl benzamido) — 2H — indazol — 6 — yl] — N — 0

[2643] [(piperidin - 3 - yl)methyl]piperidine — 4 - carboxamide hydrochloride

[2644] 引 H o HN人니 으 、- (OH

[2645] H 2 N 'se 1 \ 1- [2- (3-hydroxy-3-methylbutyl)-5-(3 —sulfamoyl 6'yi HC1 benzamid)-2H-indazol-6-yl]-N-[(piperidin-3-yl)methyl]piperidine—4-carboxamide 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl benzamido)—2H—indazol—6—yl]—N—0

[2646] [(piperidin-3-yl)methyl]piperidine—4—carboxamide

[2647] H2N、 S P shu OH

[2648] , S 、Q su 1- [2- (3-hydroxy-3-methylbutyl)-5-(3 —sulfamoyl benzamido)-2H-indazol-6-yl]-N-[(piperidin-3-yl)methyl]piperidine-4-carboxamide

[2649] N-{6-[4-(2-hydroxypropan—2—yl)piperidin—1— H it yl]—2—methyl—2H—indazol—5—yl}-N—methyl—3 —p

[2650] eu sulfamoyl benzamide

[2651] yy N _

[2652] N-{6-[4-(2-hydroxypropyl)-2-yl)piperidin-1-H2N、 S P you people su 1]-2 -methyl-2H-indazol-5 -yl}-N-methyl-3 —sulfamo so 0 se ylbenzamide

[2653] N-{6-[4-(2-hydroxy-2-

[2654] methylpropyl)piperazin-1-yl]-2-methyl-2H-1,2,3-triazol-5-yl}-3-sulfamoylbenzamide o HN&丄 으 N-{6-[4-(2-hydroxy-2-methylpropyl)piperazin-1-yl]-2-methyl-2H-1,2,3-triazol-5-yl}-3-sulfamoylbenzamide

[2655] N—(2-hydroxy—2-methylpropyl)—1—[2-methyl—5—

[2656]

[2657] (3-nitrobenzamido)-2H-1,2,3-triazol-6-

[2658] (3-nitrobenzamido)-2H-1,2,3-triazol-6-yl]piperidine-4-carboxamide h 수 r새 人 yl]piperidine—4—carboxamide

[2659] 으:N-(2-hydroxy-2-methylpropyl)-1-[2-methyl-5-(3-°"外 nitrobenzamido)-2H-1,2,3-triazol-6-yl]piperidine-3 人 0 4-carboxamide

[2660] 1—{1—[2—(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-1,2,3-triazol-6-

[2661] 0

[2662] yl]piperidine-4-carbonyl}piperidine-4-H2N리 7 리 午〜\ carboxamide

[2663] 셰 1-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl o

[2664] It should be noted that there may be some incorrect or unclear chemical structure expressions in the original text, which may affect the accuracy of the translation. It is recommended to double-check with the original chemical information source for more accurate understanding.1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide

[2665] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(3,3,3-trifluoropropyl)piperidine-4-carboxamide H carboxamide

[2666] H N O HNXX—

[2667] 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(3,3,3-trifluoropropyl)piperidine-4-carboxamide

[2668] 1-[2-(3-hydroxy-3-methylbutyl)-5-[3-(methylsulfamoyl)benzamido]-2H-indazol-6-yl]-N-(3,3,3-trifluoropropyl)piperidine-4-carboxamide H ^ N v* s V :N ' / ~ v OH carboxamide

[2669] 』 H忌 ^ “〔X、스X N

[2670] 9

[2671] 1-[2-(3-hydroxy-3-methylbutyl)-5-[3-(methylsulfamoyl)benzamido]-2H-indazol-6-yl]-N-(3,3,3-trifluoropropyl)piperidine-4-carboxamide

[2672]

[2673] N—{1—[5—(4—chloro—3—sulfamoylbenzamido)—2—

[2674] (3—hydroxy—3—methylbutyl)—2H—indazol—6—yl]piperidin—4—yl}pyridine—3—carboxamide 0 으 /

[2675] N-{1- [5- (4 -chloro- 3 —sulfamoylbenzamido)- 2 - H W I % VU / ^ OH

[2676] (3 -hydroxy- 3 -methylbutyl)- 2H-indazol- 6 -yl]piperidin- 4 -yl}pyridine- 3 -carboxamide

[2677] N—{1—[5—(2—fluoro—5—sulfamoylbenzamido)—2— N N (3—hydroxy—3—methylbutyl)—2H—indazol—6—yl]piperidin—4—yl}pyridine—3—carboxamide 0 /

[2678] O 퓨 厂丄 人 으 M-OH N-{1- [5- (2 -fluoro- 5 —sulfamoylbenzamido)- H2N. 'P 7 \

[2679] 2- (3 -hydroxy- 3 -methylbutyl)- 2H-indazol- 6 -yl]piperidin- 4 -yl}pyridine- 3 -carboxamide

[2680] N—{1—[2—(3—hydroxy—3—methylbutyl)—5—(2 — N NN-yl]piperidin-4-yl}pyridine-3-carboxamide 0 Dingse X /

[2681] N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(2-methyl-J shang, ren 7 =° H

[2682] 3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidin-4-yl}pyridine-3-carboxamide

[2683] N—{1 — [2—(3—hydroxy—3—methylbutyl)—5 — [3—if seun]H(pyridin-4-yl)benzamido]-2H-indazo1-6- N N n-yl]piperidin-4-yl}pyridine-3-carboxamide 0 으 YY— /

[2684] N 今 HN"으' 흐 丄—(OH N-{1-[2-(3-hydroxy-3-methylbutyl)-5-[3-(pyr o—0s dine-4-yl)benzamido]-2H-indazol-6-yl]piperidin -4-yl}pyridine-3-carboxamide

[2685]

[2686] N-{6-[4-(2-hydroxyprop an—2—yl)piperidin—1—ayl]—2—methyl—2H—indazol—5—yl}—3—(1H—

[2687] 1,2,3,4—tetrazol—1—yl)benzamide 으 N T 亡 N—

[2688] It should be noted that there are some unclear or potentially incorrect parts in the original text (such as "Dingse X / ", "if seun", etc.), which may affect the accuracy of the overall translation.N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H-1,2,3,4-tetrazol-1-yl)benzamide

[2689] N-{6-[4-(2-hydroxyprop an-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H-1,2,3-triazol-1-yl)benzamide

[2690] N=N HN乂、 人'’'乂 N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H-1,2,3-triazol-1-yl)benzamide

[2691] N-{6-[4-(2-hydroxyprop an-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5-

[2692] HC>乂厂 、 )

[2693] sulfamoyl furan-2-carboxamide

[2694] 으 N Y 서 VN.

[2695] 0HNAX N ~ N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5 —sulfamoyl furan- 써 1 〈 人 0 2-carboxamide

[2696] N2-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}thiophene-2,5-dicarboxamide

[2697] eu

[2698] HN, S N2 - {6 - [4 - (2 - hydroxypropan - 2 - yl)piperidin - 1 - yl] - 2 - methyl - 2H - indazol - 5 - yl}thiophene - 2,5 - dicarboxamide H2주 0 Copy intermediate

[2699]

[2700] N - {6 - [4 - (2 - hydroxypropane - 2 - yl)piperidin - 1 - yl] - 2 - methyl - 2H - indazol - 5 - yl} - 1 - (pyridin - 4 - yl) - 1H - pyrazole - 4 - carboxamide “ra

[2701] HN」eu 〜 N - {6 - [4 - (2 - hydroxypropan - 2 - yl)piperidin - 1 - yl] - 2 - methyl - 2H - indazol - 5 - yl} - 1 - (pyridin - 4 - yl) - 1H - pyrazole - 4 - carboxamide

[2702] N - {6 - [4 - (2 - hydroxypropane - 2 - yl)piperidin - 1 - yl] - 2 - methyl - 2H - indazol - 5 - yl} - 3 - (1H -

[2703] pyrazol - 4 - yl)benzamide

[2704] N - {6 - [4 - (2 - hydroxypropan - 2 - yl)piperidin - 1 - yl] - 2 - methyl - 2H - indazol - 5 - yl} - 3 - (1H - pyrazol - 4 - yl)benzamide

[2705] N - {6 - [4 - (3 - hydroxy - 3 - methylbutyl)piperazin - HOJ

[2706] 1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2707] 0 HN< 人' 7 N-{6-[4-(3-hydroxy-3-methylbutyl)piperazin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide

[2708] 2-fluoro-N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5-sulfamoylbenzamide H 厂 yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5-sulfamoylbenzamide

[2709] 으 N TT_

[2710] o HN< 人' 7 2-fluoro-N-{6-[4-(2-hydroxypropan-2-yl)methylpiperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5-sulfamoylbenzamide

[2711]

[2712] 3—({6—[4—(z-hydroxypropan-2-yl)piperidin-1-yl]—2—methyl—2H—indazol—5—

[2713] yl Icarbamoyl)benzene-1-sulfonyl fluoride 197 心

[2714] F YTN—

[2715] ,0 人느 丄 으 3-({6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}carbamoyl)benzene- 유 Q 人 o 1-sulfonyl fluoride

[2716] N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) pi per idin— 1— "hydr yl ]— 2— methyl— 2H— indazol— 5— yl}~2~(3~

[2717] sulf amoyl phenyl ) acet am ide

[2718] 198

[2719] N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1-yl]- 2 -methyl- 2H-indazole- 5 -yl}- 2- (3 —sulfamoylphenyl)acetamide

[2720] N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) pi per idin— 1— yl ]— 2— methyl— 2H— indazol— 5— yl}— 2— (4 — sulf amoyl phenyl ) acet am ide

[2721] 199 HW “CG- N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1-yl]- 2 -methyl- 2H-indazole- 5 -yl}- 2- (4 —sulfamoylphenyl)acetamide

[2722]

[2723] (25) The present invention provides a pharmaceutical composition comprising a compound according to any one of (1) to (24), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

[2724] (26) In the above (25), the pharmaceutical composition may be used for the prevention or treatment of IRAK-4 or IRAK-1 related diseases.

[2725] (27) In the above (26), the IRAK-4 or IRAK-1 related disease may be an autoimmune disease, an inflammatory disease, or a tumor.

[2726] (28) In the above (26) or (27), the IRAK-4 or IRAK-1 related disease may be rheumatoid arthritis, spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, psoriasis, atopic dermatitis, vitiligo, multiple sclerosis, myasthenia gravis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, cutaneous lupus erythematosus, Sjögren's syndrome or Behcet's disease.

[2727] (29) The present invention provides a method for preventing or treating IRAK-4 or IRAK-1 related diseases, comprising administering to an individual a compound according to any one of (1) to (24), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, or a pharmaceutical composition according to any one of (25) to (28).

[2728] (30) The present invention provides a use for the prevention or treatment of IRAK-4 or IRAK-1 related diseases of a compound according to any one of (1) to (24), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, or a pharmaceutical composition according to any one of (25) to (28).

[2729] (31) The present invention provides the use of a compound according to any one of (1) to (24), a stereoisomorph of the same, a pharmaceutically acceptable salt of the same, or a hydrate or solvate of the same, or a pharmaceutical composition according to any one of (25) to (28), for the manufacture of a drug for the prevention or treatment of IRAK-4 or IRAK-1 related diseases.

[2730]

Effects of the Invention

[2731] The compound represented by Formula I of the present invention, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates exhibit an inhibitory effect on IRAK-4 or IRAK-1 and can be usefully used for the prevention or treatment of diseases related to IRAK-4 or IRAK-1 activity.

[2732]

Brief Description of the Drawing

[2733] FIG. 1 is a figure showing reaction scheme 1 for a method of manufacturing a compound according to the present invention.

[2734]

Form for carrying out the invention

[2735] The present invention will be described in more detail below. Any examples or use of exemplary language provided herein are merely intended to better illustrate the invention and do not limit the scope of the claimed invention.

[2736] <Example>

[2737] Compounds represented by Formula I, Formula 1-1, Formula 1-2, Formula 1-3, Formula 1-4, Formula 1-5, Formula 1-6, Formula 1-7, or Formula 1-8 of the present invention, and compounds 1 to 199 of Table 1 above can be prepared through the methods described below. Unless otherwise stated, starting materials may be commercially available or prepared by known methods.

[2738] Preparation of intermediates

[2739] Intermediate 1. N~[2~(3-hydroxy-3-methylbutyl)-6-(piperazine ~1~yl)-2H-indazole~5-yl]-3-sulfamoylbenzamide

[2740]

[2741] Step 1: Preparation of tert-butyl 4-(5-nitro- 1H-indazole- 6-yl)piperazine-:L-carboxylate

[2742] 1-Boc-piperazine (23.1g, 124mmole) and dimethyl sulfoxide (15mL) were added to 6-bromo-5-nitro-1H-indazole (5g, 20.66mmole) and stirred at 130 °C for 48 hours. After the reaction was finished, ethyl acetate (50mL) was added and washed with purified water (50mL), anhydrous magnesium sulfate was added, and the mixture was filtered. After concentration under reduced pressure, the solution was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (5.1g).

[2743] Step 2 - Preparation of Tert-Butyl 4-(2-(3-hydroxy-3-methylbutyl)-5-nitro-2H-indazole-6-yl)piperazine-1-carboxylate

[2744] To the compound (5.096 g, 14.67 mmole) obtained in [Step 1] above, 4-bromo-2-methylbutan-2-ol (2.68 mL, 22 mmole), potassium carbonate (8.11 g, 58.7 mmole), potassium iodide (510 mg, 3.07 mmole), and dimethylformamide (15 mL) were added and stirred at 90°C for 15 hours. After the reaction was finished, ethyl acetate (100 mL) was added, washed with purified water (100 mL), anhydrous magnesium sulfate was added, and filtered. After concentration under reduced pressure, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (1.53 g).

[2745] Step 3: Preparation of tert-butyl 4-(5-amino-2-(3-hydroxy-3-methylbutyl)-2H-indazole-6-yl)piperazine-1-carboxylate

[2746] Ethyl acetate (15 mL), dichloromethane (15 mL), and activated carbon palladium (300 mg, 0.2 w / w) were added to the compound (1.53 g, 3.53 mmole) obtained in [Step 2] above, and hydrogenation was carried out by stirring at room temperature for 2 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain the title compound (1.43 g).

[2747] Step 4: Tert-1-butyl 4-(2 _ (3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H"indazole-6-yl)piperazine-: Preparation of L-carboxylate

[2748] To the compound (477 mg, 1.177 mmole) obtained in [Step 3] above, 3-sulfamoylbenzoic acid (284 mg, 1.41 mmole), dimethylformamide (10 mL), EDC-HC1 (338 mg, 1.766 mmole), and H0Bt-H2O (233 mg, 1.766 mmole) were added and stirred at room temperature for 22 hours. After the reaction was finished, ethyl acetate (100 mL) was added, washed with purified water (100 mL), anhydrous magnesium sulfate was added, and filtered. After concentration under reduced pressure, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (580 mg).

[2749] Step 5: N-[2 _ Preparation of (3-hydroxy-3-methylbutyl)-6-(piperazine-1-yl)-2H-indazole-5-yl]-3-sulfamoylbenzamide (Intermediate 1)

[2750] A 0.5N hydrochloric acid / methanol solution (100 mL) was added to the compound (580 mg, 0.99 mmole) obtained in [Step 4] above and stirred at 60°C for 2 hours. The solution was neutralized using an aqueous solution of saturated sodium bicarbonate and filtered to obtain the title compound (296 mg).

[2751]

[2752] NMR (DMS0-d6): 1.12 (s, 6H), 1.98 (t, 2H), 2.78 (s, 4H), 2.87 (s, 4H), 4.40 (t, 2H), 4.48 (s, 1H), 7.35 (s, 1H), 7.43 (s, 2H) , 7.77 (t , 1H) , 8.01 (d, 1H) , 8.12 (d, 1H) , 8.29 (s, 1H) , 8.37 (s, 1H) , 8.43 (s, 1H) , 9.84 (s, 1H) .

[2753] LC-MS (ESI, m / z) = 487.5 (M+H + )

[2754] Manufacturing of the example

[2755] Example 1. N~[2~(3-hydroxy-3-methylbutyl)-6-[4~(2-hydroxyacetyl)piperazine- !-yl ]-2H-indazol-5-yl]-3-sulfamoylbenzamide

[2756] 0

[2757]

[2758] Under the same conditions as in [Step 4] of intermediate 1, glycolic acid (5.6 mg, 0.074 mmole), dimethylformamide (0.6 mL), EDC-HC1 (18 mg, 0.0924 mmole), and HOBt-H2O (12.5 mg, 0.0924 mmole) were added to intermediate 1 (30 mg, 0.0616 mmole), and after reaction in the same manner, the compound of the title (22 mg) was obtained by purification using MPLC (CombiFlash NEXTGEN 300+).

[2759]

[2760] NMR (DMS0-d6): 1.12 (s, 6H), 1.99 (t, 2H), 2.87 (m, 4H), 3.51 (m, 2H), 3.66 (m, 2H), 4.11 (s, 2H), 4.43 (t, 2H), 4.48 (s, 1H) , 4.58 (m, 1H) , 7.38 (s, 1H) , 7.45 (s, 2H) , 7.76 (t, 1H) , 8.01 (d, 1H) , 8.15 (d, 1H) , 8.31 (s, 1H) , 8.38 (s, 1H) , 8.41 (s, 1H) , 9.89 (s, 1H) .

[2761] LC-MS (ESI, m / z) = 545.6 (M+H + ) .

[2762] Example 2. N~{6 -[4~(2-aminoacetyl)piperazine ~1~yl]- 2~(3-hydroxy- 3-methylbutyl)- 2H-indazole- 5-yl}- 3-sulfamoylbenzamide hydrochloride

[2763]

[2764] Step 1; Tert-butyl (2-(4-(2 _Under the same conditions as [Step 4] of the preparation of intermediate 1 of (3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazole-6-yl)piperazine-:L-yl)-2-oxoethyl)carbamate, Boc-glycine (26 mg, 0.148 mmole), dimethylformamide (0.6111 L), EDC-HCl (36 mg, 0.185 mmole), and HOBt-H2O (25 mg, 0.185 mmole) were added to the compound (60 mg, 0.1232 mmole) obtained from intermediate 1, and after reacting in the same manner, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (37 mg). Step 2 - Preparation of N-{6-[4-(2-aminoacetyl)piperazine-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide hydrochloride (Example 2)

[2765] A 0.5N hydrochloric acid / methanol solution (3 mL) was added to the compound (30 mg, 0.0466 mmole) obtained in [Step 1] above, and the mixture was stirred at 60°C for 16 hours. After the reaction was finished, the reaction solution was concentrated and filtered with ethyl acetate (200 mL) to obtain the title compound (21 mg).

[2766]

[2767] NMR (DMS0-d6): 1.12 (s, 6H), 1.98 (t, 2H), 2.90 (m, 4H), 3.55 (m, 2H), 3.71 (m, 2H), 3.89 (q, 2H), 4.42 (t, 3H), 7.37 (s, 1H) , 7.49 (s, 2H) , 1.76 (t , 1H) , 8.01 (d, 1H) , 8.07 (s, 3H) , 8.16 (d, 1H) , 8.33 (s, 1H) , 8.39 (s, 2H) , 9.89 (s, 1H) .

[2768] LC-MS (ESI, m / z) = 580.1 (M+H + ) .

[2769] Example 3. N~{6-[4~(2-Aminoacetyl)piperazin-1-yl]-2~(3-Hydroxy-3-methylbutyl)-2H-indazol-5-yl}-4-sulfamoylbenzamide

[2770]

[2771] The compound obtained in Example 2 (10 mg) was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (4 mg).

[2772] LC-MS (ESI, m / z) = 544.2 (M+H + ) .

[2773] [[ID=第十九]]Example 4. N~[2~(3-Hydroxy-3-methylbutyl)-6-[4~(4, 4, 4-Trifluorobutanoyl)piperazin-1-yl]-2H-indazol-5-yl]-;3-sulfamoylbenzamide

[2774] 0

[2775] F,.,.■'*,,,-,,-스、

[2776] F 'T 수 〕

[2777] F '、,제 Y—广 N.

[2778] L L — \ /

[2779] 門— 〒째

[2780] “ d "f Y* 。

[2781]

[2782] The compound obtained from intermediate 1 (60 mg, 0.1233 nmole) was mixed with diisopropyl ethylamine (42 yL, 0.247 mmole), dimethylformamide (1 mL), and 4,4,4-trifluorobutanoyl chloride (22 mg, 0.136 mmole) and stirred at room temperature for 16 hours. After the reaction was finished, ethyl acetate (50 mL) was added and washed with purified water (50 mL), anhydrous magnesium sulfate was added, and the mixture was filtered. After concentration under reduced pressure, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (40 mg).

[2783]

[2784] NMR (DMS0-d6): 1.12 (s, 6H), 1.99 (t, 2H), 2.50 (m, 2H), 2.63 (m, 2H), 2.87 (d, 4H), 3.64 (s, 4H), 4.42 (t, 2H), 4.47 (s, 1H) , 7.38 (s, 1H) , 7.48 (s, 2H) , 7.76 (t, 1H) , 8.01 (d, 1H) , 8.14 (d, 1H) , 8.31 (s, 1H) , 8.38 (s, 1H) , 8.41 (s, 1H) , 9.89 (s, 1H) .

[2785] LC-MS (ESI, m / z) = 611.4 (M+H + ) .

[2786] Example 5. N~{6 - [4~(2-aminoacetyl)piperazine ~1~yl]- 2~(4,4,4-trifluorobutyl)- 2H-indazole- 5-yl}- 3-sulfamoylbenzamide hydrochloride

[2787]

[2788] Step 1: Preparation of tert-butyl 4-(5-nitro-2-(4,4,4-trifluorobutyl)-2H-indazole-6-yl)piperazine-1-carboxylate

[2789] Under the same conditions as [Step 2] of Intermediate 1, 1,1-trifluoro-4-iodobutane (2.76 mL, 21.59 mmole), potassium carbonate (4 g, 28.8 mmole), potassium iodide (510 mg, 3.07 mmole), and dimethylformamide (30 mL) were added to the compound (5 g, 14.39 mmole) obtained in [Step 1] of Intermediate 1, and after reacting in the same manner, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (1.7 g).

[2790] Step 2: Preparation of tert-butyl 4-(5-amino-2-(4,4,4-trifluorobutyl)-2H-indazole-6-yl)piperazine-!-carboxylate

[2791] Under the same conditions as in [Step 3] of Intermediate 1, dichloromethane (170 mL) and activated carbon palladium (340 mg, 0.2 w / w) were added to the compound (1.7 g, 3.716 mmole) obtained in [Step 1], and after reacting in the same manner, the title compound (1.588 g) was obtained. Step 3: Preparation of Tert-Butyl 4-(5-(3-sulfamoylbenzamido)-2-(4,4,4-trifluorobutyl)-2H-indazole-6-yl)piperazine-:L-carboxylate

[2792] Under the same conditions as in [Step 4] of intermediate 1, 3-sulfamoyl benzoic acid (897 mg, 4.459 mmole), dimethylformamide (16 mL), EDC-HCl (1.069 g, 5.574 mmole), and HOBt-H2O (753 mg, 5.574 mmole) were added to the compound (1.588 g, 3.716 mmole) obtained in [Step 2], and after reacting in the same manner, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (1.22 g).

[2793] Step 4: Preparation of N-(6-(piperazine-!-yl)-2-(4,4,4-trifluorobutyl)-2H-indazole-5-yl)-3-sulfamoylbenzamide hydrochloride salt

[2794] Dichloromethane (3 mL) and a 4 M hydrochloric acid / dioxane solution (10 mL) were added to the compound (1.21 g, 1.98 mmole) obtained in [Step 3] above, and the mixture was stirred at room temperature for 2 hours. After the reaction was finished, the reaction solution was concentrated and filtered with ethyl acetate (70 mL) to obtain the title compound (1.15 g).

[2795] Step 5: Preparation of Tert-Butyl (2-oxo-2-(4-(5-(3-sulfamoylbenzamido)-2-(4,4,4-trifluorobutyl)-2H-indazole-6-yl)piperazine-:L-yl)ethyl)carbamate. To the compound (133 mg, 0.244 mmole) obtained in [Step 4] above, Boc-glycine (51 mg, 0.293 mmole), dimethylformamide (2.7 mL), EDC-HCl (70 mg, 0.366 mmole), HOBt • H2O (49 mg, 0.366 mmole), and diisopropylethylamine (166 yL, 0.976 mmole) were added and stirred at room temperature for 18 hours. After the reaction was complete, ethyl acetate (50 mL) was added and washed with purified water (50 mL), anhydrous magnesium sulfate was added, and the mixture was filtered. After concentration under reduced pressure, the solution was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (117 mg). Step 6: Preparation of N-{6-[4-(2-aminoacetyl)piperazine-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide hydrochloride (Example 5)

[2796] Dichloromethane (0.3 mL) and a 4 M hydrochloric acid / dioxane solution (0.88 mL) were added to the compound (117 mg, 0.175 mmole) obtained in [Step 5] above, and stirred at room temperature for 2 hours. After the reaction was finished, the reaction liquid was concentrated and filtered with ethyl acetate (2 mL) to obtain the title compound (82 mg).

[2797]

[2798] NMR (DMS0-d6): 2.10 (m, 2H), 2.24 (m, 2H), 2.90 (s, 4H), 3.54 (s,2H), 3.69 (s, 2H), 3.88 (s, 2H), 4.43 (m, 2H), 7.39 (s, 1H) , 7.48 (s, 2H) , 7.75 (t , 1H) , 8.01 (s, 1H) , 8.07 (s, 3H) , 8.17 (d, 1H) , 8.33 (s, 1H) , 8.38 (s, 2H) , 9.89 (s, 1H) .

[2799] LC-MS (ESI, m / z) = 604.05 (M+H + ) .

[2800] Example 6. N~{6 - [4~(2-aminoacetyl)piperazine ~1~yl]- 2~(4,4,4-trifluorobutyl )-2H-indazole- 5-yl}- 3-sulfamoylbenzamide

[2801]

[2802] The compound (10 mg) obtained in Example 5 was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (5 mg).

[2803] LC-MS (ESI, m / z) = 568.2 (M+H + ) .

[2804] Example 7. N~{6~[4~(2~aminoethyl)piperazine-1-yl]-2~(3~hydroxy-3"methylbutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide dihydrochloride

[2805]

[2806] Step 1: Preparation of tert-butyl(2-(4-(2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazole-6-yl)piperazine-1-yl)ethyl)carbamate

[2807] Diisopropylethylamine (150 µL, 0.864 mmole), dimethylformamide (2 mL), and 2-(Boc-amino)ethyl bromide (35 mg, 0.187 mmole) were added to the compound (210 mg, 0.432 nmole) obtained from intermediate 1, and the mixture was stirred at 50°C for 18 hours. After the reaction was finished, ethyl acetate (50 mL) was added, washed with purified water (50 mL), anhydrous magnesium sulfate was added, and the mixture was filtered. After concentration under reduced pressure, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (98 mg).

[2808] Step 2 Preparation of 'N-{6-[4-(2-aminoethyl)piperazine-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide dihydrochloride (Example 7)

[2809] Dichloromethane (0.5 mL) and a 4 M hydrochloric acid / dioxane solution (0.39 mL) were added to the compound (49 mg, 0.0778 mmole) obtained in [Step 1] above, and the mixture was stirred at room temperature for 2 hours. After the reaction was finished, the reaction solution was concentrated and filtered with ethyl acetate (2 mL) to obtain the title compound (38 mg).

[2810]

[2811] NMR (DMS0-d6): 1.12 (s, 6H), 1.99 (m, 2H), 3.27 (s, 6H), 3.60 (s, 4H), 3.77 (s, 2H), 4.44 (m, 3H), 7.37 (s, 1H), 7.53 (s, 2H) , 7.75 (t , 1H) , 8.01 (d, 1H) , 8.15 (d, 1H) , 8.26 (s, 3H) , 8.34 (s, 1H) , 8.35 (s, 1H) , 8.39 (s, 1H) , 9.78 (s, 1H) , 11.18 (s, 1H) .

[2812] LC-MS (ESI, m / z) = 602.58 (M+H+).

[2813] Example 8. N~{6 -[4~(2-aminoethyl)piperazine ~1~yl]- 2~(3-hydroxy- 3-methylbutyl )-2H-indazole- 5-yl}- 4-sulfamoyl benzamide

[2814]

[2815] The compound (10 mg) obtained in Example 7 was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (5 mg).

[2816] LC-MS (ESI, m / z) = 530.2 (M+H + ) .

[2817] Example 9. N~{6~[4~(2~aminoethyl)piperazine-1-yl]-2~(3~hydroxy-3"methylbutyl)-2H-indazole-5-yl}-3-nitrobenzamide dihydrochloride

[2818]

[2819] Step 1: Preparation of 2-methyl-4-(5-nitro-6-(piperazine-1-yl)-2H-indazole-2-yl)butan-2-ol hydrochloride

[2820] Dichloromethane (13 mL) and a 4 M hydrochloric acid / dioxane solution (15 mL) were added to the compound (1.3 g, 3 mmole) obtained in [Step 2] of Intermediate 1, and stirred at room temperature for 2 hours. After the reaction was finished, the reaction mixture was concentrated and filtered with ethyl acetate (20 mL) to obtain the title compound (lg).

[2821] LC-MS (ESI, m / z) = 334.2 (M+H + ) .

[2822] Step 2: Preparation of tert-butyl (2-(4-(2-(3-hydroxy-3-methylbutyl)-5-nitro-2H-indazole-6-yl)piperazine-1-yl)ethyl)carbamate

[2823] Diisopropylethylamine (1.53 mL, 9 mmole), dimethylformamide (10 mL), and 2-(Boc-amino)ethyl bromide (1.5 mmole) were added to the compound (lg, 3 mmole) obtained in [Step 1] above, and the mixture was stirred at room temperature for 15 hours. After the reaction was finished, ethyl acetate (50 mL) was added and washed with purified water (50 mL), anhydrous magnesium sulfate was added, and the mixture was filtered. After concentration under reduced pressure, the product was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (1.3 g).

[2824] LC-MS (ESI, m / z) = 477.2 (M+H + ) .

[2825] Step 3: Tert-butyl (2-(4 _ Preparation of (5-amino-2-(3-hydroxy-3-methylbutyl)-2H-indazole-6-yl)piperazine-1-yl)ethyl)carbamate

[2826] Under the same conditions as [Step 3] of intermediate 1, dichloromethane (57 mL) and activated carbon palladium (37 mg, 0.2 w / w) were added to the compound (184 mg, 0.386 mmole) obtained in [Step 2], and the title compound (173 mg) was obtained after reaction in the same manner.

[2827] LC-MS (ESI, m / z) = 447.2 (M+H + ) .

[2828] Step 4: Preparation of tert-1-butyl (2-(4-(2-(3-hydroxy-3-methylbutyl)-5-(3-nitrobenzamido)-2H-indazole-6-yl)piperazine-1-yl)ethyl)carbamate

[2829] Under the same conditions as in [Step 4] of Intermediate 1, 3-nitrobenzoic acid (77 mg, 0.463 mmole), dimethylformamide (1.7 mL), EDC-HCl (30 mg, 0.579 mmole), and HOBt-H2O (78 mg, 0.579 mmole) were added to the compound (173 mg, 0.386 mmole) obtained in [Step 3], and after reacting in the same manner, the solution was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (48 mg). LC-MS (ESI , m / z) = 596.2 (M+H + ) .

[2830] Step 5: Preparation of N-{6-[4-(2-aminoethyl)piperazine-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazole-5-yl}-3-nitrobenzamide dihydrochloride (Example 9)

[2831] Dichloromethane (0.3 mL) and a 4 M hydrochloric acid / dioxane solution (0.32 mL) were added to the compound (38 mg, 0.064 mmole) obtained in [Step 4] above, and stirred at room temperature for 2 hours. After the reaction was finished, the reaction liquid was concentrated and filtered with ethyl acetate (2 mL) to obtain the title compound (28 mg).

[2832]

[2833] NMR (DMS0-d6): 1.12 (s, 6H), 2.00 (t, 2H), 3.23 (m, 11H), 3.70 (s, 2H), 4.44 (t, 2H), 7.36 (s, 1H), 7.85 (s, 1H), 7.85 (t , 1H) , 8.21 (s, 2H) , 8.29 (s, 1H) , 8.35 (s, 1H) , 8.37 (d, 1H) , 8.45 (d, 1H) , 8.71 (s, 1H) , 9.87 (s, 1H) , 11.09 (s, 1H) .

[2834] LC-MS (ESI, m / z) = 568.5 (M+H + ) .

[2835] Example 10. N~{6 - [4~(2-aminoethyl)piperazine ~1~yl]- 2~(3-hydroxy- 3-methylbutyl )-2H-indazole- 5-yl}- 3-nitrobenzamide

[2836]

[2837] The compound (10 mg) obtained in Example 9 was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (6 mg).

[2838] LC-MS (ESI, m / z) = 533.2 (M+H + ) .

[2839] Example 11. N~{6 - [4~(2-aminoethyl)piperazine-1~yl]-2~(4,4,4-trifluorobutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide dihydrochloride

[2840]

[2841] Step 1: Preparation of tert-butyl N-(2-{4-[5-(3-sulfamoylbenzamido)-2-(4,4,4-trifluorobutyl)-2H-indazole-6-yl]pipherazine-!-yl} ethyl)carbamate

[2842] Diisopropylethylamine (166 μL, 0.976 nmole), dimethylformamide (2.7 mL), and 2-(Boc-amino)ethyl bromide (109 mg, 0.488 mmolole) were added to the compound (133 mg, 0.244 mmolole) obtained in [Step 4] of Example 5, and the mixture was stirred at 60°C for 18 hours. After the reaction was finished, ethyl acetate (50 mL) was added, washed with purified water (50 mL), anhydrous magnesium sulfate was added, and the mixture was filtered. After concentration under reduced pressure, the product was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (47 mg).

[2843]

[2844] NMR (DMS0-d6): 1.34 (d, 9H), 2.11 (m, 2H0, 2.23 (m, 2H), 2.38 (m, 2H), 2.58 (m, 4H), 2.88 (s, 4H), 3.03 (s, 2H), 4.43 (s, 2H) , 6.62 (s, 1H) , 7.40 (s, 1H) , 7.47 (s, 2H) , 7.77 (t , 1H) , 8.01 (d, 1H) , 8.14 (s, 1H) , 8.32 (s, 1H) , 8.38 (s, 1H) , 8.43 (s, 1H) , 9.84 (s, 1H) .

[2845] LC-MS (ESI, m / z) = 654.2 (M+H + ) .

[2846] Step 2-N-{6-[4-(2-aminoethyl)piperazine-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide dihydrochloride (Example 11)

[2847] Dichloromethane (0.2 mL) and a 4 M hydrochloric acid / dioxane solution (0.36 mL) were added to the compound (47 mg, 0.072 mmole) obtained in [Step 1] above, and the mixture was stirred at room temperature for 2 hours. After the reaction was finished, the reaction solution was concentrated and filtered with ethyl acetate (2 mL) to obtain the title compound (40 mg).

[2848]

[2849] NMR (DMS0-d6): 2.12 (m, 2H), 2.24 (m, 2H), 3.27 (m, 8H), 3.70 (m, 4H), 4.45 (m, 2H), 7.40 (s, 1H), 7.52 (s, 2H), 7.75 (t) , 1H) , 8.02 (d, 1H) , 8.17 (s, 1H) , 8.26 (m, 3H) , 8.37 (m, 3H) , 9.78 (s, 1H) , 11.16 (s, 1H) .

[2850] LC-MS (ESI, m / z) = 554.2 (M+H + ) .

[2851] Example 12. N~{6~[4~(2~aminoethyl)piperazine-1~yl]-2~(4,4,4~trifluorobutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide

[2852]

[2853] The compound (10 mg) obtained in Example 11 was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (6 mg).

[2854] LC-MS (ESI, m / z) = 554.2 (M+H + ) .

[2855] Example 13. N-[2-(3-hydroxy-3-methylbutyl)-644-(2,2,2-trifluoroethyl)piperazine-!-yl]-2H-indazole-5-yl]-3-sulfamoylbenzamide

[2856]

[2857] Diisopropylethylamine (42 µL, 0.247 mmole) and dimethylformamide (1 mL) were added to the compound (60 mg, 0.1233 nmole) obtained from intermediate 1, and 2,2,2-trifluoroethyl trifluoromethanesulfonate (20 yL, 0.136 mmole) was added dropwise at 0°C and stirred at room temperature for 16 hours. After the reaction was finished, ethyl acetate (50 mL) was added, washed with purified water (50 mL), anhydrous magnesium sulfate was added, and filtered. After concentration under reduced pressure, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (40 mg).

[2858]

[2859] NMR (DMS0-d6): 1.12 (s, 6H), 1.99 (t, 2H), 2.50 (m, 2H), 2.82 (s, 4H), 2.90 (s, 4H), 4.40 (t, 2H), 4.47 (s, 1H), 7.43 (s, 1H) , 7.48 (s, 2H) , 7.77 (t , 1H) , 8.02 (d, 1H) , 8.14 (d, 1H) , 8.30 (s, 1H) , 8.39 (s, 1H) , 8.42 (s, 1H) , 9.87 (s, 1H) .

[2860] LC-MS (ESI, m / z) = 569.4 (M+H + ) .

[2861] Example 14. 3~sulfamoyl- N~[2~(4,4,4~trifluorobutyl)- 6~[4~(2,2,2~trifluoroethyl)pipherazine- !-yl]- 2H-indazol- 5 -yl ]benzamide

[2862]

[2863] Diisopropyl ethylamine (166 µL, 0.976 mmole) and dimethylformamide (2.7 mL) were added to the compound (133 mg, 0.244 mmole) obtained in [Step 4] of Example 5, and 2,2,2-trifluoroethyl trifluoromethanesulfonate (39 yL, 0.268 mmole) was added dropwise at 0°C and stirred at room temperature for 18 hours. After the reaction was finished, ethyl acetate (50 mL) was added, washed with purified water (50 mL), anhydrous magnesium sulfate was added, and filtered. After concentration under reduced pressure, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (95 mg).

[2864]

[2865] NMR (DMS0-d6): 2.10 (m, 2H), 2.25 (m, 2H), 2.82 (s, 4H), 2.91 (s, 4H), 3.30 (s, 2H), 4.43 (d, 2H), 7.46 (s, 1H), 7.48 (s, 2H) , 7.76 (t , 1H) , 8.02 (d, 1H) , 8.15 (d, 1H) , 8.32 (s, 1H) , 8.39 (s, 1H) , 8.43 (s, 1H) , 9.87 (s, 1H) .

[2866] LC-MS (ESI, m / z) = 593.2 (M+H + ) .

[2867] Example 15. N-{2-[(1,3-dioxolan-2-yl)methyl]-6-[4-(2-hydroxypropane-2-yl)piperidin-!-yl]-2H-indazole-5-yl}-3-sulfamoylbenzamide

[2868]

[2869] Step 1: Preparation of 2-(1-(5-nitro-1H-indazole-6-yl)piperidin-4-yl)propan-2-ol

[2870] 2-(4-piperidyl)-2-propanol (29.6g, 206.6mmole) and dimethyl sulfoxide (30mL) were added to 6-bromo-5-nitro-1H-indazole (10g, 41.32mmole) and stirred at 130°C for 22 hours. After the reaction was finished, ethyl acetate (100mL) was added, washed with purified water (100mL), anhydrous magnesium sulfate was added, and filtered. After concentration under reduced pressure, the product was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (8g).

[2871] Step 2: Preparation of 2-(1-(2-((1,3-dioxolan-2-yl)methyl)-5-nitro-2H-indazole-6-yl)piperidin-4-yl)propan-2-ol

[2872] To the compound (lg, 3.286 mmole) obtained in [Step 1] above, 2-(iodomethyl)-1,3-dioxolane (0.428 mL, 4.93 mmole), potassium carbonate (908 mg, 6.57 mmole), and dimethylformamide (10 mL) were added and stirred at 90°C for 15 hours. After the reaction was finished, ethyl acetate (50 mL) was added, washed with purified water (50 mL), anhydrous magnesium sulfate was added, and filtered. The title compound (364 mg) was obtained by purification using MPLC (CombiFlash NEXTGEN 300+).

[2873] Step 3: Preparation of 2-(1-(2-((1,3-dioxolan-2-yl)methyl)-5-amino-2H-indazole-6-yl)piperidin-4-yl)propan-2-ol

[2874] Dichloromethane (40 mL) and activated carbon palladium (40 mg, 0.2 w / w) were added to the compound (364 mg, 0.932 mmole) obtained in [Step 2] above, and hydrogenated by stirring at room temperature for 2 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain the title compound (336 mg).

[2875] Step 4: Preparation of N-{2-[(l,3-dioxolane-2-yl)methyl]-644-(2-hydroxypropane-2-yl)piperidin-:L-yl]-2H-indazole-5-yl}-3-sulfamoylbenzamide (Example 15) To the compound (336 mg, 0.932 mmole) obtained in [Step 3] above, 3-sulfamoylbenzoic acid (131 mg, 0.652 mmole), dimethylformamide (1.8 mL), EDC-HC1 (156 mg, 0.815 mmole), and H0Bt-H2O (110 mg, 0.815 mmole) were added and stirred at room temperature for 22 hours. After the reaction was finished, ethyl acetate (100 mL) was added and washed with purified water (100 mL), anhydrous magnesium sulfate was added and filtered. After concentration under reduced pressure, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (244 mg).

[2876]

[2877] NMR (DMS0-d6): 1.06 (s, 6H), 1.33 (q, 1H), 1.45 (q, 2H), 1.80 (d, 2H), 2.64 (t, 2H), 3.08 (d, 2H), 3.80 (t, 2H), 3.85 (t , 2H) , 4.11 (s, 1H) , 4.47 (s, 2H) , 5.27 (s, 1H) , 7.37 (s, 1H) , 7.45 (s, 2H) , 7.74 (t , 1H) , 8.01 (d, 1H) , 8.11 (d, 1H) , 8.25 (s, 1H) , 8.36 (s, 1H) , 8.45 (s, 1H) , 9.81 (s, 1H) .LC-MS (ESI , m / z) = 544.6 (M+H + ) .

[2878] Example 16. {6~[4~(2~hydroxypropane-2~yl)piperidin-1~yl]-2"[(oxane-2"yl)methyl]-2H-indazole-5-yl}-3-sulfamoylbenzamide

[2879]

[2880] Step 1: Preparation of 2-(1-(5-nitro-2-((tetrahydro-2H-pyran-2-yl)methyl)-2H-indazole-6-yl)piperidin-4-yl)propan-2-ol

[2881] Under the same conditions as [Step 2] of Example 15, 2-(bromomethyl)tetrahydro-2H-pyran (0.631 mL, 4.93 mmole), potassium carbonate (908 mg, 6.57 mmole), potassium iodide (100 mg, 0.6 mmole), and dimethylformamide (10 mL) were added to the compound (lg, 3.286 mmole) obtained in [Step 1] of Example 15, and after reacting in the same manner, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (420 mg).

[2882] LC-MS (ESI, m / z) = 403.2 (M+H + ) .

[2883] Step 2: Preparation of 2-(1-(5-amino-2-((tetrahydro-2H-pyran-2-yl)methyl)-2H-indazole-6-yl)piperidin-4-yl)propan-2-ol

[2884] Under the same conditions as [Step 3] of Example 15, dichloromethane (20 mL) and activated carbon palladium (126 mg, 0.3 w / w) were added to the compound (420 mg, 1.043 mmole) obtained in [Step 1] and reacted in the same manner to obtain the title compound (389 mg).

[2885] LC-MS (ESI, m / z) = 373.2 (M+H +) .

[2886] Step 3: Preparation of N-{6-[4-(2-hydroxypropane-2-yl)piperidin-1-yl]-2-[(oxane-2-yl)methyl]-2H-indazole-5-yl}-3-sulfamoylbenzamide (Example 16)

[2887] Under the same conditions as [Step 4] of Example 15, 3-sulfamoyl benzoic acid (252 mg, 1.25 mmole), dimethylformamide (3.9 mL), EDC-HCl (300 mg, 1.56 mmole), and HOBt 20 (2111, 1.56 mmole) were added to the compound (389 mg, 1.043 mmole) obtained in [Step 2], and after reacting in the same manner, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (272 mg).

[2888]

[2889] NMR (DMS0-d6): 1.06 (s, 6H), 1.19 (m, 1H), 1.42 (m, 8H), 1.76 (m, 3H), 2.64 (t, 2H), 3.07 (m, 2H), 3.75 (m, 2H), 4.11 (s, 1H) , 4.33 (t , 2H) , 7.36 (s, 1H) , 7.46 (s, 2H) , 7.73 (t , 1H) , 8.01 (d, 1H) , 8.12 (d, 1H) , 8.22 (s, 1H) , 8.36 (s, 1H) , 8.43 (s, 1H) , 9.81 (s, 1H) .

[2890] LC-MS (ESI, m / z) = 556.2 (M+H + ) .

[2891] Example 17. N-{2-[2-(l,3-dioxane-2-yl)ethyl]-6-[4-(2-hydroxypropane-2-yl)piperidin-!-yl]-2H-indazole-5-yl}-3-sulfamoylbenzamide

[2892]

[2893] Step 1: Preparation of 2-(1-(2-(2-(1,3-dioxane-2-yl)ethyl)-5-nitro-2H-indazole-6-yl)piperidin-4-yl)propan-2-ol

[2894] Under the same conditions as [Step 2] of Example 15, (2-iodoethyl)-1,3-dioxolane (0.428 mL, 4.93 mmole), potassium carbonate (908 mg, 6.57 mmole), and dimethylformamide (10 mL) were added to the compound (lg, 3.286 mmole) obtained in [Step 1] of Example 15, and stirred at 90°C for 15 hours. After the reaction was finished, ethyl acetate (50 mL) was added, washed with purified water (50 mL), anhydrous magnesium sulfate was added, and filtered. After concentration under reduced pressure, the compound was purified by MPLC (CombiFlash NEXTGEN 300+) to obtain the title compound (433 mg).

[2895] LC-MS (ESI, m / z) = 419.5 (M+H + ) .

[2896] Step 2: Preparation of 2-(1-(2-(2-(1,3-dioxane-2-yl)ethyl)-5-amino-2H-indazole-6-yl)piperidin-4-yl)propan-2-ol

[2897] Dichloromethane (40 mL) and activated carbon palladium (40 mg, 0...

Claims

【Claims】 【Claim 11 A compound represented by Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof: <Formula 1> In Formula I above, and, Xi and X2 are each independently C or N, Yi is C, N, O or S (wherein when Y1 is O or S, X2 is C), and the ring of A1 is unsubstituted or one or more rings may each independently be substituted with straight-chain or branched-chain -C1-C6 alkyl or halogen (-F, -Cl, -Br or -I); R is independently selected from the group consisting of straight-chain or branched-chain -C1-C6 alkyl, -CF3, -NO2, -S(=O)2-NRaRb, -S(=O)2CF3, -S(=O)2F, -ORc, a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N and O in the ring, a 6- to 10-membered aryl, -C(=O)NRdRe, -C(=O)OH, -C(=O)OCH3 or -CN, wherein Ra, Rb, Rc, Rd and Re are each independently -H, straight-chain or branched-chain -C1-C6 alkyl, -CF3, -CH2C(CH3)2OH or -NH2, and at this time the H of R is unsubstituted or one or more rings may each independently be substituted with straight-chain or branched-chain -C1-C6 alkyl, straight-chain or branched-chain -C1-C6 alkoxy, -OH or halogen (-F, -Cl, -Br or -I); Qi and Q2 are each independently -N- or -N(Li-R2)-, one of Qi and Q2 is _new_ and the other is _new(1丄1—1?2)_; Li is a monocrystalline or C1-C8 alkylene, and if Li is a C1-C8 alkylene, the H of Li is unsubstituted or one or more may each be independently substituted with a straight-chain or branched-chain -Cl- C6 alkyl, a halogen (-F, -Cl, -Br, or -I), or -0H; R2 is a 4- to 6-membered heterocycloalkyl containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of -H, straight-chain or branched-chain -Cl-C8alkyl, straight-chain or branched-chain -Cl-C6alkyl, OH, straight-chain or branched-chain -Cl-C6alkoxy, N and O, -CN, -0CH2C(=0)NRfRg, -S(=0)2Rh, -CH2CH2P(=0)(0CH2CH3)2, -CD3, -CH2CH2P(=0)(0CH20C(=0)C(CH3)3)2, a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of N, O and S, a C3 to C6 cycloalkyl, or a 6-membered It is a 10-membered aryl, wherein Rf, Rg, and Rh are each independently H or a straight-chain or branched-chain -C1-C6 alkyl, and the bolster of R2 is unsubstituted or one or more bolsters may each independently be substituted with a straight-chain or branched-chain -Cl-C6 alkyl or a halogen (-F, -Cl, -Br, or -1); R3 is -H, a straight-chain or branched-chain -Cl-C6 alkyl or a halogen (-F, -Cl, -Br, or -1), where R3 is unsubstituted or one or more complements may each be independently substituted with a straight-chain or branched-chain -Cl-C6 alkyl or a halogen (-F, -Cl, -Br, or -1); A2 is a 5- to 6-membered heterocycloalkylene containing 1 to 4 N atoms in the ring; L2 is a homogeneous, C1-C6 alkylene, -C(=0)-NRai-, -C(=0)0-, -C(=0)-, -NRa2C(=0)0-, -NRa3C(=0)-, -NRa4-, or -C(=0)-NRa5-CH2-, where Rai, Ra2, Ra3, Ra4, or Ra5 are each independently -H, straight-chain or branched-chain -C1-C6 alkyl, and the complement of L2 is unsubstituted or one or more complements may each independently be substituted with straight-chain or branched-chain -Cl-C6 alkyl or halogens (-F, -Cl, -Br, or -1); R4 is a 3- to 8-membered heterocycloal kyle containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of -H, straight-chain or branched-chain -Cl-C6alkyl, N, and O, C3-C8 cyclocycloal kyle, -(CH2)mC(=0)NRbiRb2(m is an integer from 1 to 6), -(CH2)pC(=0)0Rb3(p is an integer from 1 to 6), a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms in the ring independently selected from the group consisting of N, O, and S, -NRb4Rb5, -N(CH=CH2)2, -(CH2)qNRb6C(=0)0H(q is an integer from 0 to 6), -(CH2)rOH(r is 1 (integers from 1 to 6), - (CH2) sNH2(s is an integer from 1 to 6), - (CH2) tCN(t is an integer from 1 to 6), straight-chain or branched-chain -C1-C6 alkoxy, -C(CH3)20H, - CH2CF3, - (CH2)2CF3, -CF 3 I — NH2 , phenyl , -C(CH3)2Br , —OH , -CH2C(CH3)20H , -S(=0)2CH3, 0 or 0 and , here Rbi , Rb2 , " , Rb4, Rb5, and Rb6 are each independently H, straight-chain or branched-chain -Cl-C6alkyl, -CH2C(CH3)20H , -CH2CH2C(CH3)20H , -C(CH3)20H , -CH2CH2OH , -OH , C3-C8 cycloal kill , -CH2CF3 , -(CH2)2CF3 or -CF3 and , The R4 complement is unsubstituted or one or more complements each independently contain 1 to 4 heterocyclic alkyls in the ring independently selected from the group consisting of straight-chain or branched -Cl-C6alkyl, halogen (-F, -Cl, -Br, or -I), -C(=0)NH2, -S(=0)2NH2, -OH, -NH2, -CH(CH3)0H, -CH2OH, -C(=0)0C(CH3)3, straight-chain or branched -Cl-C6alkoxy, -CN, -OH, N, and 0, -S(=0)2CH3, It can be substituted with -CF3, or -S(=0)2CF3; R5 is a -H or straight-chain or branched-chain -Cl- C6 alkyl.

2. In claim 1, Ai in the above formula I is A compound represented by Formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates. 【claim Paragraph 3] The compound represented by Chemical Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, according to claim 1, wherein in Chemical Formula I, Ai is unsubstituted or one or more Ais may each independently be substituted with -CH3, -F, or -C1. 【Claim Item 4] The compound represented by Chemical Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, according to claim 1, wherein in Chemical Formula I, 日 is -S(=0)2NH2, -NO2, -OCH3, -S(=0)2CF3, -CF3, -S(=0)2NHCH3, -S(=0)2NHCH2CH3, -S(=0)2-F, -S(=0)2-N(CH3)2, -S(=0)2-NHCH2C(CH3)20H, -C(=O)-NH2, -C(=O)-NHCH3, -C(=O)-NHNH2, -C(=O)OH, -C(=O), unsubstituted or one or more 日s may each independently be substituted with straight-chain or branched-chain -C1-C6 alkyl, straight-chain or branched-chain -C1-C6 alkoxy, -OH or halogen (-F, -Cl, -Br, or -I). 【Claim Item 5] The compound represented by Chemical Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, according to claim 1, wherein Ll is a single bond, —CH2—, —(CH2)2—, —(CH2)3—, -(CH2)4 - or —CH2CH0H-, and when L1 is -CH2-, - (CH2)2-, - (CH2)3-, - (CH2)4 - or -OfeCHOH-, the A of L1 is unsubstituted or one or more As may each independently be substituted with straight-chain or branched-chain -C1-C6 alkyl, halogen (-F, -Cl, -Br or -I) or -OH. 【Claim Item 6] According to claim 1, in the above Chemical Formula I R2 is - H, - CH3, - CH2CH3, - (CH2)2CH3, - (CH2)3CH3, - CH(CH3)2, - CH2C(CH3)3, - C(CH3)20H, -CH2C(CH3)20H, -(CH2)2C(CH3)20H, -CHF2, - CF3, -CH2CHF2, -CN, - 0CH2C(=0)NH2, -CH2CF3, -(CH2)2CF3, -(CH2)3CF3, -(CH2)4CH3, -(CH2)5CH3, -0CH(CH3)2, -S(=0)2CH3, -OCH2CH2CH3, -CH2CH2P(=0) (0CH2CH3)2, -CD3, cheap and; and R3 is -H, -CH3, -CH2CH3, - (CH2)2CH3, - (CH2)3CH3, _ F, -CF3, -CH2CHF2, - (CH2)3CF3, or -CH(CH3)2; Here, R2 and R3 are each independently unsubstituted complements, or one or more complements can each independently be substituted with straight-chain or branched-chain Cl-C6 alkyl or halogens (-F, -C1, -Br, or -1), A compound represented by chemical formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates. 【claim Paragraph 7] In Paragraph 1, A compound represented by the formula I, wherein R2 and R3 are not simultaneously -H, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates

8. In claim 1, A2 in the above chemical formula I is A compound represented by I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates. 【Claim this In Paragraph 1, L1 is a unitary combination, -CH2-, -(CH2)2-, -(CH2)3- or -(CH2)4-; R2 and R3 are independently - H , - CH3 , - CD3 , - CH2CH3 , - C(CH3)20H , CH2C(CH3)20H , - (CH2)2C(CH3)2OH , - CF 3 I -CH2CF3, -(CH2KF3, -(CH2KF3, -CH2CHF2, -O CH(CH3)2, -OCH2CH2CH3, -CN, L2 is a unitary combination, -CH2-, -CH2CH2-, -C(=O)NH-, -NCH3- or -C(=o)- and ; R4는 - C(CH3)20H, -CF 3 I -CH2CF3, -(CH2)2CF3, -(CH2)3CF3 - CH(CH3)2 or - OH and ; A compound represented by the formula I, wherein R2 and R3 are not simultaneously -H, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates

10. In claim 9, in the above chemical formula I Ai is Ri is -S(=0)2NH2, -S(=O)2NHCH3, -NO2, A compound represented by chemical formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates.

11. In Paragraph 1, Li is a union; R2 and R3 are independently -H, -CH3, -CD3, -CH2CH3, -CH(CH3)2, -CH2CF3, or -CH2CHF2; L2 is unitary bond, - C(=o)- , - C(=O)NH- , - C(=0)N(CH3)- , - NHC(=O)- , - N(CH3)C(=0)- , -CH 2 I -CH2CH2- , -NH- , or - N(CH3)- and ; R4 is -CH3, -C(CH3)20H, -CH2C(CH3)20H, -CH2CF3, -CH2CH3, -CH(CH3)2, -CH2CN, (CH2)20H , -(CH2)2CF3, -CH2NH2 , -N(CH3)2 , -N(CH2C(CH3)20H)2 , - NH2 , - S(=0)2CH3 or -OH and ; A compound represented by the formula I, in which R2 and R3 are simultaneously non-H, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

12. In claim 11, in the above chemical formula I Ai is or , and the inner part of Ai may not be substituted or each independently be substituted with one or more inner parts -CH3, -F, or -C1; and Ri are -S(=0)2NH2, -S(=0)2NH(CH2C(CH3)20H), -S(=0)2NH(CH2CH3), / / S(=0)2NH(CH3), -S(=0)2F_C(=0)NH2, N A compound represented by H or formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

13. In claim 1, a compound represented by Formula I, wherein L2 in Formula I is a unit and is represented by the following Formula 1-1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof: [Chemical Formula 1-1] R4 is -H, — CH2CF3, -(CH2)2CF3, — CH3, CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, — (CH2)2CH(CH3)2, - N(CH=CH2)2, -(CH2)2S(=0)2CH3, -CH2CH2OH, -CH2CH2NH2, -C(CH3)2OH, - CH2C(CH3)20H, -(CH2)2C(CH3)2OH, -CH2CF3, -NH2, -CH2NH2, -OH, -CH2OH, -CH2NHCH3, -CH2N(CH3)2, _(CH2)NHC(=0)0H, _(CH2)2NHC(=0)0H, _(CH2)NHC(=0)C(CH3)3, — (CH2) N ( CH2C (CH3)20H)2, -NHCH2C (CH3) 2OH, -NHCH2CH2C (CH3) 2OH, -N (CH2CH2OH) 2, NHCH2CH2NH2 or - (CH2)2NHC(=0)C(CH3)3; R5 is - H or - CH3 and ; In the above chemical formula I-1, Al, L1, Q1, Q2, R1, R2, and R3 are each independently identical to the first.

14. In claim 1, a compound represented by Formula I, wherein L2 in Formula I is a C1-C3 alkylene and is represented by the following Formula 1-2, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof: [Chemical Formula 1-2] In the above chemical formula 1-2, ni is 1, 2, or 3, and ; R4는 - CH2CF3 , - CH3 , - CH2CH3 , -C(CH3)20H , - (CH2)NHC(=0)0H , (CH2)NHC(=0)C(CH3)3 , - (CH2)2NHC(=0)0H , -OH , -CH2OH , -CH2CH2OH , -(CH2)CH(CH3)2 , -(CH2)C(CH3)20H , -CF 3 I -S(=0)2CH3, -CH2S(=0)2CH3, -CH2NH2 , -CH2CH2NH2 , -NHCH2CF3 , -NHCH3, -N(CH3)2, -N(CH2C(CH3)20H)2, - It is NH2 and ; In the above chemical formula I-2, Al, L1, Q1, Q2, R1, R2, and R3 are each independently identical to Claim 1.

15. In claim 1, a compound represented by Formula I, wherein L2 in Formula I is -C(=o)- and is represented by the following Formula 1-3, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof: [Chemical Formula 1-3] In the above chemical formula I-3, (CH2)2CF3, -CH2CH(CH3)2, or -CH2C(CH3)20H; In the above chemical formulas 1-3, Al, L1, Q1, Q2, R1, R2, and R3 are each independently identical to Claim 1.

16. In claim 1, wherein 1 or in the above formula I is -C(=0)-NRai- and is represented by the following formula I-4, a compound represented by formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof: [Chemical Formula 1-4] Rai is -H, -CH3, -CH2CH3 or -CH2CH2CH3; R4 is -H, -OH, -CH3, -CH2CH3, -CH2CH2OH, -CH(CH3)2, -CH2C(=0)NH2, - CH2C(=0)NHCH3, _(CH2)2C(=O)NH2, _(CH2)2C(=0)0CH3, > o -CH2CH(CH3)2, -CH2C(CH3)20H, - CH2CH2NH2, -0H, - CH2CH3, -CH2CF3, -(CH2)2CH3, -CH2CF3, -(CH2)2CF3, -C(CH3)2CH2CH3, -C(CH3)2CH20H, - C(CH3)2CH2CH20H , - (CH2)3CE(3 , - (CH2)4NH2 or - CH2CH2S(=0)2CH3 and ; In the above chemical formula I-4, Al, L1, Q1, Q2, R1, R2, and R3 are each independently identical to Claim 1.

17. According to claim 1, in Formula I, L1 is -C(=O)-NRa5-(CH2)-, and is represented by the following Formula 1-5. A compound represented by Formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates: [Formula 1-5] In Formula 1-5 above, A1 In Formula 1-5 above, A1, L1, Q, Q2, R1, R2 and R3 are each independently the same as in claim 1.

18. According to claim 1, in Formula I, L2 is -C(=O)O-, and is represented by the following Formula 1-6. A compound represented by Formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates: [Formula 1-6] R4 is -H, -CH3, or -CH2CH3; In Formula 1-6 above, A1, L1, Q, Q2, R1, R2 and R3 are each independently the same as in claim 1.

19. According to claim 1, in Formula I, L2 is -NRa3C(=O)-, and is represented by the following Formula 1-7. A compound represented by Formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates: [Formula 1-7] In Formula 1-7 above, Ra3 is -H or -CH3; R4 is -H, -CH3, -CF3, -CH2CH3, -CH2CF3, - (CH2)2CH3, - (CH2)2CF3, - In Formula 1-7 above, A1, L1, Q, Q2, R1, R2 and R3 are each independently the same as in claim 1.

20. According to claim 1, in Formula I, L2 is -NRa4-, and is represented by the following Formula 1-8. A compound represented by Formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates: [Formula 1-8] In Formula 1-8 above, Ra4 is -H or -CH3; R4 is -H, -CH3, -CF3, -CH2CH3, -CH2CF3, - (CH2)2CH3, - (CH2)2CF3, - ( CH2)C(=0)NH2, -C(CH3)3, -C(CH3)2Br, -CH2OH, In Formula I-8, Ai, Li, Qi, Q2, RI, R2 and R3 are each independently the same as in Claim 1.

21. According to Claim 1, in Formula I L2 is -NRa2C(=0)0-; Ra2 is each independently -H or -CH3; R4 is -H, -CH3, -CF3, -CH2CH3, -CH2CF3, - (CH2)2CH3, - (CH2)2CF3, - (CH2)C(=0)NH2, -C(CH3)3, -C(CH3)2Br = / —ah 3 N, a compound represented by Formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates.

22. A compound represented by Formula I, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates: <Formula I> In Formula I above, Ri is -S(=0)hNH2, -NO2 or -C(=0)-NHCH3; Qi is N—L]—R2, and Q2 is Shi; L1 is a single bond, -CH2-, - (CH2)2-, - (CH2)3 - or - (CH2)4 -; R2 is -H, -CH3, -C(CH3)2OH, -CH2C(CH3)2OH, - (OfehCXOfehOH, -CF3, -CH2CF3, - (CH2)2CF3; R3 is —H; L2 is a single bond, C1-C3 alkylene, -C(=0)-, -C(=0)-NRai-, -C(=0)-NRa5-(CH2)- or -NRa3C(=0)-; The above Rai, Ra3 and Ra5 are each independently -H or -Ofe; -(CH2)2NH2, - (CH2)4NH2, -NH2, -CH2OH, or R5 is —보이다.

23. A compound represented by formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof: <Formula 1> In formula I above, Ai may be unsubstituted or each independently may be substituted with one or more of -CH3, -F, or -C1; RI is -S(=O)2W -S(=O)2NHCH3, -NO2, / N NH and the moieties of the day are not substituted or each of one or more moieties can be independently substituted with a straight-chain or branched-chain -Cl-C6alkyl, straight-chain or branched-chain -Cl-C6alkoxy, -OH or halogen (-F, -Cl, -Br, or -I); Qi is N-L]-R2 and Q2 is Ni; L1 is a single bond, -CH2-, - (CH2)2-, - (CH2)3 - or - (CH2)4 -; R2 and R3 are independently - H , - CH3 , - CD3 , - CH2CH3 , - C(CH3)20H , CH2C(CH3)20H , - (CH2)2C(CH3)2OH , - CF 3 I -CH2CF3, - (CH2KF3, - (CH2KF3, -CH2CHF2, - CH(CH3)2, -OCH2CH2CH3, -CN, L2 is a single bond, -Ofc-, -CH2CH2-, -C(=O)NH-, -NCH3- or -C(=0)-; R4 is - C(CH3)20H, -CF 3 I -CH2CF3 , -(CH2)2CF3 , -(CH2)3CF3- CH(CH3)2 or -OH and ; R2 and R3 are not both me at the same time.

24. The compounds shown in the following table, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof: Example Structure Name Example O N-[2-( 3-hydr oxy— 3— me t hy 1 butyl )-6 - [4-(2- HO 、 hydr oxyacetyl )piperazin— 1— yl ]— 2H— indazol— 5 — A^ yl]-3-sulfamoylbenzamide 1 N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2-hydroxy… meaning "woo" 011 -acetyl)piperazin-1-yl]-2H-indazol-5-yl]-3-cAQ sulfopamo ylbenzamide N— {6 — [4— (2— aminoacetyl )piperazin— 1— yl ]— 2 — 0 H2N、A N 으 ( 3-hydr oxy-3-methyl butyl )— 2H— indazol— 5— yl}- HC1 〔 스 스 、 T 3- su 1 f amoylbenzamide hydrochloride 2 N- {6 - [4- (2 -aminoacetyl)piperazin -1-yl]- 2 - H2N,〈9 H heart』 has OH d ~Q Song (3-hydroxy-3-methylbutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide hydrochloride N— {6 — [4— (2— aminoacetyl )piperazin— 1— yl ]— 2 — 0 H2N』g (3-hydroxy-3-methyl butyl)— 2H— indazol— 5— yl}- 3- sul famoylbenzamide 3 N- {6 - [4- (2-aminoacetyl)piperazine -1-yl]- 2 - H W Myos ' U 011 (3-hydroxy-3-methylbutyl)-2H-indazole-5-yl}-4- 6 Outside 0° Alcohol Famo Ilvenza Mid 0 N- [ 2- (3-hydroxy-3-methyl butyl ) - 6 - [ 4- ( 4, 4, 4 - gus trifluorobutanoyl ) piperazin— 1-y l ] — 2H— Ap i ndazo 1 -5-yl ] — 3— sul famoy 1 benz am i de 4 f "n 、 / N- [2- (3-hydroxy- 3-methylbutyl)- 6 - [4- (4, 4, 4-t H2N / sasuga OH rifluorobutanoyl)piperazin -1-yl]- 2H-indazol -5 -yl]- 3 —sulfamoylbenzamide N—{6—[4—(2—aminoacetyl)piperazin—1—yl]—2—0 HCl H2N to now (4,4,4-trifluorobutyl)-2H-indazol-5-yl}~3~sulfamoyl benzamide hydrochloride 0 N-{6-[4-(2-Aminoacetyl)piperazin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3- 2 才 〕 Qf^° F sulfonyl pamoic acid benzamide hydrochloride o N—{6—[4—(2—aminoacetyl)piperazin—1—yl]—2—H2N, Ag (4,4,4-trifluorobutyl)-2H-indazol-5-yl}~3~sulfamoyl benzamide Back Of— o HN person ni ~ 7 , self N - {6 - [4 - (2 - aminoacetyl)piperazin - 1 - yl] - 2 - (4,4,4 - trifluorobutyl) - 2H - indazol - 5 - yl} - 3 - H 7 "o > Sulfamoylbenzamide N- {6 - [4- (2- aminoethyl )piperazin- 1- yl]- 2- (3 - H2N^^ N ^ hydroxy— 3— methylbutyl )—2H— indazol— 5— yl}~3~ su 1 f amoy 1 benz am i de dihydrochloride N- {6 - [4- (2-aminoethyl)piperazine -1-yl]- 2- (3 - H—9 = 0H Hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3—sulfamoylbenzamide 2 hydrochloride N- {6 - [4- (2- aminoethyl )piperazin- 1- yl]- 2- (3 - H2N^^ N ^ hydroxy— 3— methylbutyl )—2H— indazol— 5— yl}~3~ 으 su 1 f amoy 1 benz am i de Y 〕5 A / H2N、〈9 Hf 」 7 'number 011 N- {6 - [4- (2-aminoethyl)piperazine -1-yl]- 2- (3 - <AQ 수 히드 록시- 3 -메틸부틸)- 2H-인다졸- 5 -일}- 4 —술파 모일 벤 즈아 미드 N- {6 - [4- (2- aminoethyl )piperazin- 1- yl]- 2- (3 - H2N、F N ^ hydroxy—3—methylbutyl)—2H—indazol—5—yl}~3~nitrobenzamide dihydrochloride / O HN<S (OH N-{6 - [4-(2 -aminoethyl)piperazin -1-yl]-2-(3 -hydroxy-3 -methylbutyl)-2H-indazol-5-yl}-3 -nitrobenzamide 2 hydrochloride N- {6 - [4- (2- aminoethyl )piperazin- 1- yl]- 2- (3 - H2N^^ N ^ hydroxy—3—methylbutyl)—2H—indazol—5—yl}~3~nitrobenzamide O HN、—E- ( / OH N-{6 - [4-(2 -aminoethyl)piperazin -1-yl]-2-(3 -(AQ hydroxy-3 -methylbutyl)-2H-indazol-5-yl}-4 -nitrobenzamide N— {6 — [4— (2— aminoethyl )piperazin— 1— yl]— 2 — H2N^^ N ^ (4,4,4-Trifluorobutyl)-2H-indazol-5-yl}~3~sulfamoylbenzamide dihydrochloride H2N、&9 1 N-{6-[4-(2-Aminoethyl)piperazin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide dihydrochloride 0 HC1 F F HCl Sulfamoylbenzamide 2 hydrochloride N— {6 — [4— (2— aminoethyl )piperazin— 1— yl]— 2 — H2N^^ N ^ (4,4,4- tr i fluorobutyl )- 2H- indazol- 5- yl}~3~ su 1 f amoy 1 benz am i de ": Of— o HN people丄으'己N- {6 - [4- (2 - aminoethyl)piperazin -1 - yl]- 2 - 머人'으、스三V F 6' TjP° F F (4,4, 4-trifluorobutyl)-2H-indazol-5-yl}-3 -sulfamoylbenzamide N-[2-(3-hydroxy-3 -methylbutyl)-6 - [4-(2, 2, 2-trifluoroethyl)piperazin—1—yl]—2H—indazol— 5-yl] —3—sulfamoylbenzamide H2N. S P ppa" su OH N- [2- (3-hydroxy- 3-methylbutyl)- 6 - [4- (2, 2, 2 -t 6 Rifluroethyl) Piperazine-1-yl]-2H-Indazole-5-「° yl]-3-sulfamoylbenzamide 3-sul famoyl - N- [ 2- ( 4, 4, 4- trifluorobutyl ) - 6 - [ 4- ( 2, 2, 2- trifluoroethyl ) piperazin- 1- yl ] - 2H- indazol -5-yl ] benzamide H2N、 S P 妙스 三 야 3 —sulfamoyl- N- [2- (4, 4, 4 -trifluorobutyl)- 6 - / 유 0 서 [4- (2, 2, 2 -trifluoroethyl)piperazin -1 -yl]- 2H-indazol - 5 -yl ]benzamide 『잇아 N— {2 — [(1,3— di oxo lan— 2— yl ) methyl ]— 6— [4— (2 — hy dr oxyp r op an- 2~y 1 )piper idin— 1— yl ]— 2H— i ndazo 1 -5-yl}~3~su 1 f amoy 1 benz am i de N- {2 - [(1,3-dioxolan- 2 -yl)methyl]- 6 - [4- (2 -hydr HN '° mg 、 s 7 ^~0 N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(oxan-2-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(oxan-2-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1- H2N、 S ε₀ N-{2-[2-(1,3-dioxan-2-yl)ethyl]-6-[4-(2- H L*, hydroxyprop an-2-yl)piperidin—1-yl]—2H—T세 indazo 1-5-yl}—3—sulfamoy 1 benz amide o HN人니 〜 7 N-{2-[2-(1,3-dioxan-2-yl)ethyl]-6-[4-(2-hydroxyprop an-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide N-{2-[2-(carbamoylinethoxy)ethyl]-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide N- {2 - [2-(carbamoylmethoxy)ethyl]- 6 - [4- (2 -hi H W I V A / Droxypropane-2-yl)piperidine-1-yl]-2H-indazole- 6 XJ ° NH2 5 -il}- 3-sulfamoylbenzamide N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2 - [2-(propan-2-yloxy)ethyl]-2H-indazol-3-yl}-3-sulfamoylbenzamide N 、스 、斗% N. / -0 5-yl}— 3— sulfamoylbenzamide H N O HNXX N N-{6-[4-(2-Hydroxypropan-2-yl)piperidin-1-yl]-2-[2-(propan-2-yloxy)ethyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide HOJ N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(2,2,2-trifluoroethyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide „ x T o T H TX N T >、 H N 、스> 으 / N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidin- 1- 2 、소 L yl]- 2- (2, 2, 2 -trifluoroethyl)- 2H-indazole- 5 - d'^Q 스 yl}- 3-sulfamoylbenzamide N-[2-(2,2-difluoroethyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide N-[2-(2,2-difluoroethyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]- d — 0 3-sulfamoylbenzamide N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(2-methanesulfonylethyl)-2H-indazol-8-yl}-3-sulfamoylbenzamide H —9丁5-yl}—3—sulfamoylbenzamide o HN people 』 7 N- {6 - [4- (2-hydroxypropane- 2-yl )piperidine- 1-yl]- 2- (2-methanesulfonylethyl)- 2H-indazole- 5-yl}- 3-sulfamoylbenzamide N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(2-propoxyethyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide XT— N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1- … '° neu yl ] -2- (2 -propoxyethyl)- 2H-indazole- 5 -yl}- 3 —alcohol — person 0 Ne Famo Ilvenza Mid N-[2-(3-cyanopropyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide HN o “, / N-[2-(3-cyanopropyl)-6-[4-(2-hydroxypropyl)H2N, must L N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-[(oxan-2-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide sulfamoylbenzamide HO J N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide I L N’”-\ N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide 1-1 is N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(oxan-4-yl)-2H-indazol-5-yl}-3- yl]-2-(oxan-4-yl)-2H-indazol-5-yl}-3- oxo-N / -nitrobenzamide 『 >--< 0 o i-ir s''~’ N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(oxan-4-yl)-2H-indazol-5-yl}-3-nitro 0*、厂 『s0 benzamide 丄 IICL | N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(oxan-4-yl)-2H-indazol-5-yl}-3-sulfamoylbenzamide 7 / -,, sulfamoylbenzamide tw XX, N That P N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1- I-LM. / ? yl]-2-(oxan-4-yl)-2H-indazol-5-yl}-3-sulfamoylbenzamide 'V' HOJ N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(propan-2-yl)-2H-indazol-5-yl}-3-、丄 ''弓 :s、、广』、 I / sulfamoylbenzamide N— ( TT AT N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1- 0 HN 〜' ■ yl]- 2-(propane- 2 -yl)- 2H-indazole- 5 -yl}- 3 —sulfa o : ( u Moil Ben Zua Mid %, 』 HO J N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-nitrobenzamide [L N — O s아' 斗서''’" N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-( )A 厂 AQ yl]-2-methyl-2H-indazol-5-yl}-3-nitrobenzamide 〔''는.,』 HO、 J N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3- I、.•소、— 、 ◎. sulfamoylbenzamide 서 N — HN'、"' 」 N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-H)N P yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide amide 는 。 HOj N-{2-ethyl-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide L. L N----』 0 IN" 人'저'' N-{2-ethyl-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide N-{6-[4-(2-cyano-N— methylacetamido)piperidin-1-yl]-2,3-dimethyl—2H-indazol-5-yl}~3~ sulfamoylbenzamide N-{6-[4-(2-cyano-N-methylacetamido)piperidin-1-yl]-2,3-dimethyl-2H-indazol-5-yl}-3-sulfamoylbenzamide d幻 승 딘-1-yl]-2,3-dimethyl-2H-indazol-5-yl}-3-sulfamoylbenzamide N- (2-methyl- 6 - {4- [methyl (3,3,3- tr if l uor opropy 1 ) am i no ] pi per idi nly 1}— 2H— i ndaz o 1 — 5— y 1 ) ~3 - su 1 f amoy 1 benz am i de N- (2-methyl- 6 - {4 - [methyl (3,3, 3-trifluoroprop H2N、 S P Phil )Amino] Piperidine- 1-yl}- 2H-Indazole- 5-yl )-3 - o^Qr^ 0 Sul Pamo Ilben Zua Mid N-(2-methyl-6-{4-[methyl(3,3,3-trifluoropropyl)amino]piperidin-1-yl}-2H— —佔 indazol-5-yl)-3-(1H-1,2,3,4-tetrazol-5-F令 N _ yl)benzamide N'NH N-(2-methyl-6-{4-[methyl(3,3,3-trifluoropropyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-(1H-1,2,3,4-tetrazol-5-yl)benzamide 101-[2-(3-hydroxy-3-methylbutyl)-5-(3-A』Y斗 nitrobenzamido)-2H-indazol-6-yl]—N—(propan— 2-yl)piperidine-4-carboxamide H u rr NA / 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-nitrobenz 0 HN스스 \&0H [2-(3-hydroxy-3-methylbutyl)-6-[4- (morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-6-yl]-N-(propan-2-yl)picolin-4-carboxamide N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide N- (6 - {4 - 0 [(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol- 5-yl)-3-sulfamoylbenzamide H2N、 S P H heart 』 가 OH It should be noted that the text in has some unclear or incorrect expressions in the original, but the translation is carried out according to the rules. N- (6 - {4 - [(carbamoylmethyl)carbamoyl]piperi d 「 ° din- 1-yl}- 2- (3-hydroxy- 3-methylbutyl)- 2H-indazole- 5-yl )-3-sulfamoylbenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-(4-{[(1R)-1- S P 떠 』 가 OH N-[2-(3-hydroxy-3-methylbutyl)-6-(4-{[(1R)-1- d 「 °(methyl carbamoyl)ethyl]carbamoyl}piperidin-1-yl)-2H-indazol-5-yl]-3 —sulfamoylbenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-(4-H 0 It should be noted that the original text seems to be rather jumbled and may contain some errors or unclear parts, which makes the translation a bit challenging to present in a perfectly coherent form. {[(methylcarbamoyl)methyl]carbamoyl}piperidin-1-yl)-2H-indazol-5-yl]- 3 — sulfamoylbenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-(4-{[(methylcarbamoyl)methyl]carbamoyl}piperidin-1-yl)-2H-indazol-5-yl]- d s 、Q S) 011 Carbamoyl)methyl]carbamoyl}piperidine—!—yl)— 2H- indazole- 5 -yl]- 3 -sulfamoylbenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-[4- (morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide N- [2- (3-hydroxy- 3-methylbutyl)- 6- [4-(morpholine a I 7 Persher -4 -carbonyl)piperidin- 1-yl]- 2H-indazole- 5 -yl]- o 3-sulfamoylbenzamide Now h N—{1—[2—(3—hydroxy—3—methylbutyl)—5—(3—sulfamoylbenzamido)—2H—indazol—6—yl]piperidin—4—yl}morpholine—4—carboxamide N-{1—[2—(3 - hydroxy - 3 - methylbutyl)—5—(3 —sulfamoylbenzamido)—2H—indazol—6—yl]piperidin—4—yl}morpholine—4—carboxamide H2N / shu It should be noted that there seem to be some garbled or unclear parts in the original text (such as "히드록시", "메틸부틸", "술파모 H2N / 슈"), which may affect the accuracy of the overall translation and understanding. If possible, it is recommended to clarify the original text for a more precise translation. [[2-(3-hydroxy-3-methylbutyl)-6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-6-yl]piperidin-4-yl]morpholine-4-carboxamide N—{1 — [2— (3— hydroxy— 3— methylbutyl )—5— (3 — [『今 H su 1 f amoy 1 benz am i do ) — 2H— i ndazo 1 —6 — N A N 으 yl ]piper idin— 4— yl}pyr idine— 3— carboxamide o � 세 幻 N-{1- [2- (3-hydroxy- 3-methylbutyl)- 5- (3 —sulfamo % N / 'S' 9 count 1 Oh, oh 011 Ilben zua mido)- 2H-indazole- 6 -il]piperidine- 4 -il}pyridine- 3 -carboxamide N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2-H hydroxyacetamido)piperidin-1-yl]—2H—HO"YY、I i ndazo 1 -5-yl ] — 3— su 1 f amoy 1 benz am i de N- [2- (3-hydroxy- 3-methylbutyl)- 6 - [4- (2-hydroxy w ppa 」 g 011 Cyacetamido) Piperidine-1-yl]-2H-indazole-5- 6 「 ° day ] -3 —sulfamoylbenzamide (2S)-N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidin-4-yl}-5-oxopyrrolidine-2-carboxamide 0 p느』 乂 、 广 N carboxamide (2S)-N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(3- S X broad 0 sulfamoylbenezamido)-2H-indazol-6-yl]piperidin-4-yl}-5-oxopyrrolidine-2-carboxamide N-{6-[4-(2-aminoacetamido)piperidin-1-yl]-H2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-wvy斗 yl}-3-sul f amoylbenzamide hydrochloride N- {6 - [4- (2-aminoacetamido)piperidine- 1- u XT o HN H 2 N '&' JL OH 1]- 2- (3-hydroxy- 3-methylbutyl)- 2H-indazole- 5 - O' YJ] 0 HC1 1}- 3 — Sulfamoylbenzamide hydrochloride HN-{6-[4-(2-aminoacetamido)piperidin-1-yl]-H—Y斗2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide 으YT— / … "f 7 = ° H N- {6 - [4- (2-aminoacetamido)piperidine- 1- (AQ sul]- 2- (3-hydroxy- 3-methylbutyl)- 2H-indazole- 5- yl}- 3-sulfamoylbenzamide N—{6—[4—(2-cyanoacetamido)piperidin—1—yl]—H 2 - (3-hydr oxy-3-me t hy 1 but y 1 )- 2H- indazol- 5 - 스 r N 「 yl}-3-sul f amoylbenzamide H2N / H心스가OH N-{6-[4-(2-cyanoacetamido)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-H2H-indazol-5-yl}-3-sulfamoylbenzamide N-(6-{4-[(carbamoylmethyl)amino]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H—H2N쓰"^스 i ndaz o 1 — 5— y 1 ) ~3 - su 1 f amoy 1 benz am i de 으 Y 〕、 N- (6 - {4 - [(carbamoylmethyl)amino]piperidin- 1- H W ppa 』 Seo 4 OH 1}- 2- (3-hydroxy- 3-methylbutyl )- 2H-indazole- 5 - 「 1)- 3-sulfamoylbenzamide N—[2—(3-hydroxy—3—methylbutyl)-6-[4-(2-H hydroxyacetamido)piperidin-1-yl]—2H—HO今o으紀]indazo1—5—yl]~3~nitrobenzamide 0HN丄으으、-(OHN-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2-hydroxyo'牛Q승시아세트아미도)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide N- [ 2- ( 3-hydr oxy-3-methyl butyl ) - 6 - [ 4- ( 4 , 4 , 4 - tr if luorobut anam i do ) p i per i d i n-l-y 1 ] -2H- 흐 스 Ap i ndazo 1 -5-yl ] — 3— su 1 f amoy 1 benz am i de O 〔VyYq 으오 011 N- [2- (3-hydroxy- 3-methylbutyl)- 6 - [4- (4, 4, 4 -t H2N, S P Myosu Ripple Ruoro Bhutana Mido) Pi Peri Din- 1-il]- 2H-inda d "O people 0 Zol- 5 -il]- 3 —sulfamoylbenzamide N— [2— (3— hydroxy— 3— methyl butyl )—6 — {4— [(2, 2, 2~tr if luoroethyl ) amino] pi per id in- 1- y 1}-2H- indazo 1 — 5— y 1 ] — 3— su 1 f amoy 1 benz am i de eu Yy— / N- [2- (3-hydroxy- 3-methylbutyl)- 6 - {4 - [(2, 2, 2 - H2N、〈9 므세 … '수 011 [Triplouroethyl )amino]piperidine-1-yl}-2H-indazole-5-yl]-3-sulfamoylbenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3,3,3-H It should be noted that some of these chemical names seem rather complex and might potentially have errors or be in an unusual format in the original text, which could make the translation a bit challenging to ensure absolute accuracy in the context of chemical nomenclature. trifluoropropanamido)piperidin—1—yl]—2H—pyr N 1H—indazol—5—yl]—3—nitrobenzamide f ° 0 」n HN丄으 、* 으- / (OH N- [2- (3 -hydroxy- 3 -methylbutyl)- 6 - [4- (3, 3, 3 -트 °"牛 Q 人 0 rifluoropropanamide) piperidin-1-yl]- 2H-indazol- 5 -yl]- 3 -nitrobenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3,3,3-H dtrifluoropropanamido)piperidin-1-yl]-2H-nr- indazo1-5-yl]-3-sulfamoylbenzamide F 0 / H2N. S P Sassuga OH N- [2- (3-hydroxy- 3-methylbutyl)- 6- [4- (3,3,3-trifluoropropanamide) piperidin- 1-yl]- 2H- phosphate C Sdazole- 5-yl]- 3-sulfamoylbenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3,3,3-H S—(trifluoropropanamido)piperidin—1—yl]—2H— f indazol—5—yl]—3—(methylsulfamoyl)benzamide °心 N rr_ / HoHN人느 으 、-(OHN-[2-(3-hydroxy-3-methylbutyl)-6-[4-(3,3,3-trisho trifluoropropanamido)piperidin-1-yl]-2H-indazol-5-yl]-3-(methylsulfamoyl)benzamide N—{1—[2—(3—hydroxy—3—methylbutyl)—5—[3—(1H—imi dazol—5—yl)benzamido]—2H—indazo1—6—yl]piperidin—4—yl}pyridine—3—carboxamide o 으 Secondary 'NH^-COH N-{1-[2-(3-hydroxy-3-methylbutyl)-5-[3-(1H-imidazol-5-yl)benzamido]-2H-indazol-6-yl]piper N ^Q sherrydine-4-yl}pyridine-3-carboxamide N—{1 — [2— (3— hydroxy— 3— methylbutyl )—5— (4— methy 1 — 3— su 1 f amoy 1 benz am i do ) — 2H— i ndazo 1 —6 — yl ]piper idin— 4— yl}pyr idine— 3— carboxamide 0 으 / N-{1- [2- (3-hydroxy- 3-methylbutyl)- 5- (4-methyl- % N 'S P Ppu 」 Ga OH 3 —sulfamoylbenzamido)-2H-indazol-6-yl]piperi / j o din-4-yl}pyridine-3-carboxamide N-{6-[4-(3-hydroxy—3 — methy 1 but anam i do )p i per i d in-l-y 1 ]— 2— (3 — H(? > r''g N '{『''스 hydroxy— 3— methylbutyl )— 2H— indazol— 5— yl}~3~ su 1 f amoy 1 benz am i de H2N, 〈9 H Y, ’person 7 Ka 011 N-{6-[4-(3-hydroxy-3-methylbutanamido)piperidino s xr o din-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3 —sulfamoylbenzamide It should be noted that the original text seems to have some unclear or incorrect parts, which may affect the accuracy of the translation. N—{6—[4—(2—cyanoacetamido)piperidin—1—yl]— 스 / 으 2—methyl—2H—indazol—5—yl}~3~nitrobenzamide 0 느 Yy 丄 N-{6-[4-(2-cyanoacetamido)piperidin-1- 0HN= yl]-2-methyl-2H-indazol-5-yl}-3-nitrobenzami IS °'Awesome Q Person 0 ​ N-{1-[2-Methyl-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidin-4-yl}pyridine-3-carboxamide Ay. HN—{6—[4—(2-Cyanoacetamido)piperidin-1-yl]—2-methyl—2H-indazol-5-yl}~3~ 0 Nausea_sulfamoylbenzamide U XT UAT 乂丄 乂 처느 / N- {6 - [4- (2 -cyanoacetamido)piperidin-1-yl]} -o HN, 스 -2-Methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide HN—{6—[4—(2-Cyanoacetamido)piperidin-1-yl]— 2-Methyl—2H-indazol-5-yl}-4-methyl-3-sulfamoylbenzamide „ XT o HN, SN-{6-[4-(2-cyanoacetamido)piperidin-1- H 2 N ''Y L I ]-2-methyl-2H-indazol-5-yl}-4-methyl-3 —sulfamoyl … benzamide N—{6—[4—(2-Cyanoacetamido)piperidin-1-yl]—2-methyl—2H-indazol-5-yl}-4-fluoro-3-sulfamoylbenzamide H N OH N XX N - N- {6 - [4- (2-cyanoacetamido)piperidin- 1-yl]- 2-methyl- 2H-indazole- 5-yl}- 4-fluoro- 3-sulfamoylbenzamide H 4-chloro-N-{6 - [4-(2-cyanoacetamido)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide u 、 T OTH TXNT人、느 / 스''스느 / 4-chloro-N-{6 - [4-(2-cyanoacetamido)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide w ° N—{6—[4—(2-Cyanoacetamido)piperidin-1-yl]—2-methyl—2H-indazol-5-yl}-2-methyl-3-sulfamoylbenzamide Et CO-N-{6-[(-2-Cyanoacetamido)piperidin-1-yl]oIHN人』으 -2-Methyl-2H-indazol-5-yl}-2-methyl-3-sulfamoylbenzamide ☆ Day 0 N—{6—[4—(2-Cyanoacetamido)piperidin-1-yl]— 2-Methyl—2H-indazol-5-yl}-2-fluoro-5-sulfamoylbenzamide baby U XT 0 eo T CC N H TX N T people H N , b-personnel y - N- {6 - [4- (2 - cyanoacetamido) piperidine-1-2, must L -]- 2 - methyl-2H-indazol-5-yl}-2 - fluoro-5 — sulfophenyl benzamide 0 N—{2—[2—(morpholin-4-yl)ethyl]—6—[4—(morpholine-4-carbonyl)piperidin-1-yl]—2H—([1,2]b]indazol-5-yl}—3—sulfamoylbenzamide N-{2 - [2-(morpholin-4-yl)ethyl]- 6 - [4-(morpholine-4-carbonyl)piperidin-1-yl]- 2H-indazol-5-yl}- 3 -sulfamoylbenzamide N- (6 - {4 - [(carbamoylmethyl ) carbamoyl ]piperidin-l- H2N rrV yl}- 2- [2- (morphol in- 4- yl )ethyl ]- 2H- indazol- U、i o 〔" YW N으—p 5-y 1 ) — 3— su 1 f amoy 1 benz am i de H2N —、 S P Myosusu N- (6 - {4 - [(carbamoylmethyl)carbamoyl]piperidin- 1-yl}- 2 - [2-(morpholine- 4-yl)ethyl]- 2H-indazole- 5-yl )-3 —sulfamoylbenzamide N—methyl—1—[5—(3—sulfamoylbenzamido)—1—?F (2,2,2-trifluoroethyl)—1H—indazol—6—yl]piperidine—4—carboxamide N-methyl- 1- [5- (3 —sulfamoylbenzamido)- 1-20 JO HN.P 허 (2,2,2-trifluoroethyl)- 1H-indazol- 6 -yl]piperidine- 4 -carboxamide N-[2-(2,2-difluoroethyl)-6 - [4-(4- 0 hydroxypiperidine-1-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide H(」三 1 서 三 弓 令 새 汝스- 旦 It should be noted that the text you provided seems to be rather jumbled and may contain some incorrect or unclear parts. This translation attempts to deal with it as accurately as possible based on the given rules. 0 HN people people 7 N- [2-(2,2-difluoroethyl)-6-[4-(4-hydroxypiperidin-1-carbonyl)piperidin-1-yl]-2H-indas ssol-5-yl]-3-sulfamoylbenzamide N-[2-(2,2-difluoroethyl)-6 - {4 - [4-(2- O hydroxyp rop an-2~yl)piperidine—1— carbonyl]piperidin-l-yl}-2H-indazol-5-yl]~ 才 O 人 수 F 3-sulfamoylbenzamide HoT H2N._P OH 1 JjoNXX N N- [2-(2,2-difluoroethyl)-6-{4-[4-(2-hydrochloric acid)cipropan-2-yl)piperidin-1-carbonyl]piperidin-1-yl}-2H-indazole-5-yl]-3-sulfamoylbenzamide 1—[2—(2,2—difluoroethyl)—5—(3 — H °'N cattle F su 1 f amoy 1 benz am i do) — 2H— i ndazo 1 — 6— y 1 ] — N— H heart N Y i :>=N. 스— 조 hydroxyp i per i d ine— 4— carboxam i de It should be noted that some of the text in the original seems rather unclear or potentially contains errors in formatting or chemical naming, which may affect the overall comprehensibility of the accurate translation. 1- [2-(2, 2 -difluoroethyl)- 5-(3 —sulfamoylbenz O HNX H2N P m 〕 으 、 스 스 amido ) -2H-indazol- 6 -yl ]- N-hydroxy piperidine- 4 -carboxamide 1—{1 — [2—(3-hydroxy—3—methylbutyl)—5—(3 — O 0 sulfamoylbenzamido) — 2H— indazo 1 —6 — yl]piperidine-4-carbonyl}piperidine-3-carboxamide % Receive 9 hearts Sugaah! 1-{1- [2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamo 6 X wide 0 yl benzamide)-2H-indazol-6-yl]piperidine-4-carboxamide}piperidine-3-carboxamide l-[2-(3-hydroxy-3-methylbutyl)-5-(3-0 su 1 f amoy 1 benz am i do ) — 2H— i ndazo 1 — 6— y 1 ] — N— ( 2~ hydroxyethyl )piper idine— 4— carboxamide H2N、 S P H心 』 — OH 1- [2- (3 -히드록시- 3 -메틸부틸)- 5- (3 —술파모일 벤 즈아 미도)- 2H-인다졸- 6 -일 ]- N- (2 -히드록시에 d s xr° 틸) 피페리 딘- 4 -카르복사미드 N-(2-Aminoethyl)-1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-1,2,3-triazol-6-yl]piperidine-4-carboxamide N 1H-indazol-6-yl]piperidine-4-carboxamide H hydrochloride YT— / H V��, person 7 ga 0 h N-(2-aminoethyl)-1-[2-(3-hydroxy-3-methylbut 0 HCI yl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide hydrochloride N-(2-aminoethyl)-1-[2-(3-hydroxy-3-0 N-(2-aminomethylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide H u N-(2-aminoethyl)-1-[2-(3-hydroxy-3-methylbutyl)]H2N〈9 people』 7 water 011 thyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide N-hydroxy—1—[2—(3-hydroxy—3—methylbutyl)-5-0 (3-sulfamoylbenzamido)-2H-indazol-6- H %v yl]piperidine-4-carboxamide H "n 、 / N-hydroxy- 1- [2- (3-hydroxy- 3-methylbutyl)- 5 - H2N、〈9 '수 0 H (3 —sulfamoylbenzamido)- 2H-indazole- 6 -yl]pipheridin- 4 -carboxamide N—(1-hydroxy—2—methylpropan-2-yl)-1-[2-(3-hydroxy—3—methylbutyl)—5—(3— Also, [[(4 - sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide H yl]piperidine-4-carboxamide HW妙스、》N-(1-hydroxy-2-methylpropan-2-yl)-1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-.OH sulfamoyl benzamido)-2H-indazol-6-yl]-N—어'N午[(1R,2R)-2-hydroxycyclopentyl]piperidine-4— H 으 N 、스^N. carboxamide O HA丄少、4OH 1- [2- (3 - hydroxy - 3 - methylbutyl)- 5- (3 — sulfamoyl H 2 N 才X \ d Benzuamido)- 2H-indazole- 6-yl]- N- [(1R,2R)- 2-hi 「 ° droxycyclopentyl ]piperidine- 4-carboxamide 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-osulfamoylbenzamido)—2H—indazol—6—yl]—N— [(pyrrolidin-3-yl)methyl]piperidine-4-m / 丁'숴人厂'1 u 1 에 — / carboxamide hydrochloride H2N / ≠ OH ≠ 1- [2- (3-hydroxy- 3-methylbutyl)- 5- (3-sulfamoyl 6 , XJ ° HC1 Benzamido)-2H-indazole-6-yl]-N-[(pyrrolidine-3-yl)methyl]piperidine—4-carboxamide hydrochloride 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-0sulfamoylbenzamido)—2H—indazol—6—yl]—N— [(pyrrolidin-3-yl)methyl]piperidine-4-HNVYY、! carboxamide 心Yr— / H2N, / Miao Si Jia OH 1- [2- (3-hydroxy-3-methylbutyl)-5- (3 — sulfamoyl 6 X ] person 0 benzene amidino)-2H-indazol-6-yl]-N-[(pyrrolidin-3-yl)methyl] piperidine-4-carboxamide It should be noted that the original text seems to contain some unclear or incorrect expressions, which may affect the accurate understanding and translation. It is recommended to check and correct the original text for a more accurate translation result. N—(4-aminobutyl)—1—[2—(3-hydroxy—3— methylbutyl)—5—(3-sulfamoylbenzaniido)-2H-O indazol— 6— yl ]piper idine— 4— carboxamide HCI H Neu" Su 011 hydrochloride (Seo / Myo In 7 N-(4-Aminobutyl)-1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide hydrochloride N-(4-aminobutyl)-1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-pyrrole N 」k丁 / 斗 indazol— 6— yl ]piper idine— 4— carboxamide H Heart N 'f 스 y己 — ( OH (S)-N-(4-aminobutyl)-1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N- (2,2,2-trifluoroethyl)piperidine-4- F — carboxamide H2N、 S P H heart s ga OH 1 - [2 - (3 - hydroxy - 3 - methylbutyl) - 5 - (3 - sulfamoyl d'outside Q s 0 benzoylamido) - 2H - indazol - 6 - yl] - N - (2, 2, 2 - trifluoroethyl) piperidine - 4 - carboxamide It should be noted that the content you provided seems to be rather complex and may contain some incorrect or unclear chemical - related terms in the original Korean part. The translation is done as accurately as possible based on the original text structure. 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-(2-methanesulfonylethyl)piperidine-4- 1 in carboxamide N A / % d 、 / SQ 1 Heart 'will 1 - [2 - (3 - hydroxy - 3 - methylbutyl) - 5 - (3 - sulfamoylbenzamido) - 2H - indazol - 6 - yl] - N - (2 - methanesulfonyl ethyl) piperidine - 4 - carboxamide N-{6-[4-(4-hydroxypiperidine-1-carbonyl)piperidin-1-yl]-2-(4,4,4- trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide OH N H 2 N Person'..., myself '<v, in>V F N-{6-[4-(4-Hydroxy piperidine-1-carbonyl) piperidine-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide N-{6-[4-(4-aminopiperidine-1- carbonyl)piperidin-1-yl]-2-(4,4,4- trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide sulfamoylbenzamide H2N^P ™^、 '조 F N- {6 - [4- (4-aminopiperidin- 1-carbonyl )piperi 6 Xj ° F [Din-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazole-5-yl}-3-sulfamoylbenzamide N-hydroxy-1-[5-(3-sulfamoylbenzamido)-2- HO、 N A 스 (4,4,4- tr i f luorobutyl )- 2H- indazol- 6 - yl ]piper idine— 4— carboxamide H " 〕o 、 o HN people people' 7 N-hydroxy- 1- [5- (3 —sulfamoylbenzamido)- 2 - 2 S'^xAn VF (4, 4,4-trifluorobutyl)- 2H-indazole- 6 -il]pi o' 〕3T° f f Peridin- 4 - Carboxamide N-(6-{4-[4-(2-hydroxypropan-2- [[ID= ​ H ^°? Uh OH H2N, S P H ? N- (6 - {4 - [4- (2-hydroxypropane- 2-yl )piperidine- (se 0 1-carbonyl ]piperidine- 1-yl}- 2-(propane- 2-yl )- 2H-indazole- 5-yl )- 3 —sulfamoylbenzamide 0 1- [2-Methyl-5-(3-sulfamoylamidobenzamido)-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide trifluoroethyl)piperidine—4—carboxamide f - TTXT'人으X丄즈그才1- [2 -methyl- 5- (3 —sulfamoylbenzamido)- 2H-indene „ XT 0 HN 、스 N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide N-{2-Methyl-6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylamidobenzamide 0 N-{2-Methyl-6-[4-(morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl}-3-sulfamoylamidobenzamide 1-[2-Methyl-5-(3-sulfamoylamidobenzamido)-2H-indazol-6-yl]-N-(propan-2-yl)piperidine-4-carboxamide 1-[2-Methyl-5-(3-sulfamoylamidobenzamido)-2H-indazol-6-yl]-N-(propan-2-yl)piperidine-4-carboxamide H eww N r 〕fv 1 - [2 - Methyl - 5 - (3 - sulfamoylbenzamido)-2H - inda H2N S P 1 妙* 우 It should be noted that the text seems to be a bit incomplete or contain some unclear parts in the original, especially the "妙* 우" which is difficult to accurately understand its meaning and may need further clarification in the source context. N-(propan-2-yl)piperidine-4-carboxamide N-(2-Hydroxyethyl)-N-methyl-1-[2-methyl-5-(3-sulfamoylamidobenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide 1 Dou - w, T o T H T , NT느느∼, ∼**느 = 누 / N - (2 - hydroxyethyl)-N - methyl - 1 - [2 - methyl - 5 - (3 - sulfophenylamidoyl)-2H - indazol - 6 - yl]piperidine - 6 X 广 0 4 - carboxamide o N-hydr oxy— 1- [ 2-methy 1 — 5— ( 3 — H0 / n su 1 f amoy 1 benz am i do ) — 2H— i ndazo 1 —6 — yl ]piper idine— 4— carboxamide T TXT o HN people, 느으스스느구乂 N-hydroxy-1-[2-methyl-5-(3-sulfamoylbenzeneamine H 2 N ., just L Do)- 2H-Indazole- 6-1]Piperidine- 4-Carboxamide 6 Illusion 0 S 0 N,N-Dimethyl-1-[2-methyl-5-(3-sulfamoylamidobenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide _ 〕丁 Xz— H2N, S PN,N-dimethyl-1-[2-methyl-5-(3-sulfamoylbenzamide) 6 Xx people 0 Do)- 2H-Indazole- 6-1]Piperidine- 4-Carboxamide N-{6-[4-(2-Hydroxyethyl)piperidin-1-yl]-2H-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylamidobenzamide H2N^9 ™^, 'Three VF N-{6-[4-(2-Hydroxyethyl)piperidin-1-yl]-2- 6 ° F (4,4,4-Trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzenesulfonamide HO, / , Ding Jin N—{6—[4—(2—hydroxyethyl)piperidin—1—yl]—2—methyl—2H—indazol—5—yl}~3~ LN YT N—sulfamoyl benzamide T TXT TJ XT o HN people, 느스 / 人건그 / It should be noted that the text in seems to be rather unclear and might contain some incorrect or unrecognizable characters which could affect the overall understanding and accuracy of the translation. If possible, it would be beneficial to clarify the original text for a more precise translation. N- {6 - [4- (2-hydroxyethyl )piperidine- 1-yl ]- 2-methyl- 2H-indazole- 5-yl}- 3 —sulfamoylbenzamide d s "ah N-{6-[4-(Hydroxymethyl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide N-{6-[4-(Hydroxymethyl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide HO^다 斗 N-{6-[4-(Hydroxymethyl)piperidin-1-yl]-2- 으라 methy 1 — 2H— indazo 1 — 5— y 1}~3~ sulfamoylbenzamide 0 H수 」、 人으 N-{6-[4-(Hydroxymethyl)piperidin-1-yl]-2-methyl W 。 -2H-indazol-5-yl}-3-sulfamoylbenzamide 쟈,&"'' 、 厂' 斗 N—{6 — [4— (Aminomethyl)piperidin—1— yl ]~2~ 1 、스'— methy 1 — 2H— indazo 1 — 5— y 1}~3~ 1 XJ-su 1 famoy 1 benz am i de hydrochloride O.P 으 띠 UP| N-{6-[4-(aminomethyl)piperidin-1-yl]-2-methyl- 、 、弓:슈 、,** 、泊 11C1 It should be noted that the original text contains some characters that may be encoding or formatting issues and may not be fully legible in the current form for a completely accurate translation. The translation above is done as much as possible based on the recognizable parts. H,N r 사 ° 2H-indazol-5-yl}-3-sulfamoylbenzamide hydrochloride 오 M H2N『Y 斗 N-{6 - [4-(Aminomethyl)piperidin—1— yl ]~2~ methy 1 — 2H— indazo 1 — 5— y 1}~3~ 으라 sulfamoylbenzamide „ XT 0 T HJXNT themselves, themselves are the people It should be noted that the original text "0 T HJXNT스스、、스스는느人" seems rather unclear and may contain some incorrect or unrecognizable characters, which may affect the overall understanding and the quality of the translation. H 2 N 2. N-{6-[4-(aminomethyl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide <foreign text> 0 N-{6-[(35)-3-[(Carbamoylmethyl)carbamoyl]piperidin-l-yl]-2-(3-hydroxy—3—methylbutyl) ~2H~ indazo 1 — 5-y 1}~3~nitrobenzamide 0 ° HN」、」으 (OH o斗 Q 人 o N-{6-[(3S)-3-[(Carbamoylmethyl)carbamoyl]piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-nitrobenzamide N-{6-[4-(2-hydroxy—2 — methylpropyl )piper idin—l—yl]— 2— methyl— 2H— 으 i ndazo 1 -5-yl}~3~su 1 f amoy 1 benz am i de TTXT : 05 — 스스丄 / 느 느 / o HN, * N-{6-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide N—{6—[4—(aminomethyl)piperidin—1—yl]—2—(4,4,4-trifluorobutyl)-2H-indazol-5-yl}—3—sulfamoylbenzamide dihydrochloride H2N. S P 义 」 고 F N-{6-[4-(aminomethyl)piperidin-1-yl]-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide 2 hydrochloride N-{6-[4-(aminomethyl)piperidin-1-yl]-2H-(4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide o HN people 7 즈 itself N - {6 - [4-(aminomethyl)piperidin-1-yl]-2 - H 7 a a > (4,4,4-trifluorobutyl)-2H-indazol-5-yl}-3-sulfopamo-ylbenzimidamide It should be noted that the original text seems to have some unclear or incorrect expressions, which may affect the accuracy of the translation. N-[6-(3-{[(bis(2-hydroxy-2-H-methylpropyl)amino]methyl}piperidin-1-yl)-2-methyl-2H-indazol-5-yl]-3-[(2-hydroxy-2- f l>? H methylpropyl)sulfamoyl]benzamide % N-[6-(3-{[bis(2-hydroxy-2-methylpropyl)amino]methyl}piperidin-1-yl)-2-methyl-2H-indazol-5-yl]-3-[(2-hydroxy-2-methylpropyl)sulfamoyl]benzamide 3-(ethylsulf amoy 1 ) — N— (6 - {3-[( 2-hydr oxy— 2 — methylpropyl ) amino] piper id in-l-yl}— 2— H methyl -2H- indazo 1 -5-yl ) benz am i de °r / s >- 3-(ethylsulfamoyl )- N- (6 - {3 - [ (2 -hydroxy- 2 -methyl d s [Athylpropyl )amino]piperidine-1-yl}-2-methyl-2H-indazole—5-yl)benzamide N-(6-{4-[(methylamino)methyl]piperidin-1-yl}-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl)-3-sulfamoylbenzamide " 6 s' 9 N- (6 - {4 - [(methylamino)methyl]piperidine- 1-yl}- 2 - 「0 「s 0 (4,4,4-trifluorobutyl)-2H-indazole-5-yl)-3-sulfamoylbenzamide N—(6—{4—[(dimethylamino)methyl]piperidin-1-yl}-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl)-3-sulfamoylbenzamide H2N d、&9 black 0 、 '즈 F v FF N- (6 - {4 - [(dimethylamino)methyl]piperidine- 1-yl}- 2- (4,4,4-trifluorobutyl)- 2H-indazole- 5-yl)- 3-sulfamoyl benzamide N-[2-(2,2-dimethylpropyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide N-[2-(2,2-dimethylpropyl)-6-[4-(2-hydroxypropyl)-2-yl]piperidin-1-yl]-2H-indazol-5-yl]-3-d' S P 妙 人 厂 V ropan-2-yl]piperidin-1-yl]-2H-indazol-5-yl]-3-d' S You 0 sulfamoylbenzamide N-[2-(cyclopropylmethyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide N-[2-(Cyclopropylmethyl)-6-[4-(2-hydroxypropyl)-2-pyridin-1-yl]-2H-indazol-5-yl]-3-sulfophenylbenzamide S P subtract people people 7 -2-yl]piperidin-1-yl]-2H-indazol-5-yl]-3-sulfophenylbenzamide It should be noted that the original text seems to have some unclear or incorrect expressions in part, which may affect the overall understanding and translation accuracy. The translation is done as accurately as possible based on the existing content. N-[2-(cyclobutylmethyl)-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide N- [2-(cyclobutylmethyl)- 6 - [4- (2 -hydroxypro H2N. P 』 7 7 Pan- 2 -il)piperidine- 1-il]- 2H-indazole- 5 -il]- 3 —sulfamoylbenzimide diethyl (2-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-5-(3- {sulfamoylbenzamido)}-2H-indazol-2-yl)ethyl)phosphonate H N O JO Le 、?— 0g dietyl (2 - {6 - [4- (2 -hydroxypropane- 2 -yl)piphe H 7 「 o 0 Lidin- 1-yl]- 5- (3 —sulfamoylbenzamido)- 2H-indazole- 2-yl}ethyl )phosphonate N-[2-(di f luoromethyl )-6 - [4-(2- hy dr oxyp r op an- 2-y 1 )piper idin— 1— yl ]— 2H— ugh yy M F i ndazo 1-5-yl ] — 3— su 1 f amoy 1 benz am i de o HN 、s F N- [2-(difluoromethyl)- 6 - [4- (2-hydroxypropan- 2-yl)piperidine- 1-yl]- 2H-indazole- 5-yl]- 3 —sulfamoylbenzamide N-{6 - [4-( 2-hydr oxypr op an- 2-y 1 ) p i per i d i n— 1— H 잇 p yl ]— 2— methyl— 2H— indazol— 5— yl}— 3— (2— methyl— 2H-1,2,3,4-tetrazol-1-yl)benzamide N=N ➡ HN* 5 ➡ N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)benzamide N <Q⬜]-2-methyl-2H-indazol-5-yl}-3-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)benzamide It should be noted that there seems to be some unclear or incorrect symbols in the original text (such as "➡", "⬜", "Q⬜"), which may affect the accurate understanding and translation. If possible, it is recommended to clarify the original content. N-{6 - [4-( 2-hydr oxypr op an- 2-y 1 ) p i per i d i n— 1— H 잇 p yl ]— 2— methyl— 2H— indazol— 5— yl}— 3— (1H— 느 y _ _ imidazol-l-yl ) benz am ide N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H-imidazol-1-yl)benzamide N-{6 - [4-( 2-hydr oxypr op an- 2-y 1 ) p i per i d i n— 1— H 잇 p yl]-2-methyl-2H-indazol-5-yl}-3-(lH-l,2,4- tr iazol-l-yl ) benz am ide —YTN— / That N mr" 1 、• People 〜 7 N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1- N 1]-2-methyl-2H-indazole-5-yl}-3-(1H-1,2,4-tri-joazole-1-yl)benzamide N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) p i per i d i n— 1— yl ]— 2— methyl— 2H— indazol— 5— yl}— 4— methyl— 3 — H 잇 p —TY sulfamoylbenzamide 人、 / 」수으 u XT O HN N— N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidin- 1- 、s {]-2-methyl-2H-indazol-5-yl}-4-methyl-3-sulfamoylbenzamide 4 - f 1 uor o— N— { 6 — [4 - ( 2-hydr oxypr opan— 2 — yl )piper idin—l—yl ]— 2— methyl— 2H— indazol— 5 — H V yl}-3-sulfamoylbenzamide —Y丁v 리느b丄극구 / 4 -fluoro- N- {6 - [4- (2 -hydroxypropane- 2 -yl) u XT 0 HN 、S H 2 N ''[2-(1-piperidin-1-yl)-2-methyl-2H-indazol-5-yl]-3-sulfonyl O sulfamoylbenzamide 4-chloro-N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5- H0 丄 yl}-3-sulfamoylbenzamide TTXT乂丄스으 / '''느극 / 4-chloro-N-{6-[4-(2-hydroxypropan-2-yl)phenyl]pyrimidin-4-yl}benzamide XT 0 HN 、스 {piperidin-1-yl}-2-methyl-2H-indazol-5-yl}-3-sulfamoylbenzamide w° N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) p i per i d i n— 1— yl ]- 2- ( 2 H3 ) me t hy 1 - 2H- indazol- 5-y 1}~3~ 아 sulfamoylbenzamide eww N :O5 O N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1- H2N、 / pu 」 D [Day]- 2-( 2 H3)methyl-2H-indazole-5-yl}-3-sulfamoylbenzamide 6 「 ° N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) p i per i d i n— 1— H 잇으 yl ]- 2 - [2- (thiophen- 2- yl )ethyl ]- 2H- indazol- 5-y 1}— 3— su 1 f amoy 1 benz am i de 心으幻 N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1- H2N、 S P 1 Heart 1]-2-[2-(thiophen-2-yl)ethyl]-2H-indazol-5-sulfonyl 0 1}-3-sulfamoylbenzamide N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) pi per idin— 1— yl ]- 2 - [2- (1H- pyrazol- 1- yl )ethyl ]- 2H- H it n eu i ndazo 1 -5-yl}— 3— su 1 f amoy 1 benz am i de o ji N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidin- 1- 2 [She 0 yl]- 2 - [2- (1H-pyrazole- 1-yl)ethyl]- 2H-indazole- 5 - yl}- 3-sulfamoylbenzamide N-(2-methyl-6-{4-[2-oxo-2-(piperidin-1-yl)ethyl]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide N- (2-methyl-6-{4-[2-oxo-2-(piperidine-1-yl) X T TXT „ T o HN乂 、으스丄으人 [Tyl] piperidin- 1-yl}- 2H-indazole- 5-yl )-3 —sulfamoshe 0 Ilben Zua Mid N-(2-methyl-6-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide °으VYV N-(2-methyl-6-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide N-{6-[4-(2-hydroxypropyl)piperidin-1-yl]-2-(1,3-thiazol-2-yl)-2H-indazol-5-yl}-3-sulfamoylbenzamide w ° N-{6-[4-(2-hydroxypropyl)piperidin-1-yl]-2-(1,3-thiazol-2-yl)-2H-indazol-5-yl}-3-sulfamoylbenzamide „ XT o 3 HN o,: S 〕 N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-(1,3-thiazol-2-yl)-2H-indazol-5-yl}-3-sulfophenylbenzenesulfonamide 0 yl]-2-(1,3-thiazol-2-yl)-2H-indazol-5-yl}-3-sulfophenylbenzenesulfonamide N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(hydroxymethyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide O HN〜 人흐 우 OH N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(hydroxymethyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide 3-({1-[2-(3-hydroxy-3-methylbutyl)-5-(3-nitrobenzamido)-2H-indazol-6-yl]piperidin-1-yl} H N-[4-(4-chlorophenyl)-2-oxo-3-oxa-4-aza-5-phenylpentanoyl]-L-proline It should be noted that the original "느』 f 、广 4— yl}formainido)propanoic acid" seems to be an incorrect or unclear chemical name. The translated "N-[4-(4-chlorophenyl)-2-oxo-3-oxa-4-aza-5-phenylpentanoyl]-L-proline" is a more standard way to represent a chemical compound name, but it's based on a guessed correction. If the original name has a specific correct form, the translation should be adjusted accordingly. N. / — (OH o HNXX N 3-({1-[2-(3-hydroxy-3-methylbutyl)-5-(3-nitrobenzamido)-2H-indazol-6-yl]piperidin-4-yl}formamido)propanoic acid 0 ​ N-(6-{4-[(2-carbamoylethyl)carbamoyl]piperidin-1-yl}-2- (3-hydroxy-3-methylbutyl)-2H-indazol-5-yl)-H2N스 "YYW 수아 0 HN、 스 1 3-nitre obenez am i de N-(6-{4-[(2-carbamoylethyl)carbamoyl]piperidin-1-yl}-2- (3-hydroxy-3-methylbutyl)-2H-indazol-5-yl)-3-nitrobenzamide N-{6-[4-(diethenylamino)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sulfamoylbenzamide H* I 〉 1 , -N-{6-[4-(diethylamino)piperidin-1-yl]-2-dou Q people o (3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-3-sul pamoylbenzene amid 1- [3-Fluoro—2—(3-hydroxy—3-methylbutyl)—5—(3-sulfamoylbenzamido)—2H-indazol—6-yl]—N— (2,2,2-trifluoroethyl)piperidine—4-carboxamide H N p HfXX— 1- [3-fluoro- 2- (3-hydroxy- 3-methylbutyl)- 5- ve o F (3-s-sulfamoylbenzamido)-2H-indazole-6-yl]-N-(2,2,2-tripluoroethyl)piperidine-4-carboxamide N—[2—(3-hydroxy—3-methylbutyl)-6-{4-[4-(2-hydroxypropan-2-yl)piperidine—1— -carbonyl]piperidin-1-yl}-2H-indazol-5-yl]~ 3-sulfamoylbenzamide Herl N 0 mA 。— 、즈 4 / OH N-[2-(3-Hydroxy-3-methylbutyl)-6-{4-[4-(2-Hydroxypropan-2-yl)piperidine-1-carbonyl]piperidin-1-yl}-2H-indazol-5-yl]-3—sulfamoylbenzamide N—{1—[2—(3-hydroxy—3-methylbutyl)—5—(3-sulfamoylbenzamido)—2H-indazol—6 — -yl]piperidin—4-yl}—5—methanesulfonylfuran— 2-carboxamide H2N. S P 」 OH N-{1- [2- (3-hydroxy- 3-methylbutyl)- 5- (3-sulfamo "serylbenzamido)- 2H-indazole- 6-yl]piperidine- 4-yl}- 5-methanesulfonylfuran- 2-carboxamide methyl 3-({1-[2-(3-hydroxy-3-methylbutyl)-5-(3-nitrobenzamido)—2H-indazol—6 —yl]piperidin—4-yl}formamido)propanoate '、"•午刀、广 N. 『〈OH o HA 〕 ☆ 丁 메틸 3-({1-[2-(3-Hydroxy-3-methylbutyl)-5-(3-nitrobenzamido)-2H-indazol-6-yl]piperidin-4-yl}formamido)propanoate N—[2—(3-hydroxy—3-methylbutyl)—6—[(3S)—3—(2-hydroxyacetamido)pyrrolidin-1-yl]—2H—HOP indazol-5-yl]—3—sulfamoylbenzamide 매。—』. dihydrochloride 0 HA 』- N 、4OH N- [2- (3-hydroxy- 3-methylbutyl)- 6 - [(3S)- 3- (2 - H 7x 0 J 히드록시아세트아미도)피롤리딘-1-일]-2H-인다졸-5-일]-3—술파모일벤즈아미드2염산염 N—[2—(3-hydroxy—3-methylbutyl)—6—[(3S)—3—HOP(2-hydroxyacetamido)pyrrolidin-1-yl]—2H—indazol-5-yl]—3-sulfamoylbenzamide / N-[2-(3-hydroxy-3-methylbutyl)-6-[(3S)-3-(2-hydroxyacetamido)pyrrolidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide 0 -5-yl]-3 —sulfamoylbenzamide N—{1 — [2— (3— hydroxy— 3— methylbutyl )— 5 — [3— (1H— if서은] H imidazol-l-yl ) benz am i do] -2H- i ndazo 1 -6- N N n yl ]piper idin— 4— yl}pyr idine— 3— carboxamide 0 으 Yy— / 쓰 HN人으 브丄-(OHN-{1-[2-(3-히드록시-3-메틸부틸)-5-[3-(1H-이스Q\미다졸-1-일)벤즈아미도]-2H-인다졸-6-일]피페리딘-4-일}피리딘-3-카르복사미드 Nl-{6 - [4-(aminomethyl)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-N3-H2N-4-methylbenzene-1,3-dicarboxamide N hydrochloride OHN人이 으 느-(OH Nl-{6-[4-(aminomethyl)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-N3-methylbenzene-1,3-dicarboxamide hydrochloride hci droxy-3-methylbutyl)-2H-indazol-5-yl}-N3-methylbenzene-1,3-dicarboxamide hydrochloride Nl-{6-[4-(aminomethyl)piperidin-1-yl]-2-(3-hydroxy—3-methylbutyl)—2H—indazol—5—yl}—N3—HX'Y'l methyl benzene-1,3~dicarboxamide o 으 mT흐흐 으( / OH Nl-{6-[4-(aminomethyl)piperidin-1-yl]-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl}-N3-methylbenzene-1,3-dicarboxamide 0 ​ N— {1 — [2—(3— hydroxy— 3— methylbutyl)— 5 — [3—(1H— pyr azo 1 -4-yl) benz am i do ] — 2H— i ndazo 1 —6 — N 『、져A수1 『N H 、p yl]piperidin—4—yl}pyridine—3—carboxamide ° / HN■、人… 느-(OH N-{1-[2-(3-히드록시-3-메틸부틸)-5-[3-(1H-피"j o라졸—4-일)벤즈아미도]-2H-인다졸-6-일]피페리딘-4-일}피리딘-3-카르복사미드 N-{6-[4-(2-hydroxyprop an—2—yl)piperidin—1—yl]-2-[(pyridin-3-yl)methyl]-2H-indazol -5 -가 yl}-3-sulfamoylbenzamide It should be noted that some of the content in the original text seems rather unclear or contains possible errors in formatting or terms, which may affect the accuracy of a perfect translation. If possible, it would be beneficial to have a more accurate and clear original text for a more precise translation. o HN^^ 7 ^=\ N- {6 - [4-(2 -hydroxypropan-2-yl)piperidin-1- 2 / Dou people o D day]- 2 - [(pyridin-3-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide N— { 1 — [ 5— ( 4— f 1 uor o—3 — su 1 f amoy 1 benz amido) ~2~ if Joo-eun] H (3— hydroxy— 3— methyl butyl )— 2H— indazol— 6 — N N N-{1-[5-(4-fluoro-3-sulfamoylbenzamido)-2-(3-hydroxy-3-methylbutyl)-2H-indazole-6-yl]piperidin-4-yl}pyridine-3-carboxamide N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2,2,2-trifluoroacetamido)piperidin-1-yl]-2H- F V,o O-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2,2,2-trifluoroacetamido)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide 7 '우 011 N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2,2,2-trifluoroacetamido)piperidin-1-yl]-2H-indazol-5-yl]-3-sulfamoylbenzamide d 「 ° indazol-5-yl]-3-sulfamoylbenzamide N-(l-{5 - [3-( hydr azinecar bony 1 ) benz am i do ] — 2 — 『저은| H (3— hydroxy— 3— methylbutyl )— 2H— indazol— 6 — N A N 、O yl}piper idin— 4— yl )pyr idine— 3— carboxamide 0 으 Y]fN A / 0 * People: : 』~'' COH N-(l- {5 - [3-(hydrazine carbonyl)benzamido]- 2 - (3-hydroxy- 3-methylbutyl)- 2H-indazole- 6-yl}pipe H VO S Ridin- 4 -il )Pyridin- 3 -Carboxamide N—{1 — [2— (3— hydroxy— 3— methylbutyl )—5 — [3 — (methylsulfamoyl ) benzamido] — 2H— indazol—6 — yl ]piperidin— 4— yl}— 5— methanesulfonyl furan—2-carboxamide 2-carboxamide ; o be— N-{1- [2- (3-hydroxy- 3-methylbutyl)- 5 - [3- (methylsulfamoyl ) benzamido]- 2H- indazol- 6 -yl ]piperidin- 4 -yl}- 5 -methanesulfonyl furan- 2 -carboxamide N-{6 - [4-( 2-hydroxyprop an— 2— yl ) piperidin— 1— yl]-2-methyl-2H-indazol-5-yl}-3-(lH-l,2,4-triazol-5-yl) benzamide N-{6 - [4-( 2-hydroxyprop an— 2— yl ) piperidin— 1— yl]-2-methyl-2H-indazol-5-yl}-3-(lH-l,2,4-triazol-5-yl) benzamide N~NH N- {6 - [4- (2-hydroxypropane- 2-yl )piperidine- 1-yl]- 2-methyl- 2H-indazole- 5-yl}- 3- (1H- 1,2,4-triazole- 5-yl)benzamide N S 0S° N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) p i per i d i n— 1— yl ]— 2 — [(1— methyl— 1H— pyrazol— 4— yl )methyl]— H 잇 p 2H- indazol — 5— yl}— 3— sulfamoyl benzamide N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]pyridin-3-yl}methanesulfonamide S 'Nong Sanyi, Shu Cha' 1]-2-[(1-Methyl-1H-pyrazol-4-yl)methyl]-2H-indazole' 0 N ' 2H- indazol — 5— yl}— 3— sulfamoyl benzamide N-{6 - [4-( 2-hydroxyprop an— 2— yl ) piperidin— 1— yl]-2-methyl-2H-indazol-5-yl}-3-(lH-l,2,4-triazol-5-yl) benzamide N1— [ 2— ( 3-hydroxy— 3— methylbutyl ) -6 - [ 4— (pyridine-3 -amido ) piperidin— 1-yl ] — 2H— indazol—5— yl ]— N3— methylbenzene— 1,3 —dicarboxamide N1— [ 2— ( 3-hydroxy— 3— methylbutyl ) -6 - [ 4— (pyridine-3 -amido ) piperidin— 1-yl ] — 2H— indazol—5— yl ]— N3— methylbenzene— 1,3 —dicarboxamide dicarboxamide ° "rtx / Nl-[2-(3-hydroxy-3-methylbutyl)-6-[4-(pyridin-3-amido)piperidin-1-yl]-2H-indazol-5-yl]-N3-, sand 0 people 0 0 HN^、』 으- (OH N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) p i per i d i n— 1— yl ]-2 - [2-(pyr idin-2-yl )ethyl ]— 2H— indazol— 5 — H 잇、 / 、 N1— [ 2— ( 3-hydroxy— 3— methylbutyl ) -6 - [ 4— (pyridine-3 -amido ) piperidin— 1-yl ] — 2H— indazol—5— yl ]— N3— methylbenzene— 1,3 —dicarboxamide yl}-3-sulfamoyl benzamide N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1- H2N、 S P Myos 丁 〕 Vyw 石 yl]- 2 - [2-(pyridine- 2 -yl)ethyl]- 2H- indazol- 5 -yl}- 3 -sulfamoyl benzamide yl]- 2 - [2-(pyridine- 2 -yl)ethyl]- 2H- indazol- 5 -yl}- 3 -sulfamoyl benzamide l-[2-( 3-hydroxy-chemistry 3-methyl butyl ) - 5- ( 3 -sulfamoyl benzamido ) — 2H— indazol—6 — yl ] — N— 〈丄 / y" 斗 [(3S)— pyrrolidin— 3— yl ]piperidine— 4— 盐酸羧酰胺 H2N / 〒 OH 1- [2- (3-hydroxy- 3-methylbutyl)- 5- (3-sulfamoyl d "O people 0 hci Benzamido)- 2H-indazole- 6-yl]- N- [(3S)-pyrrolidine- 3-yl]piperidine- 4-carboxamide hydrochloride 1-[2-(3-羟基-3-甲基丁基)-5-(3-磺酰胺基苯甲酰胺基)-2H-吲唑-6-基]-N-〈人[(3S)-吡咯烷-3-基]哌啶-4- 羧酰胺 H , H W wide I X VU ^ OH 1 - [2 - (3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl o 苯甲酰胺基)-2H-吲唑-6-基]-N-[(3S)-吡咯烷-3-基]哌啶-4-羧酰胺 3-磺酰胺基-N-[2-(4,4,4-三氟丁基)-6-FJ[4-(3,3,3-三氟丙基)哌嗪-1-基]-F〜斯N今2H-吲唑-5-基]苯甲酰胺 "IT o H low person』V Buddha, ,, 3 —sulfapyrimidine - N - [2 - (4, 4, 4 - trifluorobutyl) - 6 - 2 number XJ person 0 f pF [4 - (3, 3, 3 - trifluoropropyl)piperazin - 1 - yl] - 2H - indazol - 5 - yl]benzamide N-[2-(3-羟基-3-甲基丁基)-6-(4-{[(2,2,2- 으냬胡三氟乙基)氨基甲酰基]氨基}哌啶-1- p 0 uh yl ) -2H- indazo 1 -5-y 1 ] ~3~su 1 f amoy 1 benz am i de H2N、 S P Sims N- [2- (3-hydroxy- 3-methylbutyl)- 6- (4 - {[(2, 2, 2 - d "O people 0 Trifluoroethyl )carbamoyl]amino}piperidine-1-yl)-2H-indazole-5-yl]-3-sulfamoylbenzamide N-{6-[4-(2-氨基乙基)哌嗪-1-基]-2-H2N으、自今甲基-2H-吲唑-5-基}~3~ 磺酰胺基苯甲酰胺二盐酸盐 "라 o HN&丄〜 7 N - {6 - [4 - (2 - aminoethyl)piperazin - 1 - yl] - 2 - methyl H 2 N '〒 / 、 X HC1 -2H-Indazole- 5 -yl}- 3 —Sulfamoylbenzamide dihydrochloride 0' Xj ° HC1 盐 N-{6-[4-(2-氨基乙基)哌嗪-1-基]-2-甲基-2H-吲唑-5-基}~3~ 으磺酰胺基苯甲酰胺 … T o T H TXNT丄스 H 、eusseuneugu / 2 N 、 led LN-{6-[4-(2-aminoethyl)piperazin-1-yl]-2-methyl cAQ west -2H-吲唑-5-基}-3-磺酰胺基苯甲酰胺 N-[2-(3-羟基-3-甲基丁基)-6-[4-(2-甲磺酰基乙基)哌嗪-1-基]-2H- / 、세〕 N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2-methylsulfonyl)phenyl]imidazo[1,5-a]pyridin-3-yl]-3-sulfamoylbenzamide H2N. P 푀 广 」 '수 0 H / 으)人0羰基乙基)哌嗪-1-基]-2H-吲唑-5-基]-3-磺酰胺基苯甲酰胺 N-(6-{4-O-[(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol- o 5-yl)-3-nitrobenzamide ° "rr— / 0 HN人』 이 우수 0H N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl)-3-nitrobenzamide N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl)-3-nitrobenzamide N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2-O hydroxyacetyl)piperazin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide yl]-3-nitrobenzamide "rr— / O HN人 으스 으 (OH N-[2-(3-hydroxy-3-methylbutyl)-6-[4-(2-hydroxyacetyl)piperazin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H- pyrazol-3-yl)benzamide 으 N TT_ N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H-pyrazol-3-yl)benzamide N— [ 2— ( 3-hydr oxy— 3— me t hy 1 butyl ) — 6 — { 4— [ ( 2S ) — u ° 5-oxopyr rol idi ne— 2— car bony l]pi per az in— 1— 0 Lee 0 Evening Now 』. y 1}-2H- indazo 1 — 5— y 1 ] — 3— su 1 f amoy 1 benz am i de N- [2- (3-hydroxy- 3-methylbutyl)- 6 - {4 - [(2S)- 5 - - ☆So" Ge 011 Oxopyrrolidine-2-carbonyl]piperazine-1-yl}-2H- / XJ °Indazole-5-yl]-3-sulfamoylbenzamide 1-[2-( 3-hydr oxy— 3— me t hy 1 butyl ) — 5 — [ 3 — (methyl su 1 famoyl ) benz am i do] — 2H— indazo 1 —6 — ■ 으 yl ]-N-(2, 2, 2-tri f luoroethyl )piper idine- 4- f u n5 A / carboxamide H o 印才 〜스 으- (OH " / J O 1-[2-(3-hydroxy-3-methylbutyl)-5-[3-(methylsulfamoyl)benzamido]-2H-indazol-6-yl]-N-(2,2,2-trifluoroethyl)piperidine-4-carboxamide N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol-1-yl)-N'-(5-yl)-3-trifluoromethanesulfonylbenzamide H , N 5-yl)-3-trifluoromethanesulfonylbenzamide p 베 가 OH F Talented Kung S N-(6-{4-[(carbamoylmethyl)carbamoyl]piperidin-1-yl}-2-(3-hydroxy-3-methylbutyl)-2H-indazol-5-yl)-3-trifluoromethanesulfonylbenzamide 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N-Ao ​ U ：O ​ H2N, several people are ☆으 으 - $ / OH 1 - [2 - (3 - hydroxy - 3 - methylbutyl) - 5 - (3 1 \ —sulfamoyl benzo'amido)- 2H-indazole- 6 -yl ]- N- (piperidine- 3 - d , Xj ° HC1 yl)piperidine - 4 - carboxamide hydrochloride 1 - [2 - (3 - hydroxy - 3 - methylbutyl) - 5 - (3 - sulfamoylbenzamido) — 2H — indazol — 6 — yl] — N — 으(piperidin - 3 - yl)piperidine — 4 — carboxamide Vo H / 1- [2- (3-hydroxy- 3-methylbutyl)- 5- (3-sulfamoyl H2N, S P Myosu Ga OH benzamido) - 2H - indazol - 6 - yl] - N - (piperidin - 3 - yl)piperidine - 4 - carboxamide N — {1 — [2 — (3 — hydroxy — 3 — methylbutyl) — 5 — (3 - nitrobenzamido) — 2H — indazol — 6 — yl]piperidin - - HVp 4 - yl} - 5 - methanesulfonyl furan — 2 - carboxamide; ho — N - {1 - [2 - (3 - hydroxy - 3 - methylbutyl) - 5 - (3 - nitro o - X0 人 o benzamido) - 2H - indazol - 6 - yl]piperidin - 4 - yl} - 5 - methanesulfonyl furan - 2 - carboxamide N - [2 - (3 - hydroxy — 3 — methylbutyl) — 6 — {4 — [4 — (trifluoromethyl)piperidine — 1 - carbonyl]piperidin - 1 - yl} - 2H - indazol - 5 - yl] ~ 丄 스 스 3 - sulfamoylbenzamide H2N. P H心 人 / 가 OH 세 N - [2 - (3 - hydroxy - 3 - methylbutyl) - 6 - {4 - [4 - (트리 0 fluoromethyl)piperidine - 1 - carbonyl]piperidin - 1 - yl} - 2H - indazol - 5 - yl] - 3 — sulfamoylbenzamide 、'9 N — {6 — [4 — (2 - methanesulfonylethyl)piperazin — 1 - yl] — 2 — methyl — 2H — indazol — 5 — yl} ~ 3 ~ 으 Y 亡 su 1 f amoy 1 benz am i de It should be noted that there seem to be some unclear or incorrect characters in the original text which might affect the comprehensibility and accuracy of the translation. N— o eu N- {6 - [4- (2 -methanesulfonylethyl)piperazine -1-yl]- 2 - 2 (Hymethyl-2H-indazole-5-yl}-3-sulfamoylbenzamide N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2 - [(5-methyl-1,2-oxazol-3-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide 0 HgK 으 으 己 可 N- {6 - [4- (2-hydroxypropyl)piperidin-1- 2 djo 후 일]-2 - [(5-methyl-1,2-oxazol-3-yl)methyl]-2H-indazol-5-yl}-3-sulfamoylbenzamide N-(2-Hydroxy-2-methylpropyl)-1-[2-(3-hydroxy-3-methylbutyl)-5-(3- sulfamoylbenzamido)-2H-indazol-6-yl]piperidine-4-carboxamide H2N, S P OH N- (2-hydroxy- 2-methylpropyl) -1- [2- (3-hydroxy d "O people 0 C-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazole-6-yl]piperidine-4-carboxamide N-[2-(3-Hydroxy-3-methylbutyl)-6-[(3S)-3- (morpholine-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide N-[2-(3-Hydroxy-3-methylbutyl)-6-[(3S)-3-(morpholin-4-carbonyl)piperidin-1-yl]-2H-indazol-5-yl]-3-nitrobenzamide 0 -3-nitrobenzamide N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5-sulfamoylthiophene-2-carboxamide "TTN-HN 人』* N-{6 - [4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5 —sulfamoylthiophene 1 쎄 《 丁 人 0 -2-carboxamide N-{6-[4-(2-Hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(methylsulfamoyl)benzamide B,9 Ppa Ins N- {6 - [4- (2-hydroxypropane-2-yl)piperidine-1-yl]-2-methyl-2H-indazole-5-yl}-3 - (methylsulfamoyl) Nsuh? 0 Benzah Mid N-{2-methyl-6-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide O HNXX N -H2N. P is N-{2-methyl-6-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide N-(2-Methyl-6-{4-[(2,2,2-trifluoroethyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide, YD-N-(2-Methyl-6-{4-[(2,2,2-trifluoroethyl)amino]piperidin-1-yl}-2H-indazol-5-yl)-3-sulfamoylbenzamide, H2N、 S Pyrims mino] piperidine-1-yl}-2H-indazol-5-yl)-3-sulfamoyl 0 Moyl benzamide N-{2-Methyl-6-[4-(3,3,3-trifluoropropyl)piperazin-1-yl]-2H-indazol- 5-yl}-3-sulfamoylbenzamide N- {2-methyl- 6- [4- (3,3,3-trifluoropropyl)p H2N, / 1 Perazine- 1-yl]- 2H-Indazole- 5-yl}- 3 —sulfamoylbenz 0 amides „ 0 N-(2-methyl-6-{4-[(2S)-5-oxopyrrolidine-2-carbonyl]piperazin-1-yl}-2H-indazol-5-yl)- 1 L 스 carbonyl ]piperazin-1-yl}-2H-indazol-5-yl)- 0== o 0나 背 3-sulfamoylbenzamide H N o H 2 N ' HN XX 6L N - N-(2-methyl-6-{4-[(2S)-5-oxopyrrolidin-2-carboxylic acid {6-[4-(2-Hydroxy-2-methylpropyl)piperazin-1-yl]-2H-indazol-5-yl}-3-sulfamoylbenzamide sulfamoylbenzamide N-hydroxy—1-[2-methyl-5-(3-nitrobenzamido)- H0 / n 2H-indazo1—6-yl]piperidine—4-carboxamide 0 HN人^ 스 N-hydroxy -1- [2-methyl- 5- (3-nitrobenzamido)- 2H-indazol- 6 -yl ]piperidine- 4 -carboxamide o쓰 Q 人 o 1-[2-(3-Hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N- [(piperidin-3-yl)methyl]piperidine-4-carboxamide hydrochloride Introduction H o HN people Ni, - (OH H 2 N '1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl-6'- HC1 benzamido)-2H-indazol-6-yl]-N-[(piperidin-3-yl)methyl]piperidine-4-carboxamide hydrochloride 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoyl benzamido)-2H-indazol-6-yl]-N-0 [(piperidin-3-yl)methyl]piperidine-4-carboxamide H2N, S P water OH , S 、Q s 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazole-6-yl]-N-[(piperidin-3-yl)methyl]piperidin-4-carboxamide N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) p i per i d i n— 1— H 잇 yl ]— 2— methyl— 2H— indazol— 5— yl}— N— methyl— 3 — p sulfamoylbenzamide yy N _ N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1- H2N、 S P Woo In-s Il ] -2-methyl- 2H-indazole- 5-yl}- N-methyl- 3-sulfamosorba 0 ylbenzamide N-{6-[4-(2-Hydroxy-2- methylpropyl)piperazin—1—yl]—2—methyl—2H—11(^1세、 ur la indazo1 -5-yl}—3—sulfamoy1 benz amide o HN&丄으N-{6 - [4-(2 -hydroxy- 2 -methylpropyl)piperazin- 스1-yl]- 2-methyl- 2H-indazol- 5 -yl}- 3 —sulfamoylbenz amide N—(2—hydroxy—2—methyl propyl)—1 —[2—methyl—5 — (3-Nitrobenzamido)-2H-indazol-6- h [(2S)-2-(hydroxymethyl)piperidin-4-yl]piperidine-4-carboxamide E: N-(2-Hydroxy-2-methylpropyl)-1-[2-methyl-5-(3-((2-nitrobenzyl)amino))-2H-indazol-6-yl]piperidine-3-carboxamide 0 4-Carboxamide 1—{1 —[2—(3—hydroxy—3—methylbutyl)—5—(3 —sulfamoy1 benz amido)—2H—indazo1 —6 — 0 yl]piperidine—4—carbonyl}piperidine—4—H2N리7리午〜\ carboxamide 셰1-{1-[2-(3 -hydroxy- 3 -methylbutyl)- 5-(3 —sulfam o ylbenzamido)- 2H-indazol- 6 -yl]piperidine- 4 -carboxy nil}piperidine- 4 -carboxamide 1-[2-(3-hydroxy-3-methylbutyl)-5-(3-sulfamoylbenzamido)-2H-indazol-6-yl]-N,N-bis(3,3,3-trifluoropropyl)piperidine-4-carboxamide H —VOH carboxamide H N Of HNXX— 1-[2-(3 -hydroxy- 3 -methylbutyl)- 5-(3 —sulfamoyl 으0스 benzamido)- 2H-indazol- 6 -yl]- N-(3, 3, 3 -trifluoro propyl)piperidine- 4 -carboxamide 1-[2-(3-hydroxy-3-methylbutyl)-5-[3-(methylsulfamoyl)benzamido]-2H-indazol-6-yl]-N-(3,3,3-trifluoropropyl)piperidine-4-carboxamide H ^ N v* s V :N ' / ~ v OH carboxamide 』 H忌 ^ "〔X、스X N 9 세1-[2-(3 -hydroxy- 3 -methylbutyl)- 5 -[3-(methylsulfamo yl)benzamido]- 2H-indazol- 6 -yl]- N-(3, 3, 3 -trifluoro propyl)piperidine- 4 -carboxamide N—{1 —[5—(4—chloro—3 —sulfamoy1 benzamido)~2~ (3— hydroxy— 3— methyl butyl )— 2H— indazol— 6 — yl ]piper idin— 4— yl}pyr idine— 3— carboxamide 0 으 / N-{1- [5- (4 -chloro- 3 —sulfamoylbenzamido)- 2 - H W I % VU / ^ OH (3 -hydroxy- 3 -methylbutyl)- 2H-indazol- 6 -yl]piper 「°ridine- 4 -yl}pyridine- 3 -carboxamide N— {1 — [5— (2— f luoro— 5— sulf amoy 1 benz ami do)— 2 — [f저우} H (3— hydroxy— 3— methyl butyl )— 2H— indazol— 6 — N N n yl ]piper idin— 4— yl}pyr idine— 3— carboxamide 0 / O 퓨厂丄人으M-OH N-{1- [5-(2 -fluoro- 5 —sulfamoylbenzamido)- H2N.'P 7 \ 2-(3 -hydroxy- 3 -methylbutyl)- 2H-indazol- 6 -yl]piper idine- 4 -yl}pyridine- 3 -carboxamide It should be noted that there seem to be some unclear or incorrect notations in the original text which might affect the accuracy of the translation. It's recommended to double-check and correct the original if possible for a more meaningful and accurate translation. N—{1—[2—(3—hydroxy—3—methylbutyl)—5—(2—{저은]H methyl—3—sulfamoylbenzamido)—2H—indazol—6— N N nyl]piperidin—4—yl}pyridine—3—carboxamide 0 丁세X / It should be noted that there seems to be some unclear or incorrect characters in the original text (such as "저은"), which may affect the accurate understanding and translation. This translation is based on the best effort to handle the recognizable parts. N-{1-[2-(3-hydroxy-3-methylbutyl)-5-(2-methyl-J on, people 7 =° H It should be noted that the original text seems to be incomplete or contains some unclear parts, which may affect the accuracy of the overall translation. 3-(sulfamoylfuran-2-carboxamido)-2H-indazol-6-yl}piperidin-4-yl}pyridine-3-carboxamide N—{1 — [2— (3— hydroxy— 3— methylbutyl )—5 — [3 — if서은] H (pyr idin-4-yl ) benz am i do] -2H- i ndazo 1 -6- N N n yl ]piper idin— 4— yl}pyr idine— 3— carboxamide 0 으 YY— / N Now HN"으' 흐 丄— (OH N-{1- [2- (3-hydroxy-3-methylbutyl)-5 - [3- (pyrido-0-stidine-4-yl)benzamido]-2H-indazol-6-yl]piperidin-4-yl}pyridine-3-carboxamide N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H- (1,2,3,4 - tetrazol - 1 - yl)benzamide N TEN - N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H-1,2,3,4-tetrazol-1-yl)benzamide N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H-1,2,3-triazol-1-yl)benzamide N=N HN乂、 人'’'乂 N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-3-(1H-1,2,3-triazol-1-yl)benzamide N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5- HC>乂厂 、 ) sulfamoylfuran-2-carboxamide eww N Y West VN. 0HNAX N ~ N- {6 - [4- (2-hydroxypropane- 2-yl )piperidine- 1-yl]- 2-methyl- 2H-indazole- 5-yl}- 5 —sulfamoylfuran- sher 1 〈 people 0 2 - Carboxamide N2-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}thiophene-2,5-dicarboxamide 으 HN、S N2 - {6 - [4- (2-hydroxypropane-2-yl)piperidine-1-yl]-2-methyl-2H-indazole-5-yl}thiophene-2,5-dicart H2 0 Copy American drama N-{6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-2-methyl-2H-indazol-5-yl}-1-(pyridin-4-yl)-1H-pyrazole-4-carboxamide "라 HN」으 〜 N- {6 - [4- (2 -히드록시프로판- 2 -일 )피페리딘- 1- 흐 N구 일]- 2 -메틸- 2H-인다졸- 5 -일}- 1-(피리딘- 4 -일)- 1H-피라졸一 4— 7}르복人}日]드 N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) p i per i d i n— 1— 가 yl ]— 2— methyl— 2H— indazol— 5— yl}— 3— (1H— pyr az o 1 — 4— y 1 ) benz am i de N- {6 - [4- (2 -히드록시프로판- 2 -일 )피페리딘- 1- 일]- 2 -메틸- 2H-인다졸- 5 -일}- 3- (1H-피라졸- 4 - 일)벤즈아 미드 N-{6 - [4-( 3-hydr oxy— 3— met hy 1 but y 1 ) p i per az i n— HOJ 1— yl ]— 2— methyl— 2H— indazol— 5— yl}~3~ su 1 f amoy 1 benz am i de 0 HN< people' 7 N- {6 - [4- (3-hydroxy- 3-methylbutyl)piperazine-1-yl]- 2-methyl- 2H-indazole- 5-yl}- 3-sulfamoylbenzamide 2 - fluoro - N - {6 - [4 - (2 - hydroxypropan - 2 - H yl)piperidin - 1 - yl] - 2 - methyl - 2H - indazol - 5 - yl}-5 - sulfamoylbenzamide 으 N TT_ o HN< person' 7 2-Fluoro-N-{6-[4-(2-hydroxypropan-2-yl)methylpiperidin-1-yl]-2-methyl-2H-indazol-5-yl}-5-sulfamoylbenzamide 3— ({6 — [4— (2— hydroxypropan— 2— yl )piper idin— 1— yl ]— 2— methyl— 2H— indazol— 5 — yl Icarbamoyl )benzene— 1— sul fonyl f luoride 197 心 F YTN— ,0 人느 丄 으 3- ({6 - [4- (2 -히드록시프로판- 2 -일)피페리딘- 1- 일]- 2 -메틸- 2H-인다졸- 5 -일}카르바모일)벤젠- 유 Q 人 o 1-술포닐 플루오 라이 드 N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) p i per i d i n— 1— "수 yl ]— 2— methyl— 2H— indazol— 5— yl}~2~(3~ sulf amoyl phenyl ) acet am ide 198 N- {6 - [4- (2 -히드록시프로판- 2 -일 )피페리딘- 1- 일]- 2 -메틸- 2H-인다졸- 5 -일}- 2- (3 —술파모일페 닐)아세트아미드 It should be noted that the original text contains some non-standard or unclear characters which might lead to potential inaccuracies in the translation. It might be beneficial to double-check and correct the original text for a more precise translation. N-{6 - [4-( 2-hydr oxypr op an— 2— y 1 ) pi per idin— 1— yl ]— 2— methyl— 2H— indazol— 5— yl}— 2— (4 — sulf amoyl phenyl ) acet am ide 199 HW "CG- N- {6 - [4- (2 -hydroxypropane- 2 -yl )piperidine- 1-yl]- 2 -methyl- 2H-indazole- 5 -yl}- 2- (4 —sulfamoylphenyl)acetamide

25. A pharmaceutical composition comprising a compound according to claim 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

26. In claim 25, the above pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of IRAK-4 or IRAK-1 related diseases.

27. A pharmaceutical composition according to claim 26, wherein the IRAK-4 or IRAK-1 related disease is an autoimmune disease, an inflammatory disease, or a tumor. [Claim] Paragraph 28] In paragraph 26, the above IRAK-4 or IRAK-1 related disease is rheumatoid arthritis, spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, psoriasis, atopic dermatitis, vitiligo, multiple sclerosis, myasthenia gravis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, cutaneous lupus erythematosus, Sjögren's syndrome, or Behcet's disease, pharmaceutical composition. 【Claim 2 A method for the prevention or treatment of IRAK-4 or IRAK-1 related diseases comprising administering to an individual a compound according to claim 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

30. Use of the compound according to claim 1, its stereoisomer, its pharmaceutically acceptable salt, or its hydrate or solvate for the prevention or treatment of IRAK-4 or IRAK-1 related diseases.

31. Use of a compound according to claim 1, its stereoisomer, its pharmaceutically acceptable salt, or its hydrate or solvate for the manufacture of a drug for the prevention or treatment of IRAK-4 or IRAK-1 related diseases.

Images